

EAU22 | AMSTERDAM

1-4 July 2022

Cutting-edge Science at Europe's largest Urology Congress

Join us in
Amsterdam!



www.eau22.org

eau European
Association
of Urology

Challenges in renal cancer

Plenary Session 01

Friday 1 July
08:00 - 10:15

Location Orange Area, eURO Auditorium 1

Chairs
A. Breda, Barcelona (ES)
M. Oya, Tokyo (JP)

08:00 - 08:05

Welcome and introduction

08:05 - 08:40

Small renal mass

08:05 - 08:08

Case presentation Bilateral cT1

T. Kuusk, London (GB)

08:08 - 08:18

When do we have to genetically screen in kidney cancer?

To be confirmed

08:18 - 08:23

When do we perform biopsy?

A. Volpe, Novara (IT)

08:23 - 08:28

Pro: Focal treatment

To be confirmed

08:28 - 08:33

Pro: Nephron sparing surgery

A. Minervini, Florence (IT)

08:33 - 08:40

Panel discussion

08:40 - 09:10

Locally advanced tumour

08:40 - 08:43

Case presentation Locally advanced tumour with level III/IV cava thrombus

L. Serra De Oliveira Marconi, Coimbra (PT)

08:43 - 08:48

Role of imaging

P.F.A. Mulders, Nijmegen (NL)

08:48 - 08:53

Role of neoadjuvant treatment?

C.K. Bensalah, Rennes (FR)

08:53 - 08:58

Surgical strategies and pitfalls

T.S. O'Brien, London (GB)

08:58 - 09:03

Adjuvant treatment

J. Bedke, Tübingen (DE)

09:03 - 09:10

Panel discussion

09:10 - 09:38

Oligometastatic disease

09:10 - 09:13

Case presentation Oligometastatic renal cancer

A. Ingels, Creteil (FR)

Scientific Programme - EAU22 Amsterdam

09:13 - 09:18	Role of metastasectomy: How far should we go? To be confirmed
09:18 - 09:23	Role of stereotactic RT C. Berghen, Leuven (BE)
09:23 - 09:28	Adjuvant treatment A. Bex, London (GB)
09:28 - 09:38	Panel discussion
09:38 - 09:58	Metastatic disease
09:38 - 09:43	Guideline presentation Role of cytoreductive nephrectomy in 2022 M.C. Mir Maresma, Valencia (ES)
09:43 - 09:48	Update on systemic treatment P. Maroto Rey, Barcelona (ES)
09:48 - 09:58	Panel discussion
09:58 - 10:13	State-of-the-art lecture Patient engagement is a potential blockbuster treatment that urologists should prescribe for their cancer patients M. Jewett, Toronto (CA)
10:13 - 10:15	Closing remarks

Going viral in urology

Plenary Session 02

Friday 1 July
08:00 - 10:15

Location Grey Area, eURO Auditorium 2
Chairs O.R. Brouwer, Amsterdam (NL)
F.M.E. Wagenlehner, Giessen (DE)

Learning objectives

Viruses have not been at the forefront in urology at all. The COVID-19 pandemic has changed this, revealing that viral infections may have a severe impact on everyday clinical practice in urology. This session deals with lessons learned from the COVID-19 pandemic and its impact on urology and extends to other known viral infections and their impact on fertility, endocrine function and potential to cause urogenital neoplasias, such as HPV associated penile cancer. Finally the role of viral vaccines to treat uro-oncological diseases is discussed, which represents a highly innovative approach to uro-oncology.

08:00 - 08:02	Welcome and introduction
08:02 - 08:12	The COVID-19 pandemic and it's impact on urological care: What lessons have we learnt? C.R. Chapple, Sheffield (GB)
08:12 - 08:22	Large simple trails after the COVID-19 pandemic: Lessons learnt for urology research To be confirmed
08:22 - 09:00	Urogenital manifestations of viral infections: What urologists need to know
08:22 - 08:29	COVID-19: Male reproductive and endocrine function A. Salonia, Milan (IT)
08:29 - 08:36	HIV To be confirmed
08:36 - 08:43	Polyoma viruses L. Schneidewind, Greifswald (DE)
08:43 - 08:50	The importance of viruses in semen and male genital tissue N. Dejucq-Rainsford, Rennes (FR)
08:50 - 09:00	State-of-the-art lecture Eliminating HPV-related cancers: A call for action To be confirmed
09:00 - 09:25	Case-based debate Should we treat HPV+ and HPV- penile cancer differently?
09:00 - 09:05	Case presentation pN3 M. Bandini, Milan (IT)
09:05 - 09:10	Pro S.R. Ottenhof, Amsterdam (NL)
09:10 - 09:15	Con A. Parnham, Manchester (GB)

Scientific Programme - EAU22 Amsterdam

09:15 - 09:25	Discussion
09:25 - 09:40	Society of Urologic Oncology (SUO) lecture Where are the data gaps in HPV-driven penile cancer? P.E. Spiess, Tampa (US)
09:40 - 09:55	State-of-the-art lecture Oncolytic virusses in urological tumours G. Van Der Horst, Leiden (NL)
09:55 - 10:10	State-of-the-art lecture Recombinant viral vaccines in uro-oncology To be confirmed
10:10 - 10:15	Closing remarks

Prostate cancer early detection: What men need to know

Special Session

Friday 1 July
10:30 - 13:30

Location Orange Area, eURO Auditorium 1

Chairs P. Albers, Düsseldorf (DE)
A. Deschamps, Antwerp (BE)
M.J. Roobol, Rotterdam (NL)

Panel T. Albrecht, Ljubljana (SI)
S. Carlsson, New York (US)
S.A. Clark-Wehinger, Meudon (FR)
R. Hogenhout, Rotterdam (NL)
N. Mottet, Saint-Étienne (FR)
To be confirmed

Learning objectives

This special session on prostate cancer early detection will bring together patients, scientists and politicians. Europe-wide there is no consensus on how to establish a proper early detection strategy. Level-I evidence for MRI in screening has been shown, but how realistic is it to bring it to earth. How can we simply combine early detection tools and, most important, what do men need to know. A multidisciplinary and interprofessional discussion on the best way to detect or not detect prostate cancer will try to find practical solutions.

10:30 - 10:35

Welcome and introduction

10:35 - 10:45

The lack of information on PCa and PSA
S.A. Clark-Wehinger, Meudon (FR)

10:45 - 11:00

ERSPC update plus long FU Cohorts
M.J. Roobol, Rotterdam (NL)

11:00 - 11:15

What went wrong with PSA and PCa?
H. Van Poppel, Leuven (BE)

11:15 - 11:30

We have the way out! Risk calculators and algorithm
R. Hogenhout, Rotterdam (NL)

11:30 - 12:10

Trial updates

11:30 - 11:40

ProScreen
A.P. Auvinen, Tampere (FI)

11:40 - 11:50

PROBASE
P. Albers, Düsseldorf (DE)

11:50 - 12:00

MRI trials
R. Nam, Toronto (CA)

12:00 - 12:10

STHLM3
T. Nordström, Stockholm (SE)

12:10 - 12:25

How should early detection be organised in 2022?
S. Carlsson, New York (US)

Scientific Programme - EAU22 Amsterdam

12:25 - 12:40

EAU guidelines or recommendations?

N. Mottet, Saint-Étienne (FR)

12:40 - 12:55

Role of primary care

To be confirmed

12:55 - 13:00

EUomo: The last word

A. Deschamps, Antwerp (BE)

13:00 - 13:30

How to finally move forward?

13:00 - 13:10

When can we expect a Europe-wide early detection strategy?

T. Albreht, Ljubljana (SI)

13:10 - 13:30

Panel discussion

Closing remarks

Controversies on EAU Guidelines I

EAU Guidelines Session

Friday 1 July
10:30 - 12:00

Location	Grey Area, eURO Auditorium 2
Chairs	O.R. Brouwer, Amsterdam (NL) S. Gravas, Larissa (GR) M.P. Laguna Pes, İstanbul (TR)
Discussants	N.W. Clarke, Manchester (GB) C. De Nunzio, Rome (IT) M.S. Van Der Heijden, Amsterdam (NL)
Speakers	J. Oldenburg, Oslo (NO) F. Janisch, Hamburg (DE) M.P. Laguna Pes, İstanbul (TR) S. Gravas, Larissa (GR) M. Rieken, Zürich (CH) To be confirmed O.R. Brouwer, Amsterdam (NL) A. Necchi, Milan (IT) To be confirmed

Learning objectives

Guidelines follow evidence, but evidence may be weak or controversial. The EAU Guideline Office has put together three controversial topics where clear recommendations are difficult or impossible. Guideline panel members and experts in the field will explain and discuss pros and cons of the different concepts. The first topic is the follow-up after curative treatment of germ cell testicular cancer: should this be intense or cool? Should it be CT or non-CT based?

The EAU Guidelines Panel on non-Neurogenic male LUTS requires studies with adequate length of follow-up in order to evaluate invasive therapies for the treatment of benign prostatic obstruction (BPO). In addition, some patients may prefer therapies less effective/durable if they result in a smaller risk of complications or a faster return to normal activities. Therefore, the question remains if durability or morbidity is more important in the management of BPO.

Penile cancer is a rare but potentially devastating disease. Progress has been made in early stage disease like penile sparing surgery and SN biopsy. However, advanced disease is still associated with a very poor prognosis. Currently, the guidelines recommend to consider chemotherapy in a neoadjuvant or adjuvant setting for advanced disease. However, prospective data is lacking. Should we give neoadjuvant chemotherapy to N2-N3 penile cancer patients? The current evidence, and pros and cons will be discussed.

10:30 - 10:33

Welcome and introduction

10:33 - 10:57

Debate Follow up after curative treatment of germ cell testicular cancer: Intense or cool? CT or non-CT based?

10:33 - 10:36

Introduction
M.P. Laguna Pes, İstanbul (TR)

10:36 - 10:42

Intense
F. Janisch, Hamburg (DE)

Scientific Programme - EAU22 Amsterdam

10:36 - 10:42	Cool J. Oldenburg, Oslo (NO)
10:42 - 10:57	Discussion
10:57 - 11:12	Debate Does durability value more than morbidity in the management of BPO?
10:57 - 11:00	Introduction S. Gravas, Larissa (GR)
11:00 - 11:06	Yes M. Rieken, Zürich (CH)
11:06 - 11:12	No To be confirmed
11:12 - 11:27	Discussion
11:27 - 11:57	Debate Should we give neoadjuvant chemotherapy to N2-N3 penile cancer patients?
11:27 - 11:30	Introduction O.R. Brouwer, Amsterdam (NL)
11:30 - 11:36	Yes A. Necchi, Milan (IT)
11:36 - 11:42	No To be confirmed
11:42 - 11:57	Discussion
11:57 - 12:00	Closing remarks

Joint Session of the European Association of Urology (EAU) and the Société Internationale d'Urologie (SIU)

Urology beyond Europe

Friday 1 July
10:30 - 13:00

Location Green Area, Room 2

Chairs R. Gomez, Santiago (CL)
Ph. E. V. Van Kerrebroeck, Berchem- Antwerp (BE)

Learning objectives

Aspects of functional and neuro-urology still remain underscored at international meetings. However worldwide the clinical problems in this field remain an important aspect of any urological practice. In this joint Session of the European Association of Urology (EAU) and the Société Internationale d'Urologie (SIU) worldwide recognised specialists will deal with aspects of reconstructive urological surgery presenting not only existing options but also dealing with emergent therapies. This session will present you an unique overview of evidence and experience based state of the art strategies in the field of functional and neuro-urology.

10:30 - 10:40

Welcome and introduction

10:30 - 10:40

R. Gomez, Santiago (CL)

10:30 - 10:40

Ph. E. V. Van Kerrebroeck, Berchem- Antwerp (BE)

10:40 - 10:55

Introductory lecture Functional urology: Lessons learned from the past
Ph. E. V. Van Kerrebroeck, Berchem- Antwerp (BE)

10:55 - 11:45

Reconstructive urology

10:55 - 11:05

Bladder augmentation and catheterisable channels: Tips and tricks
To be confirmed

11:05 - 11:15

Dealing with incontinence: Slings, strings and other things!
E. Chartier-Kastler, Paris (FR)

11:15 - 11:25

Urethral reconstruction: A waste of time?
S. Kulkarni, Pune (IN)

11:25 - 11:35

Urinary retention: What's new?
D.M. Castro Díaz, Santa Cruz de Tenerife (ES)

11:35 - 11:45

Discussion

11:45 - 12:35

Emergent therapies in functional and neuro-urology

11:45 - 11:55

Botulinum toxin: What have we learned after 20 years?
F. Cruz, Porto (PT)

11:55 - 12:05

Non-invasive neuromodulation: Fact or fiction?
B.F.M. Blok, Rotterdam (NL)

12:05 - 12:15

Neuromodulation and neurostimulation in 2022
J.C. Castaño, Medellín (CO)

Scientific Programme - EAU22 Amsterdam

12:15 - 12:25	New modalities: Stem cells, tissue engineering and afferent denervation To be confirmed
12:25 - 12:35	Discussion
12:35 - 12:50	Concluding lecture Reconstructive urology: A view on the future R. Gomez, Santiago (CL)
12:50 - 13:00	Conclusions
12:50 - 13:00	R. Gomez, Santiago (CL)
12:50 - 13:00	Ph. E. V. Van Kerrebroeck, Berchem- Antwerp (BE)

Joint Session of the European Association of Urology (EAU) and the Federation of ASEAN Urological Associations (FAUA)

Urology beyond Europe

Friday 1 July
10:30 - 13:00

Location	Green Area, Room 1
Chairs	K.A. Mohd Ghani, Kuala Lumpur (MY) J. Palou, Barcelona (ES)
Moderators	To be confirmed To be confirmed To be confirmed To be confirmed V.L. Chuyen, Ho Chi Minh City (VN) To be confirmed S. Proietti, Milan (IT) L. Mosquera Seoane, A Coruña (ES)

10:30 - 10:35	Welcome and introduction
10:30 - 10:35	K.A. Mohd Ghani, Kuala Lumpur (MY)
10:30 - 10:35	J. Palou, Barcelona (ES)
10:35 - 11:10	Reconstructive urology
10:35 - 10:50	Reconstructive surgery in the treatment of post prostatectomy complications F. Campos Juanatey, Santander (ES)
10:50 - 11:05	South East Asia trends in urethral reconstruction surgery: The new insights and collaboration To be confirmed
11:05 - 11:10	Discussion
11:10 - 11:45	Prostate cancer
11:10 - 11:25	Focal therapy for prostate cancer in the era of multiparametric MRI J. Walz, Marseille (FR)
11:25 - 11:40	Trans-perineal approach for prostatic biopsy: Is it the new standard in Asia? J. Letran, Makati City (PH)
11:40 - 11:45	Discussion
11:45 - 12:20	Minimal invasive surgery
11:45 - 12:00	Minimal invasive treatment of BPH: Is TURP still the gold standard? J-N.L. Cornu, Rouen (FR)
12:00 - 12:15	Outcomes of robotic assisted retroperitoneal lymph node dissection for testicular cancer: prospective from Malaysia To be confirmed

Scientific Programme - EAU22 Amsterdam

12:15 - 12:20	Discussion
12:20 - 12:55	Urolithiasis
12:20 - 12:35	Role of miniaturized PCNL after the introduction of disposable flexible ureteroscopes O. Angerri Feu, Barcelona (ES)
12:35 - 12:50	Endoscopic Combined Intrarenal Surgery (ECRIS): What are the selection criteria? H. Chin Tiong, Singapore (SG)
12:50 - 12:55	Discussion
12:55 - 13:00	Conclusion and closing remarks
-	K.A. Mohd Ghani, Kuala Lumpur (MY)
12:55 - 13:00	J. Palou, Barcelona (ES)

Joint Session of the European Association of Urology (EAU) and the Urological Society of Australia and New Zealand (USANZ)

Urology beyond Europe

Friday 1 July
10:30 - 13:00

Location Grey Area, Room Emerald

Chairs C.R. Chapple, Sheffield (GB)
P. Rashid, Port Macquarie (AU)

This session will be pre-recorded. It will be shown in the session room at EAU22 and it will be available On Demand on the EAU22 Virtual Platform as of 1 July, 8:30 CEST

Learning objectives

In this joint session of the EAU and USANZ we will discuss current practice in the different regions of the world, dealing with the sensitive issue of the use of mesh in the management of female urogenital prolapse with an update on the status of the use of vaginal mesh in Australia, the use of robotic surgery for repair of apical prolapse, and concluding with an update from a European perspective of the use of polypropylene mesh for both prolapse and stress urinary incontinence.

In the second section, there will be a review of the new application of PSA-based machine learning technology for the diagnosis of prostate cancer, a review of the EAU position statement on case findings of prostate cancer PSA, and an update on novel focal laser therapy treatment for localised prostate cancer, which can be discussed in the context of the existing evidence base provided by the EAU guidelines.

The third section will focus on benign prostatic hyperplasia with the discussion of the LISA HTL pulsed thulium laser and its application in the surgical treatment of BPH, and review of the EAU guidelines relating to the management of male LUTS.

All three sections will be highlighted by the presentation of cases and discussion in terms of the implications of the lectures.

10:30 - 10:32

Welcome and introduction

10:30 - 10:32

C.R. Chapple, Sheffield (GB)

10:30 - 10:32

P. Rashid, Port Macquarie (AU)

10:32 - 11:22

The use of mesh in the management of female urogenital disorders

10:32 - 10:42

The vaginal mesh saga in Australia: Reflections and lessons learnt
To be confirmed

10:42 - 10:52

Robotic native tissue repairs for apical prolapse
S. Elmer, East Melbourne (AU)

10:52 - 11:02

Reflections on the use of polypropylene mesh for prolapse and stress incontinence: Current concepts and future directions
C.R. Chapple, Sheffield (GB)

11:02 - 11:07

Case study
To be confirmed

11:07 - 11:22

Discussion

11:22 - 12:22

Prostate cancer

Scientific Programme - EAU22 Amsterdam

11:22 - 11:32	Prospective application of PSA-based machine learning algorithms for prostate cancer diagnosis M. Perera, Melbourne (AU)
11:32 - 11:42	Case finding with PSA: The European perspective M.G.K. Cumberbatch, Sheffield (GB)
11:42 - 11:52	ProFocal-Rx TM: Novel focal laser therapy treatment for localised prostate cancer B. Hanna, St Leonards (AU)
11:52 - 12:02	The evidence base for treatment strategies for localised prostate cancer: The EAU Guidelines M.G.K. Cumberbatch, Sheffield (GB)
12:02 - 12:07	Case study M.G.K. Cumberbatch, Sheffield (GB)
12:07 - 12:22	Discussion
12:22 - 12:57	Benign prostatic hyperplasia
12:22 - 12:32	Early BPH experience with LISA HTL pulsed Thulium laser To be confirmed
12:32 - 12:42	The evidence base for current treatments for male LUTS thought to be due to BPH: The EAU Guidelines M. Rieken, Zürich (CH)
12:42 - 12:47	Case study To be confirmed
12:47 - 12:57	Discussion
12:57 - 13:00	Closing remarks
12:57 - 13:00	C.R. Chapple, Sheffield (GB)
12:57 - 13:00	P. Rashid, Port Macquarie (AU)

Joint Session of the European Association of Urology (EAU) and the Urological Society of India (USI)

Urology beyond Europe

Friday 1 July
10:30 - 13:00

Location Yellow Area, Room E102

Chair To be confirmed

Moderators To be confirmed
To be confirmed
To be confirmed
To be confirmed
To be confirmed
To be confirmed
To be confirmed
B. Somani, Southampton (GB)

Panel To be confirmed
P. Maheshwari, Mumbai (IN)
To be confirmed
C.M. Scoffone, Turin (IT)

This session will be pre-recorded. It will be shown in the session room at EAU22 and it will be available On Demand on the EAU22 Virtual Platform as of 1 July, 8:30 CEST

10:30 - 12:00

An update on urolithiasis and BPH

10:30 - 10:36

How to retrieve the fragments after miniaturised PCNL

A.K. Chawla, Manipal (IN)

10:36 - 10:42

Trilogy for large bulk stone PCNL is going to be standard of care

To be confirmed

10:42 - 10:48

Is TFL a game changer in RIRS

V. Chandra Mohan, Hyderabad (IN)

10:48 - 10:54

What should be future innovations in stone management – urologists perspective

To be confirmed

10:54 - 11:00

Stones in infected kidneys – managing beyond conventions

To be confirmed

11:00 - 11:06

Long live PCNL or goodbye for transcutaneous procedures

To be confirmed

11:06 - 11:12

Management of renal and ureteric stones in patients with ileal conduit/neobladder

To be confirmed

11:12 - 11:18

Urolithiasis: The story of ultimate surgical domination

To be confirmed

11:18 - 11:24

Urolithiasis: The story does not end with surgery

S. Kumar, Vellore (IN)

11:24 - 11:30

PCNL in complex anatomy – lessons learnt

To be confirmed

Scientific Programme - EAU22 Amsterdam

11:30 - 11:36	Post PCNL bleeding – Step by step management To be confirmed
11:36 - 11:42	Ongoing clinical trials on BPH: What to expect? To be confirmed
11:42 - 11:48	BPH and chronic inflammation: Re-assessing the link To be confirmed
11:48 - 11:54	EAU BPH topic To be confirmed
11:54 - 12:00	Sexual dysfunction following endourological procedures for stones – myth or reality To be confirmed
12:00 - 12:15	Debate ESWL: Hard times to come? - Should SWL be removed from modern urologists armamentarium?
12:00 - 12:05	Pro To be confirmed
12:05 - 12:10	Con To be confirmed
12:10 - 12:15	Comments from moderators
12:15 - 12:55	Urolithiasis - Case-based panel discussion
12:15 - 12:20	Case presentation
12:15 - 12:20	To be confirmed
12:15 - 12:20	B. Somani, Southampton (GB)
12:20 - 12:55	Panel discussion
12:55 - 13:00	Closing remarks
12:55 - 13:00	To be confirmed
12:55 - 13:00	To be confirmed

Joint Session of the European Association of Urology (EAU) and the Iranian Urological Association (IUA)

Urology beyond Europe

Friday 1 July
10:30 - 13:00

Location

Yellow Area, Room E103

Learning objectives

The 2022 Iranian Urological Association (IUA) and EAU joint session will address two challenging chapters of urology, management of upper urinary tract cancer and personalized approach to symptomatic BPH.

Burning questions on UTUC will be addressed by state-of-the-art lectures from experts in the field and further developed by detailing the management of real-life situations. The “troublesome prostate” will be approached in practical terms through three separate perspectives, the risk of acute retention, selecting the right procedure for the right patient and personalization of drug management.

We are looking forward to a thought-provoking session in a friendly atmosphere!

Prof. Bernard Malavaud & Prof. Abbas Basiri

Joint Session of the European Association of Urology (EAU) and the Pakistan Association of Urological Surgeons (PAUS)

Urology beyond Europe

Friday 1 July
10:30 - 13:00

Location Grey Area, Room G103

Chairs J.P.M. Sedelaar, Nijmegen (NL)
M. Sheriff, Gillingham (GB)

Moderators F. Esperto, Rome (IT)
M. Ahmad, Rawalpindi (PK)
B. Pradere, Toulouse (FR)
To be confirmed

Learning objectives

This session will collaboratively endeavor to provide an overview of the latest developments in the management of urolithiasis and provide an update on current challenges in the management of carcinoma of bladder. These two conditions has got very high prevalence in Pakistan and despite of modern management of these in the west, Pakistan has many challenges which still has to overcome to provide optimal management for these conditions.

10:30 - 10:35

Welcome and introduction
To be confirmed

10:35 - 10:40

EAU/ESU Organisation lecture
J.P.M. Sedelaar, Nijmegen (NL)

10:40 - 11:45

Urolithiasis

11:15 - 11:30

A. Pietropaolo, Southampton (GB)

10:40 - 10:55

Current status of management of urolithiasis in Pakistan
M. Ather, Karachi (PK)

10:55 - 11:10

Novel armamentarium in stone management (incl. high power lasers, single use scopes,...)
F. Esperto, Rome (IT)

11:15 - 11:30

PAUS
S.S. Qazi, Karachi (PK)

11:10 - 11:15

Challenging clinical case
F. Ur Rehman Khan, Lahore (PK)

11:15 - 11:30

Debate on clinical case management

11:30 - 11:45

Questions and answers

11:45 - 12:50

Bladder cancer

11:45 - 12:00

Challenges in the management of Non-Muscle Invasive Bladder Cancers (NMIBC) in Pakistan
To be confirmed

Scientific Programme - EAU22 Amsterdam

12:00 - 12:15	Immunotherapy in NMIBC, where are we going? B. Pradere, Vienna (AT)
12:15 - 12:20	Challenging clinical case To be confirmed
12:20 - 12:35	Debate on clinical case management
12:20 - 12:35	PAUS To be confirmed
12:20 - 12:35	Y.C.J. Teoh, Hong Kong (CN)
12:35 - 12:50	Questions and answers
12:50 - 13:00	Conclusion
12:50 - 13:00	M.S. Khan, London (GB)
12:50 - 13:00	J.P.M. Sedelaar, Nijmegen (NL)

Joint Session of the European Association of Urology (EAU) and the Pan-African Urological Surgeons Association (PAUSA)

Urology beyond Europe

Friday 1 July
10:30 - 13:00

Location Grey Area, Room G102

Chairs M. Jalloh, Dakar (SN)
J.M. Nijman, Groningen (NL)

Panel To be confirmed
H. Kouicem, Setif (DZ)
To be confirmed
S.R. Aminu, Rochdale (GB)
J.L.H.R. Bosch, Rotterdam (NL)
To be confirmed

Case presenters To be confirmed
To be confirmed

Moderators M. Jalloh, Dakar (SN)
J.M. Nijman, Groningen (NL)

Learning objectives

This years' session will focuss on the different modalities in stone treatment, urethral stricture disease and the IPPS questionnaire. During the panel discussions clinical problems will be addressed in an interactive format.

10:30 - 10:35

Welcome and introduction

10:30 - 10:35

M. Jalloh, Dakar (SN)

10:30 - 10:35

J.M. Nijman, Groningen (NL)

10:35 - 10:50

Management of urolithiasis in Africa: Where do we stand?
H. Kouicem, Setif (DZ)

10:50 - 11:05

Nephrolithiasis in Western Cape, South Africa
To be confirmed

11:05 - 11:20

Multiple modalities for stone treatment, the Dutch perspective
To be confirmed

11:20 - 11:45

Staghorn Stone: Case presentation and guidelines

11:25 - 11:45

11:45 - 12:00

Critical observations of the IPSS questionnaire and proposals to improve its quality
S.R. Aminu, Rochdale (GB)

12:00 - 12:15

Urethral reconstruction in Sub Saharan Africa
To be confirmed

12:15 - 12:30

Urethral reconstruction of proximal urethral strictures in the sphincteric region
J.L.H.R. Bosch, Rotterdam (NL)

Scientific Programme - EAU22 Amsterdam

12:30 - 12:55	Case discussion on urethral reconstruction
----------------------	---

12:35 - 12:55	
----------------------	--

12:55 - 13:00	Conclusion
----------------------	-------------------

12:55 - 13:00	M. Jalloh, Dakar (SN)
----------------------	-----------------------

12:55 - 13:00	J.M. Nijman, Groningen (NL)
----------------------	-----------------------------

Modern education and resident's surgical training in 2022

Abstract Session 02

Friday 1 July
10:45 - 12:15

Location Green Area, Room 4
Chairs S.Y. Cho, Seoul (KR)
To be confirmed
D. Veneziano, Reggio Calabria (IT)
In collaboration with EAU skills centre at ORSI Academy and ESRU

10:45 - 10:48

Introduction

10:48 - 10:56

Proficiency based robotic training in urology: A model from EAU skills centre at ORSI Academy
To be confirmed

10:56 - 11:04

Training opportunities in urology: What does EAU offer for residents and young urologists?
J. Rassweiler, Heilbronn (DE)

11:04 - 11:12

Training in urology: What do residents expect?
A. Mattigk, Ulm (DE)

A0018

Incisional negative pressure wound therapy for surgical site complications prevention in radical cystectomy

A0019

Mini-Cog to predict postoperative delirium in patients who underwent Transurethral Resection of Bladder Tumor (TURBT) under spinal anesthesia

A0020

The use of abdominal drain after robot-assisted surgery in urology: Impact on postoperative pain

A0021

Laparoscopic versus ultrasound guided Transversus Abdominis Plane (TAP) block for postoperative analgesia after radical prostatectomy: A randomized controlled trial

A0022

Do French urologists suffer from imposter syndrome? A survey
G. Fiard, Grenoble (FR)

A0023

Urology residents simulation training improves clinical outcomes in laparoscopic partial nephrectomy
A.d.O. Paludo, Porto Alegre (BR)

11:24 - 11:30

Discussion

A0024

Comparison of perioperative outcomes of single-port da Vinci SP and multiport da Vinci Xi robotic systems in robotic-assisted urologic surgeries
C. Dennis, Chicago (US)

A0025

Development and validation of the metric-based assessment of a robotic dissection task on an avian model
S. Puliatti, Modena (IT)

Scientific Programme - EAU22 Amsterdam

A0026	Development of the competency-based robot-assisted surgery instructional learning curriculum M.E.C. Esteves Chaves Campos, Belo Horizonte (BR)
A0027	A prospective, randomized, multi-centre trial on the efficiency and effectiveness of proficiency based progression robotic surgical skills training S. Puliatti, Modena (IT)
A0028	Virtual classroom proficiency-based progression for robotic surgery training (VROBOT): A prospective, cross-over, effectiveness study A. Asif, Camberley (GB)
11:40 - 11:46	Discussion
	Video Abstracts
V02	Remote training using augmented reality on surgical phantoms J. Immerzeel, Arnhem (NL)
12:10 - 12:15	Closing remarks

Affordable techniques in urology - High quality at low costs

Abstract Session 01

Friday 1 July
10:45 - 12:15

Location Green Area, Room 3
Chairs J.A. Cajigas Plata, Bogota (CO)
L. Pacheco-Figueiredo, Braga (PT)
To be confirmed

10:45 - 10:48

Introduction

Cost-effectiveness stone treatment

- A0001** **SWL is more cost-effective than fURS for the management of kidney stones: Comparative study in a tertiary care centre**
A. Bilé Silva, Lisboa (PT)
- A0002** **Allium (R) Ureteral stent: Long term results**
I. Masarwa, Haifa (IL)
- A0003** **The effectiveness and patient tolerability of urologic procedures conducted under conscious sedation**
- A0004** **Modeling of the business process management in a unit of lithotripsy and endourology of a tertiary public hospital**
J. Bolón Marset, Valencia (ES)

10:56 - 11:08

Discussion

Cost-effectiness surgical procedures

- A0005** **Patients' preferences, willingness-to-pay and cost of cystoscopy procedures: Results from a large survey-based study in the United Kingdom**
D. Batura, London (GB)
- A0006** **Application of the comprehensive complication index to a cost-prediction model for radical cystectomy: Preliminary analysis**
- A0007** **Analyzing the chemistry behind urological lubricants. Which one has greater efficacy?**
C. Munoz Calahorro, Sevilla (ES)
- A0008** **Real-world cost for first-line treatment for prostate cancer: A comparative cost analysis in the public sector**
S. Reddy, . (AU)

11:16 - 11:28

Discussion

IT/3-D Technology

- A0009** **Development of a novel diagnostic model for urological cancers using comprehensive N-glycan signatures of serum immunoglobulins with a machine learning approach**

Scientific Programme - EAU22 Amsterdam

A0010	Urine cytology reporting with computational estimates of the nuclear/cytoplasmic ratios of the urothelial cells: A deep learning model based on the Paris System W-S. Hu, Taichung (TW)
A0011	The role of 3-D imaging reconstruction in real-life urologic practice: Results from a global survey M.C. Sighinolfi, Milan (IT)
A0012	3-D Printed prostate cancer model prior to Robotic-Assisted Radical Prostatectomy: Initial experience and a surgeon, patient, radiologist, and pathologist point of view F. Vasconcelos Ordones, (NZ)
11:36 - 11:48	Discussion
	New technologies
A0013	Mechanism of action of Phenazopyridine N. Luyts, Leuven (BE)
A0015	Troubleshooting and cost-analysis of the senhance surgical robotic system in urology: A community hospital perspective Y-C. Lin, Yunlin County (TW)
A0016	Comparative simulation of T-Control® indwelling bladder catheter insertion vs. open and closed Foley urinary catheter systems M. Luque González, Las Palmas de Gran Canaria (ES)
A0017	Proposal of a miniaturized endoscopic camera to measure energy spread during bipolar cauterizing S. Siracusano, Trieste (IT)
11:58 - 12:10	Discussion
12:10 - 12:15	Closing remarks

Infections - Bench to bedside

Abstract Session 03

Friday 1 July
10:45 - 12:15

Location Green Area, Room 5
Chairs G. Bonkat, Basel (CH)
J. Corrales Riveros, Lima (PE)
To be confirmed

10:45 - 10:50

Introduction

A0029 **Dehydrated human amnion-chorion membranes can ameliorate interstitial cystitis in rats by down-regulating inflammatory cytokines and protein coding genes**
C.H. Yang, Taichung (TW)

A0030 **Role of epigenetics in the neurogenic inflammation in patients suffering CP/CPPS and relevance for the precision medicine**

A0032 **Antibody responses to BNT162b2 mRNA COVID-19 vaccine in healthcare workers and patients with urological diseases in Japan**
S. Hatakeyama, Hiroasaki (JP)

A0033 **Epidemiology of asymptomatic bacteriuria prior urological surgery: preliminary results of the retrospective and multicenter TOCUS study**
M. Vallée, Poitiers (FR)

11:00 - 11:08

Discussion

A0034 **Urinary human papilloma virus infection and bladder cancer risk: A systematic review and a prisma-compliant meta-analysis**
D. Garcia-Rojo, Barcelona (ES)

A0035 **Gardnerella vaginalis: Is it an underestimated cause of urinary symptoms in males?**

A0036 **Etiology of Acute Epididymitis (AE) in young patients under 35 years**

A0037 **Evaluation of early scoring predictors for expedited care in a large prospective patients' cohort with Emphysematous Pyelonephritis**
A.K. Chawla, Manipal (IN)

11:16 - 11:24

Discussion

A0038 **The management of recurrent cystitis in women: When a prompt identification of risk factors might make a difference**
T. Cai, Trento (IT)

A0039 **Acute uncomplicated cystitis and menstrual cycle: What is new?**
P. Samchuk, Kiev (UA)

A0040 **Smells like cystitis – diagnosing urinary tract infections with an electronic nose**
H. Heers, Marburg (DE)

11:30 - 11:38

Discussion

Scientific Programme - EAU22 Amsterdam

A0041	Possible role of the microbiota in urinary stones: A prospective study to correlate radiological density (Hounsfield Units) and cultural examination of urinary calculi
A0042	Predictive value of preoperative high sensitive C-reactive protein/ albumin ratio in systemic inflammatory response syndrome after semi-rigid ureteroscopy
A0043	The role of presepsin as predictive factor for sepsis in patients with urinary tract infection associated with urinary calculi
11:44 - 11:52	Discussion
A0044	Urine microbiome analysis in patients with Catheter-Associated Urinary Tract Infection (CAUTI) using an Association Rules Mining (ARM) methods R. Sasaki, Kitaakita (JP)
A0045	Comparison of bacterial species and antimicrobial resistance between catheter and non-catheter associated urinary tract infections L. Leitner, Zürich (CH)
A0046	The potential role of Monocyte Distribution Width (MDW) as early post-operative sepsis biomarker D. Baiamonte, Palermo (IT)
A0047	Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLR) and Lymphocyte-Monocyte Ratio (LMR) in predicting Systemic Inflammatory Response Syndrome (SIRS) and sepsis after Percutaneous Nephrolithotomy (PNL) A.K. Chawla, Manipal (IN)
12:00 - 12:08	Discussion
12:08 - 12:15	Closing remarks

Challenging situations in kidney surgery

Video Session 1

Friday 1 July
10:45 - 12:15

Location Purple Area, Room Elicium 2

Chairs To be confirmed

To be confirmed

P.F.A. Mulders, Nijmegen (NL)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

10:45 - 10:48

Introduction

V03

Robotic Pringle maneuver and suprahepatic IVC control for level 3b IVC thrombi
N. Pokala, Columbia (US)

V04

Complete minimally-invasive surgery is feasible for Renal Cancer with level IV intracardiac tumour thrombus
A. Galfano, Milano (IT)

V05

First ever reported case of continuous spinal anesthesia da Vinci robotic partial nephrectomy
P. Gontero, Turin (IT)

V06

First clinical experience with a novel approach of robot-assisted completely retroperitoneal nephroureterectomy with bladder cuff
I. Tsaur, Mainz (DE)

V07

Template lymph node dissection in retroperitoneoscopic radical nephroureterectomy for upper Urinary Tract Urothelial Carcinoma (UTUC)
P. Durai, Singapore (SG)

V08

Criss-cross hemostatic suture in nephron sparing open surgery
G. Tulone, Palermo (IT)

11:53 - 11:58

Closing remarks

Localised kidney cancer: Histology, diagnosis and prognosis

Abstract Session 04

Friday 1 July
10:45 - 12:15

Location Orange Area, Room 2
Chairs D. Amparore, Turin (IT)
C. Beisland, Bergen (NO)
To be confirmed

10:45 - 10:49

Introduction

Histological subtypes

A0048 The added value of histological subtype in the prediction of oncologic outcomes in patients with non-metastatic papillary renal cell carcinoma

A0049 Exploring the diversity and predictors of histopathological findings across the European Association of Urology Guidelines Office rapid reaction group priority groups for patients with renal tumours: Implications for prioritization of renal cancer care
R. Campi, Florence (IT)

A0050 The spectrum of renal oncocytic neoplasms with indolent behavior waiting for 5th edition of WHO Classification of Urinary Tumours

A0051 Validation of a 22-gene Epithelial-Mesenchymal Transition (EMT) prognostic signature in clear cell renal cell carcinoma

10:57 - 11:07

Discussion

Diagnosis

A0052 LiKidMiRs: Unveiling the diagnostic potential of liquid biopsy-based circulating microRNAs in renal cell tumors
C. Jeronimo, Porto (PT)

A0053 Ultrasound based CEUS-Bosniak classification for cystic renal lesions: An 8-year clinical experience

A0054 Clinical performance of 99m sestamibi SPECT/CT imaging in differentiating oncocytic tumors from renal cell carcinoma in routine clinical practice

11:13 - 11:23

Discussion

Nephrometric scores

A0055 What's the best model to predict eGFR loss at 1 year after minimally invasive partial nephrectomy?
F. Crocero, Cosenza (IT)

A0056 Prediction of significant renal function decline after open, laparoscopic and robotic partial nephrectomy: Refinement of the Martini's nomogram on the RECORD2 project cohort
R. Tellini, Firenze (IT)

A0057	<p>Association of PADUA and R.E.N.A.L. scores with cumulative morbidity after partial nephrectomy: A standardized assessment of complications in the context of preoperative nephrometry</p> <p>D.K. Filipas, Hamburg (DE)</p>
A0058	<p>Nephrometry scores predicting value of Trifecta achievement in a multicenter analysis (ROSULA database) of Robotic Partial Nephrectomy for totally endophytic “deep” renal masses</p> <p>G. Tuderti, Roma (IT)</p>
A0059	<p>Head to head comparison between RENAL and PADUA nephrometry scores in predicting TRIFECTA achievement in off-clamp Robot-assisted partial nephrectomy</p> <p>R.S. Flammia, Rome (IT)</p>
A0060	<p>External validation of the SPARE nephrometric index as a predictor of early complications after partial nephrectomy</p> <p>M. Santiago Gonzalez, Madrid (ES)</p>
11:35 - 11:45	<p>Discussion</p>
	<p>Prognostic features</p>
A0061	<p>Risk of progression after nephrectomy for non-metastatic clear cell renal cell carcinoma: Comparison of the predictive ability of validated risk models</p>
A0062	<p>Frailty status predicts worse postoperative outcomes and long-term oncologic outcomes in patients treated with partial nephrectomy</p> <p>G. Rosiello, Bacoli (IT)</p>
A0063	<p>The effect of age on cancer-specific mortality in T1a stage renal cell carcinoma patients: A population-based study across all treatment’s modalities</p> <p>D. Amparore, Turin (IT)</p>
A0064	<p>Evaluation of the utility of lymph-vascular invasion as an independent prognostic predictor of overall survival for patients with renal cell carcinoma that undergo nephrectomy</p>
A0065	<p>Prognostic features of Upstaged pT3a Renal Cell tumors with fat invasion: A single high-volume centre experience</p> <p>F. Di Maida, Florence (IT)</p>
A0066	<p>How important are morphologic subtypes on the prognosis of surgically treated non-metastatic papillary renal cell carcinoma? An analysis from a contemporary multi-institutional database</p> <p>S. Erdem, Istanbul (TR)</p>
A0067	<p>Assessment of predictors of renal cell carcinoma progression after nephrectomy at short and intermediate term follow-up and their implication on surveillance protocols</p>
11:59 - 12:09	<p>Discussion</p>
12:09 - 12:15	<p>Closing remarks</p>

NMIBC - BCG, urinary markers, therapeutic pathways and mechanisms of action

Abstract Session 05

Friday 1 July
10:45 - 12:15

Location Yellow Area, Room Forum

Chairs
To be confirmed
To be confirmed
A. Vlahou, Athens (GR)

BCG related

10:45 - 10:48

Introduction

A0068	Non-muscle invasive bladder cancer subtypes with differential response to intravesical bacillus Calmette-Guerin treatment
A0069	Immunotherapeutic effects of recombinant Bacillus Calmette-Guérin containing sic gene in ex vivo and in vivo bladder cancer models
A0070	The predictive values of RPL9 expression for BCG response in NMIBC patients W.T. Kim, Chungbuk (KR)
A0071	Characterization of T cells during BCG therapy for NMIBC W. Brochier, Brussels (BE)
A0072	Novel therapeutic targets and potential drugs for BCG incurable non-muscle-invasive bladder cancer
A0073	Efficacy of recombinant Bacillus Calmette-Guérin–dltA in three-dimensional bioprinted bladder cancer-on-a-chip with microfluidic system J. Choi, Seoul (KR)
A0074	Urinary microbiota is different in patients with or without BCG instillation K.M.J. Li, Hong Kong (HK)
Discussions	
Urine test related	
A0075	Association of Leucocyte levels in urine with tissue PD-L1 status and immune infiltration into basal bladder cancer subtype in the prospective Real World clinico-pathological register trial BRIDGister R. Wirtz, Cologne (DE)
A0076	BTA stat®, Alere NMP22® BladderChek®, UBC® rapid test, and uromonitor® in comparison to cytology as tumor marker for urinary bladder cancer: New results of a german multicentre-study T.H. Ecke, Bad Saarow (DE)
A0077	Utility of bladder EpiCheck methylation test for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin

Scientific Programme - EAU22 Amsterdam

A0078	FGFR testing from matched tissue and urine samples from pilot cohort the prospective Real World clinico-pathological register trial „BRIDGister T.H. Ecke, Bad Saarow (DE)
11:24 - 11:33	Discussion
	Model systems
A0079	A scalable setup for hyperthermic intravesical chemotherapy in rodents
A0080	Targeting the androgen receptor axis to improve response to bladder cancer immunotherapy P. Toren, Québec (CA)
A0081	Characterization of bladder cancer patient-derived organoids and potential application for personalized medicine
A0082	Application of a new 3D culture system to culture uniformly sized patient-derived bladder cancer (BLCa) organoids
11:41 - 11:50	Discussion
	Various
A0083	Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis
A0084	Subtype specific expression of radioligand targets in the prospective Real World clinico-pathological register trial BRIDGister R. Wirtz, Cologne (DE)
A0085	Bladder cancer-derived TSP4 advances lymphangiogenesis through lymphatic endothelial cell recruitment P-H. Chang, Taipei (TW)
A0086	Cell softness reveals tumorigenic potential via the F-actin/ITGB8/TRIM59/ATK/mTOR/glycolysis signaling axis in bladder cancer X. Su, Chengdu (CN)
A0087	A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology
12:00 - 12:10	Discussion
12:10 - 12:15	Closing remarks

Theranostics in prostate cancer

ESU Course 01

Friday 1 July
11:00 - 14:00

Location Grey Area, Room G104

Chair B.A. Hadaschik, Essen (DE)

Learning objectives

Recently theranostics, the combination of diagnosis and treatment based on the same concept, was introduced in the management of prostate cancer based on nuclear medicine technologies. This is an emerging field with promising clinical data being published very recently. The concept of theranostics has the potential to change the management of prostate cancer and to become an essential part of our armamentarium. The aim of the course is to provide an in depth overview on these new concepts and to critically assess their performance, efficacy and limitations.

Introduction and objectives of course

B.A. Hadaschik, Essen (DE)

The different PET tracers and radioligands

W.J.G. Oyen, Arnhem (NL)

Diagnosis and initial staging of prostate cancer

Diagnosis of the primary

B.A. Hadaschik, Essen (DE)

Initial Staging of prostate cancer with PET imaging

W.J.G. Oyen, Amsterdam (NL)

What to do with the information?

P. Cornford, Liverpool (GB)

Biochemical recurrence

Staging of biochemical recurrence with PET imaging

W.J.G. Oyen, Arnhem (NL)

Treatment options and risk stratification for salvage treatment

B.A. Hadaschik, Essen (DE)

What to do with the information?

P. Cornford, Liverpool (GB)

Advanced and metastatic disease

Use of PET in the management of advanced and metastatic prostate cancer

B.A. Hadaschik, Essen (DE)

Radioligand treatment for metastatic prostate cancer

W.J.G. Oyen, Arnhem (NL)

The place of radioligand treatment in the M1 prostate cancer arena

W.J.G. Oyen, Arnhem (NL)

Chronic pelvic pain in men and women

ESU Course 02

Friday 1 July
11:00 - 14:00

Location

Grey Area, Room G105

Chair

E.J. Messelink, Leeuwarden (NL)

Learning objectives

The urologist is often dealing with patients having Chronic Pelvic Pain. This course will offer the urologist practical guidance in treating these patients. In the case discussion the participants will have the opportunity to help outlining the problem. In the lectures theoretical knowledge will be translated into daily guidelines for diagnostics and treatment of patients with pelvic pain.

At the end of this course the participant will:

- Know the basic principles of treating patients with chronic pelvic pain.
- Know how to rule out well known causes.
- Have knowledge of the myofascial and psychological aspects.
- Be able to refer patients at the right time to the right team.

Chronic pelvic pain, the basics: Mechanisms and terminology

E.J. Messelink, Leeuwarden (NL)

Chronic pelvic pain in men: Case presentation and discussion

B. Parsons, Exeter (GB)

Chronic pelvic pain in men: Practical guidelines on diagnostics and treatment

B. Parsons, Exeter (GB)

Chronic pelvic pain in women: Case presentation and discussion

E.J. Messelink, Leeuwarden (NL)

Chronic pelvic pain in women: Practical guidelines on diagnostics and treatment

E.J. Messelink, Leeuwarden (NL)

The interdisciplinary approach: Team members and organisation

B. Parsons, Exeter (GB)

New technologies and urological applications

Special Session

Friday 1 July
12:15 - 13:45

Location Grey Area, eURO Auditorium 2
Chairs C.H. Bangma, Rotterdam (NL)
J.P.F.A. Heesakkers, Maastricht (NL)

Learning objectives

New technologies continue to appear and continue to shape society into a better and more beautiful world with increasing health and happiness. These new technological developments also will emerge at one moment in the urological field. This session highlights some new technologies that will most likely have a big influence and healthcare in the future. Moreover a major role in the development of these new techniques is played by the host country of this EAU meeting. The implications for the various subspecialties of urology are discussed by experts in the field

12:15 - 12:18

Welcome and introduction
C.H. Bangma, Rotterdam (NL)

12:18 - 12:33

Organoids for innovation in cancer research
S. Boj, Utrecht (NL)

12:33 - 12:43

Patient derived organoids: A preclinical model to investigate chemoresistance in muscle-invasive bladder cancer
T. Zuiverloon, Rotterdam (NL)

12:43 - 12:58

Clinical application of patient derived organoids in urology: Possibilities and limitations
R. Seiler, Bellmund (CH)

12:58 - 13:08

Discussion

13:08 - 13:23

Developments in digital technology with respect to ingestible sensors and digital profiling
C. Van Hoof, Leuven (BE)

13:23 - 13:33

Reflections on the digitalisation of urology
T. Loch, Flensburg (DE)

13:33 - 13:43

Discussion

13:43 - 13:45

Closing remarks
J.P.F.A. Heesakkers, Maastricht (NL)

Meeting of the Young Academic Urologists (YAU)

Special Session

Friday 1 July
12:30 - 15:00

Location	Purple Area, Room Elicium 1
Chair	J. Gómez Rivas, Madrid (ES)
Moderators	J. Gómez Rivas, Madrid (ES) To be confirmed J. Gómez Rivas, Madrid (ES) L.A. Kluth, Frankfurt (DE) A. Pietropaolo, Southampton (GB)
Speakers	V.M.J. De Coninck, Brasschaat (BE) A. Larcher, Milan (IT) M. Falcone, Torino (IT) G. Cacciamani, Los Angeles (US) R. Boissier, Marseille (FR) R. Campi, Florence (IT)
Discussants	E. Emiliani, Barcelona (ES) T.E. Şener, Istanbul (TR) V. Phé, Paris (FR) A-F. Spinoit, Ghent (BE) M.G. Gül, Konya (TR) G.I. Russo, Catania (IT) To be confirmed F. O'Kelly, Dublin (IE) M. Moschini, Milan (IT) Y.C.J. Teoh, Hong Kong (CN) U. Capitanio, Milan (IT) A. Ingels, Creteil (FR)

Learning objectives

The Young Academic Urologists (YAU) is a group of talented and already renowned European young urologists. We aim to promote high-quality studies in order to provide strong evidence for the best urological practice. In this session both scientific and educational context will be discussed among the members of YAU and the leaders of European Urology.

12:30 - 13:00

EAU Young Academic Urologists (YAU)

12:30 - 12:40

Overview of the Young Academic Urologists

J. Gómez Rivas, Madrid (ES)

12:40 - 12:50

Overview of the non-oncology group achievements

B. Bañuelos Marco, Berlin (DE)

12:50 - 13:00

Overview of the oncology & technology group achievements

M. Moschini, Milan (IT)

13:00 - 13:10

YAU Awards

Best paper published in 2021 by a YAU group

M. Moschini, Milan (IT)

Scientific Programme - EAU22 Amsterdam

	Best poster presented at EAU 2022 by a YAU group F. O'Kelly, Dublin (IE)
	YAU reviewer of the year D. D'Andrea, Vienna (AT)
13:10 - 13:55	Hot topics: Part I
13:10 - 13:25	Radiation exposure among patients and urologists during urolithiasis management: Does a standardisation exist?
13:25 - 13:40	Can robotic surgery be the future in complex urological condition?
13:40 - 13:55	Penile augmentation
13:55 - 14:40	Hot topics: Part II
13:55 - 14:10	Introperative Complication Assessment and Reporting with Universal Standards (ICARUS) project: A cross- surgical specialties projects that aim to standardise the intraoperative complication reporting
14:10 - 14:25	Radical cystectomy vs. BCG instillation in kidney transplant recipients with non-muscle invasive high risk bladder cancer
14:25 - 14:40	Current clinical trials in the field of renal cell carcinoma
14:40 - 14:50	EAU Opportunities for Young Academic Urologists: Where are we heading to? G. Gandaglia, Milan (IT)
14:50 - 15:00	Closing remarks

Virtual platforms and the future of urology

Abstract Session 06

Friday 1 July
12:30 - 14:00

Location Green Area, Room 4
Chairs To be confirmed
To be confirmed
F. Sanguedolce, Barcelona (ES)

12:30 - 12:34

Introduction

Virtual platform for patients

A0088 **Hospital rating websites play a minor role in hospital choice of uro-oncologic patients in Germany: Results of the multicentric NAVIGATOR-study**
C. Groeben, Dresden (DE)

A0089 **Improving digital accessibility for urological patients with disabilities: A quality review of urology resources within websites of leading global hospitals**

A0090 **Online public interest in urological cancers during the Covid-19 pandemic: What can “Dr. Google” teach us?**
Z-E. Khene, Rennes (FR)

A0091 **Saving the Trees: Digital methods of providing patient information leaflets**

A0092 **Testicular pain and YouTube™: Are uploaded videos a reliable source to get information?**

12:44 - 12:55

Discussion

Virtual platforms for urologists

A0093 **Virtual multi-institutional tumor board: Feasibility and physicians acceptance, a GSTU foundation project in Sicily**
V. Serretta, Palermo (IT)

A0094 **Peer-to-peer counseling in non-metastatic prostate cancer: Results from a randomized controlled trial**
J. Huber, Dresden (DE)

A0095 **The optimal dissemination of scientific manuscripts via social media: A prospective randomized trial comparing visual abstracts with key figures using consecutive original manuscripts published in European Urology**

A0096 **Do patients prefer telecommunication to traditional face-to face clinic review: A benefit of covid-19?**
K. Kapriniotis, London (GB)

13:03 - 13:14

Discussion

Future of urology

Scientific Programme - EAU22 Amsterdam

A0097	Who is shaping the future of urology? A descriptive analysis of current urology residency program directors N. Corsi, Detroit (US)
A0098	Gender disparities in editorial board of academic urology journals
A0099	Gender differences in Urologic training – results of the second GeSRU (Germany Society of Residents in Urology) training survey C. Siech, Frankfurt Am Main (DE)
A0100	Can artificial intelligence enhance clinical outcomes and patient flow in a urology walk-in clinic? J.M. Charnock, London (GB)
13:22 - 13:33	Discussion
	Miscellaneous
A0101	Accuracy validation of a novel automated bladder diary device, Minze Diary Pod L. Bladt, Antwerp (BE)
A0102	Application of blockchain technology and internet of things in uroflowmetry for clinical trials: A pilot test
A0103	Video-assisted informed consent in endoscopic urology: A randomized trial on ureteroscopy R. Malinaric, Genoa (IT)
A0104	Mapping temporal trends in the presentation of urologic emergencies T. Sholklapper, Los Angeles (US)
A0105	Medications mostly associated with haematuria: Assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries G. Gallo, Roma (IT)
13:43 - 13:54	Discussion
13:54 - 14:00	Closing remarks

Infections - Prophylaxis, treatment and complications

Abstract Session 07

Friday 1 July
12:30 - 14:00

Location Green Area, Room 5
Chairs T. Cai, Trento (IT)
H.M. Çek, Edirne (TR)
O.V. Shulyak, Lviv (UA)

12:30 - 12:33

Introduction

- | | |
|--|--|
| A0106 | Artificial intelligence to guide antibiotic choice in recurrent uti: Is it the right way for improving antimicrobial stewardship?
T. Cai, Trento (IT) |
| A0108 | Medications mostly associated with Urinary Tract Infections (UTIs): assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries
C. Gravina, Roma (IT) |
| A0109 | Reappraisal of the treatment duration of antibiotic regimens for acute uncomplicated cystitis in adult women: A systematic review and network meta-analysis of 61 randomised clinical trials
K. Do Kyung, Seoul (KR) |
| A0110 | Antibiotic prophylaxis for percutaneous nephrolithotomy: An updated systematic review and meta-analysis |
| 12:43 - 12:54 Discussion | |
| A0111 | Report on microbial and resistance patterns of the causative pathogens of nosocomially-acquired urinary tract infections: Preliminary data analysis of the GPIU-Studies 2015-2020 |
| A0112 | Risk factors of infectious complications after benign prostatic hyperplasia surgery: Preliminary results from the retrospective and multicenter TOCUS cohort |
| A0113 | Assessing the safety of transperineal prostate biopsy with only a single dose of amoxicillin/clavulanic acid using the PrecisionPoint™ Transperineal Access System (PPTAS); A retrospective review of 500 cases and technique description
H. Islam, Leeds (GB) |
| A0114 | Risk factors for postoperative infections after urological surgery: Preliminary results from the national and multicenter TOCUS study
M. Vallée, Poitiers (FR) |
| A0115 | Complications of transperineal prostate biopsies with antibiotic prophylaxis on indication only versus transrectal prostate biopsies with standard prophylactic antibiotics |
| 13:04 - 13:15 Discussion | |
| A0116 | Evaluation of overactive bladder symptoms in patients recovering from post-acute COVID-19 syndrome
A. Zachariou, Volos (GR) |

Scientific Programme - EAU22 Amsterdam

A0118	Management aspects of urinary tract infection in diabetic patients: A national survey among different specialties S. Zouari, Tunis (TN)
13:23 - 13:34	Discussion
A0120	Rapid detection of bacterial UTIs via reporter phage-based bioluminescence assay L. Leitner, Zürich (CH)
A0121	Epigenetic dysregulation of tumor suppressor genes in cp/cpps: Studies on liquid biopsies for biomarker development H. Yan, Giessen (DE)
A0122	Closed-loop audit of antibiotic stewardship in ureteroscopic stone surgery
A0123	Catheter-associated urinary tract infections: Current preventative measures and management from the literature M.G Abdelaziz Gad, Łódź (PL)
A0124	The feasibility and advantages of an at-home intravesical therapy service for benign conditions
13:44 - 13:55	Discussion
13:55 - 14:00	Closing remarks

Shining a laser on endourology

Video Session 2

Friday 1 July
12:30 - 14:00

Location Purple Area, Room Elicium 2

Chairs F. Gomez Sancha, Madrid (ES)
J-T. Klein, Ulm (DE)
D. Staïos, Papagou - Athens (GR)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

12:30 - 12:33

Introduction

V09

Transperineal fusion laser ablation for benign prostatic hyperplasia: Technique and 6 months results
F. Bianco, Miami Lakes (US)

V10

Dual circular incision at prostate apex and bladder neck to optimize sphincter preservation during thulium laser enucleation of the prostate
Y. Chang, Taipei (TW)

V11

Transperineal interstitial Laser Ablation (TPLA) of the prostate for selected patients with benign prostatic obstruction: Step-by-step technique and preliminary findings
F. Sessa, Florence (IT)

V15

Endoscopic treatment of parapelvic renal cysts
M. Frankiewicz, Gdańsk (PL)

13:48 - 13:53

Closing remarks

NMIBC early diagnosis and improvement of endoscopic management

Abstract Session 09

Friday 1 July
12:30 - 14:00

Location Yellow Area, Room Forum
Chairs P. Black, Vancouver (CA)
L-M. Krabbe, Münster (DE)
E.N. Xylinas, Paris (FR)

Prognosis and early detection

12:30 - 12:33

Introduction

- | | |
|------------------------------|---|
| A0145 | Bladder EpiCheck in clinical decision making in the follow up of non muscle invasive bladder cancer
F. Lozano Palacio, Barcelona (ES) |
| A0146 | Randomized trial comparing electrical ERBT vs. laser ERBT for treatment of NMIBC, preliminary report |
| A0147 | The updated EAU prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin |
| A0149 | Predictors of residual tumor at re-staging transurethral resection for high-risk non-muscle invasive bladder cancer: Insights from a large multi-institutional collaboration
F. Claps, Trieste (IT) |
| A0150 | Outpatient Transurethral Laser Ablation (TULA) for non-muscle invasive bladder cancer; results from a multi-centre prospective 1 year EORTC risk matched study
H. Syed, London (GB) |
| A0151 | Management, surveillance patterns, and costs associated with low-grade Papillary (Ta) non-muscle invasive bladder cancer |
| 12:47 - 13:01 | |
| Discussion | |
| Endoscopic management | |
| A0152 | Incidence of bladder cancer in neuro-urological patients in France: A nationwide study |
| A0153 | En-bloc versus conventional transurethral resection of bladder tumors: Single-center prospective randomized trial
A. Gallioi, Barcelona (ES) |
| A0154 | RE-TUR + BCG vs. upfront BCG in high-risk non-muscle invasive bladder cancer: A feasibility phase of a randomized controlled study |
| A0155 | Multicentre real world long-term outcomes in 2773 primary Non-Muscle Invasive Bladder Cancer (NMIBC) patients managed within the Scottish Bladder Cancer Quality Performance Indicator programme
P. Mariappan, Edinburgh (GB) |

A0156	Ceasing surveillance in low risk non-muscle invasive bladder cancer after only 12 months of being recurrence free is un-safe: A validation study from the Scottish bladder cancer Quality Performance Indicator (QPI) programme P. Mariappan, Edinburgh (GB)
A0158	The Paris system-based artificial intelligence algorithm for reporting urinary cytopathology: Clinical evaluation and assessment
13:15 - 13:29	Discussion
	Adjuvant treatment
A0159	Long-term prospective results of the Spanish multicentre experience using recirculant hyperthermic MMC with Combat BRS HIVEC system F. Guerrero-Ramos, Madrid (ES)
A0160	Global variation in quality of transurethral resection of bladder surgery, results from the RESECT study K.M. Gallagher, Edinburgh (GB)
A0161	A phase I study of intravesical camrelizumab for BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC)
A0162	Local bladder hyperthermia with concomitant intravesical instillation of Mytomycin C (Synergo®Rite) in patients with non-muscle invasive bladder cancer (NMIBC). The long-term experience of a single center
A0163	Compared Efficacy of Adjuvant Intravesical BCG TICE vs. RIVM for High-risk Non-muscle Invasive Bladder Cancer: A Multicenter Propensity Score Matched Analysis F. Del Giudice, Rome (IT)
A0164	Clinical presentation of Bacille Calmette-Guérin (BCG) infections following BCG instillation therapy of non-muscle invasive Bladder Cancer P. Nurminen, Turku (FI)
13:41 - 13:55	Discussion
13:55 - 14:00	Closing remarks

Robot renal surgery

ESU Course 05

Friday 1 July
12:30 - 15:30

Location Grey Area, Room G107

Chair B.J. Challacombe, London (GB)

Learning objectives

This course will cover all principal indications for robotic surgery of the upper urinary tract. The standard techniques will be explained on a video-based fashion and will be followed by discussing advanced cases as well as troubleshooting and complication management. On top of that, technical innovations and new applications will be discussed as well.

Don't miss this course, a must for all robotic surgeons!:

- Video based step-by-step approach.
- Standard techniques.
- Complex cases.
- Troubleshooting and complication management.
- Technical innovations: What's new in robotics?

Introduction

B.J. Challacombe, London (GB)

Patient positioning, trocar positioning, trans- and retroperitoneal access in renal robotic surgery

B.J. Challacombe, London (GB)

Robotic pyeloplasty: Multichannel or single technique

N.M. Buffi, Milan (IT)

Renal surgery: Nephrectomy and nephroureterectomy: How I do it

B.J. Challacombe, London (GB)

Partial nephrectomy I: Step 1: Isolation of renal hilum; Step 2: Mobilisation of the kidney; Step 3: Clamping of renal pedicle: Different techniques

N.M. Buffi, Milan (IT)

Partial nephrectomy II: Step 4: Different tumour resection techniques

R. De Groote, Gent (BE)

Partial nephrectomy III: Step 5: Different renography techniques

B.J. Challacombe, London (GB)

Partial nephrectomy IV: Special and difficult indications

R. De Groote, Gent (BE)

Partial nephrectomy V: Complication management and new tools

R. De Groote, Gent (BE)

Wrap up and conclusions

B.J. Challacombe, London (GB)

Lower urinary tract dysfunction and urodynamics

ESU Course 04

Friday 1 July
14:30 - 17:30

Location Grey Area, Room G106

Chair H. Hashim, Bristol (GB)

Learning objectives

Having attended the course, the attendee should:

- Understand the basic physical principles referable to urodynamics.
- Be able to assess the quality of a urodynamic trace.
- Recognise common artefacts and know how to correct them.
- Know the indications for urodynamic studies in men, women and neurological patients.

Urodynamics: Philosophy, scientific basis and technique

H. Hashim, Bristol (GB)

Urodynamics in men

V. Phé, Paris (FR)

Urodynamics in female urology

H. Hashim, Bristol (GB)

Urodynamics in neurourology

V. Phé, Paris (FR)

Joint Session of the European Association of Urology (EAU) and the World Chinese Urologists

Urology beyond Europe

Friday 1 July
13:15 - 15:45

Location Green Area, Room 2

Chairs H. Van Poppel, Leuven (BE)
H. Wang, Kaohsiung (TW)
L-P. Xie, Hangzhou (CN)

This session will be pre-recorded. It will be shown in the session room at EAU22 and it will be available On Demand on the EAU22 Virtual Platform as of 1 July, 8:30 CEST

Learning objectives

In this Joint session EAU-CUA-TUA, the world Chinese urologists and the EAU faculty will highlight the relevance of involvement of the patients in our scientific endeavors, discuss the progress made in early detection and the emergence of radioligand therapies in advanced prostate cancer. It will be shown what the new way of learning urological surgery is, that today relies on laparoscopic and robot assisted procedures for prostate and kidney cancer. Concerning renal cancer the place of cytoreductive nephrectomy and the progress in medical treatments of advanced disease will be presented. Finally there will be an update in functional urology, on andrology, urethral strictures and female urology.

13:15 - 13:18

Welcome and introduction

To be confirmed

13:18 - 13:47

Patient affairs

13:18 - 13:26

EAU Patient Information Initiative

E. Rogers, Renmore, Galway (IE)

13:26 - 13:34

Where are we with patient involvement?

To be confirmed

13:34 - 13:42

How can we improve patient empowerment?

To be confirmed

13:42 - 13:47

Discussion

13:47 - 14:16

Prostate cancer

13:47 - 13:55

Organised early detection is urgently needed

M.J. Roobol, Rotterdam (NL)

13:55 - 14:03

Prostate cancer consortium?

Q. Wei, Chengdu (CN)

14:03 - 14:11

Radioligand therapies, a promising newcomer?

To be confirmed

14:11 - 14:16

Discussion

14:16 - 14:45

Laparoscopy - Endourology - Robotic

14:16 - 14:24

ORSI: Does the ideal training facility exist?

To be confirmed

Scientific Programme - EAU22 Amsterdam

14:24 - 14:32	Robot: The sky is the limit! S. Ren, Shanghai (CN)
14:32 - 14:40	Is pure laparoscopy out? To be confirmed
14:40 - 14:45	Discussion
14:45 - 15:14	Functional urology
14:45 - 14:53	Complex urethral strictures: An every day job for a happy few? C.R. Chapple, Sheffield (GB)
14:53 - 15:01	Female? To be confirmed
15:01 - 15:09	Andrology? To be confirmed
15:09 - 15:14	Discussion
15:14 - 15:38	Kidney cancer
15:14 - 15:22	Open surgery has still a place in partial nephrectomy U. Capitanio, Milan (IT)
15:22 - 15:30	Cytoreductive nephrectomy in ImmunOnco era: In or out? M. Liu, Beijing (CN)
15:30 - 15:38	State of the art M+ medical treatment and sequencing? To be confirmed
15:38 - 15:43	Discussion
15:43 - 15:45	Conclusion

Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU)

Urology beyond Europe

Friday 1 July
13:15 - 15:45

Location Green Area, Room 1

Chairs A.R. Rodriguez, Rochester (US)
A. Stenzl, Tübingen (DE)

Learning objectives

The aim of this session is to show the possibly varying strategies for clinical scenarios in Europe and Latin America. The scenarios include case based debates and state of the art lectures in the field of non muscle invasive bladder cancer, upper tract urothelial cancer, recurrent presumably localised as well as oligometastatic prostate cancer, treatment options for benign prostatic enlargement and endoscopic access variations of upper tract stone treatment. All these topics will be presented and discussed by recognised expert representatives from both EAU and CAU.

Attendees will be confronted and thus be able to learn updates on the diagnosis and management.

13:15 - 13:20

Welcome and introduction

13:20 - 13:33

Case-based debate Current options in high risk NMIBC

13:20 - 13:23

Case presentation
G.M. Villoldo, Buenos Aires (AR)

13:23 - 13:28

Early cystectomy
J. Palou, Barcelona (ES)

13:28 - 13:33

Bladder preservation
To be confirmed

13:33 - 13:43

Trimodality therapy for MIBC: Present and future directions
J.A. Witjes, Nijmegen (NL)

13:43 - 13:48

Discussion

13:48 - 13:58

Update on kidney sparing management for UTUC
M. Rouprêt, Paris (FR)

13:58 - 14:08

Update on management of small renal masses
A.R. Rodriguez, Rochester (US)

14:08 - 14:13

Discussion

14:13 - 14:38

Radiotherapy after prostate cancer surgery

14:13 - 14:23

Pro adjuvant
To be confirmed

14:23 - 14:33

Pro early salvage
A. Bossi, Villejuif (FR)

Scientific Programme - EAU22 Amsterdam

14:33 - 14:38	Discussion
14:38 - 14:56	Case-base debate Oligometastatic prostate cancer in a fit patient
14:38 - 14:41	Case presentation A. Stenzl, Tübingen (DE)
14:41 - 14:46	Surgery R. Sanchez-Salas, Montreal (CA)
14:46 - 14:51	No surgery J. Bedke, Tübingen (DE)
14:51 - 14:56	Discussion
14:56 - 15:06	Advances in flexible ureteroscopy: Tips and tricks O. Traxer, Paris (FR)
15:06 - 15:16	Percutaneous nephrolithotomy: Update, trends and future directions N. Bernardo, Buenos Aires (AR)
15:16 - 15:21	Discussion
15:21 - 15:39	Case-based debate Urinary retention in 150 ml BPH: Options?
15:21 - 15:24	Case presentation A.R. Rodriguez, Rochester (US)
15:24 - 15:29	Bipolar D. Moser, São Paulo (BR)
15:29 - 15:34	Laser C. Gratzke, Freiburg (DE)
15:34 - 15:39	Laparoscopic/Robotic S. Guzmán, Santiago (CL)
15:39 - 15:45	Closing remarks
15:39 - 15:45	A.R. Rodriguez, Rochester (US)
15:39 - 15:45	A. Stenzl, Tübingen (DE)

Joint Session of the European Association of Urology (EAU) and the Arab Association of Urology (AAU)

Urology beyond Europe

Friday 1 July
13:15 - 15:45

Location	Green Area, Room 3
Chairs	Y. Farahat, Umm Al Quwain (AE) J.O.R. Sønksen, Herlev (DK)
Panel	A.A. Al-Zarooni, Sharjah (AE) A.R. Hammady, Sohag (EG) P.J.S. Osther, Fredericia (DK) To be confirmed S. Gravas, Larissa (GR) N. Ramadan, Amdurman (SD) To be confirmed N. Al-Hamdani, Baghdad (IQ) M.J. Ribal Caparros, Barcelona (ES)

Learning objectives

Leading experts from the Arab Association of Urology and European Association of Urology will present updates and discuss clinical challenges in urolithiasis, BPH and non-muscle invasive bladder cancer followed by an expert panel discussion led by key opinion leaders. After each sub session there will be active involvement with the audience through Q&A.

13:15 - 13:16	Introduction
13:15 - 13:16	Y. Farahat, Umm Al Quwain (AE)
13:15 - 13:16	J.O.R. Sønksen, Herlev (DK)
13:16 - 14:05	Urolithiasis
13:16 - 13:25	Asymptomatic lower calyceal stone management: Doctor or patient decision P.J.S. Osther, Fredericia (DK)
13:25 - 13:34	Fragments clearance after Miniperc: Tips and tricks U. Nagele, Hall in Tirol (AT)
13:34 - 13:43	Single use flexible ureteroscopy: Is it the way to go? Y. Farahat, Umm Al Quwain (AE)
13:43 - 13:52	PCNL in difficult renal anatomy M. Lezrek, Meknes (MA)
13:52 - 14:00	Expert discussion
14:00 - 14:05	Questions and answers
14:05 - 14:54	BPH
14:05 - 14:14	Male LUTS/BPE - Contemporary management and updates To be confirmed

Scientific Programme - EAU22 Amsterdam

14:14 - 14:23	Thulium laser enucleation of the prostate: Efficient or style? T. Bach, Hamburg (DE)
14:23 - 14:32	Robotic assisted simple prostatectomy: Is it an option in the era of laser? R.A. Azhar, Jeddah (SA)
14:32 - 14:41	Water vapor therapy of the prostate: Patient or commercial benefit? T.R.W. Herrmann, Frauenfeld (CH)
14:41 - 14:49	Expert discussion
14:49 - 14:54	Questions and answers
14:54 - 15:43	NMIBC
14:54 - 15:03	En bloc resection vs. TUR for nonmuscle invasive bladder cancer efficacy from the oncological point of view J. Bjerggaard Jensen, Aarhus (DK)
15:03 - 15:12	Intravesical chemotherapy for the NMIBC: An update S. Shariat, Vienna (AT)
15:12 - 15:21	Open radical cystectomy in NMIBC: Is it the final destination? To be confirmed
15:21 - 15:30	BCG unresponsive, non-muscle invasive bladder cancer M. Bulbul, Riad El Solh - Beirut (LB)
15:30 - 15:38	Expert discussion and questions and answers
15:38 - 15:43	Questions and answers
15:43 - 15:45	Closing remarks
15:43 - 15:45	Y. Farahat, Umm Al Quwain (AE)
15:43 - 15:45	J.O.R. Sønksen, Herlev (DK)

Joint Session of the European Association of Urology (EAU) and the Maghreb Union countries

Urology beyond Europe

Friday 1 July
13:15 - 15:45

Location Grey Area, Room Emerald

Chairs R. El Kamel, Kairouan (TN)
J. Rassweiler, Heilbronn (DE)

Moderators To be confirmed
F. Cruz, Porto (PT)
M. Ghadouane, Rabat (MA)
A.S. Zribi, Tunis (TN)
To be confirmed
A. Belkacem Nacer, Algiers (DZ)
A. Volpe, Novara (IT)
A.S. Zribi, Tunis (TN)
To be confirmed
M. Harouni, Oran (DZ)
To be confirmed
M. Rouprêt, Paris (FR)

Learning objectives

This session features key opinions leaders from both sides of the Mediterranean Sea. Thanks to the strong personal relationships established along the years between the members of the National Associations of Urology of the Maghreb and of the EAU, this joint session has become essential for those interested in state-of-the-art lectures and practice-oriented discussions.

Participants can expect an update on the most recent advances on timely topics, such as the surgical management of large volume BPH, the management of storage LUTS in BPH and the diagnostic and treatment of small renal masses. The session will also include oncology interactive case discussion.

13:15 - 13:20

Welcome and introduction
A.S. Zribi, Tunis (TN)

BPH management in Maghreb countries

13:20 - 13:50

Surgical management of large volume BPH

13:20 - 13:22

Case presentation
I. Ziouziou, Agadir (MA)

13:22 - 13:29

Laser endoscopic enucleation
O. Kammoun, sfax (TN)

13:29 - 13:36

Bipolar endoscopic enucleation
To be confirmed

13:36 - 13:43

Let's keep simple prostatectomy!
K. Benakila, Alger (DZ)

13:43 - 13:50

Summary of guidelines
To be confirmed

Scientific Programme - EAU22 Amsterdam

13:50 - 14:20	Interactive case discussion: Management of storage LUTS in BPH
13:50 - 13:52	Case presentation To be confirmed
13:52 - 14:02	Results of medical treatments K. Hachi, Alger (DZ)
14:02 - 14:12	Results of surgery To be confirmed
14:12 - 14:20	Urodynamics: When and why? J.P.F.A. Heesakkers, Maastricht (NL)
	Challenges in management of small renal masses
14:20 - 14:30	Update on imaging of small renal masses To be confirmed
14:30 - 14:40	Biopsy or not biopsy? To be confirmed
14:40 - 14:55	Partial nephrectomy: Open vs. minimally invasive
14:40 - 14:45	What about evidence-based medicine? S. Bouras, Setif (DZ)
14:45 - 14:50	What about guidelines? M. Mrabti, Rabat (MA)
14:50 - 14:55	What about real life practice in Maghreb Union countries? To be confirmed
14:55 - 15:05	Management of small renal masses in elderly
14:55 - 15:00	Ablative therapy E. Barret, Paris (FR)
15:00 - 15:05	Active surveillance To be confirmed
	Interactive clinical case discussion
15:05 - 15:11	Case presentation Locally advanced prostate cancer M. Ghadouane, Rabat (MA)
15:11 - 15:17	Discussion
15:17 - 15:23	Case presentation Testicular seminoma M. Raboudi, Tunis (TN)
15:23 - 15:29	Discussion
15:29 - 15:35	Case presentation Challenging case of UTUC S. Kerroumi, Oran (DZ)

Scientific Programme - EAU22 Amsterdam

15:35 - 15:41

Discussion

15:41 - 15:45

Conclusion

J. Rassweiler, Heilbronn (DE)

Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA)

Urology beyond Europe

Friday 1 July
13:15 - 15:45

Location	Yellow Area, Room E102
Chairs	S.K. Hong, Seongnam (KR) A.S. Merseburger, Lübeck (DE)
Moderators	H.J. Ahn, Seoul (KR) M.C. Mir Maresma, Valencia (ES) J-N.L. Cornu, Rouen (FR) S-D. Lee, Busan (KR) To be confirmed A.S. Merseburger, Lübeck (DE)
Panel	To be confirmed To be confirmed B.S. Kim, Daegu (KR) E. Laukhtina, Vienna (AT) M.C. Roesch, Lübeck (DE) R. Dasgupta, London (GB) F. Fusco, Naples (IT) K.J. Ko, Seoul (KR) J.K. Oh, Incheon (KR) H.C. Son, Seoul (KR) To be confirmed U-S. Ha, Seoul (KR) Y.H. Ko, Daegu (KR) L-M. Krabbe, Münster (DE)

Learning objectives

This session will address a variety of hot urology topics with the help of specialists and key opinion leaders from South Korea and Europe. Delegates can expect detailed and up-to-date coverage of topics of urothelial cancer, voiding dysfunction and LUTS/BPH and prostate cancer.

In this session some of the regional similarities and differences in approaches will be explored.

13:15 - 13:20	Welcome and introduction
13:15 - 13:20	EAU C.R. Chapple, Sheffield (GB)
13:15 - 13:20	S-D. Lee, Busan (KR)
13:20 - 14:07	Urothelial cancer
13:20 - 13:30	Innovative therapies of bladder preservation strategy for BCG-unresponsive, non-muscle invasive bladder cancer M.C. Roesch, Lübeck (DE)
13:30 - 13:40	What is the optimal future therapy for bladder preservation in muscle invasive bladder cancer? New and updated protocol and outcome S.C. Lee, Seongnam (KR)

13:40 - 13:50	Role of definite local treatment after complete response to neoadjuvant chemotherapy in muscle invasive bladder cancer To be confirmed
13:50 - 14:07	Panel discussion
14:07 - 14:54	Voiding dysfunction, LUTS/BPH
14:07 - 14:17	Autonomic dysfunction in patients with urgency other than overactive bladder A.R. Kim, Seoul (KR)
14:17 - 14:27	How to manage distinguishing symptoms of female bladder outlet obstruction accompanied with interstitial cystitis/bladder painful syndrome (IC/BPS)? S. Goonewardene, Sutton Coldfield (GB)
14:27 - 14:37	Robot-assisted sacrohysteropexy: Surgical technique and management of complications R.G. Bertolo, Torino (IT)
14:37 - 14:54	Panel discussion
14:54 - 15:41	Prostate cancer
14:54 - 15:04	The impact of PSMA PET CT on therapeutic strategies in metastatic prostate cancer B.A. Hadaschik, Essen (DE)
15:04 - 15:14	How to follow up and when to stop the active surveillance: Does the prostate MRI and its targeted biopsy give better prognostic outcome for patients with active surveillance? S-W. Park, Busan (KR)
15:14 - 15:24	What therapeutic shift of indications might be in advanced prostate cancer with secondary hormone therapy? J.W. Park, Seoul (KR)
15:24 - 15:41	Panel discussion
15:41 - 15:45	Closing remarks

Joint Session of the European Association of Urology (EAU) and the Caucasus/Central Asian countries

Urology beyond Europe

Friday 1 July
13:15 - 15:45

Location Grey Area, Room G102

Chairs M. Babjuk, Prague (CZ)
D. Nikoleishvili, Tbilisi (GE)

Moderators P.L. Chlosta, Cracow (PL)
F. Guliyev, Baku (AZ)
Z. Tchanturaia, Tbilisi (GE)
H.G. Van Der Poel, Amsterdam (NL)
To be confirmed
To be confirmed
M. Babjuk, Prague (CZ)
D. Yunusov, Tashkent (UZ)

Learning objectives

This session serves to exchange knowledge between the EAU and neighbouring regions in the Caucasus and Central Asia. Presentations will address current approach to the diagnosis and treatment of urological tumours, particularly prostate, renal and urothelial carcinoma. Lectures will be presented by top experts from participating countries. They will offer a medium for discussions and exchange of experience.

13:15 - 13:20

Welcome and introduction

13:15 - 13:20

M. Babjuk, Prague (CZ)

13:15 - 13:20

D. Nikoleishvili, Tbilisi (GE)

13:20 - 14:00

Subsession 1

13:20 - 13:30

Indication and extent of LND during radical prostatectomy in 2022 – European approach
H.G. Van Der Poel, Amsterdam (NL)

13:30 - 13:40

Laparoscopic en bloc extended pelvic lymph node dissection in prostate cancer: How we do it
To be confirmed

13:50 - 14:00

Laparoscopic partial nephrectomy: Our initial results of 100 cases
B. Ayubov, Tashkent (UZ)

14:00 - 14:06

Discussion

14:06 - 14:46

Subsession 2

14:06 - 14:16

How to do a good TURB?
M. Babjuk, Prague (CZ)

14:16 - 14:26

Photodynamic therapy in the treatment of non-invasive bladder cancer. First experience in Kazakhstan
To be confirmed

Scientific Programme - EAU22 Amsterdam

14:26 - 14:36	Our initial experience of endoscopic management (percutaneous, ureteroscopic, endoscopic combined) of low risk UTUC A. Tursunkulov, Tashkent (UZ)
14:46 - 14:52	Discussion
14:52 - 15:32	Subsession 3
14:52 - 15:02	Nephron sparing surgery for T2 RCC – Indication and approach P.L. Chlosta, Cracow (PL)
15:02 - 15:12	Laparoscopic ureterolithomy for the treatment of large upper and middle ureter stones R. Naghiyev, Baku (AZ)
15:12 - 15:22	The treatment of NMIBC with bipolar TUR-B, Turkmenistan experience D. Nikoleishvili, Tbilisi (GE)
15:22 - 15:32	Our experience of cryodestruction of small renal tumours S. Kussymzhanov, Almaty (KZ)
15:32 - 15:38	Discussion
15:38 - 15:43	Conclusion
15:38 - 15:43	M. Babjuk, Prague (CZ)
15:38 - 15:43	D. Nikoleishvili, Tbilisi (GE)

Joint Session of the European Association of Urology (EAU) and the Canadian Urological Association (CUA)

Urology beyond Europe

Friday 1 July
13:15 - 15:45

Location Grey Area, Room G103

Chairs P. Albers, Düsseldorf (DE)
R.A. Rendon, Halifax (CA)

Moderators J-N.L. Cornu, Rouen (FR)
C.V. Kesch, Essen (DE)
H. Razvi, London, Ontario (CA)
P. Black, Vancouver (CA)

Learning objectives

For the second time the Canadian Urological Association (CUA) is joining the Urology Beyond Europe sessions at the Annual EAU Congress!

The session is organised in four parts, covering non-oncology (BPH, stones) and oncology issues (prostate cancer imaging, advanced bladder cancer perioperative treatment). Canadian and European expert speakers will update their experience and discuss newest developments, always taking patients' perspectives into account.

13:15 - 13:20	Welcome and introduction
13:15 - 13:20	J-N.L. Cornu, Rouen (FR)
13:15 - 13:20	R.A. Rendon, Halifax (CA)
13:20 - 13:50	Made to measure. How to decide which surgical option is best for large volume prostate glands – a patient-centered approach
13:20 - 13:30	CUA Lecture N. Bhojani, Montreal (CA)
13:30 - 13:40	EAU lecture T.R.W. Herrmann, Frauenfeld (CH)
13:40 - 13:50	Discussion
13:50 - 14:20	Modern imaging of prostate cancer: Microultrasound vs. MRI
13:50 - 14:00	CUA lecture R. Sanchez-Salas, Montreal (CA)
14:00 - 14:10	EAU lecture J.P. Radtke, Düsseldorf (DE)
14:10 - 14:20	Discussion
14:20 - 14:50	Case-based discussion Contemporary PCNL: Options for gaining renal access
14:20 - 14:30	CUA lecture N. Bhojani, Montreal (CA)

Scientific Programme - EAU22 Amsterdam

14:30 - 14:40	EAU lecture T. Taily, Ghent (BE)
14:40 - 14:50	Discussion
14:50 - 15:20	Perioperative systemic treatment of bladder cancer: Is ctDNA already standard for prediction?
14:50 - 15:00	Yes! G. Vandekerkhove, Vancouver (CA)
15:00 - 15:10	No! To be confirmed
15:10 - 15:20	Discussion
15:20 - 15:40	State-of-the-art lecture How patients should nowadays be involved in treatment decisions M. Jewett, Toronto (CA)
15:40 - 15:45	Conclusion P. Albers, Düsseldorf (DE)

Active surveillance for intermediate risk prostate cancer: What urologist and patients should know

Special Session

Friday 1 July
14:00 - 16:00

Location Grey Area, eURO Auditorium 2

Chairs A. Villers, Lille (FR)
J. Walz, Marseille (FR)

Discussants M.R. Cooperberg, San Francisco (US)
L.G. Gomella, Philadelphia (US)
F. Preisser, Frankfurt Am Main (DE)

Learning objectives

This session will address the current incidence trends of intermediate-risk low percentage of grade 4, low volume cancers. What is their place in active surveillance? How to deal with MRI visible lesions? How to use PSA kinetics, new biomarkers, and genomics at inclusion and during follow-up? Finally, is it safe? Shared decision making and patient information should be adequate.

14:00 - 14:10

Risk classification and intermediate risk prostate cancer: Challenging the guidelines

F. Preisser, Frankfurt Am Main (DE)

14:10 - 14:20

Less overdiagnosis of low risk PCa means mainly intermediate risks for AS: Dream or reality

M.J. Roobol, Rotterdam (NL)

14:20 - 14:30

Patient information and potential risk for metastatic progression during AS for intermediate risks

L.G. Gomella, Philadelphia (US)

14:30 - 14:50

Panel discussion A trend over time towards including more intermediate risks in AS?

14:30 - 14:35

Case presentation

G. Marra, Turin (IT)

14:35 - 14:50

Discussion

14:50 - 15:00

Does MRI visible lesion is intermediate risk PCa?

C. Moore, London (GB)

15:00 - 15:20

Debate MRI for tailoring the need for biopsy: Is it reliable?

15:00 - 15:10

Yes

A. Padhani, Northwood (GB)

15:10 - 15:20

No

To be confirmed

15:20 - 15:30

Genomics, PSAD and PSAV: Good predictors of biopsy reclassification?

M.R. Cooperberg, San Francisco (US)

15:30 - 15:40

How to personalise biopsy schedules during AS

A.S. Bjartell, Malmö (SE)

Scientific Programme - EAU22 Amsterdam

15:40 - 15:50

PSA Kinetics in practice: What urologist and patients should know

A.S. Rannikko, Helsinki (FI)

15:50 - 16:00

Is it safe to offer AS for intermediate risk: Midterm outcomes

J. Rubio Briones, Valencia (ES)

Searching the evidence in urology: Systematic reviews and meta-analysis

Abstract Session 10

Friday 1 July
14:15 - 15:45

Location Green Area, Room 4
Chairs S. Canfield, Houston (US)
K.A.O. Tikkinen, Helsinki (FI)
To be confirmed

14:15 - 14:18

Introduction

Prostate cancer

A0165

Does size matter? Extension of positive surgical margins after radical prostatectomy – a systematic review and meta-analysis
A. John, Hilton (AU)

14:20 - 14:23

Discussion

Andrology - Penile - Testis

A0166

The role of conservative combination therapies for active and stable Peyronie's disease: A systematic review and meta-analysis
N. Pyrgidis, Nuremberg (DE)

A0167

Does testicular sperm extraction improve ICSI outcomes in non-azoospermic infertile men with raised sperm DNA fragmentation: A systematic review and meta-analysis
A.A. Cayetano Alcaraz, London (GB)

14:27 - 14:33

Discussion

LUTS

A0168

The complications of synthetic mid-urethral slings: The discrepancy between demographic data and clinical trials- a systematic review with meta-analysis
F. Farag, Ipswich (GB)

A0169

The beneficial effects of alpha-blockers, antimuscarinics, beta 3-agonist and PDE5-inhibitors for ureteral stent-related discomfort: A systematic review and meta-analysis from KSER update series

A0170

Safety and feasibility of outpatient surgery in benign prostatic hyperplasia: A systematic review and meta-analysis
F. Del Giudice, Rome (IT)

A0171

Placebo response is up to four times more in conventional drugs compared to herbal medicine in male LUTS: A systematic review and meta-analysis

A0172

Desmopressin is twice effective in females: A systematic review and meta-analysis on medical treatment of nocturia

Scientific Programme - EAU22 Amsterdam

A0173	<p>Comparison of the efficacy and safety of minimally invasive simple prostatectomy and endoscopic enucleation of prostate for large benign prostatic hyperplasia: A systematic review and meta-analysis</p> <p>L. Jinze, Chengdu (CN)</p>
A0175	<p>Urethral stricture following endoscopic prostate surgery: A systematic review and meta-analysis of prospective, randomized trials</p>
14:49 - 15:05	<p>Discussion</p>
	<p>Bladder cancer</p>
A0176	<p>Comparison of maintenance of intravesical BCG therapy between 1 year and more than 1 year therapies for recurrence rate in high-risk NMIBC: Systematic review and network meta-analysis according to EAU COVID-19 recommendation</p>
A0177	<p>Concomitant endoscopic surgery for bladder tumors and prostatic obstruction; safely hitting two birds with one stone? A systematic review and meta-analysis</p> <p>N. Pyrgidis, Nuremberg (DE)</p>
15:09 - 15:15	<p>Discussion</p>
	<p>Functional urology</p>
A0179	<p>Risk factors for urethral stricture or bladder neck contracture after transurethral resection of the prostate: A Systematic Review and Meta-Analysis</p> <p>Z. Shiyu, Chengdu (CN)</p>
15:19 - 15:25	<p>Discussion</p>
	<p>Stones</p>
A0180	<p>Role of pre-operative ureteral stent on outcomes of Retrograde Intra Renal Surgery (RIRS): Systematic review and meta-analysis of 3219 patients and comparison of Asian and non-Asian cohorts</p> <p>Y.X.T. Law, Singapore (SG)</p>
15:27 - 15:30	<p>Discussion</p>
	<p>Reconstructive/urological trauma surgery</p>
A0181	<p>Prevention and detection of iatrogenic ureteral injury during abdominal or pelvic surgery: A systematic review and meta-analysis</p> <p>T. Yanagiswawa, Tokyo (JP)</p>
A0182	<p>A systematic review of bladder and ureteric injury during caesarean section and hysterectomy: Incidence, risk factors and prevention</p>
15:34 - 15:40	<p>Discussion</p>
15:40 - 15:45	<p>Closing remarks</p>

New techniques in penile cancer and urethral surgery

Video Session 3

Friday 1 July
14:15 - 15:45

Location Purple Area, Room Elicium 2

Chairs F. Campos Juanatey, Santander (ES)
M. Falcone, Torino (IT)
S.C. Morgenstern, Frankfurt am Main (DE)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

14:15 - 14:18

Introduction

V16

New surgical technique: A single long spiral preputial graft for panurethral stricture

S. Kulkarni, Pune (IN)

V17

Technique of Inner preputial graft urethroplasty: Feasibility, advantages and long-term outcomes

S. Tyagi, Hapur (IN)

V18

Dynamic sentinel lymph node biopsy for penile cancer: Accuracy is in the technique

J. O'Brien, East Melbourne (AU)

V19

Video-endoscopic inguinal lymphadenectomy (VEIL) in penile cancer: Step by step surgical procedure

V20

Robot-assisted video-endoscopic radical inguinal lymphadenectomy for penile cancer: surgical anatomy and technique

A. Brassetti, Rome (IT)

V21

Fluorescence image guidance in robotic inguinal dissection

V22

Robot-assisted videoendoscopic inguinal lymphadenectomy: Our experience from a tertiary care center

S. Tyagi, Hapur (IN)

15:33 - 15:38

Closing remarks

Localised kidney cancer: Treatment outcomes and complications

Abstract Session 08

Friday 1 July 12:30 - 14:00	Location	Orange Area, Room 2
	Chairs	To be confirmed P.L. Chlosta, Cracow (PL) A. Minervini, Florence (IT)
12:30 - 12:34	Introduction	
	Outcomes	
A0125	Impact of surgical experience prior to robot-assisted partial nephrectomy on surgical outcomes: Large multicenter analysis with 2,500 patients P. Zeuschner, Homburg (DE)	
A0126	Does the surgical technique impact the oncologic outcomes after partial nephrectomy? A comparison between open, laparoscopic and robotic approach in a single high-volume tertiary center P. Piazza, Bologna (IT)	
A0127	The learning curve of radical nephrectomy for kidney cancer: Implications for surgical training F. Belladelli, Milan (IT)	
12:40 - 12:50	Discussion	
	Renal function	
A0128	New onset end stage renal disease after treatment of renal cell carcinoma S. Lundstam, Göteborg (SE)	
A0129	Real-time Estimation of Nephron Activity with a Linear Measurement System (RENAL-MS) obviates the need for nuclear medicine scans to predict estimated glomerular filtration rate after nephrectomy	
A0130	Renal scintigram assessment of the residual renal function following partial nephrectomy and embolization of postoperative pseudoaneurysm or arteriovenous fistula: A single center series G. Novara, Padova (IT)	
A0131	Assessment of changes in arterial blood pressure after nephrectomy for kidney cancer: VAPANCER (UroCCR 26)_prospective study	
A0132	Renal functional and cardiovascular outcomes of partial nephrectomy versus radical nephrectomy for renal tumors: A systematic review and meta-analysis R. Pallares-Mendez, Monterrey Nuevo Leon (MX)	
A0133	Risks assessment of significant renal function deterioration after partial nephrectomy and call for reconsidering the imperative setting	
A0134	Assessing the effect of red blood cell transfusion on the risk of acute kidney injury after nephron-sparing surgery	

Scientific Programme - EAU22 Amsterdam

13:04 - 13:14	Discussion
	Clinical practice
A0135	Disparities in cancer-specific mortality between Asian and Caucasian patients with non-metastatic renal cell carcinoma: Analysis of the INMARC registry H. Tanaka, Tokyo (JP)
A0136	Neglected lymph nodal metastases in patients with renal cancer: When to extend the anatomical template of lymph node dissection during nephrectomy G. Rosiello, Bacoli (IT)
A0137	The role of lymph node dissection for non-metastatic renal cell carcinoma: an updated systematic review and meta-analysis S. Xu, Chengdu (CN)
A0138	Practice-level variation in rates positive surgical margins at partial nephrectomy: A music-kidney analysis
A0139	Clinical outcomes of patients with renal cell carcinoma and imperative indication to become anephric: Implications for multidisciplinary board evaluation
13:24 - 13:34	Discussion
	Miscellaneous
A0140	When to de-intensify oncologic surveillance scheme for non-clear cell renal cell carcinoma
A0141	Impact of renal cell carcinoma histological variants on recurrence after partial nephrectomy: A multi-institutional, prospective study (UROCCR study 82) T. Tabourin, ()
A0142	Evaluation of an uncomplicated recovery after nephrectomy: MUSIC-KIDNEY NOTES (Notable Outcomes and Trackable Events after Surgery)
A0143	Positive surgical margins after Robot-Assisted Partial Nephrectomy (RAPN): Does it really matter? (MARGINS Study – UroCCR 96)
A0144	Reducing post-operative emergency department visits and readmissions after nephrectomy: An initial evaluation of the MUSIC-KIDNEY registry
13:44 - 13:54	Discussion
13:54 - 14:00	Closing remarks

Localised kidney cancer: Alternative treatments in special situations

Abstract Session 12

Friday 1 July
14:15 - 15:45

Location Orange Area, Room 2
Chairs V. Gomez Dos Santos, Madrid (ES)
T. Kuusk, London (GB)
To be confirmed

14:15 - 14:18

Introduction

Body mass

A0205 **The detrimental effect of frailty status on renal function recovery after partial nephrectomy – long-term results from a prospective surgical cohort**
G. Rosiello, Bacoli (IT)

A0206 **Body mass index, obesity and acute kidney injury after robot-assisted partial nephrectomy: Results from a high-volume robotic center**
M. Paciotti, Rozzano, Milan (IT)

A0207 **Impact of obesity in the management of kidney cancer, study URO-CCR n°87**

A0208 **Should Body Mass Index (BMI) be included in patients selection in those undergoing robotic partial nephrectomy?**
Y. Abu Ghanem, Ramat Gan (IL)

14:26 - 14:36

Discussion

Toxic fat

A0209 **The relationship between adherent perinephric fat and the Mayo Adhesive Probability (MAP) score and post-operative functional outcomes in patients subjected to robot-assisted partial nephrectomy**
P. Diana, Rozzano, Milan (IT)

A0210 **Perinephric toxic fat: Impact on surgical complexity, perioperative outcome and surgical approach in partial nephrectomy**
N.N. Harke, Hannover (DE)

A0211 **The relationship between adherent perinephric fat and sex hormone levels in serum and perinephric fat tissue of patients treated by robotic assisted partial nephrectomy**
Y. Miyazawa, Maebashi, Gunma (JP)

14:42 - 14:52

Discussion

Ablative treatment

A0212 **The role of percutaneous renal tumor biopsy in frail patients with indeterminate small renal masses**

A0213 **Can ablation therapy be an alternative treatment to partial nephrectomy for clinical T1b renal tumors?: A systematic review and meta-analysis**
T. Yanagisawa, Tokyo (JP)

Scientific Programme - EAU22 Amsterdam

A0214	Developing of a novel nephrometry score to predict the outcomes of percutaneous ablation of renal masses: The PCT score A. Uleri, Milan (IT)
A0215	Validation of the recommended size cut-off for thermal ablation in T1 renal cell carcinoma patients, according to the EAU Guidelines S. Luzzago, Brescia (IT)
A0216	Impact of partial nephrectomy and percutaneous cryoablation on short-term health-related quality of life – a prospective comparative cohort study
A0217	Percutaneous microwave ablation is comparable to cryoablation for the treatment of T1a renal masses: Results from a cross-sectional study G. Lucignani, Milan (IT)
A0218	Peri-operative complications in patients treated with thermal ablation for T1 renal cell tumors: Descriptive analysis and independent predictors S. Luzzago, Brescia (IT)
15:06 - 15:16	Discussion
	Miscellaneous
A0219	Assessing renal mass management of patients with increased comorbidities: Results from a statewide registry
A0220	Device-related complications during renal cryoablation: Insights from the manufacturer and user facility device experience (MAUDE) database Z.D. Michael, Durham (US)
A0221	Variation in the management of T1 renal cancer. A nationwide study in the Netherlands H. Yildirim, Amsterdam (NL)
A0222	Decision-making and management strategies for patients with bilateral synchronous non-metastatic renal masses: Insights from a multi-centre European dataset R. Campi, Florence (IT)
A0223	Systematic definition of treatment modality and clinical outcomes reporting system in case of surgical treatment for Von Hippel-Lindau renal cell carcinoma F. Belladelli, Milan (IT)
A0224	Natural history of renal angiomyolipomas in a tertiary center: Our experience during more than 15 years of follow-up A. Bravo-Balado, Barcelona (ES)
A0225	Management of renal cell carcinoma in transplant kidney: An individual patient data meta-analysis and evidence-based guide F. Crocerossa, Cosenza (IT)
15:30 - 15:40	Discussion
15:40 - 15:45	Closing remarks

NMIBC - Advancements in diagnostics, follow-up and treatment

Abstract Session 13

Friday 1 July
14:15 - 15:45

Location Yellow Area, Room Forum

Chairs B. Ali-El-Dein, Mansoura (EG)
S. Crabb, Southampton (GB)
J.A. Witjes, Nijmegen (NL)

14:15 - 14:18

Introduction

- | | |
|-----------------------|---|
| A0226 | The update from Bladder Cancer Italian Active Surveillance (BIAS) project for low-grade bladder tumors: Long-term oncological outcomes of patients under active surveillance |
| A0227 | Prognostic risk factors of grade and stage migration in patients under active surveillance: A prospective cohort study from Bladder cancer Italian Active Surveillance register (BIAS) |
| A0228 | A urine-based molecular assay refines the risk stratification of the recent American Urological Association guideline on hematuria |
| A0229 | [18F]-FDG PET/CT for bladder cancer staging and decision-making in patients with High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) |
| A0230 | Variability in diagnostic performance of non-muscle invasive bladder cancer for each region using fluorescence cystoscopy with orally administered 5-aminolevulinic acid |
| A0231 | Prospective validation of the ROL system in substaging pT1 high-grade bladder cancer: A confirmatory progression risk analysis to ease decision making |
|
 | |
| 14:30 - 14:40 | Discussion |
| A0232 | Development of novel stratification systems to guide treatment for NMIBC based on results from SIPRES study (multi-institutional prospective study) |
| A0233 | Accuracy of AUA and EAU risk stratification groups in predicting early recurrence in Hg Ta non-muscle invasive bladder cancer: A comparison analysis
R. Contieri, Pieve Emanuele (IT) |
| A0234 | Assessing the impact of BCG on progression of NMIBC in the new EAU high risk and very high-risk groups
P. Gontero, Turin (IT) |
| A0235 | Bladder biopsies to assess treatment response after intravesical Bacillus Calmette-Guerin induction cycle: Are they necessary?
G.M. Busetto, Rome (IT) |
| A0236 | Two-year follow-up after dose-dense chemoresection with mitomycin C compared with adjuvant instillations for recurrent NMIBC – a randomised controlled trial
M. Skydt Lindgren, Højbjerg (DK) |

Scientific Programme - EAU22 Amsterdam

A0237	A randomized study to compare outcomes of intravesical chemohyperthermia with mitomycin c vs. intravesical BCG for intermediate and high risk Non-Muscle Invasive Bladder Cancer (NMIBC) K. Guleria, (IN)
14:52 - 15:02	Discussion
A0238	Ferroptosis patterns and tumor microenvironment infiltration characterization in bladder cancer
A0239	Identification of specific miRNA signatures to detect a highly invasive phenotype of pT1G3 tumors of the bladder S. Rau, Homburg/Saar (DE)
A0240	Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA D.G. Ward, Birmingham (GB)
A0241	Urine cellular DNA point mutation and methylation as potential biomarkers for early detection of urothelial carcinoma L. Wang, Changsha (CN)
15:10 - 15:20	Discussion
A0242	Energy source comparison in en-bloc resection of bladder tumor: A step to energy indication P. Diana, Rozzano, Milan (IT)
A0244	Oncological and safety profiles in patients undergoing simultaneous transurethral resection of bladder tumor and prostate: Results from a large multicenter international collaboration E. Laukhtina, Vienna (AT)
A0245	Orally administered 5-aminolevulinic acid can cause intraoperative hypotension in patients with bladder cancer undergoing transurethral resection
A0246	Effectiveness of ultrasound-guided obturator nerve interfascial block with an inguinal approach during transurethral resection of bladder tumour: A prospective randomized double-blinded clinical trial
15:30 - 15:40	Discussion
15:40 - 15:45	Closing remarks

Advanced endourology in the non-standard patients with urolithiasis

ESU Course 06

Friday 1 July
14:30 - 17:30

Location Grey Area, Room G104

Chair G.M. Kamphuis, Amsterdam (NL)

Learning objectives

Discuss available literature and practical management options and examples treatment of urolithiasis in 'non-index' patients, covering:

- Horse shoe kidney, caliceal diverticula, duplicate urinary system.
- Pregnancy, complex metabolic patients.
- After bladder substitution/ileal conduit/reimplantation.
- In transplant kidneys and spinal malformation.

Introduction

G.M. Kamphuis, Amsterdam (NL)

Urolithiasis in urinary system anomalies: Horse shoe kidneys

E. Emiliani, Barcelona (ES)

Urolithiasis in urinary system anomalies: Calyceal diverticula stones

S. Doizi, Paris (FR)

Urolithiasis in pregnancy

G.M. Kamphuis, Amsterdam (NL)

Urolithiasis in urinary system anomalies: After bladder substitution/ ileal conduit/ ureteral reimplantation

E. Emiliani, Barcelona (ES)

Medullary sponge kidneys

S. Doizi, Paris (FR)

Urolithiasis in transplant kidneys

G.M. Kamphuis, Amsterdam (NL)

Urolithiasis in urinary system anomalies: Duplicate urinary system and ectopic kidney

S. Doizi, Paris (FR)

Bilateral stone treatment; do's and don'ts

E. Emiliani, Barcelona (ES)

Patients with relative contraindications: Spinal malformation / bleeding diathesis

G.M. Kamphuis, Amsterdam (NL)

Advanced vaginal reconstruction

ESU Course 03

Friday 1 July
14:30 - 17:30

Location Grey Area, Room G105

Chair T.J. Greenwell, London (GB)

Learning objectives

Clinicians involved in the care of female patients should know vaginal surgery. A specific goal of the faculty is to employ scientific principles, published information and clinical experience to describe and position newly developed techniques in current management of urinary incontinence. Special attention will be given to new techniques that use synthetics tapes in SUI surgery. This course will also cover the management of complications of surgery for stress incontinence and mesh complications. Treatment of recurrent urinary incontinence and incontinence with mixed symptoms also will be under discussion.

Management of vesicovaginal fistulae, urethral diverticula and some rare conditions will be shown both during podium and video presentations. An interactive course means active participation by the audience and participants are encouraged to prepare and present interesting and challenging clinical cases for consultation by the faculty. After this course, participants should know how to apply the newest technique in patients with stress incontinence, urethral loss and iatrogenic injuries of lower urinary tract. This course will facilitate the decision making process for those who are just starting their careers and for advanced surgeons.

Introduction

T.J. Greenwell, London (GB)

Mostly vaginal surgery for stress urinary incontinence (SUI)

T.J. Greenwell, London (GB)

Mostly vaginal repair of pelvic organ prolapse (POP)

To be confirmed

K-D. Sievert, Detmold (DE)

Management of mesh complications

To be confirmed

K-D. Sievert, Detmold (DE)

Surgery for female urethral stricture and urethral diverticulum

T.J. Greenwell, London (GB)

Urethral loss in females

To be confirmed

Vesico-vaginal fistulae: From simple to complicated

To be confirmed

Discussion and conclusions

To be confirmed

Nightmares in surgery of retroperitoneal disease

Plenary Session 03

Saturday 2 July
08:15 - 10:30

Location Orange Area, eURO Auditorium 1

Chairs
A. Breda, Barcelona (ES)
M-O. Grimm, Jena (DE)

08:15 - 09:00

Ruptured kidney tumour

08:15 - 08:30

Case presentation and discussion
A. Minervini, Florence (IT)

08:30 - 08:50

Cross-examination

08:30 - 08:50

B. Leigh, London (GB)

08:30 - 08:50

A. Minervini, Florence (IT)

08:50 - 09:00

Case solution and audience questions

09:00 - 09:45

The burned ureter

09:00 - 09:15

Case presentation and discussion
P. Albers, Düsseldorf (DE)

09:15 - 09:35

Cross-examination

09:15 - 09:35

B. Leigh, London (GB)

09:15 - 09:35

P. Albers, Düsseldorf (DE)

09:35 - 09:45

Case solution and audience questions

09:45 - 10:30

Complications in cytoreductive nephrectomy

09:45 - 10:00

Case presentation and discussion
T.S. O'Brien, London (GB)

10:00 - 10:20

Cross-examination

10:00 - 10:20

B. Leigh, London (GB)

10:00 - 10:20

T.S. O'Brien, London (GB)

10:20 - 10:30

Case solution and audience questions

Perioperative treatment of urothelial cancer in 2022

Plenary Session 04

Saturday 2 July
08:15 - 10:30

Location Grey Area, eURO Auditorium 2
Chairs M.J. Ribal Caparros, Barcelona (ES)
M. Rouprêt, Paris (FR)

Learning objectives

Participants of the session will expand their knowledge on the pathology and the molecular landscape in BCa and its treatment consequences, including variant (aberrant) pathologies, the molecular classification of BCa and the genomic approach in BCa.

They will also be updated on diagnostics and staging of BCa, and learn about NMIBC, specifically endoscopic diagnosis and therapy, treatment optimisation and the role of local and new systemic approaches and their optimal timing.

When it comes to MIBC, participants will learn specifically about surgery (both the role of TURB and Open vs. Robotics), about systemic therapy (neoadjuvant and adjuvant systemic chemotherapy and immunotherapy) and the bladder-sparing approach.

Finally, participants will have been instructed on systemic therapy in metastatic bladder and urothelial cancer and have developed an understanding on BCa recurrence and follow-up.

08:15 - 08:17

Welcome and introduction

08:17 - 08:27

State-of-the-art lecture Landscape of current trials with intravesical treatment in high risk BCG naïve NMIBC
A.M. Kamat, Houston (US)

08:27 - 08:37

State-of-the-art lecture Lynch syndrome: What urologists need to know
J.W.F. Catto, Sheffield (GB)

08:37 - 08:57

Debate NMIBC BCG refractory tumour

08:37 - 08:47

What are the systemic options in the pipeline?
J.A. Witjes, Nijmegen (NL)

08:47 - 08:57

What are the intravesical options in the pipeline?
A. Masson-Lecomte, Paris (FR)

08:57 - 09:22

Case discussion Localised MIBC cystectomy, neobladder, extended lymph node pT3a N0 R0 and no neoadjuvant chemo

08:57 - 09:02

Clinical case presentation What are the options?
M. Moschini, Milan (IT)

09:02 - 09:12

Urologist's point of view
J. Palou, Barcelona (ES)

09:12 - 09:22

Oncologist's point of view
A. Necchi, Milan (IT)

Scientific Programme - EAU22 Amsterdam

09:22 - 09:32	Oligo Metastatic: Definition, local and/or systemic treatment strategy in bladder cancer U. Vogl, Bellinzona (CH)
09:32 - 09:42	State-of-the-art lecture Molecular classification in bladder cancer to guide systemic treatment: ready from prime time? P. Black, Vancouver (CA)
09:42 - 10:07	Case discussion Multifocal right renal pelvis and ureter UC in otherwise healthy 70 years old woman with 2 functional kidneys
09:42 - 09:47	Clinical case presentation Room for systemic treatment? J.L. Domínguez Escrig, Valencia (ES)
09:47 - 09:57	Urologist's point of view S. Shariat, Vienna (AT)
09:57 - 10:07	Oncologist's point of view A. Birtle, Preston (GB)
10:07 - 10:27	Debate Adjuvant immune checkpoint inhibitors for everybody
10:07 - 10:17	Pro M.S. Van Der Heijden, Amsterdam (NL)
10:17 - 10:27	Con T. Powles, London (GB)
10:27 - 10:30	Closing remarks

How to write the introduction and methods

ESU Course 07

Saturday 2 July
08:30 - 10:30

Location Grey Area, Room G104

Chair J.W.F. Catto, Sheffield (GB)

Learning objectives

Understand how to construct a well written introduction and methods section for your manuscript. Learn how to work through examples of good and bad practices, and understand key points when writing.

Obtain insight from editors on what they expect to see.

- To understand what makes good introduction.
- To understand what makes a good methods section.
- To understand about systematic reviews and meta-analysis.
- To learn from experienced editors.

Welcome

J.W.F. Catto, Sheffield (GB)

Writing the introduction

S. Psutka, Seattle (US)

How to write the methods section

G. Novara, Padova (IT)

Key features for a systematic review

G. Giannarini, Udine (IT)

What to look for in the statistics section

R. L. Dunn, ()

Treatment of small renal masses

ESU Course 09

Saturday 2 July
08:30 - 10:30

Location Grey Area, Room G103

Chair P. Gontero, Turin (IT)

Learning objectives

- The course aims to address the multiplicity of treatment options for small renal masses (SRM).
- Essential concepts to guide the clinical decision making process will be interactively discussed with the help of clinical cases.
- Practical tips for a safe and effective treatment delivery will be provided on the current standard of ablative therapies and minimally invasive surgery.
- Attendees should become familiar on when and how to propose active surveillance in their daily clinical practice.

Introduction

P. Gontero, Turin (IT)

Active surveillance and ablative therapies: When and how

P. Gontero, Turin (IT)

Minimally invasive surgery: Tips and tricks

F. Keeley, Bristol (GB)

How to choose the best treatment for small renal masses: A clinical case based approach

P. Gontero, Turin (IT)

F. Keeley, Bristol (GB)

Metabolic workup and non-surgical management of urinary stone disease

ESU Course 08

Sunday 3 July
08:30 - 11:30

Location Grey Area, Room G102

Chair T. Tailly, Ghent (BE)

Learning objectives

Urolithiasis is an increasingly prevalent worldwide disease with recurrence rates up to 50% over 5 years. Metabolic assessment to identify predisposing factors and prevention therefore play an important role in patient management. This course will address common findings on dietary and metabolic workup and highlight medical and non-medical treatment options for these metabolic abnormalities in the prevention of stone recurrence.

The goal of the course is for participants to be able to

- Identify patients that would benefit from metabolic workup.
- Interpret standard metabolic workup, including dietary and medical history and biochemical analyses.
- Understand what the guidelines say on targeted medical treatment for prevention of urinary stone disease.
- Understand the influence of dietary changes on metabolic urinary values and provide dietary counseling.

Who needs a metabolic evaluation and why should this be done

T. Tailly, Ghent (BE)

How to do a metabolic evaluation, step-by-step

R. Siener, Bonn (DE)

Common stone types: What abnormalities might we find on investigation?

T. Tailly, Ghent (BE)

Stone and diet: What advice should we give?

R. Siener, Bonn (DE)

Medical treatment for stones: What works?

T. Tailly, Ghent (BE)

Interactive case discussions

T. Tailly, Ghent (BE)

R. Siener, Bonn (DE)

A. Skolarikos, Athens (GR)

Oligometastatic prostate cancer

ESU Course 10

Saturday 2 July
08:30 - 10:30

Location Grey Area, Room G106

Chair S. Joniau, Leuven (BE)

Learning objectives

- Provide an introduction to working definition(s), background, and biology of oligometastatic prostate cancer.
- Update the current molecular imaging to provide such a diagnosis.
- Review the potential roles of surgery and/or radiation as metastasis directed therapy.
- Understand opportunities and challenges in individualizing care of the oligometastatic prostate cancer patient.

Introduction: Oligometastatic prostate cancer as a diagnosis

S. Joniau, Leuven (BE)

Surgery of primary oligometastatic prostate cancer (N1/M1)

S. Joniau, Leuven (BE)

Surgery for recurrent nodal metastasis with updates on molecular/PET imaging

A. Briganti, Milan (IT)

Radiation in oligometastatic prostate cancer (primary and recurrent) and clinical trial updates

T. Zilli, Genève (CH)

Further cases (case illustrations throughout)

A. Briganti, Milan (IT)

S. Joniau, Leuven (BE)

T. Zilli, Genève (CH)

Discussion and conclusion

S. Joniau, Leuven (BE)

Prosthetic surgery in urology

ESU Course 11

Saturday 2 July
08:30 - 10:30

Location Grey Area, Room G107

Chair A. Muneer, London (GB)

Learning objectives

An increasing number of urological surgeons are developing a surgical practice which involves prosthetic surgery. This course will aim to cover the key areas of prosthetic surgery in urology with the aid of a video based platform. The course is aimed at urological trainees as well as established urologists wishing to develop a practice or gain an update and surgical tips in this area.

Surgical techniques with the aid of semi-live surgery will be a key focus of this course. At the end of the course participants should have a good understanding of:

- Minimising the risk of prosthesis infection and understand the role of biofilms.
- Theatre preparation and set up for prosthetic surgery.
- Patient selection and prosthetic surgery for male and female urinary incontinence including artificial urinary sphincters and sacral neuromodulation.
- Penile prosthesis surgery – surgical techniques, avoiding complications and revision surgery.

Introduction to biofilms and prosthetic infections

A. Muneer, London (GB)

Theatre set up and preparation of patients

A. Muneer, London (GB)

Prosthetic surgery for male urinary incontinence: Male slings and artificial urinary sphincter (AUS)

S. Malde, London (GB)

Prosthetic surgery for female urinary incontinence

S. Malde, London (GB)

Penile prosthesis surgery – Surgical technique and avoiding complications

A. Muneer, London (GB)

Dealing with intraoperative complications and penile prosthesis revision surgery

A. Muneer, London (GB)

EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU)

YUORDay22

Saturday 2 July
10:00 - 17:00

Location	Green Area, Room 1
Chairs	F. Esperto, Rome (IT) J.P.M. Sedelaar, Nijmegen (NL)
Moderators	L. Afferi, Lucerne (CH) R. Campi, Florence (IT) A. Mattigk, Ulm (DE) To be confirmed G. Mantica, Genoa (IT) To be confirmed E.C. Bujoreanu, Cluj Napoca (RO) To be confirmed N. Luyts, Leuven (BE) D.M. Carrión Monsalve, Madrid (ES) To be confirmed D.M. Carrión Monsalve, Madrid (ES) F. Esperto, Rome (IT) J.P.M. Sedelaar, Nijmegen (NL)

Learning objectives

In this session we introduce the European Society of Residents in Urology (ESRU) and the Young Urology Office (YUO). The main aim of this session is to offer talks tailored to residents' educational needs. We present the traditional surgical tips and tricks with all you need to know about certain surgical procedures. Furthermore, we show what residents need to know on the most recent oncological studies. Modern surgical practice requires technical and non-technical skills. As a consolidated feature, we also present this year a session together with the Young Endourological society. We will finish with the great finale of the EAU Guidelines cup, a competition between the three finalists and the audience.

10:00 - 10:10	Welcome and introduction
10:00 - 10:10	F. Esperto, Rome (IT)
10:00 - 10:10	J.P.M. Sedelaar, Nijmegen (NL)
10:10 - 10:57	European Urology Scholarship Programme (EUSP)
10:10 - 10:20	EUSP Overview programmes & EUSP during the pandemic A.S. Merseburger, Lübeck (DE)
10:20 - 10:30	Why is it important to apply? What does the EUSP scholarship offer in your career? P. Nyirády, Budapest (HU)
10:30 - 10:35	EUSP Application: Tips and tricks V. Phé, Paris (FR)
10:35 - 10:40	Future of the EUSP To be confirmed

Scientific Programme - EAU22 Amsterdam

10:40 - 10:45	Collaborations with EAU offices To be confirmed
10:45 - 10:47	EUSP Best Scholarship Award 2022 A.S. Merseburger, Lübeck (DE)
10:47 - 10:52	Presentation Best Scholar award winner clinical research G. Marra, Turin (IT)
10:52 - 10:57	Presentation Best Scholar award winner lab research E. Laukhtina, Vienna (AT)
10:57 - 11:57	Research and academic
10:57 - 11:09	How to build collaborative prospective trials To be confirmed
11:09 - 11:12	Questions and answers
11:12 - 11:24	How to become a good consultant, how to cope with residency E. Emiliani, Barcelona (ES)
11:24 - 11:27	Questions and answers
11:27 - 11:39	Women in surgical urology S. Ferretti, Parma (IT)
11:39 - 11:42	Questions and answers
11:42 - 11:54	Women in academic urology V. Phé, Paris (FR)
11:54 - 11:57	Questions and answers
11:57 - 12:57	Surgery tips and tricks
11:57 - 12:09	How to master TURBT Y.C.J. Teoh, Hong Kong (CN)
12:09 - 12:21	How to master flexible ureteroscopy A. Pietropaolo, Southampton (GB)
12:21 - 12:33	Incontinence surgery for residents N.I. Osman, Sheffield (GB)
12:33 - 12:45	New treatments for Peyronie's disease F. Castiglione, London (GB)
12:45 - 12:57	Questions and answers
12:57 - 13:57	Clinical case discussion Nightmare cases
12:57 - 13:12	Nightmare in ureteroscopy E. Liatsikos, Patras (GR)

Scientific Programme - EAU22 Amsterdam

13:12 - 13:17	Questions and answers
13:17 - 13:32	Nightmare in TURBT J. Palou, Barcelona (ES)
13:32 - 13:37	Questions and answers
13:37 - 13:52	Nightmare of acute scrotum surgery L.A. Kluth, Frankfurt a.M. (DE)
13:52 - 13:57	Questions and answers
13:57 - 15:42	Hot updates What a resident should know
13:57 - 14:09	New evidences in prostate cancer J. Gómez Rivas, Madrid (ES)
14:09 - 14:12	Questions and answers
14:12 - 14:24	New evidences in bladder cancer B. Pradere, Vienna (AT)
14:24 - 14:27	Questions and answers
14:27 - 14:39	New evidences in UTUC S. Shariat, Vienna (AT)
14:39 - 14:42	Questions and answers
14:42 - 14:54	What's new in stone treatment E.X. Keller, Zürich (CH)
14:54 - 14:57	Questions and answers
14:57 - 15:09	What is new in BPH treatment T. Bach, Hamburg (DE)
15:09 - 15:12	Questions and answers
15:12 - 15:24	What is new in erectile dysfunction treatment G.I. Russo, Catania (IT)
15:24 - 15:27	Questions and answers
15:27 - 15:39	ESU: New opportunities for residents E. Liatsikos, Patras (GR)
15:39 - 15:42	Questions and answers
15:42 - 16:42	Guidelines cup
	Guideline masters
15:42 - 16:42	To be confirmed

Scientific Programme - EAU22 Amsterdam

15:42 - 16:42	M.J. Ribal Caparros, Barcelona (ES)
15:42 - 16:42	J.L. Vázquez, Roskilde (DK)
16:42 - 17:00	Prizes and awards
16:42 - 16:44	Introduction
16:44 - 16:48	First prize - Best Abstract by a resident: Update from the PEDAL trial: A prospective single arm paired comparison of ability to diagnose and locate prostate cancer between multiparametric MRI and 18F-PSMA-PET/CT V. Tran, Melbourne (AU)
16:48 - 16:52	Second prize - Best Abstract by a resident: Non-muscle invasive bladder cancer subtypes with differential response to intravesical bacillus Calmette-Guerin treatment To be confirmed
16:52 - 16:56	European Urology Residents' Corner Award: Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab? To be confirmed
16:56 - 17:00	European Urology Residents' Corner Award: Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial To be confirmed

Ongoing studies and upcoming changes in imaging

Meeting of the EAU Section of Urological Imaging (ESUI)

Saturday 2 July
14:15 - 18:00

Location	Purple Area, Room Elicium 2
Chair	To be confirmed
Moderators	To be confirmed
	To be confirmed
	V. Panebianco, Rome (IT)
	To be confirmed
	To be confirmed
	J. Barentsz, Nijmegen (NL)
	T. Loch, Flensburg (DE)
	To be confirmed
	To be confirmed
	F. Sanguedolce, Barcelona (ES)
	To be confirmed
	T. Loch, Flensburg (DE)
	J. Walz, Marseille (FR)
	To be confirmed
	To be confirmed

Learning objectives

The main focus of this ESUI session is to present the most important studies in the field of imaging. Not only is this important for planning a study, but will provide a picture of upcoming changes in imaging. The artificial intelligence is illuminated as well as its development. Still up to date and exciting: MRI for everyone or not.

14:15 - 14:20	Welcome and introduction
14:20 - 15:45	Preview of the most relevant ongoing studies on urological imaging
14:20 - 14:30	Essentials for game changing studies: How to set up the perfect study To be confirmed
14:30 - 14:40	The OPTIMUM trial: 3-arm randomized 29 Mhz microultrasound H. Cash, Berlin (DE)
14:40 - 14:50	The PRIME study: Cheap and faster MRI L. Budäus, Hamburg (DE)
14:50 - 15:00	The PROSTAGE New vs Traditional imaging in primary distant metastasis staging pof prostate cancer M.H.J. Anttinen, Turku (FI)
15:00 - 15:10	The SCOT trial: Optimizing the number of systematic cores during an MRI targeted biopsy V. Scattoni, Milan (IT)
15:10 - 15:20	68Ga-PSMA PET/CT and nano-MRI Study To be confirmed
15:20 - 15:30	Capture Study: Cone Beam CT scan for PCNL To be confirmed

Scientific Programme - EAU22 Amsterdam

15:30 - 15:40	Decentralized community-based prostate cancer detection by AI TRUS - the BW-PC1 study S. Kruck, Pforzheim (DE)
15:40 - 15:45	Discussion
15:45 - 16:13	The neverending story: mpMRI for all?
15:45 - 15:53	Upfront mpMRI for all J. Barentsz, Nijmegen (NL)
15:53 - 16:01	Who does not need it routinely at all? T. Loch, Flensburg (DE)
16:01 - 16:09	The fight: Who is right?
16:01 - 16:09	J. Barentsz, Nijmegen (NL)
16:01 - 16:09	T. Loch, Flensburg (DE)
16:09 - 16:13	Discussion
16:13 - 16:51	Next steps in molecular and AI imaging
16:13 - 16:23	AI and imaging : Overview and new developments To be confirmed
16:23 - 16:33	AI in pathology To be confirmed
16:33 - 16:43	Intraoperative digital analysis of ablation margins (DAAM) by fluorescent confocal microscopy E. Barret, Paris (FR)
16:43 - 16:51	Discussion
16:51 - 17:19	Evolution of ultrasound
16:51 - 17:01	A brief history of TRUS imaging: What will be gone and what will remain? To be confirmed
17:01 - 17:11	Moleucalur ultrasound imaging: Extravasation and targeting PSMA expression To be confirmed
17:11 - 17:19	Discussion
17:19 - 17:42	Last but not least and of utmost importance
17:19 - 17:42	An overview on PSMA PET in urologic malignancies To be confirmed
17:42 - 18:00	Final remarks and discussion To be confirmed

Technology developments never ends!

Meeting of the EAU Section of Uro-Technology (ESUT) in cooperation with ERUS and EULIS

Saturday 2 July
11:00 - 18:30

Location	Orange Area, eURO Auditorium 1
Chair	A.S. Gözen, Heilbronn (DE)
Coordinators	A.S. Gözen, Heilbronn (DE) A.J. Gross, Hamburg (DE) To be confirmed
Moderators	To be confirmed C. Fiori, Orbassano (IT) To be confirmed To be confirmed B. Petrut, Cluj Napoca (RO) A. Skolarikos, Athens (GR) To be confirmed G. Cacciamani, Los Angeles (US) O.R. Durutovic, Belgrade (RS) D. Nikoleishvili, Tbilisi (GE) To be confirmed M. Cepeda, Valladolid (ES) To be confirmed C. Netsch, Hamburg (DE) M. Rieken, Zürich (CH) L. Tunc, Ankara (TR) T. Knoll, Sindelfingen (DE) J.I. Martínez Salamanca, Majadahonda (ES) S. Micali, Baggiovara (IT) A. Papatsoris, Athens (GR) J.B. Roche, Bordeaux (FR)

Coordinators at Auditorium

Coordinator at Academic Medical Center, Amsterdam (NL)

Patient advocates

-	To be confirmed
11:00 - 11:05	Welcome and introduction A.S. Gözen, Heilbronn (DE)
11:05 - 13:20	Live surgery - Part I
11:05 - 11:35	3D laparoscopic partial nephrectomy To be confirmed
11:35 - 12:00	Supine combined PCNL
11:35 - 12:00	To be confirmed
12:00 - 12:00	T. Tailly, Ghent (BE)

Scientific Programme - EAU22 Amsterdam

12:00 - 12:28	Robotic assisted partial nephrectomy C. Vaessen, Paris (FR)
12:28 - 12:48	Enucleation of prostate with holmium laser P. Kallidonis, Patras (GR)
12:48 - 12:56	Pre-recorded video HoLEP procedure – Special emission set F. Gomez Sancha, Madrid (ES)
12:56 - 13:04	Pre-recorded video Holep with moses 2.0 laser To be confirmed
13:04 - 13:12	Pre-recorded video PLASMA en-bloc resection of NMIBC incl. NBI B. Malavaud, Toulouse (FR)
13:12 - 13:20	Pre-recorded video Retrograde intrarenal surgery E. Emiliani, Barcelona (ES)
13:20 - 14:50	Live surgery - Part II
13:20 - 13:32	Flexible ureteroscopic lithotripsy I. Kartalas Goumas, Vigevano (IT)
13:32 - 13:50	Percutaneous nephrolithotripsy G. Giusti, Milan (IT)
13:50 - 13:58	Pre-recorded video Robotic assisted benign prostatectomy A. Ingels, Creteil (FR)
13:58 - 14:06	Pre-recorded video Treating BPH patients with GreenLight laser therapy L. Cindolo, Modena (IT)
14:06 - 14:14	Pre-recorded video Enucleation of prostate with holmium laser D. Abt, Biel-Bienne (CH)
14:14 - 14:22	Pre-recorded video PCNL with moses 2.0 M.D. Duvdevani, Mevaseret-Zion (IL)
14:22 - 14:34	Flexible ureteroscopic lithotripsy E. Liatsikos, Patras (GR)
14:34 - 14:42	Pre-recorded video Aquablation therapy for BPH N. Barber, Camberley (GB)
14:42 - 14:50	Robotic assisted cystectomy C. Schwentner, Stuttgart (DE)
14:50 - 17:03	Live surgery - Part III
14:50 - 15:20	3D laparoscopic partial nephrectomy P.J. Zondervan, Amsterdam (NL)
15:20 - 15:35	Laser endoscopic enucleation of the prostate for BPH J. Ellinger, Bonn (DE)

Scientific Programme - EAU22 Amsterdam

15:35 - 16:03	Robotic assisted prostatectomy with sentinel lymph node mapping H.G. Van Der Poel, Amsterdam (NL)
16:03 - 16:11	Pre-recorded video Enucleation of prostate with thulium fiber laser
16:03 - 16:11	C.M. Cracco, Turin (IT)
16:03 - 16:11	C.M. Scoffone, Turin (IT)
16:11 - 16:19	Pre-recorded video Photodynamic diagnostics (PDD) for bladder cancer To be confirmed
16:19 - 16:27	Pre-recorded video TBD To be confirmed
16:27 - 16:39	Flexible ureteroscopic lithotripsy B. Somani, Southampton (GB)
16:39 - 16:47	Pre-recorded video Endoscopic combined intrarenal surgery To be confirmed
16:47 - 16:55	Pre-recorded video Simultaneous bilateral endoscopic surgery S. Proietti, Milan (IT)
16:55 - 17:03	En-bloc TURB with PDD L. Lusuardi, Salzburg (AT)
17:03 - 18:30	Live surgery - Part IV
17:03 - 17:15	Flexible ureteroscopic lithotripsy M. Straub, Munich (DE)
17:15 - 17:23	Pre-recorded video Retrograde intrarenal surgery for stones O. Traxer, Paris (FR)
17:23 - 17:31	Pre-recorded video Rezum™ water therapy: A solution for BPH treatment H-H. Seifert, Basel (CH)
17:31 - 17:39	Pre-recorded video TBD To be confirmed
17:39 - 17:47	Pre-recorded video Mini supine combined intrarenal surgery O. Angerri Feu, Barcelona (ES)
17:47 - 18:02	Enucleation of prostate with thulium fiber laser C.M. Scoffone, Turin (IT)
18:02 - 18:14	Flexible ureteroscopic lithotripsy with thulium fiber laser G.M. Kamphuis, Amsterdam (NL)
18:14 - 18:22	Pre-recorded video Minimally invasive BPH treatment with iTind C. Fiori, Orbassano (IT)
18:22 - 18:30	Pre-recorded video Partial nephrectomy with our single port system S.C. Crivellaro, Chicago (US)

Urinary incontinence: Are doctors, guidelines and patients all in agreement?

Meeting of the EAU Section of Female and Functional Urology (ESFFU)

Saturday 2 July
10:30 - 14:00

Location	Purple Area, Room Elicium 2
Chair	F. Cruz, Porto (PT)
Moderators	E. Kocjancic, Chicago (US) F. Cruz, Porto (PT) M. Drake, Bristol (GB) S.A. Arlandis, Valencia (ES) S.A. Arlandis, Valencia (ES) E. Chartier-Kastler, Paris (FR) S. Charalampous, Limassol (CY) H. Hashim, Bristol (GB)
Panel	To be confirmed To be confirmed C. Harding, Newcastle upon Tyne (GB) B.Y. Padilla Fernandez, San Cristóbal De La Laguna (ES) F. Van Der Aa, Leuven (BE) T. Antunes Lopes, Porto (PT) P. Blasco, Sevilla (ES) E. Finazzi Agrò, Rome (IT)
Speaker	R. Hamid, London (GB)

Learning objectives

The treatment of urinary incontinence require different methods which may be influenced by the physician background. The role of urodynamics for choosing the best treatment is a matter of intense debate. Universally accepted cure criteria are lacking. And treatment may be followed by complications that require new skills. Attendees are expected to update their knowledge in these topics.

10:30 - 10:35	Welcome and introduction F. Cruz, Porto (PT)
10:35 - 12:05	Round-table discussion The different views of female stress urinary incontinence management
10:35 - 11:50	Discussion
11:50 - 12:05	Proper understanding of recurrent stress urinary incontinence treatment in women (PURSUIT): A randomised controlled trial of endoscopic and surgical treatment M. Drake, Bristol (GB)
12:05 - 12:50	ESFFU meets other societies
12:05 - 12:20	International Continence Society (ICS) lecture Post prostatectomy incontinence: To sling or to sphincter? D.M. Castro Díaz, Santa Cruz de Tenerife (ES)
12:20 - 12:35	Turkish Continence Society (TCS) lecture Urodynamics before surgical treatment of incontinence: Are there differences between males and females? T. Tarcn, Istanbul (TR)

Scientific Programme - EAU22 Amsterdam

12:35 - 12:50	SUFU lecture AUA guideline on neurogenic lower urinary tract dysfunction To be confirmed
12:50 - 13:20	Underactive and overactive bladder update
12:50 - 13:05	Is prostatectomy an effective therapeutic option for men with DU caused by chronic prostatic BOO? S. Mourad, Heliopolis (EG)
13:05 - 13:20	Posterior tibial nerve stimulation or sacral nerve neuromodulation J.P.F.A. Heesakkers, Nijmegen (NL)
13:20 - 13:55	Bladder augmentation and urodynamic tests update
13:20 - 13:30	Augmented reality surgery: Which role in functional urology? To be confirmed
13:30 - 13:55	Urodynamic quiz
13:55 - 14:00	Closing remarks F. Cruz, Porto (PT)

Urological surgery and interventions in an office and outpatient setting

Meeting of the EAU Section of Urologists in Office (ESUO)

Saturday 2 July
10:30 - 14:00

Location	Green Area, Room 4
Chairs	H. Haas, Heppenheim (DE) To be confirmed
Moderators	F. Dimitriadis, Kalamaria, Thessaloniki (GR) L.P. Zapala, Warsaw (PL) To be confirmed A. Zachariou, Ioannina (GR) To be confirmed A. Zachariou, Ioannina (GR) H. Haas, Heppenheim (DE) To be confirmed
Panel	To be confirmed P. Tsafarakidis, Limassol (CY) L.P. Zapala, Warsaw (PL)

Learning objectives

Outpatient surgery is a usual task of office urologists in Europe. The procedures include open surgery as well as endoscopic interventions. Furthermore, recent developments offer the opportunity of prostate treatment in an outpatient and day surgery setting, these procedures are demonstrated in this session illustrated by videos. As key conditions, the aspects of anaesthesia and sedation and the prevention and management of complications in outpatient procedures are presented. Regarding the great spectrum of complexity in outpatient surgery a debate together with the audience will discuss the question which of the procedures should be done in which institution: in the office, in uro-surgical centres or in collaboration with local hospitals. Legal aspects playing an increasing role in outpatient surgery will complement the interactive meeting which is interesting not only for office urologists but also for urologists in clinic.

10:30 - 10:35	Welcome and introduction To be confirmed
10:35 - 10:40	Outpatient surgery by outpatient urologists in Europe H. Haas, Heppenheim (DE)
10:40 - 11:15	Before surgery and interventions
10:40 - 10:50	Patient's preparation To be confirmed
10:50 - 11:00	The diversified nursing roles in the coordination and delivery of urology outpatient and day care services To be confirmed
11:00 - 11:10	The Impact of sedation and local anesthesia on day case urology To be confirmed
11:10 - 11:15	Discussion
11:15 - 12:10	Open surgery and diagnostic procedures

Scientific Programme - EAU22 Amsterdam

11:15 - 11:25	Office-based penile surgery F. Dimitriadis, Kalamaria, Thessaloniki (GR)
11:25 - 11:40	Vasectomy
11:25 - 11:40	To be confirmed
11:40 - 12:00	Prostate Biopsy
11:40 - 12:00	A. Zachariou, Volos (GR)
11:40 - 12:00	P. Tsafrakidis, Limassol (CY)
12:00 - 12:10	Discussion
12:10 - 13:10	Endoscopic interventions
12:10 - 12:20	Urethral stricture management and all relevant current and emerging office based technologies P. Tsafrakidis, Limassol (CY)
12:20 - 12:30	Management of ureteral stents To be confirmed
12:30 - 12:45	Botox-Therapy To be confirmed
12:45 - 12:55	Urolift, Rezum P. Tsafrakidis, Limassol (CY)
12:55 - 13:05	iTind, Embolisation To be confirmed
13:05 - 13:10	Discussion
13:10 - 13:55	Conditions of surgery and interventions
13:10 - 13:20	The complications of day case scrotogenital and endoscopic interventions: Prevention and management To be confirmed
13:20 - 13:40	Debate Which operation in which institution
13:40 - 13:50	Day case surgery and the law: How vulnerable is the urologist? To be confirmed
13:50 - 13:55	Discusssion
13:55 - 14:00	Closing remarks H. Haas, Heppenheim (DE)

Biomarkers in uro-oncology: From bench to bedside

Joint meeting of the EAU Section of Urothology (ESUP) and the EAU Section of Urological Research (ESUR)

Saturday 2 July
10:30 - 13:50

Location Green Area, Room 5

Chairs M. Colecchia, Milan (IT)
K. Junker, Homburg (DE)

Moderators E.S. Martens-Uzunova, Rotterdam (NL)
A. Hartmann, Erlangen (DE)
A. Masson-Lecomte, Paris (FR)
A. Lopez-Beltran, Lisbon (PT)
To be confirmed
To be confirmed

Learning objectives

Biomarkers are essential tools for precision medicine in oncology. In contrast to other tumor entities, those biomarkers are still not a part of decision making in urological malignancies. However, more and more valid data are available from basic research with great potential for prognostic evaluation and therapy selection. This session gives an overview on hot topics in biomarker development addressing both clinicians and researchers to discuss together the most recent developments. This includes the role of RNA modifications in tumors biology and their potential as biomarkers, molecular classification of bladder and prostate cancer to individualize therapy and the role of circulating tumor cells as biomarkers from liquid biopsy.

10:30 - 10:35

Welcome and introduction
K. Junker, Homburg (DE)

10:35 - 11:40

Emerging role of RNA modifications in tumor biology of urological carcinomas for new therapeutic strategies and biomarker development

10:35 - 10:50

The RNA modification network
To be confirmed

10:50 - 11:05

The role of miRNAs in the management of germ cell tumours
R. Hamilton, Toronto (CA)

11:05 - 11:20

Non-coding RNAs in liquid biopsy as biomarkers in urological malignancies
C. Jeronimo, Porto (PT)

11:20 - 11:40

Discussion

11:40 - 12:40

Molecular subtypes of muscle-invasive bladder cancer: A real step towards individual treatment?

11:40 - 11:55

Prognostic and predictive value of molecular subtypes
M. Eckstein, Erlangen (DE)

11:55 - 12:10

FGFR3 alterations: Leading personalised therapy?
L.S. Mertens, Amsterdam (NL)

12:10 - 12:40

Panel discussion Discussion

12:40 - 13:25

Molecular differentiation: On the way to individualise treatment in prostate cancer

Scientific Programme - EAU22 Amsterdam

12:40 - 12:55	Predictive biomarkers and molecular targets in metastatic prostate cancer P. Rescigno, London (GB)
12:55 - 13:10	Assessment of molecular status to predict progression in prostate cancer To be confirmed
13:10 - 13:25	Circulating tumour cells: What is the future in urology? To be confirmed
13:25 - 13:45	Discussion
13:45 - 13:50	Closing remarks M. Colecchia, Milan (IT)

Answering clinically important questions in reproductive and sexual medicine and surgery

Meeting of the EAU Section of Andrological Urology (ESAU)

Saturday 2 July
10:30 - 14:00

Location Purple Area, Room Elicium 1

Chair N. Sofikitis, Ioannina (GR)

Moderators M. Dinkelman-Smit, Rotterdam (NL)
J. Rassweiler, Heilbronn (DE)
To be confirmed
To be confirmed
To be confirmed
F. Fusco, Naples (IT)
To be confirmed
To be confirmed
Z. Kopa, Budapest (HU)
To be confirmed

Learning objectives

The Scientific Meeting of The European Section of Andrological Urology attempts to unravel the most important points of several surgical procedures in the sexual and reproductive medicine. Emphasis will be given to microsurgical procedures that are currently performed worldwide. Surgical and non-invasive treatments of the Peyronie's disease depending on the stage of the disease will be thoroughly discussed. Additionally the role of testosterone treatment in hypogonadal males with history of localized prostatic cancer will be extensively discussed. The importance of detecting abnormal values in the standard parameters of the semen analysis or recognizing disorders in the testicular endocrine and exocrine function for the early identification

10:30 - 10:35

Welcome and introduction
N. Sofikitis, Ioannina (GR)

10:35 - 11:10

State-of-the-art lectures

10:35 - 10:45

Testosterone therapy in hypogonadal men with treated localized prostatic cancer
A. Salonia, Milan (IT)

10:45 - 10:55

Ooplasmic injections of early haploid male gametes for the treatment of men with non-obstructive azoospermia: Where are we today?
N. Sofikitis, Ioannina (GR)

10:55 - 11:05

Regenerative medicine in the field of sexual medicine: A critical reappraisal (indications, techniques, and risks)
P. Capogrosso, Milan (IT)

11:05 - 11:10

Discussion

11:10 - 11:35

Debate Is there in the era of evidence-based medicine a role of non-surgical treatments for the stable Peyronie's disease

11:10 - 11:20

Pro
To be confirmed

Scientific Programme - EAU22 Amsterdam

11:20 - 11:30	Con G.I. Russo, Catania (IT)
11:30 - 11:35	Discussion
11:35 - 12:35	Surgery-in-motion 1: Tips and tricks in penile surgery
11:35 - 11:43	Associated video presentation Restoring male genitalia with bladder exstrophy R. Djinoovic, Belgrade (RS)
11:43 - 11:51	Associated video presentation Peyronie's disease: Choosing the appropriate graft D.J. Ralph, London (GB)
11:51 - 11:59	Associated video presentation Cosmetic elongation penile surgery C. Bettocchi, Bari (IT)
11:59 - 12:07	Associated video presentation Placing a penile prosthesis via penoscrotal approach To be confirmed
12:07 - 12:15	Associated video presentation Penile trauma or fracture A. Muneer, London (GB)
12:15 - 12:23	Associated video presentation Peyronie's disease: Critical points in the general surgical planning/strategy To be confirmed
12:23 - 12:35	Discussion
12:35 - 12:56	Surgery-in-Motion 2: Surgery for male infertility
12:35 - 12:43	Associated video presentation Epididymo-vasostomy To be confirmed
12:43 - 12:51	Associated video presentation Microsurgical varicocelectomy S. Çayan, Mersin (TR)
12:51 - 12:56	Discussion
12:56 - 14:00	Joint session of the European Academy of Andrology (EAA) and the ESAU: Male reproductive health is a guard for general health in the man
12:56 - 13:06	Male childlessness as an independent predictor of risk of cardiovascular and all-cause mortality A. Giwercman, Malmö (SE)
13:06 - 13:16	Male infertility and development of cancer in the male genital tract S. Minhas, London (GB)
13:16 - 13:26	Decreased general health is associated with impaired endocrine and exocrine testicular function and abnormalities in the semen analysis T. Diemer, Giessen (DE)
13:26 - 13:36	Syndromic infertility and cancer predisposition To be confirmed

Scientific Programme - EAU22 Amsterdam

13:36 - 13:46	Male infertility and development of malignancies outside the male reproductive tract F. Dimitriadis, Thessaloniki (GR)
13:46 - 13:56	Discussion
13:56 - 14:00	Closing remarks N. Sofikitis, Ioannina (GR)

Controversies in onco-urology

Joint meeting of the EAU Section of Oncological Urology (ESOU), the EAU Robotic Urology Section (ERUS), the EAU Section of Uro-Technology (ESUT)

Saturday 2 July
10:30 - 14:35

Location Orange Area, Room 2

Chairs G. Giannarini, Udine (IT)
M. Rouprêt, Paris (FR)

Moderators G. Giannarini, Udine (IT)
M. Rouprêt, Paris (FR)
M.C. Mir Maresma, Valencia (ES)
M. Rouprêt, Paris (FR)

Learning objectives

To strengthen the leading role of European urologists in providing care to patients with genitourinary malignancies. To recognise the value of multidisciplinary collaborations between urologists, medical oncologists, radiation oncologists, and other stakeholders involved in the multifaceted care of patients with genitourinary malignancies. To navigate the evolving landscape of multimodal therapeutic options with the aim to implement personalised pathways of care across the wide spectrum of genitourinary malignancies.

10:30 - 10:35

Welcome and introduction

10:30 - 10:35

G. Giannarini, Udine (IT)

10:30 - 10:35

M. Rouprêt, Paris (FR)

10:35 - 12:20

Session 1 Hot topics in onco-urology

10:35 - 10:45

Transperineal MRI-directed prostate biopsy: The new gold standard?
To be confirmed

10:45 - 10:50

Questions and answers

10:50 - 11:00

When and how to de-escalate surveillance in low-risk non-muscle-invasive bladder cancer
H. Mostafid, Guildford (GB)

11:00 - 11:05

Questions and answers

11:05 - 11:15

The future of cytoreductive nephrectomy for advanced renal cell carcinoma in the immunotherapy era
A. Bex, London (GB)

11:15 - 11:20

Questions and answers

11:20 - 11:30

Sequencing therapies in metastatic castration-resistant prostate cancer: Challenges and opportunities for a precision medicine
A. De La Taille, Créteil (FR)

11:30 - 11:35

Questions and answers

11:35 - 11:45

Bladder-sparing strategies in the management of muscle-invasive bladder cancer
A. Choudhury, Manchester (GB)

Scientific Programme - EAU22 Amsterdam

11:45 - 11:50	Questions and answers
11:50 - 12:00	Lymph node management in penile cancer: Principles and controversies O. Hakenberg, Rostock (DE)
12:00 - 12:05	Questions and answers
12:05 - 12:15	The role of advanced nurse practitioners in the follow-up of kidney cancer patients C.N. Tillier, Amsterdam (NL)
12:15 - 12:20	Questions and answers
Session 2 ESOU-ERUS-ESUT: Common problems in onco-urology	
12:20 - 12:45	Debate Should young surgeons be still trained to open surgery in the robotic era?
12:20 - 12:30	Pro S. Shariat, Vienna (AT)
12:30 - 12:40	Con To be confirmed
12:40 - 12:45	Discussion
12:45 - 13:20	Case-based debate How should PET-detected oligorecurrent prostate cancer best treated?
12:45 - 12:50	Case presentation J. Olivier, Lille (FR)
12:50 - 13:00	Systemic therapy C. Sweeney, Boston (US)
13:00 - 13:10	Metastasis-directed therapy A. Briganti, Milan (IT)
13:10 - 13:20	Discussion
13:20 - 13:55	Case-based debate Kidney-sparing treatment of upper urinary tract urothelial carcinoma should be expanded
13:20 - 13:25	Case presentatoin W. Krajewski, Wrocław (PL)
13:25 - 13:35	Pro A. Breda, Barcelona (ES)
13:35 - 13:45	Con M. Burger, Regensburg (DE)
13:45 - 13:55	Discussion
13:55 - 14:35	Case-based debate Should the robotic approach for partial nephrectomy be systematically recommended?

Scientific Programme - EAU22 Amsterdam

13:55 - 14:00

Case presentation
R. Campi, Florence (IT)

14:00 - 14:10

Pro
C.K. Bensalah, Rennes (FR)

14:10 - 14:20

Con
G. Giannarini, Udine (IT)

14:20 - 14:30

Discussion

14:30 - 14:35

Closing remarks
M. Rouprêt, Paris (FR)

Surgical matters in kidney transplant

Joint meeting of the EAU Section of Transplantation Urology (ESTU), the EAU Section of Oncological Urology (ESOU) and the EAU Section of Genitourinary Reconstructive Surgeons (ESGURS)

Saturday 2 July
10:30 - 14:00

Location Grey Area, Room Emerald

Chairs E. Lledó García, Madrid (ES)
M. Musquera Felip, Barcelona (ES)

Moderators C. Hernández Fernández, Madrid (ES)
E. Lledó García, Madrid (ES)
F.J. Burgos Revilla, Madrid (ES)
A.J. Figueiredo, Coimbra (PT)
E. Lledó García, Madrid (ES)
R. Dahlem, Hamburg (DE)
B. Da Costa Parada, Coimbra (PT)
V. Tugcu, İstanbul (TR)
F.J. Burgos Revilla, Madrid (ES)
To be confirmed

Learning objectives

Objective of the meeting is to focus on different medical and surgical critical aspects of kidney transplant, and specially, at this time to stress the importance of the surgical management of uro-oncological diseases and also the importance of treating BPH and urethral strictures in the candidate and transplanted patients.

10:30 - 10:35

Welcome and introduction

10:30 - 10:35

F.J. Burgos Revilla, Madrid (ES)

10:30 - 10:35

A.J. Figueiredo, Coimbra (PT)

10:30 - 10:35

E. Lledó García, Madrid (ES)

10:35 - 11:15

Polycystic kidney disease: The nephrectomy

10:35 - 10:45

Indication

J. Gómez Rivas, Madrid (ES)

10:45 - 10:55

Surgical technique

F.J. González García, Madrid (ES)

10:55 - 11:05

The side and the timing: Unilateral versus bilateral

P.T. Coelho Nunes, Coimbra (PT)

11:05 - 11:15

A controversial case

V. Gomez Dos Santos, Madrid (ES)

11:15 - 11:55

ESTU-ESOU Joint topics Urological cancer management in the ESRD and KT population: Choosing the best technique to combine with future transplant

11:15 - 11:25

Prostate cancer How to proceed with the LP/RA radical prostatectomy: Tips and tricks

I. Moncada Iribarren, Madrid (ES)

Scientific Programme - EAU22 Amsterdam

11:25 - 11:35	Bladder cancer and urinary diversion How to proceed with the LP/RA radical cystectomy and the urinary diversion: Tips and tricks To be confirmed
11:35 - 11:45	Renal cancer How to proceed with the partial/radical LP/RA nephrectomy: Tips and tricks A. Breda, Barcelona (ES)
11:45 - 11:55	Controversial case T. Ajami Fardoun, Barcelona (ES)
11:55 - 12:35	ESTU-ESGURS Joint topics Genitourinary reconstructive surgery in the ESRD and KT population
11:55 - 12:05	Surgical treatment of posterior urethral strictures L. Martínez-Piñeiro , Madrid (ES)
12:05 - 12:15	Penile epispadias reconstruction techniques: An update R. Djinovic, Belgrade (RS)
12:15 - 12:25	The penile urethroplasty with BMG: Tips and tricks V. Kojovic, Belgrade (RS)
12:25 - 12:35	Complex peyronie disease surgical management: Tips and tricks J.I. Martínez Salamanca, Majadahonda (ES)
12:35 - 13:45	Situations during and after transplant
12:35 - 12:45	The complicate transplant case: 3rd transplant. The technique R. Boissier, Marseille (FR)
12:45 - 12:55	The low-weight pediatric case: Technique To be confirmed
12:55 - 13:05	The catastrophic iliac vessels: Technical options To be confirmed
13:05 - 13:15	The giant lymphocele: Technical options A. Kocot, Würzburg (DE)
13:15 - 13:25	The robotic assisted kidney transplant: Technique M. Musquera Felip, Barcelona (ES)
13:25 - 13:45	Covid-19 pandemic and solid organ transplants: Lessons learned for the future To be confirmed
13:45 - 13:50	Awards
13:45 - 13:50	Rene-Ku?ss Prize 2022 To be confirmed
13:50 - 14:00	Closing remarks

Common problems in bladder cancer

Rapid-fire debates

Saturday 2 July
10:45 - 13:45

Location Grey Area, eURO Auditorium 2

Chairs A.M. Kamat, Houston (US)
A. Stenzl, Tübingen (DE)

Moderators M. Babjuk, Prague (CZ)
S. Psutka, Seattle (US)
R. Cathomas, Chur (CH)
S. Shariat, Vienna (AT)
J.W.F. Catto, Sheffield (GB)
K. Pohar, Columbus, Ohio (US)
M. Rouprêt, Paris (FR)
A. Birtle, Preston (GB)

Discussants To be confirmed
J. Palou, Barcelona (ES)
P.J. Goebell, Erlangen (DE)
Y.C.J. Teoh, Hong Kong (CN)
E. Compérat, Paris (FR)
J.A. Witjes, Nijmegen (NL)
R. Li, Houston (US)
J.A. Witjes, Nijmegen (NL)
R. de Wit, Rotterdam (NL)
S. Lerner, Houston (US)
A. Choudhury, Manchester (GB)
J. Palou, Barcelona (ES)
N. James, London (GB)
M.J. Ribal Caparros, Barcelona (ES)
To be confirmed
A. Siefker-Radtke, Houston (US)

Learning objectives

- Using case based discussions, allow the presenters an opportunity to discuss nuances of common dilemmas facing urologic oncology patients and providers.
- Use evidence based debates to provide clear, rationale guidance on the management of difficult situations in bladder cancer.

10:45 - 10:48

Welcome and introduction
A.M. Kamat, Houston (US)

10:48 - 11:08

Management of TaHG tumour, 3 cm, single, no CIS, 65 yr old patient: Are the 2021 EAU Guidelines correct?

10:48 - 10:50

Case presenter
M. Babjuk, Prague (CZ)

10:50 - 10:55

Debater 1 Should be classified/treated as intermediate risk, chemotherapy or BCG
J. Palou, Barcelona (ES)

10:55 - 11:00

Debater 2 Should be treated as high risk, ideally treated with BCG
To be confirmed

Scientific Programme - EAU22 Amsterdam

11:00 - 11:08	Discussion and Q&A
11:10 - 11:30	Fertility in women: T3 tumour, posterior wall, RC planned in 37 yr old, has 1 child already but not sure about wanting 2nd child so wants to keep options open
11:10 - 11:12	Case presenter S. Psutka, Seattle (US)
11:12 - 11:17	Debater 1 Reproductive organ sparing procedure recommended P.J. Goebell, Erlangen (DE)
11:17 - 11:22	Debater 2 Wide excision = better cancer control Y.C.J. Teoh, Hong Kong (CN)
11:22 - 11:30	Discussion and Q&A
11:32 - 11:52	Tumour profiling should be done before starting any decision for MIBC: Healthy patient, GFR 60, T2 disease with small focus glandular and micropapillary noted on TURBT
11:32 - 11:34	Case presenter R. Cathomas, Chur (CH)
11:34 - 11:39	Debater 1 GEP/NGS is a must – it will drive decision making E. Comp��rat, Paris (FR)
11:39 - 11:44	Debater 2 We don't need additional information – we have all the information we need already from good pathology J.A. Witjes, Nijmegen (NL)
11:44 - 11:52	Discussion and Q&A
11:54 - 12:14	reTUR – depends on tumour biology or surgeon skill? T1HG tumour, 3 cm , blue light done, muscle present, surgeon says 'completely resected'
11:54 - 11:56	Case presenter S. Shariat, Vienna (AT)
11:56 - 12:01	Debater 1 reTUR not needed, skill of surgeon matters J.A. Witjes, Nijmegen (NL)
12:01 - 12:06	Debater 2 Tumour biology matters, reTUR needed for all R. Li, Houston (US)
12:06 - 12:14	Discussion and Q&A
12:16 - 12:36	BCG Unresponsive disease: Treat with IO (Pembro) or Chemo (Gem/Doce): 63 yr old health male, T1HG+CIS, treated with BCG induction and maintenance, has initial response but at 12 mos check up has small TaHG and CIS
12:16 - 12:18	Case presenter J.W.F. Catto, Sheffield (GB)
12:18 - 12:23	Debater 1 Pembro ideal based on data/approval R. de Wit, Rotterdam (NL)

Scientific Programme - EAU22 Amsterdam

12:23 - 12:28	Debater 2 Gem/Doce ideal based on data S. Lerner, Houston (US)
12:28 - 12:36	Discussion and Q&A
12:38 - 12:58	Concomitant bladder and prostate cancer: Gleason 4+3, 3 cores + T1HG 3 cm tumour, no CIS in healthy 67 yr old male - started BCG and NED after induction and 2 maintenance courses; now what?
12:38 - 12:40	Case presenter K. Pohar, Columbus, Ohio (US)
12:40 - 12:45	Debater 1 Recommend RARP, continue to treat bladder, XRT would not be recommended given bladder history J. Palou, Barcelona (ES)
12:45 - 12:50	Debater 2 Can do XRT to prostate, will not affect bladder outcome A. Choudhury, Manchester (GB)
12:50 - 12:58	Discussion and Q&A
13:00 - 13:20	Radical cystectomy/PLND vs. Bladder preservation in localised MIBC; T3 disease at high posterior wall, good ECOG, 53 yr female, received NAC and has good response on imaging/cysto
13:00 - 13:02	Case presenter M. Rouprêt, Paris (FR)
13:02 - 13:07	Debater 1 Surgery (RC or partial) +PLND has best chance to cure M.J. Ribal Caparros, Barcelona (ES)
13:07 - 13:12	Debater 2 XRT is ideal for this patient N. James, London (GB)
13:12 - 13:20	Discussion and Q&A
13:22 - 13:42	Adjuvant therapy for MIBC: Does approval of nivolumab in the adjuvant setting change indication for NAC? T2HG MIBC no adverse histology or LVI etc, imaging clean, otherwise healthy patient, GFR 68
13:22 - 13:24	Case presenter A. Birtle, Preston (GB)
13:24 - 13:29	Debater 1 Use NAC in this patient To be confirmed
13:29 - 13:34	Debater 2 Recommend straight to RC, we can use Nivo (or even cisplatinium?) if needed based on path A. Siefker-Radtke, Houston (US)
13:34 - 13:42	Discussion and Q&A
13:42 - 13:45	Closing remarks A. Stenzl, Tübingen (DE)

Evolving surgical technologies in prostate cancer

Video Session 4

Saturday 2 July
10:45 - 12:15

Location Green Area, Room 2

Chairs F. Gómez Veiga, Salamanca (ES)
A. Mattei, Luzern (CH)
A. Messas, Paris (FR)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

10:45 - 10:48

Introduction

V23

Vector prostate biopsy: A novel electro-magnetic biopsy technique for mpMRI/US fusion transperineal prostate biopsies under local anaesthesia

V24

Anatomical robotic-assisted radical prostatectomy: Step-by-step nerve-sparing technique for different grades of preservation

V25

SP approach to radical prostatectomy: Step-by-step technique comparing the Xi and SP consoles

V26

Introducing the SynchroSeal: A new robotic setting for robot-assisted radical prostatectomy and super-extended lymph node dissection for locally advanced prostate cancer
L. Sarchi, Milano (IT)

V27

Robot-assisted radical prostatectomy feasibility and optimal setting with a novel robotic platform
L. Sarchi, Milano (IT)

V28

^{99m}-technetium-psma radio-guided surgery to detect nodal metastases in prostate cancer patients undergoing radical prostatectomy and extended pelvic lymph node dissection: A phase 2 prospective, single-institution study
G. Gandaglia, Milan (IT)

V29

A drop-in gamma probe for sentinel lymph node dissection in prostate cancer: Interim results from a multicentre clinical trial
C. Solà Marqués, Barcelona (ES)

12:02 - 12:07

Closing remarks

Stones - Decision-making, imaging and shock wave lithotripsy

Abstract Session 14

Saturday 2 July
10:45 - 12:15

Location Green Area, Room 3
Chairs M. Ather, Karachi (PK)
To be confirmed
L. Tzelves, Athens (GR)

10:45 - 10:48

Introduction

A0247

Worldwide survey on the current practice of asymptomatic urinary stone management: A survey from EAU, Young Academic Urologists (YAU), Endourology and Urolithiasis Working Party
T.E. Şener, Istanbul (TR)

A0248

The effect of COVID-19 outbreak on endourological treatments for urinary stones: A retrospective multicentric study
G. Mazzon, Portogruaro (VE) (IT)

A0249

Impact of COVID-19 on the management of ureteric stones in the UK: The COVID Stones study

10:54 - 11:02

Discussion

A0250

Spontaneous passage rate of ureteral stones and predictive factors after pre-stenting
C. Schregel, Seuzach (CH)

A0251

IPDE-5 versus Alpha-blockers in the treatment of patients with distal ureteral stones: Prospective, randomized, multi-centric comparative study
H. Khouni, Tunis (TN)

A0252

Efficacy of mirabegron as medical expulsive therapy for distal ureteral stones: A prospective randomized, double blind, controlled study

A0253

The impact of stenting prior to oral chemolysis of upper urinary tract uric acid stones

11:10 - 11:18

Discussion

A0254

Does hydronephrosis is equal to obstruction? - Non-contrast computerized tomography radiodensity changes in an obstructed kidney
S. Fishberg, Ness ziona (IL)

A0255

Stone CT scanner using artificial intelligence

A0256

Radiation exposure using lead-lined versus regular latex surgical gloves during endourological procedures: A single-center prospective comparative study
A. Bravo-Balado, Barcelona (ES)

A0257

Estimated doses of radiation received by the eye lens during endourological procedures: Are we being careful enough? ESUT-YAU endourology group collaboration
A. Bravo-Balado, Barcelona (ES)

Scientific Programme - EAU22 Amsterdam

A0258	Clinical implications of ultrasound shear wave elastography of urinary stones in patient candidate for ureteroscopy M. Romani, Brescia (IT)
11:28 - 11:36	Discussion
A0259	Clinical and time-related predictors of sepsis in patients with obstructive uropathy due to ureteral stones in the emergency setting C. Bebi, Milan (IT)
A0260	Asymptomatic bacteriuria in candidates for active treatment of renal stones: Results from an international multicentric study on more than 2600 patients
A0261	Management of urolithiasis in patients with renal anomaly: Multicenter KSER research series
A0262	Urolithiasis in patients with kidney transplantation: Multicenter KSER research series
11:44 - 11:52	Discussion
A0263	Shockwave lithotripsy for distal ureteric stones: Real world outcomes from the Endourological Society T.O.W.E.R. research initiative J. Bjazevic, London (CA)
A0264	Tamsulosin as medical expulsive therapy after shock wave lithotripsy for renal stones: A randomised controlled trial (NCT05032287)
A0265	Predictors of success of the non-invasive treatment for uncomplicated steinstrasse post shockwave lithotripsy for renal stones
A0266	In vitro evaluation of optimal device settings of a novel 3rd generation lithotripter C.J. O'Connor, Cork (IE)
A0267	Is it safe and effective to increase the energy dose accumulated in the lithiasis by increasing the number of shock waves per session in extracorporeal lithotripsy? New prospective and randomized study J. Bolón Marset, Valencia (ES)
12:02 - 12:10	Discussion
12:10 - 12:15	Closing remarks

Active surveillance and modern diagnostics

Abstract Session 15

Saturday 2 July
10:45 - 12:15

Location Yellow Area, Room Forum

Chairs
A. Alberts, Bleiswijk (NL)
M.E. Alvarez-Maestro, Madrid (ES)
A. Lamb, Oxford (GB)

Use of AS

10:45 - 10:50

Introduction

A0268 Evaluating the baseline mental wellbeing of newly diagnosed prostate cancer patients

A0269 Active surveillance for prostate cancer: Uptake over time and the impact of an organized protocol
S. Remmers, Rotterdam (NL)

A0270 Large varieties in the use and uptake of active surveillance for low risk prostate cancer between an academic center and the remaining urology community in the canton of Zurich, Switzerland
C. Poyet, Zürich (CH)

10:56 - 11:04

Discussion

New tools for selection

A0271 Comparison of 4K score, prostate health index, and PSA density in active surveillance
B.J. Trock, Baltimore (US)

A0272 3-year outcomes from the prospective 'MRIAS' trial: A novel active surveillance protocol which incorporates multiparametric MRI to reduce frequency of biopsy in men with prostate cancer
P.N. Doan, Northmead (AU)

A0273 Radiomic-based model for prediction of clinically significant prostate cancer in patients with a PI-RADS 3 MRI lesion
T.A. Nguyen, BREST (FR)

A0274 Radiomic features on MRI enable progression risk in patients on active surveillance: preliminary findings

11:12 - 11:20

Discussion

Grading

A0275 Development of novel machine learning algorithms for real-time progression risk recalibration during active surveillance for early prostate cancer
V.J. Gnanapragasam, Cambridge (GB)

A0276 External validation of a model predicting increase in Gleason grade for men on Active Surveillance in the GAP3 consortium database

A0277	Does centralized revision of prostate biopsy impact on active surveillance outcomes? Results from a single, high-volume institution series
A0278	Predicting true pathologic Gleason grade during active surveillance for prostate cancer: Calibration of the Johns Hopkins ActiveCare Model in five large active surveillance cohorts
11:28 - 11:36	Discussion
	Biopsy
A0279	The additional role of Standard prostate biopsy combined to Target biopsy in biopsy naïve patients after radical prostatectomy: Results of a prospective randomized clinical trial E. Checcucci, Venaria Reale (IT)
A0280	A phase II prospective trial of MRI and in-bore biopsy in the reclassification of men considering active surveillance for prostate cancer B. Langbein, Boston (US)
A0281	Role of target biopsy, perilesional biopsy, and random biopsy in the detection of clinically significant prostate cancer by mpMRI-guided transrectal ultrasound fusion biopsy during active surveillance protocol
A0282	Risk of adverse outcomes after prostatectomy in patients diagnosed with IUSP <= 2 prostate cancer on MRI/TRUS fusion biopsy C.V. Kesch, Essen (DE)
11:44 - 11:52	Discussion
	Outcome
A0283	Conditional survival of patients with low-risk prostate cancer: Temporal changes in active surveillance permanence according to risk stratification F. Mistretta, Milan (IT)
A0284	Drop-out rates from active surveillance for disease progression remain consistent and not negligible over time. A plea for long-term assessment based on a large, prospectively collected active surveillance cohort
A0285	Quality of life for higher vs. lower educated men following active surveillance, radical prostatectomy or radiotherapy in the patient-initiated EUPROMS study L.D.F. Venderbos, Rotterdam (NL)
A0286	A feasibility study of the therapeutic response and durability of short-term androgen targeted therapy in early prostate cancer managed by surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) study V.J. Gnanapragasam, Cambridge (GB)
12:00 - 12:08	Discussion
12:08 - 12:15	Closing remarks

Robotic-assisted laparoscopic prostatectomy

ESU Course 12

Saturday 2 July
11:00 - 14:00

Location Grey Area, Room G102

Chair P-T. Piéchaud, Bordeaux (FR)

Learning objectives

The course objective is to explain the surgical technique of radical prostatectomy performed through robotic-assisted laparoscopy for the treatment of prostatic carcinoma.

The outline of this course will give a detailed reminder of anatomical basic principles of radical prostatectomy.

General principles regarding ports placement will be also reminded considering the different possible options and the different types of robotic systems used. Then each teacher will make a presentation of his surgical technique using a video of 20 minutes explaining all the steps of the surgery in details. Other options of anatomical approach will be also introduced (posterior approach, lateral approach).

Finally, the course will present the possible intraoperative risks of complications and the functional and oncological results of this surgery.

Introduction

P-T. Piéchaud, Bordeaux (FR)

General principles of robotic radical prostatectomy, patient position, ports placement, ways of access

To be confirmed

To be confirmed

Anatomical and oncological supports of radical prostatectomy:

- Bladder neck preservation: Useful? Dangerous?

P-T. Piéchaud, Bordeaux (FR)

- Neurovascular bundle dissection: Anatomical reminders of the peri-prostatic fascia and space of dissection

To be confirmed

Step-by-step operative procedure: How I do it?

To be confirmed

To be confirmed

P-T. Piéchaud, Bordeaux (FR)

Technical alternatives:

- Posterior approach: Bocciardi technique

To be confirmed

- Lateral approach: Gaston technique

P-T. Piéchaud, Bordeaux (FR)

- Lymphadenectomy: Technical principles

To be confirmed

Operative and postoperative complications

To be confirmed

Oncological and functional results

To be confirmed

Conclusion

P-T. Piéchaud, Bordeaux (FR)

Adrenals for urologists

ESU Course 14

Friday 1 July
14:30 - 17:30

Location Grey Area, Room G109

Chair A.S. Gözen, Heilbronn (DE)

Learning objectives

To teach all about the adrenal gland minimal invasive approach; starting with the correct indications for surgery and preoperative medical preparation. The different approaches and new equipment will be shown including special instructions. The operations will be given step by step in high quality videos in detail with tips and tricks. The complication videos and intraoperative management will be discussed interactively with the experts.

Introduction

A.S. Gözen, Heilbronn (DE)

Indications and patient preparation (medical and surgical)

J.F. Langenhuijsen, Nijmegen (NL)

Surgical anatomy of adrenals

C. Fiori, Orbassano (IT)

How I do it; step by step operative procedure, technical tips and tricks

- Transperitoneal

J.F. Langenhuijsen, Nijmegen (NL)

- Retroperitoneal and prone

A.S. Gözen, Heilbronn (DE)

- Mini-laparoscopic

C. Fiori, Orbassano (IT)

Partial adrenalectomy and challenging cases in adrenalectomy

J.F. Langenhuijsen, Nijmegen (NL)

Complications and management

A.S. Gözen, Heilbronn (DE)

Discussion and interaction

A.S. Gözen, Heilbronn (DE)

J.F. Langenhuijsen, Nijmegen (NL)

C. Fiori, Orbassano (IT)

Practical approach to paediatric urology

ESU Course 15

Saturday 2 July
11:00 - 14:00

Location Grey Area, Room G105

Chair F. O'Kelly, Dublin (IE)

Learning objectives

Many children with congenital anomalies will present to the adult urologist with long-term sequelae. It is important to know what has been done in terms of surgical procedures so that the adult urologist knows what is expected and what should or can be done. It is also important to know how the urological follow-up of these patients should be done. The most common pediatric conditions will be explored by interactive case presentations.

- Many children born with hydronephrosis may not require surgical intervention, but need close follow-up until after puberty.
- The clinical presentation of congenital anomalies of the urinary tract has changed, because of prenatal US, but sometimes adults may present with the classical symptoms.
- Obstructive uropathy and VUR are not always surgical anomalies, but may be functional in nature. The treatment modalities and long-term outcomes depend on the pathophysiology.

Vesico-ureteral reflux (VUR)

F. O'Kelly, Dublin (IE)

Vesico-ureterale reflux and voiding dysfunction

F. O'Kelly, Dublin (IE)

Ureteropelvic junction (UPJ) obstruction

S. Tekgöl, Ankara (TR)

Most frequent penile abnormalities

S. Tekgöl, Ankara (TR)

Megaureter

S. Tekgöl, Ankara (TR)

Urethral valves

J.M. Lammers, Groningen (NL)

Neurogenic bladder

J.M. Lammers, Groningen (NL)

Ectopic ureter

F. O'Kelly, Dublin (IE)

Dutch and anniversary contributions to urology

EAU History office

Saturday 2 July
11:00 - 13:30

Location Grey Area, Room G107

Chairs R.A. Schipper, Den Bosch (NL)
Ph. E. V. Van Kerrebroeck, Berchem- Antwerp (BE)

Learning objectives

This session focuses on two topics related to the history of urology in Europe. The first part deals with the anniversaries of the EAU (50 years), the History Office of the EAU (30 years) and intracavernous injections for ED (40 years). In the second part an overview is presented of major Dutch contributions to urological surgery and urology. The session concludes with a special lecture, by its authors, on 'Roma Intima', the 2022 EAU gift book. Participants will gain a thorough insight in these aspects of urology and will have the possibility for an interactive discussion.

11:00 - 11:05	Welcome and introduction
11:05 - 11:55	Urological anniversaries
11:05 - 11:20	EAU 1972-2022: 50 years of excellence in urology! F.M.J. Debruyne, Arnhem (NL)
11:20 - 11:25	Discussion
11:25 - 11:35	Intracavernous injections for erectile dysfunction: 40 years later!
11:25 - 11:35	C. Schulman, Brussels (BE)
11:25 - 11:35	R. Virag, Paris (FR)
11:35 - 11:40	Discussion
11:40 - 11:50	EAU History Office: Amsterdam 1990 and beyond! J. Mattelaer, Kortrijk (BE)
11:50 - 11:55	Discussion
11:55 - 12:55	History of urology in the low countries
11:55 - 12:05	Nicolaas Tulp: Mayor of Amsterdam, anatomist and proto-urologist To be confirmed
12:05 - 12:10	Discussion
12:10 - 12:20	Pieter Donker and Patrick Walsh: Two hands in one glove R.C.M. Pelger, Leiden (NL)
12:20 - 12:25	Discussion
12:25 - 12:35	"Desnos lecture": Frère Jacques and his lithotomies in Amsterdam in 1699 To be confirmed
12:35 - 12:40	Discussion

Scientific Programme - EAU22 Amsterdam

12:40 - 12:50	Dutch urological innovations in perspective P. Dik, Utrecht (NL)
12:50 - 12:55	Discussion
12:55 - 13:15	Book presentation 'Roma Intima'
12:55 - 13:15	To be confirmed
12:55 - 13:15	J. Mattelaer, Kortrijk (BE)
13:15 - 13:25	Presentation of the first copy of 'Roma Intima' to the EAU Executive
13:25 - 13:30	Closing remarks

How to write results and discussion

ESU Course 13

Saturday 2 July
12:00 - 14:00

Location Grey Area, Room G104

Chair J.W.F. Catto, Sheffield (GB)

Learning objectives

Learn the best way to draft the results and discussion section of a scientific paper. Understand how to work through examples of good and bad practices, to find the key points of the manuscript. Obtain insight from editors on what they expect to see.

- To understand what makes good results section and how best to present your data.
- To understand what makes a good discussion.
- To learn from experienced editors.

Welcome

J.W.F. Catto, Sheffield (GB)

Choosing and presenting your statistical analysis

R. L. Dunn, ()

How to write the results section

J-N.L. Cornu, Rouen (FR)

Writing the discussion section

M. Rieken, Zürich (CH)

What the editor looks for when reviewing the results and discussion

J.W.F. Catto, Sheffield (GB)

Functional urology: The full Monty

Video Session 5

Saturday 2 July
12:30 - 14:00

Location Green Area, Room 2

Chairs To be confirmed
T.J. Greenwell, London (GB)
H.V. Holm, Stabekk (NO)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

12:30 - 12:33

Introduction

V30

Long term evaluation of the Argus-T® adjustable male sling: A prospective study
R. Zanotti, Sao Paulo (BR)

V31

Robot-assisted artificial urinary sphincter implantation in female patients with ileal neobladder
B. Peyronnet, Rennes (FR)

V32

Robotic artificial urinary sphincter implantation in female patients under constant direct vision
B. Peyronnet, Rennes (FR)

V33

Robot-assisted Mitrofanoff appendicovesicostomy
C. Haudebert, Rennes (FR)

V34

Laparoscopic colposacropexy technical considerations

V35

Dorsal onlay lingual mucosa graft urethroplasty for female urethral stricture

V36

Urethral augmentation using oral mucosa grafts after distal urethrectomy during radical vulvectomy
J. García Herrero, Santander (ES)

13:49 - 13:54

Closing remarks

Focal therapy in prostate cancer

Abstract Session 17

Saturday 2 July
12:30 - 14:00

Location Yellow Area, Room Forum

Chairs
H.U. Ahmed, London (GB)
S.K. Hong, Seongnam (KR)
W. Lam, Hong Kong (HK)

Trends

12:30 - 12:34

Introduction

A0307 **Focal therapy trends for prostate cancer: A total population analysis in Germany from 2006 to 2019**

12:36 - 12:45

Discussion

HIFU

A0308 **A prospective comparative and functional analysis of different ablative techniques for MRI/real-time ultrasound image fusion guided High Intensity Focused Ultrasound (HIFU)**
F. Piramide, Torino (IT)

A0309 **Partial ablation and total ablation with High Intensity Focused Ultrasound (HIFU) compared to radical prostatectomy (RP): A propensity score-matched study**
C. Ye, Seongnam (KR)

A0310 **3-year oncological outcome of a prospective trial using focal therapy for localized prostate cancer with High-Intensity Focused Ultrasound (HIFU)**

A0311 **Adverse pathology and metastatic progression in patients treated by focal HIFU for unilateral localized prostate cancer: Results at mid-term follow-up in a series of 96 patients**
J. Olivier, Lille (FR)

A0312 **Focal treatment of prostate cancer with High-Intensity Focused Ultrasound (HIFU): Oncological, functional and morbidity outcomes of a prospective and unicentric series**
A.D. Partezani, Sao Paulo (BR)

A0313 **5-year outcomes of High-Intensity Focused Ultrasound (HIFU) treatment of localised prostate cancer**
C. Deleuze, Paris (FR)

12:57 - 13:06

Discussion

Ablative energies

A0314 **MRI-guided transurethral ultrasound ablation for localized clinically significant prostate cancer: 12-month clinical outcomes of a phase 2 study**
E.H.M. Yli-Pietilä, Turku (FI)

Scientific Programme - EAU22 Amsterdam

A0315	Transurethral Vapor Ablation (TUVA) of intermediate risk localized Prostate Cancer (PCa) C.A. Warlick, Minneapolis (US)
A0316	Results of in vivo focal transperineal laser ablation treatment for prostate cancer: Correlation of mpMRI and CEUS imaging to histology in radical prostatectomy specimen L.A.M.J.G. Van Riel, Amsterdam (NL)
A0318	A novel focal therapy for patients with localized prostate cancer: Targeted microwave ablation (TMA) under Organ-Based Tracking Fusion® (OBT) – preliminary results of an ablate-and-resect study (FOSTINE 01b)
13:16 - 13:25	Discussion
	Cryo
A0319	Primary focal cryotherapy for non-metastatic prostate cancer: Update from the UK ICE registry D.T. Reddy, London (GB)
A0320	Transperineal fusion biopsies and target fusion cryoablation under local anesthesia in a clinical office-setting F. Bianco, Miami Lakes (US)
13:29 - 13:38	Discussion
	IRE
A0321	Irreversible electroporation treatment using [18F] PSMA-PET CT in localized prostate cancer: Preliminary study
A0322	Focal therapy of index lesion with irreversible electroporation: Oncological and functional results at 30 months B. Miñana López, Madrid (ES)
A0323	Multicenter validation of the diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer in the follow-up of focal therapy with irreversible electroporation B. Geboers, Manly (AU)
13:46 - 13:55	Discussion
13:55 - 14:00	Closing remarks

Joint session of the EAU, EANM, ESMO and ESTRO: Modern diagnostic and therapeutic approaches in PCa

Special Session

Saturday 2 July
14:00 - 15:30

Location Grey Area, eURO Auditorium 2

Chair J. Walz, Marseille (FR)

Panel
E. Castro, Madrid (ES)
G. De Meerleer, Leuven (BE)
M. Eiber, Munich (DE)
S. Fanti, Bologna (IT)
K. Herrmann, Essen (DE)
T. Maurer, Hamburg (DE)
To be confirmed

14:00 - 14:40

Recurring disease

14:00 - 14:10

PSMA in staging for recurring prostate cancer

S. Fanti, Bologna (IT)

14:10 - 14:20

Salvage treatment options for the PSMA avid lesion: Radiotherapy

G. De Meerleer, Leuven (BE)

14:20 - 14:30

Salvage treatment options for the PSMA avid lesion: Surgery

T. Maurer, Hamburg (DE)

14:30 - 14:40

Treatment landscape of hormone sensitive recurring M1 prostate cancer

To be confirmed

14:40 - 15:10

Metastatic disease

14:40 - 14:50

Treatment landscape of castrate resistant M1 prostate cancer

E. Castro, Madrid (ES)

14:50 - 15:00

The role of PSMA radioligand treatment in castrate resistant M1 prostate cancer

M. Eiber, Munich (DE)

15:00 - 15:10

Possible synergies between radioligand and systemic treatment in M1 prostate cancer? Future perspectives

K. Herrmann, Essen (DE)

15:10 - 15:30

Panel discussion The role of the multidisciplinary team in radioligand treatment

Training models and complication management

Video Session 6

Saturday 2 July
14:15 - 15:45

Location Green Area, Room 2

Chairs A. Larcher, Milan (IT)
E. Laukhtina, Vienna (AT)
P. Wysz, Lublin (PL)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

14:15 - 14:18

Introduction

V02 **Remote training using augmented reality on surgical phantoms**
J. Immerzeel, Arnhem (NL)

V37 **In vivo feasibility test using flexible ureteroscopic robotic system, easyUretero for renal stone retrieval in porcine model**

V38 **Laparoscopic colposacropexy: Comparative anatomy of the ovine and female pelvis**

V39 **Training in transplantation - the development of a porcine cadaveric kidney retrieval course**

V40 **Robotic management of surgical complications after robot-assisted radical cystectomy with intracorporeal diversion**

V41 **Management of vascular injury in laparoscopic urology**
V. Chandra Mohan, Hyderabad (IN)

15:35 - 15:40

Closing remarks

Trials in Progress

Abstract Session 18

Saturday 2 July 14:15 - 15:15	Location	Green Area, Room 3
	Chairs	To be confirmed M. Kwiatkowski, Aarau (CH) G. Niegisch, Düsseldorf (DE)
14:15 - 14:18	Introduction	
A0325	E-Consent – an innovative solution to maintain recruitment momentum in clinical trials during the COVID-19 pandemic R. Almeida-Magana, London (GB)	
A0326	Protective effect of LCZ696 on kidney function after partial nephrectomy J.I. Brignone, Aalborg (DK)	
A0327	PROState pathway embedded comparative trial: An update to the IP3-PROSPECT study E.J. Bass, London (GB)	
A0328	Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC) (Trial in Progress) A.M. Kamat, Houston (US)	
A0329	Study gone viral: Novel post-operative erectile dysfunction treatment P. Śluzar, London (GB)	
A0330	Urological complications of radiotherapy: Clinical presentation and management in a tertiary referral center over 1 year K. Cascetta, Homburg/Saar (DE)	
A0331	RACE IT - A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) S.C. Schmid, Munich (DE)	
14:34 - 15:10	Discussion	
15:10 - 15:15	Closing remarks	

Contemporary urogenital reconstruction and continence restoration in male, female and transgender patients

Meeting of the EAU Section of Genitourinary Reconstructive Surgeons (ESGURS)

Saturday 2 July
14:15 - 18:00

Location Green Area, Room 4

Chair D.J. Ralph, London (GB)

Moderators I. Moncada Iribarren, Madrid (ES)
D.J. Ralph, London (GB)
R. Djinoovic, Belgrade (RS)
O. Sedigh, Turin (IT)
P. Anderson, Dudley (GB)
F. Campos Juanatey, Santander (ES)
B. Haid, Linz (AT)
J.M. Nijman, Groningen (NL)
B. Haid, Linz (AT)
J.M. Nijman, Groningen (NL)
S.C. Morgenstern, Frankfurt am Main (DE)
N. Lumen, Ghent (BE)
M.E. Alvarez-Maestro, Madrid (ES)
F. Van Der Aa, Leuven (BE)
M. Skrodzka, London (GB)
I. Ouzaid, Paris (FR)
R. Dahlem, Hamburg (DE)
J. Ockrim, London (GB)

Learning objectives

This year main topics covered will include urethral surgery with an exciting session on lichen sclerosis, Peyronie's disease and significant practical tips in penile prosthesis implantation. These topics will also be discussed in the transgender population. There will also be a session on testicular descent and disorders of sexual differentiation followed by updates on male incontinence surgery. Is robotic surgery going to replace open techniques in the future? This will be debated using vesico-vaginal fistula as an example. .

14:15 - 14:20

Welcome and introduction
D.J. Ralph, London (GB)

Penile surgery

14:20 - 15:00

Peyronie's disease

14:30 - 14:36

Are we still doing plications in 2022, how and for who?
S. Sansalone, Rome (IT)

14:36 - 14:42

Are we still doing grafting procedures in 2022, how and for who?
To be confirmed

14:42 - 14:48

Penile prosthesis and Peyronie's disease: An overview
W.G. Lee, London (GB)

14:48 - 14:54

The modelling procedure, how I do it and results
J. Torremade Barreda, L'Hospitalet de Llobregat (ES)

Scientific Programme - EAU22 Amsterdam

14:54 - 15:00	Lengthening procedures, options and results R. Djinovic, Belgrade (RS)
14:20 - 14:30	Conclusions
14:20 - 14:30	I. Moncada Iribarren, Madrid (ES)
14:20 - 14:30	D.J. Ralph, London (GB)
15:00 - 15:45	Penile prosthesis
15:00 - 15:05	The work before the operating room: My routines K. Van Renterghem, Hasselt (BE)
15:05 - 15:10	Type of prosthesis and options F. Dehò, Milan (IT)
15:10 - 15:15	Which approach for which patient? To be confirmed
15:15 - 15:20	How to improve cosmetic and functional aspects J Romero-Otero, Madrid (ES)
15:20 - 15:25	Reservoir implantation, options and preferences N. Tomada, Porto (PT)
15:25 - 15:30	Floppy glans: Options and management M. Skrodzka, London (GB)
15:30 - 15:35	Protocol after the operating room with penile implantation C. Bettocchi, Bari (IT)
15:35 - 15:40	Penile implants and the buried penis V. Modgil, Manchester (GB)
15:40 - 15:45	Conclusions
15:40 - 15:45	R. Djinovic, Belgrade (RS)
15:40 - 15:45	O. Sedigh, Turin (IT)
15:45 - 16:05	Trials and guidelines
15:45 - 15:50	Closure versus non-closure in buccal mucosa harvesting L.A. Kluth, Frankfurt (DE)
15:50 - 15:55	Post operative imaging in urethral surgery using retrograde pericatheter urethrography or trial of voiding cystourethrography W. Verla, Ghent (BE)
15:55 - 16:00	Urethral stricture EAU guidelines: The diagnosis, peri-operative management and follow up of urethral strictures N.I. Osman, Sheffield (GB)
16:00 - 16:05	Conclusions

Scientific Programme - EAU22 Amsterdam

16:00 - 16:05	P. Anderson, Dudley (GB)
16:00 - 16:05	F. Campos Juanatey, Santander (ES)
	Life-long urology
16:05 - 16:25	Testicular descent and disorders of sexual differentiation
16:05 - 16:10	The abnormal testes in adolescent boys – Assessment and treatment To be confirmed
16:10 - 16:15	Challenges to fertility in adolescent boys P. Sangster, London (GB)
16:15 - 16:20	Gender defining surgery P. Hoebeke, Ghent (BE)
16:20 - 16:25	Conclusions
	Gender surgery
16:25 - 16:50	What is the best way to manage post gender affirmations surgery urethral strictures
16:25 - 16:30	Strictures following male to female gender affirmation surgery S. Riechardt, Hamburg (DE)
16:30 - 16:35	Strictures following female to male gender affirmation surgery To be confirmed
16:35 - 16:40	The zephyr transgender penile prosthesis N. Morel Journel, Lyon (FR)
16:40 - 16:45	Male to female surgery - Two surgical equipes C. Trombetta, Trieste (IT)
16:45 - 16:50	Conclusions
16:45 - 16:50	S.C. Morgenstern, Frankfurt am Main (DE)
16:45 - 16:50	N. Lumen, Ghent (BE)
	Female lower urinary tract reconstruction
16:50 - 17:15	Debate Robotic vesico-vaginal fistula repair- Great improvement or waste of money?
16:50 - 16:52	Introduction and voting To be confirmed
16:52 - 16:57	Great Improvement! E. Kocjancic, Chicago (US)
16:57 - 17:02	Waste of money! T.J. Greenwell, London (GB)

Scientific Programme - EAU22 Amsterdam

17:02 - 17:04	Rebuttal E. Kocjancic, Chicago (US)
17:04 - 17:06	Rebuttal T.J. Greenwell, London (GB)
17:06 - 17:11	Q&A M.E. Alvarez-Maestro, Madrid (ES)
17:11 - 17:15	Voting and conclusions F. Van Der Aa, Leuven (BE)
	Urethral surgery
17:15 - 17:40	Challenges in penile lichen sclerosus
17:15 - 17:20	Minimally invasive treatment D.E. Andrich, London (GB)
17:20 - 17:25	One stage BMG penile urethroplasty D. Hernández Hernández, San Cristóbal de La Laguna (ES)
17:25 - 17:30	Staged BMG urethroplasty E. Palminteri, Arezzo (IT)
17:30 - 17:35	BMG augmented perineal urethrostomy M. Waterloos, Ghent (BE)
17:35 - 17:40	Conclusions I. Ouzaid, Paris (FR)
17:40 - 17:55	Male incontinence surgery
17:40 - 17:45	Overview of new devices, past, present, and future To be confirmed
17:45 - 17:50	Salvage techniques following erosion of AUS V. Phé, Paris (FR)
17:50 - 17:55	Conclusions
17:50 - 17:55	R. Dahlem, Hamburg (DE)
17:50 - 17:55	J. Ockrim, London (GB)
17:55 - 18:00	Conclusions of the meeting D.J. Ralph, London (GB)

Minimally-invasive partial nephrectomy in localised kidney cancer

Abstract Session 19

Saturday 2 July
14:15 - 15:45

Location Green Area, Room 5
Chairs To be confirmed
To be confirmed
F. Porpiglia, Turin (IT)

14:15 - 14:18

Introduction

Selective clamping

A0333 **Optimizing selective clamping during 3-D guided robotic partial nephrectomy: The application of a mathematical tool to precisely establish the perfusion areas of the organ**
D. Amparore, Turin (IT)

A0334 **On-clamp versus off-clamp robotic partial nephrectomy for totally endophytic deep renal masses: Propensity score-matched comparison of perioperative, oncologic and functional outcomes of a multicenter analysis (ROSULA database)**
G. Tuderti, Roma (IT)

A0335 **Impact of selective renal artery clamp during robot-assisted laparoscopic partial nephrectomy on postoperative renal function**

A0336 **3D modeling of renal tumors for planning and guidance of selective clamping and urinary collecting system suture**

A0337 **Head to head comparison between off-clamp vs on-clamp RAPN in high-risk RENAL score kidney tumors**
R.S. Flammia, Rome (IT)

14:28 - 14:39

Discussion

Off-clamp

A0338 **Clamp-less partial nephrectomy: A propensity score-matched analysis comparing robot-assisted with open approach**

A0339 **Tumor size and WIT are involved in the increase of contralateral kidney function after RAPN: Evaluation by MAG3**

A0340 **Perioperative and functional outcomes of off-Clamp robotic partial nephrectomy for purely hilar versus abutting the hilum and central tumors**
M. Ferriero, Rome (IT)

A0341 **Sutureless off-clamp robotic partial nephrectomy as a viable option to improve perioperative surgical outcomes: Single center analysis**
A. Brasseti, Rome (IT)

A0342 **Avoiding renorrhaphy at the end of off-clamp robotic partial nephrectomy does not jeopardize surgical and functional outcomes: A single center analysis**
A. Brasseti, Rome (IT)

Scientific Programme - EAU22 Amsterdam

A0343	Risks and benefits of partial nephrectomy with limited or without ischemia time
14:51 - 15:02	Discussion
	Surgical planning
A0344	Intraoperative dual-modality imaging in clear cell renal cell carcinoma R.I.J. Merks, Nijmegen (NL)
A0345	Surgical management of complex renal tumors treated with robotic partial nephrectomy: From the planning to the intraoperative navigation via 3D virtual models F. Piramide, Torino (IT)
15:06 - 15:17	Discussion
	Miscellaneous
A0346	Comparison of perioperative outcomes between single-port and multiport retroperitoneal robot-assisted partial nephrectomies S.C. Crivellaro, Chicago (US)
A0347	Longitudinal comparison of open vs. robot-assisted partial nephrectomy: Is the robot better from the start? P. Zeuschner, Homburg (DE)
A0348	Intraoperative touchless gesture interaction with 3D virtual models during laparoscopic partial nephrectomy: Pilot experience with ICON3D technology D. Amparore, Turin (IT)
A0349	Laparoscopic versus robotic partial nephrectomy in obese patients: Perioperative and early functional outcomes from a large contemporary series (RECORD2 project) R. Tellini, Firenze (IT)
A0350	Preliminary RCC embolization before laparoscopic partial nephrectomy. Outcomes on surgical procedure
A0351	Robot-assisted partial nephrectomy for multiple renal tumors – a multicenter analysis N.N. Harke, Hannover (DE)
15:29 - 15:40	Discussion
15:40 - 15:45	Closing remarks

Meet the experts in robotic surgery

Meeting of the EAU Robotic Urology Section (ERUS)

Saturday 2 July
14:15 - 18:00

Location Purple Area, Room Elicium 1

Chair A. Breda, Barcelona (ES)

Moderators

- C. Vaessen, Paris (FR)
- A. Minervini, Florence (IT)
- To be confirmed
- To be confirmed
- To be confirmed
- A. De La Taille, Créteil (FR)
- To be confirmed
- To be confirmed
- To be confirmed
- N.N. Harke, Hannover (DE)
- To be confirmed
- P. Wiklund, Stockholm (SE)
- C. Vaessen, Paris (FR)
- To be confirmed
- To be confirmed
- E. Liatsikos, Patras (GR)
- To be confirmed

Learning objectives

A comprehensive update of the new robotic systems in the market, with detailed tips and tricks on major robotic procedures in 2022.

14:15 - 14:20

Welcome and introduction

A. Breda, Barcelona (ES)

14:20 - 15:00

Session I-A: Intuitive

14:20 - 14:30

Da Vinci “and its variants” (X, Xi, SP)

To be confirmed

Partial nephrectomy

14:30 - 14:36

Video-assisted PowerPoint presentation Transperitoneal

B.J. Challacombe, London (GB)

14:36 - 14:42

Video-assisted PowerPoint presentation Retroperitoneal

A. Breda, Barcelona (ES)

14:42 - 14:48

Video-assisted PowerPoint presentation Single-port

To be confirmed

Pieloplasty

14:48 - 14:54

Video-assisted PowerPoint presentation X, Xi

N.M. Buffi, Milan (IT)

14:54 - 15:00

Video-assisted PowerPoint presentation Single-port

S.C. Crivellaro, Chicago (US)

Scientific Programme - EAU22 Amsterdam

15:00 - 15:37	Session I-B: Intuitive
	Prostatectomy
15:00 - 15:07	Video-assisted PowerPoint presentation Xi To be confirmed
15:07 - 15:14	Video-assisted PowerPoint presentation Single-port To be confirmed
15:14 - 15:21	Video-assisted PowerPoint presentation Single-port extraperitoneal To be confirmed
	Cystectomy
15:21 - 15:29	Video-assisted PowerPoint presentation Cystectomy + Neobladder C.J. Wijburg, Arnhem (NL)
15:29 - 15:37	Video-assisted PowerPoint presentation Single-port cystectomy P. Wiklund, Stockholm (SE)
15:37 - 16:01	Session I-C Intuitive
15:37 - 15:45	State-of-the-art lecture Inguinal LDN for penile cancer J.M. Gaya Sopena, Barcelona (ES)
15:45 - 15:53	State-of-the-art lecture RPLND for testis cancer: The Seattle technique To be confirmed
15:53 - 16:01	State-of-the-art lecture Kidney transplantation To be confirmed
16:01 - 17:05	Session II: Medtronic: The Hugo “Boss”
	Partial Nephrectomy
16:01 - 16:11	Semi-live Transplertitoneal To be confirmed
16:11 - 16:21	Semi-live Retroperitoneal To be confirmed
	Radical prostatectomy
16:21 - 16:41	Semi-live Tips and tricks A. Breda, Barcelona (ES)
	Radical cystectomy
16:41 - 16:49	Semi-live Cystectomy J. Palou, Barcelona (ES)
16:49 - 16:57	Semi-live Intracorporeal neobladder To be confirmed

Scientific Programme - EAU22 Amsterdam

16:57 - 17:05	Semi-live Kidney transplantation To be confirmed
17:05 - 17:35	Session III: Other robots in the market
17:05 - 17:15	Video-assisted PowerPoint presentation CMR: “The English gentleman” To be confirmed
17:15 - 17:25	Video-assisted PowerPoint presentation Kawasaki: “not only a motorbike” N. Hinata, Hiroshima (JP)
17:25 - 17:35	Video-assisted PowerPoint presentation Other robots here and to come J. Rassweiler, Heilbronn (DE)
17:35 - 17:55	Session IV: Training in robotic surgery
17:35 - 17:45	State-of-the-art lecture How do we train with all this: The importance of metrics and standardization To be confirmed
17:45 - 17:55	State-of-the-art lecture What are the EAU Guidelines expecting from us? M.J. Ribal Caparros, Barcelona (ES)
17:55 - 18:00	Closing remarks

New perspectives in the management of stones

Meeting of the EAU Section of Urolithiasis (EULIS)

Saturday 2 July
14:15 - 17:45

Location	Yellow Area, Room Forum
Chair	C.C. Seitz, Vienna (AT)
Moderators	E. Cicerello, Treviso (IT) P.M. Ferraro, Rome (IT) A. Skolarikos, Athens (GR) To be confirmed To be confirmed A. Papatsoris, Athens (GR) A. Szendrői, Budapest (HU) L. Villa, Milan (IT) To be confirmed S. Guven, Konya (TR) P. Kallidonis, Patras (GR) F. Sanguedolce, Barcelona (ES) To be confirmed To be confirmed D. Prezioso, NAPOLI (IT) B. Somani, Southampton (GB) S. Yalcin, Ankara (TR)
Case presenter	To be confirmed
Panel	L.B. Dragoş, Timisoara (RO) T. Knoll, Sindelfingen (DE) P.J.S. Osther, Fredericia (DK) I. Saltirov, Sofia (BG) To be confirmed

Learning objectives

In addition to the non-surgical medical management, use of new disposable instruments along with the effective application of miniaturized instruments in RIRS and PNL changes traditional treatment concepts by allowing to obtain acceptable treatment success rates with further decreasing complication rates. Expert management of stones in certain complex situations will be Video-demonstrated and discussed. This EULIS session we will take a close look on the recent developments particularly on “new minimally invasive stone treatment procedures” particularly in complex cases and will try to focus on the importance of experience with tips and tricks from the experts by discussing challenging cases in an interactive manner.

14:15 - 14:19	Welcome and introduction
14:15 - 14:19	C.C. Seitz, Vienna (AT)
14:19 - 14:59	Pathophysiology and non-surgical management of stones: An update in the light of recent advances
14:19 - 14:29	Stones and the inflammasome: Immunotherapy a new form of Ca-Ox stone treatment? To be confirmed

Scientific Programme - EAU22 Amsterdam

14:29 - 14:39	Randall's plaques, endoscopic evaluation and metabolic risk status: How could we combine them for recurrence prediction? To be confirmed
14:39 - 14:49	Drug-based stone therapy and recurrence prophylaxis: A refresher of the latest status C.A. Wagner, Zurich (CH)
14:49 - 14:59	Microbiomics and urolithiasis: A key to prophylaxis? J.A. Galán-Llopis, Alicante (ES)
14:59 - 15:39	Video session Miniaturization: The smaller the better in terms of efficacy and adverse events?
14:59 - 15:09	Mini PNL: Stone in the pelvic kidney M. Straub, Munich (DE)
15:09 - 15:19	Mini ECIRS: Bilateral multiple renal stones M. Cepeda, Valladolid (ES)
15:19 - 15:29	RIRS: Complex stone in horseshoe kidney P.A. Geavlete, Bucharest (RO)
15:29 - 15:39	RIRS: Pediatric case E.X. Keller, Zürich (CH)
15:39 - 16:29	New perspectives in the management of stones
15:39 - 15:49	Interventional stone therapy in (very young) children: An interdisciplinary challenge before, during and after the intervention E. Montanari, Milan (IT)
15:49 - 15:59	Revival of shock wave treatment: Why it is meant to stay? K. Sarica, Istanbul (TR)
15:59 - 16:09	New laser technologies: How they will change our approach to stones A. Budía Alba, Valencia (ES)
16:09 - 16:19	Impact of innovation in flexible: URS on indications R. Cansino, Madrid (ES)
16:19 - 16:29	Technology and education in urolithiasis and healthcare: New horizons K. Ahmed, London (GB)
16:29 - 17:04	Case discussion Challenging cases in endourologic management of stones
16:29 - 17:04	Discussion
17:04 - 17:44	Management of renal stones sizing 20-30 mm: What is the preferred approach RIRS or PNL?
17:04 - 17:14	Standard PNL is my preference because... W. Gamal, Sohag (EG)
17:14 - 17:24	Mini-PNL is my preference because... G. Giusti, Milan (IT)

Scientific Programme - EAU22 Amsterdam

17:24 - 17:34	RIRS is my preference because... O. Traxer, Paris (FR)
17:34 - 17:44	Super-mini PNL is my preference because... To be confirmed
17:44 - 17:45	Closing remarks
17:44 - 17:45	C.C. Seitz, Vienna (AT)

The role of infections in urology and difficult to treat situations

Meeting of the EAU Section of Infections in Urology (ESIU)

Saturday 2 July
14:15 - 17:50

Location Grey Area, Room Emerald

Chairs To be confirmed
F.M.E. Wagenlehner, Giessen (DE)

Moderators R. Bartoletti, Pisa (IT)
To be confirmed
J. Corrales Riveros, Lima (PE)
To be confirmed
D. Batura, London (GB)
K. Naber, Straubing (DE)

Learning objectives

Infections in urology are frequent and can have severe consequences in our patients. There are many urological specific situations that need dedicated management. Factors that are associated with urological infections are very heterogenous. This programme deals with specific situations in urological infections, covering renal transplantation, frail patients, urosepsis, viral infections, or HPV. Antimicrobial resistance is a pandemic of its own and strategies are needed to combat this problem. One of the accompanying problems in chronic infections are chronic pelvic pain syndromes, which are alluded to in several examples. Last but not least, novel strategies, such as bacteriophage treatment or vaccination are discussed.

14:15 - 14:20	Welcome and introduction F.M.E. Wagenlehner, Giessen (DE)
14:20 - 16:00	Urological infections in specific patient populations
14:20 - 14:30	The threat of UTI in renal transplant recipients To be confirmed
14:30 - 14:40	Management of asymptomatic bacteriuria in transplant recipients J. Medina Polo, Madrid (ES)
14:40 - 14:50	Right dose of antimicrobials in patients with renal transplants or renal dysfunction S.E. Geerlings, Amsterdam (NL)
14:50 - 15:00	Urinary tract infections and renal injury in frail patients To be confirmed
15:00 - 15:10	Gaps in the treatment of Fournier's gangrene To be confirmed
15:10 - 15:20	Urinary tract infections in patients with urolithiasis M. Vallée, Poitiers (FR)
15:20 - 15:30	Risk factors for ureteral stent-associated urinary tract infections To be confirmed
15:30 - 15:40	What parameters are critical in the management of urosepsis Z. Tandoğdu, London (GB)

Scientific Programme - EAU22 Amsterdam

15:40 - 15:50	Urinary tract infections of viral origin L. Schneidewind, Greifswald (DE)
15:50 - 16:00	Genital infections with HPV – short and long term sequelae T. Cai, Trento (IT)
16:00 - 16:35	Antibiotic resistance – how to stratify and what is to come
16:00 - 16:10	EMA priorities on antibiotic usage in urological infections To be confirmed
16:10 - 16:15	WHO priorities of antibiotic resistance G. Bonkat, Basel (CH)
16:15 - 16:20	Antibiotic resistance in outpatients To be confirmed
16:20 - 16:25	Antibiotic resistance in catheter associated UTI To be confirmed
16:25 - 16:30	Antibiotic resistance in urological patients: Outcome from the GPIU study To be confirmed
16:30 - 16:35	Therapeutic options in multiresistant/carbapenem resistant pathogens R. Bartoletti, Pisa (IT)
16:35 - 16:55	Antibiotic prophylaxis in specific patient populations
16:35 - 16:45	State-of-the-art lecture Prostate biopsy: Future trends B. Pradere, Vienna (AT)
16:45 - 16:55	State-of-the-art lecture Female: Antibiotic prophylaxis in patients undergoing pelvic surgery E. Costantini, Perugia (IT)
16:55 - 17:15	Infection and inflammation in chronic pelvic pain/bladder pain syndromes
16:55 - 17:05	Immunomodulation: A molecular solution in patients with bladder pain syndrome/ interstitial cystitis? B. Wullt, Lund (SE)
17:05 - 17:15	Pain pathways in chronic pain syndromes: All the same? To be confirmed
17:15 - 17:50	Alternative treatments of recurrent infections
17:15 - 17:25	Bacteriophages: What are the right phages? To be confirmed
17:25 - 17:35	Bacteriophages: What are the right patients? L. Leitner, Zürich (CH)
17:35 - 17:45	Vaccination of Urinary tract infections: Where do we stand? To be confirmed

17:45 - 17:50

Closing remarks

To be confirmed

Prostate cancer screening and active surveillance – Where are we now?

ESU Course 17

Saturday 2 July
14:30 - 17:30

Location Grey Area, Room G102

Chair A.R. Zlotta, Toronto (CA)

Learning objectives

- Prostate cancer is a global public health concern. While large randomized trials have shown a reduction in prostate cancer mortality with regular prostate-specific antigen (PSA) screening, there is potential for negative effects from over-diagnosis and treatment, making screening a controversial topic. This course will provide an overview of the evidence of both benefits and harm from the randomized trials as well as data from epidemiological studies illustrating the global incidence and mortality trends.
- Today's challenges include the age when to start screening, screening intervals and the optimal use of "smarter screening". This course will cover the EAU-ESTRO-SIOG guidelines and other risk-stratified approaches to screening based on age, health and PSA-values, family history, ethnicity and genetic risk.
- Active surveillance (AS) is now widely accepted as a management strategy for low risk prostate cancer with definitive treatment used if there is evidence that the patient is at increased risk for disease progression. Several AS studies have consistently shown a low rate of progression to metastatic disease or death from prostate cancer with AS, with the majority of patients remaining free from definitive therapy for many years.
- Clinical and pathological factors influencing the risk of disease progression in patients with low risk prostate cancer under AS, surveillance strategy, role of repeat biopsy, inclusion criteria, and the use of MRI will be discussed.
- The course will be interactive and include illustrative and practical clinical case discussions.

Who, when and how often to screen and when to stop? An illustrated risk-adapted strategy

S. Carlsson, New York (US)

Active surveillance

A.R. Zlotta, Toronto (CA)

TBC

M. Eklund, Stockholm (SE)

Practical aspects of cancer pathology for urologists. The 2022 WHO novelties

ESU Course 18

Saturday 2 July
14:30 - 16:30

Location Grey Area, Room G103

Chair E. Compérat, Paris (FR)

Learning objectives

This course treats urogenitary pathology. We want to improve the urologist-pathologist interaction, understanding of the whole diagnostic spectrum and to update urologists with the new WHO classification 2020

- Optimal handling of pathology specimen.
- When ask for frozen sections, surgical margins.
- Pathology report. Read and understand all included information.
- Novelties in Uro-Onco Pathology. Applications in daily practice.

Consensus conference on Gleason Grading: Proposal for a new grading system

E. Compérat, Paris (FR)

Bladder cancer classification: What is new in 2022: Classical grading and molecular grading, how to integrate?

E. Compérat, Paris (FR)

Kidney tumours with the 2022, WHO eyes

F. Algaba, Barcelona (ES)

Testis tumours: New insights with clinical impact

F. Algaba, Barcelona (ES)

Updates and controversies: Urolithiasis, Non-neurogenic Female and Male LUTS guidelines 2022: What has changed?

ESU Course 19

Saturday 2 July
14:30 - 16:30

Location Grey Area, Room G104

Chair A.K. Nambiar, Newcastle-upon-Tyne (GB)

Learning objectives

This course will focus on 3 non-oncology guidelines (Non-Neurogenic Female and Male LUTS, and Urolithiasis).

There will be a brief review of the EAU guidelines methodology and process of guideline development.

The course will then involve an interactive discussion of the main new changes to these guidelines, challenges in development, areas of inconsistency and opportunities for further research.

Welcome and introduction

A.K. Nambiar, Newcastle-upon-Tyne (GB)

Urolithiasis guideline: New Diagnostic algorithms, Best clinical practice in urinary stone intervention, How and how often to follow-up and time to discharge urinary stone patients after treatment

R. Geraghty, Newcastle upon Tyne (GB)

Non-neurogenic male LUTS guideline: Updates and controversies

J-N.L. Cornu, Rouen (FR)

Female Non-neurogenic LUTS: A re-birth, revamp and re-naming. Changes to expect in 2022

A.K. Nambiar, Newcastle-upon-Tyne (GB)

Lymphadenectomy in urological malignancies

ESU Course 20

Saturday 2 July
14:30 - 17:30

Location Grey Area, Room G105

Chair A. Mattei, Luzern (CH)

Learning objectives

Mostly, in case of tumour surgery, a loco-regional lymph node (LND) dissection is also indicated.

With the introduction of minimal invasive surgery the LND often seems to have lost the attention of the surgeons and has been practiced in less cases and/or less extensively.

Throughout our presentation we will corroborate the indications when a LND has to be performed, the templates, the techniques using different approaches and the oncological as well as functional outcomes.

After attending this course, participants should be able to:

- Know the indication when to perform LND during surgery for urological malignancies.
- Apply the most modern imaging concepts for the preoperative lymph node staging.
- Have solid knowledge about the templates that have to be removed.
- Be informed concerning the oncological and functional results of lymph node dissection as well as complications.

Welcome and introduction

A. Mattei, Luzern (CH)

Penile cancer

C.D. Fankhauser, Manchester (GB)

Prostate cancer

A. Mattei, Luzern (CH)

Urothelial cancer

A. Mattei, Luzern (CH)

Renal cancer

U. Capitanio, Milan (IT)

Testicular cancer

C.D. Fankhauser, Manchester (GB)

Retropubic radical prostatectomy: Tips, tricks and pitfalls

ESU Course 21

Saturday 2 July
14:30 - 17:30

Location Grey Area, Room G106

Chair O. Hakenberg, Rostock (DE)

Learning objectives

In many parts of Europe, open retropubic radical prostatectomy is still the gold standard for treating localised prostate cancer. The competition with radiotherapy and novel techniques like cryosurgery and HIFU, should encourage urologists to optimally perform the surgical resection.

This teaching course is a must for the elder resident and the younger urologist but well trained urologists who do not treat many patients with localised prostate cancer, will benefit.

Introduction

O. Hakenberg, Rostock (DE)

Surgical anatomy

O. Hakenberg, Rostock (DE)

Step by step radical retropubic prostatectomy

G.N. Thalmann, Bern (CH)

Tips, tricks and pitfalls

O. Hakenberg, Rostock (DE)

Treatment of complications

G.N. Thalmann, Bern (CH)

Discussion and interaction

O. Hakenberg, Rostock (DE)

Practical neuro-urology

ESU Course 22

Saturday 2 July
14:30 - 16:30

Location Grey Area, Room G107

Chair F. Cruz, Porto (PT)

Learning objectives

The course aims to introduce the basic principles of the diagnostic work-up and management of the common micturition dysfunctions in neurological disease. The early introduction of correct management contributes to the patient's quality of life and prevents potential complications for neurological patients.

The main aims are:

- To refresh the pathophysiology and the key points of the investigation and management of patients with neurogenic bladder dysfunction.
- To apply those principles to specific diseases, namely spinal cord injury, multiple sclerosis, Parkinson's disease and stroke.
- To discuss with real life clinical cases pharmacological and surgical options available for the management of neuro-urological patients.

Introduction

F. Cruz, Porto (PT)

Pathophysiology and key points of the investigation of neurogenic bladder dysfunction

M. Drake, Bristol (GB)

Management of neurogenic bladder dysfunction: Key principles

F. Cruz, Porto (PT)

Patient with cerebral vascular accident

M. Drake, Bristol (GB)

Patient with spinal cord injury

F. Cruz, Porto (PT)

Patient with Parkinson's disease

M. Drake, Bristol (GB)

Patient with Multiple Sclerosis

F. Cruz, Porto (PT)

Conclusion

F. Cruz, Porto (PT)

M. Drake, Bristol (GB)

Urinary tract and genital trauma

ESU Course 16

Saturday 2 July
11:00 - 14:00

Location Grey Area, Room G106

Chair N. Kitrey, Ramat Gan (IL)

Learning objectives

Trauma is a leading cause of morbidity and death. Most urologists are involved in the management of trauma patients, therefore need to understand and follow the basic principles.

The ESU urological trauma course details the epidemiology, mechanism of action, diagnosis, and management of urogenital trauma – renal, ureteric, bladder, urethra, and external genitalia. The course is based on the peer-reviewed yearly-updated EAU guidelines on urological trauma. Interactive case-based discussion will highlight the key points of trauma management.

Introduction and trauma management principles

N. Kitrey, Ramat Gan (IL)

Renal trauma

To be confirmed

Renal trauma case

N. Kitrey, Ramat Gan (IL)

N. Lumen, Ghent (BE)

To be confirmed

Ureteral trauma

N. Lumen, Ghent (BE)

Bladder trauma

N. Kitrey, Ramat Gan (IL)

Urethral trauma

N. Lumen, Ghent (BE)

Urethral trauma case

N. Kitrey, Ramat Gan (IL)

N. Lumen, Ghent (BE)

To be confirmed

Genital trauma

To be confirmed

Prostate cancer screening and early detection - Reloaded!

Abstract Session 20

Saturday 2 July
15:00 - 16:30

Location Orange Area, Room 2
Chairs F. Abdollah, Detroit (US)
B.A. Hadaschik, Essen (DE)
M.J. Roobol, Rotterdam (NL)

15:00 - 15:03	Introduction The difference between early detection and screening – What we need to know and change as urologists M.J. Roobol, Rotterdam (NL)
	Research/Genetics
15:03 - 15:08	Introduction
A0352	A urinary exosome assay interrogating small non-coding RNAs accurately identifies and stratifies prostate cancer into low- intermediate- or high-risk disease
A0353	Awareness of risk of prostate cancer (PCa) remains poor in families with germline mutations in DNA-repair genes
A0354	Novel germline mutations affect disease specific outcomes in men with familial prostate cancer
15:14 - 15:21	Discussion
	Risk stratification 1
A0355	Baseline PSA below 1.0 ng/ml, and then? Verification of the EAU 2021 Position and Recommendation on risk-adapted early detection using ERSPC Rotterdam data with more than 20 years of detailed follow-up M.J. Roobol, Rotterdam (NL)
A0356	Bother during screening for prostate cancer with PSA followed by MRI and transrectal biopsies R. Arnsrud Godtman, Göteborg (SE)
A0357	An evaluation of screening pathways using a combination of MRI and PSA: Results from the IP1-PROSTAGRAM study
A0358	Prostate cancer screening: A novel risk prediction tool with standard biopsies vs. PSA with MRI-targeted biopsies L. Björnebo, Stockholm (SE)
15:29 - 15:36	Discussion
	Risk stratification 2
A0359	Relevance of digital rectal examination in presence of low PSA levels
A0360	Natural history of patients discharged after low-risk findings at pre-biopsy mpMRI of the prostate – the emerging role of PSA-density in risk stratification L. Orecchia, Roma (IT)

Scientific Programme - EAU22 Amsterdam

A0361	Re-thinking how we use prostate health index for African American men K. Morris, Durham (US)
A0362	Long-term effects of 5α-reductase inhibitors on prostate cancer mortality: A large population-based prospective study L. Björnebo, Stockholm (SE)
15:44 - 15:51	Discussion
	Outcome
A0363	How long do men stay in intermediate stages between randomization and death: Results of ERSPC Rotterdam S. Remmers, Rotterdam (NL)
A0364	The value of systematic biopsies in screening for prostate cancer with PSA followed by MRI – results from the GÖTEBORG prostate cancer screening 2 trial
A0365	Men's estimation of life-time risk of receiving a prostate cancer diagnosis, results from the Göteborg-2 prostate cancer screening trial E. Palmstedt, Lidköping (SE)
A0366	Longitudinal outcomes following implementation of baseline PSA risk stratification of men in their forties Z.D. Michael, Durham (US)
A0367	Twenty-year outcome of men participating in a screening trial with an initial negative prostate biopsy
16:01 - 16:08	Discussion
	Politics
A0368	Designing and implementing an organized prostate cancer testing program E. Järbur, Jörlanda (SE)
A0369	Identifying men affected by changes in PSA screening in the COVID-19 pandemic E.J. Bass, London (GB)
A0370	Shifting risk-stratified early detection of prostate cancer to primary health care R. Hogenhout, Rotterdam (NL)
A0371	A novel EAU Guidelines based clinicial decision support software – Evaluation of Siemens AIPC Software in prostate cancer screening C. Engesser, Basel (CH)
16:16 - 16:23	Discussion
16:23 - 16:30	Closing remarks

8th ESO Prostate Cancer Observatory: Innovations and care in the next 12 months

Special Session



Saturday 2 July
15:45 - 17:45

Location Grey Area, eURO Auditorium 2

Chairs M. Salmon, Milan (IT)
U. Vogl, Bellinzona (CH)

Learning objectives

ESO Observatories are high-level sessions organised during major international congresses with the aim of providing the audience with updated and unbiased information on a given topic. An ESO Observatory lasts about one hour and concentrates on a forecast given by panel of experts of what it is expected to happen in their own field in the coming 12 months. The panel includes distinguished clinicians and/or scientists and a patient advocate. The forecast by each Panel Member is given in the form of concise take-home messages with 8 minute slide presentation for each topic + 2 minutes for discussion.

15:45 - 15:50

Welcome and introduction

15:50 - 16:00

The urologist's perspective on surgery
S. Joniau, Leuven (BE)

16:00 - 16:10

The urologist's perspective on active surveillance
P. Cornford, Liverpool (GB)

16:10 - 16:20

The radiation oncologist's perspective
G. De Meerleer, Leuven (BE)

16:20 - 16:30

The medical oncologist's perspective
R. Pereira Mestre, Bellinzona (CH)

16:30 - 16:40

The pathologist's perspective
E. Comp  rat, Paris (FR)

16:40 - 16:50

The geneticist's perspective
E. Castro, Madrid (ES)

16:50 - 17:00

The imaging specialist's perspective on PSMA-PET/CT
S. Fanti, Bologna (IT)

17:00 - 17:10

The imaging specialist's perspective on MRI
J. Barentsz, Nijmegen (NL)

17:10 - 17:20

The urologist's perspective on focal therapy
R. Sanchez-Salas, Montreal (CA)

17:20 - 17:30

The nurse's perspective
C.N. Tillier, Amsterdam (NL)

17:30 - 17:40

The patient's perspective
M. Salmon, Milan (IT)

17:40 - 17:45

Closure and take home message

Different approaches to RARP

Video Session 7

Saturday 2 July 16:00 - 17:30	Location	Green Area, Room 2
	Chairs	J.W. Collins, London (GB) To be confirmed To be confirmed
	All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.	
16:00 - 16:03	Introduction	
V42	Igloo-technique for robotic radical prostatectomy — maximum nerve sparing for early recovery of continence and sexual function C.D. Fankhauser, Manchester (GB)	
V43	Robotic radical prostatectomy for prostate cancer in renal transplant recipients: Results from a multicenter series G. Marra, Turin (IT)	
V44	Varying approaches to the prostate apex to optimize urethral stability and early continence recovery after robotic radical prostatectomy C. Mercader Barrull, Barcelona (ES)	
V45	Retzius-sparing robot-assisted radical prostatectomy in high-risk prostate cancer patients P. Dell'Oglio, Milan (IT)	
V46	Bladder-neck sparing robot assisted radical prostatectomy: Step-by step procedure F. Sessa, Florence (IT)	
V47	Robot assisted radical prostatectomy by lateral approach: technique, reproducibility, and outcomes	
17:12 - 17:17	Closing remarks	

New insights in the management of upper tract urothelial cancer

Abstract Session 16

Saturday 2 July
12:30 - 14:00

Location Green Area, Room 3
Chairs Y. Farahat, Umm Al Quwain (AE)
M. Moschini, Milan (IT)
S. Shariat, Vienna (AT)

Improving diagnosis

12:30 - 12:33

Introduction

- | | |
|---------------------------|--|
| A0287 | Xpert® bc detection as a diagnostic tool in upper urinary tract urothelial carcinoma: Preliminary results
C. D'Elia, Bolzano (IT) |
| A0288 | Clinical performance of Xpert Bladder Cancer test in patients with upper urinary tract cancer: Results and possibilities for future use |
| A0289 | Optimizing ureterorenoscopic biopsy quality in the upper urinary tract by cryobiopsy
J-T. Klein, Ulm (DE) |
| A0290 | Detection of individualized mutation using plasma and urinary circulating tumor DNA in patients with upper tract urothelial carcinoma
D. Tamura, Morioka (JP) |
| A0291 | Thulium fiber vs. thulium yag laser effect on upper urinary tract soft tissue: An ex vivo study |
| 12:43 - 12:57 | |
| Discussion | |
| Surgical treatment | |
| A0292 | Elevated hemoglobin: Creatinine ratio is a novel preoperative marker for worsened survival outcomes in upper tract urothelial carcinoma: Analysis from the robuust registry |
| A0293 | Renal function variation after nephroureterectomy for upper urinary tract carcinoma: Evaluation in a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium) |
| A0294 | Laparoscopic vs. Robot-assisted nephroureterectomy: Propensity score matched comparison of surgical and early oncologic outcomes
A. Brassetti, Rome (IT) |
| A0295 | Benefit of lymph node dissection in cn+ patients in the treatment of upper tract urothelial carcinoma: Analysis of ncdb registry
F. Abdollah, Detroit (US) |
| A0296 | Clinical significance of tumor location for ureteroscopic tumor grading in upper tract urothelial carcinoma |

Scientific Programme - EAU22 Amsterdam

A0297	Survival impact of nephroureterectomy for de novo stage IV (non-metastatic and metastatic) upper tract urothelial carcinoma
A0298	Eleven years of experience with UTUC: Survival and renal function after kidney sparing surgery versus radical nephroureterectomy N. Hendriks, Den Haag (NL)
13:11 - 13:25	Discussion
	Systemic treatment
A0299	Contemporary trends of systemic neoadjuvant and adjuvant intravesical chemotherapy for upper tract urothelial carcinomas undergoing minimally invasive or open radical nephroureterectomy: US-claims analysis on perioperative and health care costs outcomes F. Del Giudice, Rome (IT)
A0300	The impact of adjuvant chemotherapy on overall survival in patients with node-positive Upper Tract Urothelial Carcinoma (UTUC): Improving precision in medicine with a risk-stratified approach F. Abdollah, Detroit (US)
A0301	Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results of a phase II study
A0302	Biodegradable device for controlled release of cisplatin as local chemotherapy for bladder cancer
A0303	Modified dual time point 18F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract urothelial carcinoma
A0304	Oncologic surveillance for variant histology upper tract urothelial carcinoma
A0305	Implementing the follow-up schedule after radical nephroureterectomy for low risk upper tract urothelial carcinoma A. Martini, Milan (IT)
A0306	Impact of node count on survival outcomes of lymph node dissection in non-metastatic upper tract urothelial carcinoma: Analysis of the robuust registry K. Hakimi, Encino (US)
13:41 - 13:55	Discussion
13:55 - 14:00	Closing remarks

Metastasectomy and systemic treatment in mRCC - What can we achieve?

Abstract Session 21

Saturday 2 July
16:00 - 17:30

Location Green Area, Room 5
Chairs I. Duran, Santander (ES)
M. Oya, Tokyo (JP)
T-C. Wei, Taipei (TW)

Pros and cons of local treatment in mRCC

16:00 - 16:03

Introduction

A0372	Oncological results of cytoreductive partial nephrectomy in mRCC patients
A0373	Perioperative morbidity of surgical metastasectomy for renal cell carcinoma: An international multicenter study E. Roussel, Brugge (BE)
A0374	Surgical management and oncologic outcomes for local recurrence of renal cell carcinoma after radical nephrectomy J. Huang, Shanghai (CN)
A0375	Local treatment of metastasis in metastatic RCC may have a significant survival effect across all risk of recurrence groups L. Serra De Oliveira Marconi, Coimbra (PT)
A0376	Robotic radiosurgery for the treatment of lung metastases of renal cell carcinoma S. Rodler, Munich (DE)
A0377	Pancreatic metastases after surgery for renal cell carcinoma
16:15 - 16:26	
Discussion	
Prognostic factors in mRCC	
A0378	Prognostic impact of clear cell renal cell carcinoma molecular subtypes determined on formalin-fixed paraffin-embedded tissue samples on outcome after complete surgical metastasectomy E. Roussel, Brugge (BE)
A0379	A novel prognostic biomarker to predict tumor mutation burden based on deep learning from slide images
A0381	A novel nomogram predicting the overall survival of metastatic non-clear cell renal cell carcinoma patients: A large population-based investigation
A0382	Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: A systematic review and network meta-analysis F. Quhal, Vienna (AT)

16:36 - 16:47

Discussion

First-line treatment

A0383	First-line immunotherapy-based combinations for metastatic renal cell carcinoma: Systematic review and network meta-analysis F. Quhal, Vienna (AT)
A0384	First-line treatment in advanced renal cell carcinoma: A quasi-individual patient data meta-analysis
A0385	Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta-analysis of safety R. Xie, Beijing (CN)
A0386	Association between immune-related adverse events and clinical outcomes in advanced genitourinary cancers treated with immunotherapy: A systematic review and meta-analysis
16:55 - 17:06	Discussion
	Further aspects of systemic treatments
A0387	PD-L1 expression on renal cell carcinoma-derived exosomes and its effect on CD8+ T cells G. Jaschkowitz, Homburg/Saar (DE)
A0388	Deciphering the mechanistic role of PBRM1 loss in inflammatory and morphogenic signalling within the tumour microenvironment of clear cell renal cell carcinoma N. Klümper, Bonn (DE)
A0389	The effect of anti-cancer therapy on immunological response to COVID-19 vaccination F.E. Jackson-Spence, London (GB)
A0390	Microwave ablation combined with anti-PD-1/CTLA-4 therapy induces anti-tumor immune response to renal cell carcinoma in a Murine Model R-Q. Guo, Beijing (CN)
17:14 - 17:25	Discussion
17:25 - 17:30	Closing remarks

PCa high-risk local treatment

Plenary Session 05

Sunday 3 July
08:00 - 10:15

Location Orange Area, eURO Auditorium 1

Chairs A. Bossi, Villejuif (FR)
A. Briganti, Milan (IT)

Panel G. De Meerleer, Leuven (BE)
S. Fanti, Bologna (IT)
C. Sweeney, Boston (US)
To be confirmed

08:00 - 08:05	Welcome and introduction
08:05 - 08:25	Debate Optimal definition of high risk disease in 2022: Do we really need novel genomic classifications?
08:05 - 08:13	Yes, genomics should be incorporated To be confirmed
08:13 - 08:21	No, clinical features and MRI based pathology are enough S. Joniau, Leuven (BE)
08:21 - 08:25	Discussion
08:25 - 08:45	How does MRI change the local strategy in high risk men?
08:25 - 08:35	State-of-the-art lecture Surgery To be confirmed
08:35 - 08:45	State-of-the-art lecture Radiation therapy G. De Meerleer, Leuven (BE)
08:45 - 09:05	Debate Is upfront staging with PSMA PET beneficial for high risk patients?
08:45 - 08:53	Yes T. Maurer, Hamburg (DE)
08:53 - 09:01	No A. De La Taille, Créteil (FR)
09:01 - 09:05	Discussion
09:05 - 09:15	American Urological Association (AUA) lecture Genetic Testing in Localized Prostate Cancer: When and How To be confirmed
09:15 - 09:35	Debate What is the optimal multimodal approach for high risk patients?
09:15 - 09:23	Combination treatments N.W. Clarke, Manchester (GB)
09:23 - 09:31	Treatment sequencing C. Sweeney, Boston (US)

Scientific Programme - EAU22 Amsterdam

09:31 - 09:35	Discussion
09:35 - 09:55	Clinical case discussion Limited bone involvement detected by PSMA PET only: From curative to palliative treatment?
09:35 - 09:37	Case presentation: This is a palliative situation! C.V. Kesch, Essen (DE)
09:37 - 09:42	Yes N. Mottet, Saint-Étienne (FR)
09:42 - 09:47	No S.G.C. Kroeze, Zurich (CH)
09:47 - 09:55	Discussion
09:55 - 10:15	Clinical case discussion Biochemical relapse after radical prostatectomy: What is the optimal management strategy?
09:55 - 09:57	Case presentation G. Baciarello, Milan (IT)
09:57 - 10:15	Discussion

Personalised surgical management of LUTS/BPO

Plenary Session 06

Sunday 3 July
08:00 - 10:00

Location	Grey Area, eURO Auditorium 2
Chairs	J-N.L. Cornu, Rouen (FR) C. Gratzke, Freiburg (DE)
Panel	D. Abt, Biel-Bienne (CH) T. Bach, Hamburg (DE) C. De Nunzio, Rome (IT) To be confirmed S. Gravas, Larissa (GR) T.R.W. Herrmann, Frauenfeld (CH) S. Malde, London (GB) V. Misrai, Toulouse (FR) M. Rieken, Zürich (CH) B. Somani, Southampton (GB) K.A.O. Tikkinen, Helsinki (FI)

08:00 - 08:03	Welcome and introduction
08:03 - 08:18	Société Internationale d'Urologie (SIU) lecture The optimal work-up before BPO surgery: What is essential and what is optional? D. Elterman, Toronto (CA)
08:18 - 09:25	Which surgical intervention is best for LUTS BPO management?
08:18 - 08:20	Case presentation S. Malde, London (GB)
08:20 - 08:25	Resection: Still gold standard? S. Madersbacher, Vienna (AT)
08:25 - 08:30	Enucleation: The new normal? T.R.W. Herrmann, Frauenfeld (CH)
08:30 - 08:35	Vaporisation of the prostate V. Misrai, Toulouse (FR)
08:35 - 08:40	Waterjet ablation (Aquablation®) T. Bach, Hamburg (DE)
08:40 - 08:45	Vapour thermal therapy (Rezüm®) B. Somani, Southampton (GB)
08:45 - 08:50	Prostatic urethral lift (Urolift®) To be confirmed
08:50 - 08:55	Temporarily-placed urethral opening system (i-TIND®) C. De Nunzio, Rome (IT)
08:55 - 09:00	Prostatic artery embolization D. Abt, Biel-Bienne (CH)

Scientific Programme - EAU22 Amsterdam

09:00 - 09:10	Setting the certainty of evidence required for implementation of a novel technique in BPO S. Gravas, Larissa (GR)
09:10 - 09:20	How should we define surgical success/failure regarding patient expectations? K.A.O. Tikkinen, Helsinki (FI)
09:20 - 09:25	The long term view: Introducing the concept of sequential management of male LUTS M. Rieken, Zürich (CH)
09:25 - 09:50	Panel discussion How to choose what's best? Expert focus on clinical pictures
09:50 - 09:55	The future of surgical treatment for male LUTS: What's in the pipeline? C. Gratzke, Freiburg (DE)
09:55 - 10:00	Closing remarks

Flexible ureterorenoscopy and retrograde intrarenal surgery: Instrumentation, technique, tips, tricks and indications

ESU Course 24

Friday 1 July
10:00 - 13:00

Location Grey Area, Room G106

Chair O. Traxer, Paris (FR)

Learning objectives

The aims and objectives of this course is to provide a complete overview of instruments, endoscopes, indications, technique and special tips and tricks concerning Retrograde IntraRenal Surgery (RIRS) using flexible ureterorenoscopes and Holmium YAG lasers. At the end the participants will know the equipment and the technique to perform flexible ureterorenoscopy in the best conditions.

- To learn about equipment.
- To learn about technique and indications.
- To learn how to use an Holmium Laser.
- To learn tips and tricks for special circumstances.

Welcome and introduction

O. Traxer, Paris (FR)

Instrumentation: Endoscopes

O. Traxer, Paris (FR)

Instrumentation: Laser and lithotripsy devices

M. Grasso, New York (US)

Instrumentation: Disposable (wires, retrieving devices, ureteral access sheath (UAS), irrigation devices and others)

P.J.S. Osther, Fredericia (DK)

Technique: Stones

O. Traxer, Paris (FR)

Technique: Urothelial tumours and strictures

M. Grasso, New York (US)

Tips and tricks and special circumstances

O. Traxer, Paris (FR)

Indications (guidelines) and clinical cases

P.J.S. Osther, Fredericia (DK)

Conclusions

O. Traxer, Paris (FR)

Male genital diseases

ESU Course 25

Sunday 3 July
08:30 - 11:30

Location Grey Area, Room G103

Chair S. Minhas, London (GB)

Learning objectives

This novel and revised course will give a state of the art update on the variety of genital diseases that Urologists will encounter in everyday clinical practice. The faculty consists of a group of internationally renowned experts in this field.

A spectrum of pathologies can affect the male genitals, from benign disorders to cancers. There will be particular focus and emphasis on interactive case based discussions and surgical videos of the latest surgical techniques used in this evolving field. The course will also deal with the surgical management of these diseases including the surgical indications and techniques used in genital reconstructive surgery. Particular focus will be on:

- The aetiology, diagnosis and medical management of the common genital skin diseases including inflammatory conditions.
- The medical and surgical management of HPV, BXO and pre-malignant conditions of the penis, including the techniques of circumcision, skin grafting, glans resurfacing, surgery for buried penis and the correction of genital lymphoedema.
- The surgical management of Peyronie's disease including plication procedures and grafting
- The management of penile carcinoma including the aetiopathogenesis, techniques/ outcome of organ sparing surgery and ilioinguinal lymphadenectomy will be discussed and illustrated.

Surgical management of Peyronie's disease

S. Minhas, London (GB)

Penile and scrotal dermatology for the urologist

N. Watkin, London (GB)

Circumcision, frenuloplasty and preputioplasty

C. Protzel, Schwerin (DE)

The buried penis

S. Minhas, London (GB)

Management of genital lymphoedema

N. Watkin, London (GB)

Premalignant lesions of the penis and scrotum

S. Minhas, London (GB)

Penile cancer- penile preserving surgery

N. Watkin, London (GB)

Penile cancer- management of lymph nodes

C. Protzel, Schwerin (DE)

Metastatic prostate cancer

ESU Course 26

Sunday 3 July
08:30 - 11:30

Location Grey Area, Room G104

Chair A.S. Merseburger, Lübeck (DE)

Learning objectives

The three lectures of ESU course 22 will provide comprehensive state-of-the-art information about currently available therapies for hormone-naïve and castration resistant prostate cancer, such as various forms of primary androgen deprivation, immunotherapy, chemotherapy, and therapies approved for CRPC. After the course, attendees should be able to adequately treat patients with metastatic prostate cancer at all disease stages.

Treatment of castration-sensitive metastatic prostate cancer

A.S. Merseburger, Lübeck (DE)

What is the role of chemotherapy and immunotherapy in patients with castration-resistant prostate cancer (CRPC)?

E. Efstathiou, Houston (US)

Treatment of mCRPC – Sequence or combination?

B. Tombal, Brussels (BE)

Case discussion

E. Efstathiou, Houston (US)

A.S. Merseburger, Lübeck (DE)

B. Tombal, Brussels (BE)

Focal therapy in prostate cancer

ESU Course 27

Sunday 3 July
08:30 - 11:30

Location Grey Area, Room G105

Chair E. Barret, Paris (FR)

Learning objectives

Focal treatment (FT) is about eradicating the cancer lesion within the prostate while preserving genitourinary function. This interactive course offers delegates

- understanding of the rationale for focal treatment and patient selection criteria.
- update on principles, outcome and side effects of focal technologies.
- a thorough discussion of biopsy strategies and imaging in diagnostic work-up and follow-up
- information about existing registries.

As men with prostate cancer are getting younger the side effects of whole gland treatment are getting more important. With several new technologies available a significant development of focal treatment is expected in the coming years.

Definition, rationale and role in the changing landscape of localised prostate cancer

C. Orczyk, London (GB)

Patients selection tools

M. Valerio, Lausanne (CH)

How to select the energy source?

E. Barret, Paris (FR)

The post-treatment monitoring

C. Orczyk, London (GB)

The outcomes and the ongoing trials

M. Valerio, Lausanne (CH)

Clinical cases: Real life cases, stories of success and failure

E. Barret, Paris (FR)

Nerve-sparing cystectomy and orthotopic bladder substitution. Surgical tricks and management of complications

ESU Course 28

Sunday 3 July
08:30 - 11:30

Location Grey Area, Room G106

Chair A. Stenzl, Tübingen (DE)

Learning objectives

This course has over many years dealt with the technique of urethra- and nerve-sparing cystectomy and subsequent orthotopic bladder substitution in male and female patients. It will deal with indications, technique, possible complications and their prevention. Urologists with a vast experience in cystectomy and urinary diversion will present technical tips using videoclips, results in the literature as well as own data.

- Technique of nerve-sparing cystectomy.
- Optimization of sphincter preservation for optimal continence results.
- Technical tips and tricks in orthotopic neobladder surgery.
- What to observe in male and female patients.

Preoperative investigations and selection of patients for orthotopic bladder substitution

J.E. Gschwend, Munich (DE)

Arguments for nerve-sparing cystectomy with orthotopic bladder substitution

A. Stenzl, Tübingen (DE)

How to do a nerve-sparing cystectomy in male patients

To be confirmed

Surgical tricks to avoid complications with orthotopic bladder substitution

J.E. Gschwend, Munich (DE)

Video on how to obtain good functional results in female patients

A. Stenzl, Tübingen (DE)

Tips and Tricks: Male/female orthotopic urinary diversion

To be confirmed

How to treat complications during follow-up

J.E. Gschwend, Munich (DE)

Tips and tricks for an orthotopic neobladder

A. Stenzl, Tübingen (DE)

Dealing with the challenge of infection in urology

ESU Course 29

Sunday 3 July
08:30 - 11:30

Location

Grey Area, Room G107

Chair

F.M.E. Wagenlehner, Giessen (DE)

Learning objectives

This ESU course on infection diseases provides a broad, up to date coverage of the most important and recent problems of infectious diseases in urology. Antimicrobial resistance is one of the biggest worldwide challenges in medicine and gains increasing importance in urology. The management of infections in general and of urogenital tract infections especially, has been compromised by this rapid and continuous increase of antimicrobial resistance. Basic biologic principles and strategies to treat urogenital tract infections from benign infections to life threatening infections will be discussed in this course:

- Classification of UTI and surgical field contamination categories as a basis for treatment and prophylaxis.
- Diagnosis, treatment and prophylaxis strategies of urogenital tract infections.
- Uncomplicated and recurrent cystitis.
- Complicated urinary tract infections.
- Urosepsis and Fournier gangrene.
- Male genital tract infections.

Introduction

F.M.E. Wagenlehner, Giessen (DE)

Classification of urinary tract infection (UTI) and surgical field contamination categories as a basis for treatment and prophylaxis

Z. Tandoğdu, London (GB)

Low grade and recurrent UTI

F.M.E. Wagenlehner, Giessen (DE)

Male genital infections: Epididymitis and urethritis

J. Medina Polo, Madrid (ES)

Hospital acquired UTI and antibiotic resistance

Z. Tandoğdu, London (GB)

Perioperative prophylaxis with special focus on prostate biopsies

J. Medina Polo, Madrid (ES)

Sepsis and Fournier's gangrene

F.M.E. Wagenlehner, Giessen (DE)

Semi-live surgery: Robotic reconstructive surgery

Thematic Session 01

Sunday 3 July
10:30 - 11:30

Location Orange Area, eURO Auditorium 1

Chairs A. Ploumidis, Athens (GR)
V. Tugcu, Istanbul (TR)

Learning objectives

The audience will have the chance of increasing their understanding and knowledge on robotic ureteral reconstruction, robotic autotransplantation, robotic re-do anastomosis post bladder neck sclerosis after radical prostatectomy and robotic simple prostatectomy: urethral sparing technique given by the experts by video presentations with interactive live questions & answers and discussion.

10:30 - 10:40

Semi-live video Robotic ureteral reconstruction: Buccal mucosa and more
To be confirmed

10:40 - 10:45

Discussion

10:45 - 10:55

Semi-live video Robotic autotransplantation: Different techniques
To be confirmed

10:55 - 11:00

Discussion

11:00 - 11:10

Semi-live video Robotic re-do anastomosis post bladder neck sclerosis after radical prostatectomy
J. Witt, Gronau (DE)

11:10 - 11:15

Discussion

11:15 - 11:25

Semi-live video Robotic simple prostatectomy: Urethral sparing technique
F. Porpiglia, Turin (IT)

11:25 - 11:30

Discussion

Management of mHSPC

Thematic Session 02

Sunday 3 July
10:30 - 12:00

Location Grey Area, eURO Auditorium 2

Chairs T. Esen, Istanbul (TR)
D. Tilki, Hamburg (DE)

Learning objectives

Diagnosis and management of metastatic hormone naive prostate cancer has changed significantly during recent years. It is the purpose of this session to give an evidence based update on guideline recommended approaches and future perspectives.

With regard to diagnostic procedures, modern methods of molecular imaging are integrated in the pretherapeutic process in order to identify anatomic localization and extent of systemic metastases. The evidence of such an early integration in daily routine is unclear and it needs to be critically reflected.

Patients with mHSPC are to be classified in to low and high risk/volume groups in order to identify the most appropriate therapeutic approach. Furthermore, patients need to be stratified with regard to de novo or metachronous metastatic disease due to differences in the biology of the disease, prognosis and systemic therapy. Furthermore, mHSPC represents a heterogenous disease with various altered molecular pathways which might be integrated into the daily routine for optimal counselling of our patients.

In patients with low risk or low volume mHSPC, local treatment of the primary needs to be considered. The indication, advantage and disadvantage, oncological outcome and treatment associated side effects of radiotherapeutic and surgical options re presented.

Numerous systemic treatment options combining androgen deprivation with AR pathway inhibitors or chemotherapy are available. Patient and tumor specific parameters need to be taken into consideration when counselling the patient. The session will give an update in those decision tools for daily routine practice.

10:30 - 10:31

Welcome and introduction

D. Tilki, Hamburg (DE)

10:31 - 10:41

State-of-the-art lecture PSMA-PET/CT for staging and monitoring of advanced prostate cancer

T. Esen, Istanbul (TR)

10:41 - 10:51

State-of-the-art lecture Biomarkers to tailor systemic therapy in de novo mHSPC: Ready for prime time?

D. Lorente Estellés, Castellón (ES)

10:51 - 11:01

State-of-the-art lecture Local treatment of the primary in mHSPC

J. O'Sullivan, Belfast (GB)

11:01 - 11:11

State-of-the-art lecture Synchronous vs. metachronous mHSPC: What makes the difference?

C. Sweeney, Boston (US)

11:11 - 11:39

Debate Management of de novo mHSPC with oligometastases (cT3cN+cM1a)

Scientific Programme - EAU22 Amsterdam

11:11 - 11:13	Case presentation I. Heidegger, Innsbruck (AT)
11:13 - 11:21	Systemic combination therapy is the best approach E. Efsthathiou, Houston (US)
11:21 - 11:29	Targeted therapy of the primary and metastases is the way to go N.W. Clarke, Manchester (GB)
11:29 - 11:39	Case solution and discussion
11:39 - 11:49	State-of-the-art lecture mHSPC: Doublet vs. triplet combination therapy To be confirmed
11:49 - 11:59	State-of-the-art lecture Future perspectives in the management of mHSPC: Where are we heading to? E.J.K. Axcróna, Lørenskog (NO)
11:59 - 12:00	Closing remarks T. Esen, Istanbul (TR)

Andrology - Male hypogonadism and penile curvature

Abstract Session 22

Sunday 3 July
10:30 - 12:00

Location Green Area, Room 4
Chairs P. Capogrosso, Milan (IT)
M.M. Fode, Herlev (DK)
To be confirmed

10:30 - 10:33

Introduction

Basic research

A0392 Identification of SEMA4D as a novel causal gene of idiopathic hypogonadotropic hypogonadism

10:39 - 10:50

Discussion

Diagnosis and comorbidity

A0394 Firmicutes in gut microbiota correlate with blood testosterone levels in elderly men

A0395 Association between Testosterone and Serum Soluble α -Klotho in U.S. Males: NHANES 2011-2016
Z. Zhang, Chengdu (CN)

A0396 Hyperestrogenism is associated with sexual function impairment in men – findings from a cross-sectional, real-life study
L. Candela, Milan (IT)

A0397 Can we rely solely on total testosterone to screen for male hypogonadism in erectile dysfunction?
A. Morgado, Maia (PT)

A0399 Clinician's impression of erectile dysfunction's aetiology can help decide how extensive should male hypogonadism screening be
A. Morgado, Maia (PT)

A0400 Low testosterone levels and the risk of anemia in middle-aged men: A propensity score-matched analysis
J-H. Lee, Seoul (KR)

A0401 Obesity impairs hypogonadism compensation leading to age-related testosterone decline
C. Silva, Feira de Santana (BR)

11:06 - 11:17

Discussion

Therapy

A0402 The awareness of thromboembolic risk amongst Klinefelter Syndrome (47, XXY) patients- a clot in the knowledge?
S. Birch, London (GB)

Scientific Programme - EAU22 Amsterdam

A0403	Development and validation of a nomogram predicting the need for testosterone replacement (TRACE): A simple tool for everyday clinical practice T. Cai, Trento (IT)
A0404	Anemia due to hypogonadism can be successfully treated in hypogonadal men with testosterone replacement: Real-World data from a controlled Registry Study
A0405	Renal function improves under long-term treatment with testosterone in hypogonadal men with type 2 diabetes K.S. Haider, Bremerhaven (DE)
11:25 - 11:36	Discussion
	Peyronie's disease
A0406	Improvement of erectile function, weight loss and reduced inflammation under long-term treatment with testosterone treatment in hypogonadal men for up to 12 years
A0407	Verapamil for peyronie's disease: A systematic review and meta-analysis of effectiveness and patient reported outcomes
A0408	Surgical and functional outcomes of ventral Z-Plasty for correction of moderate and severe congenital penile curvature M. Omran, Zagazig (EG)
A0409	The outcomes of PICS technique for the management of end-stage Peyronie's disease M. Preto, Turin (IT)
11:44 - 11:55	Discussion
11:55 - 12:00	Closing remarks

Technically challenging partial nephrectomies

Video Session 8

Sunday 3 July
10:30 - 12:00

Location Green Area, Room 2

Chairs J-C. Bernhard, Bordeaux (FR)
A. Breda, Barcelona (ES)
A. Antonelli, Verona (IT)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

10:30 - 10:33

Introduction

V48

Predicting selective arterial clamping strategy in robot assisted partial nephrectomy using 3d simulations
P. De Backer, Aalst (BE)

V49

Sutureless purely off-clamp robotic partial nephrectomy: Technique and perioperative outcomes

V50

Multiple ipsilateral renal masses treated with robot-assisted partial nephrectomy: A multi-institutional series
A. Uleri, Milan (IT)

V51

Precision surgery for Von Hippel-Lindau renal cell carcinoma
A. Larcher, Milan (IT)

V52

Minimally-invasive partial nephrectomy employing 4K visualization system with OPAL 1 near-Infrared and indocyanine green technology
P. Diana, Rozzano, Milan (IT)

V53

ICON3D technology: The intraoperative display for hyper-accuracy 3D models in laparoscopic partial nephrectomy
D. Amparore, Turin (IT)

V54

Three-dimensional digital models in kidney cancer surgery: Results and video-illustrated technique of an institutional series

11:52 - 11:57

Closing remarks

Semi-live surgery: Transition of urological conditions - from childhood to adulthood

Thematic Session 04

Sunday 3 July
10:30 - 12:00

Location Green Area, Room 3

Chairs R. Djinoovic, Belgrade (RS)
S-D. Lee, Busan (KR)

Learning objectives

Patients born with complex congenital genitourinary anomalies (including bladder exstrophy, cloacal exstrophy, epispadias, neurogenic bladder, hypospadias and posterior urethral valves) often require major reconstructive surgery in childhood. These conditions, their treatment and sequelae require lifelong follow-up. This has created the need for adult urologists to provide care as these patients grow into adults. However very little guidance on long-term care exists. Learning objectives of this session is to discuss aspects that are important to transitioning care of pediatric surgical patients with complex or complicated urogenital disorders, and also, to understand the issues facing both pediatric and adult-care clinicians.

10:30 - 10:40

Semi-live video Complicated hypospadias surgery in adolescence & adulthood
P. Hoebeke, Ghent (BE)

10:40 - 10:45

Discussion

10:45 - 10:55

Semi-live video Re-do robotic pyeloplasty in adolescence and adulthood
L. Masieri, Florence (IT)

10:55 - 11:00

Discussion

11:00 - 11:10

Semi-live video Revision of an incontinent or non-functioning stoma in the follow-up of neurogenic bladder patients
To be confirmed

11:10 - 11:15

Discussion

11:15 - 11:25

Semi-live video Revision surgeries after bladder extrophy repairs
To be confirmed

11:25 - 11:30

Discussion

Testis cancer: Pushing boundaries in diagnosis and treatment

Thematic Session 03

Sunday 3 July
10:30 - 12:00

Location Green Area, Room 1
Chairs To be confirmed
M. Jewett, Toronto (CA)

Learning objectives

To better understand some of the rarer but important problems in management of testis tumours including:

- the biological drivers of teratoma 'de-differentiation'
- non-germ cell testis tumours
- stage II seminoma
- stage I non-seminoma with malignant transformation
- complex metastatic disease

10:30 - 10:32

Welcome and introduction

M. Jewett, Toronto (CA)

10:32 - 10:40

State-of-the-art lecture Molecular drivers in malignant transformation of teratoma

D. Nettersheim, Düsseldorf (DE)

10:40 - 10:48

State-of-the-art lecture Management of patients with malignant non-germ cell tumours of the testis

C.D. Fankhauser, Manchester (GB)

10:48 - 11:04

Debate Treatment of marker-negative seminoma stages IIA/B

10:48 - 10:55

RPLND only

To be confirmed

10:55 - 11:02

No RPLND at all

To be confirmed

11:02 - 11:04

Conclusion

J.L. Boormans, Rotterdam (NL)

11:04 - 11:22

Case-based debate It is prime time for biomarker triggered follow-up

11:04 - 11:06

Case presentation

T. Zuiverloon, Rotterdam (NL)

11:06 - 11:13

Guideline recommended approach is to be preferred

M.P. Laguna Pes, İstanbul (TR)

11:13 - 11:20

miRNA371 replaces all

R. Hamilton, Toronto (CA)

11:20 - 11:22

Conclusion

R. Leão, Braga (PT)

11:22 - 11:30

State-of-the-art lecture Management of CS I NSGCT with malignant somatic transformation

S. Daneshmand, Los Angeles (US)

Scientific Programme - EAU22 Amsterdam

11:30 - 11:58	Case-based debate Management of complex metastatic germ cell tumours
11:30 - 11:32	Case presentation F. Castiglione, London (GB)
11:32 - 11:37	Centralization of Treatment: Data from the NHS D. Nicol, London (GB)
11:37 - 11:44	Chemotherapy options To be confirmed
11:44 - 11:51	Surgical approaches P. Paffenholz, Cologne (DE)
11:51 - 11:58	The patient's perspective H. Gremmels, Utrecht (NL)
11:58 - 12:00	Closing remarks To be confirmed

Cell biology and novel therapies in prostate cancer

Abstract Session 23

Sunday 3 July
10:30 - 12:00

Location Green Area, Room 5
Chairs V.J. Gnanapragasam, Cambridge (GB)
M. Kruithof-De Julio, Bern (CH)
To be confirmed

Drug sensitivity

10:30 - 10:33

Introduction

10:33 - 10:41

Novel insights in prostate cancer biology
To be confirmed

A0410

Identifying drug sensitivity of multifocal primary prostate cancer

A0411

Comparison of multiple approaches targeting the multidrug resistance protein ABCB1 to resensitize docetaxel-resistant prostate cancer cell lines
K. Erdmann, Dresden (DE)

A0412

Novel dual inhibitor of AKR1C3 and AR/AR variants suppresses androgen signaling and inhibits tumor growth

A0413

Chemotherapy enhanced by ultrasonic cavitation in prostate cancer by opening the blood-prostate barrier

10:49 - 10:58

Discussion

Cell models

A0414

Monolayer versus spheroid: An in-vivo comparison regarding local progression and metastasis in prostate cancer
J.L. Bastian, Homburg (DE)

A0415

Single cell sequencing profiling of TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) tissue analysis: evidence of ubiquitin protein ligase binding pathway activation
Z. You, Nanjing (CN)

A0416

A genetically engineered mouse model to study oncofetal CRIPTO in aggressive lethal prostate cancer

A0417

Darolutamide short-term treatment sustainably upregulates PSMA expression in 2D and 3D prostate cancer models

A0418

Establishment and characterization of two novel patient-derived organoid xenograft models of advanced prostate cancer

11:08 - 11:17

Discussion

Disease mechanisms

Scientific Programme - EAU22 Amsterdam

A0419	Upregulation of cellular retinoic acid-binding protein 2 enhances saturated fatty acid-accelerated prostate cancer progression
A0420	SR9009 inhibits prostate cancer subtype 1 through regulating LXR α /FOXO1 pathway independently of REV-ERBs
A0421	Circular RNA EPHA3 suppresses prostate cancer cells proliferation and metastasis through miR-513a-3p/ SOX6 axis
A0422	Exploring the role of androgen signaling in prostate cancer stroma F. Bonollo, Berne (CH)
A0423	LINC00993 promoting METTL14-mediated m6A methylation in prostate cancer cell proliferation and progression
11:27 - 11:36	Discussion
	Various
A0424	Targeting mitochondria: A link between prostate cancer metabolism and novel therapeutic approaches D. Eberli, Zürich (CH)
A0425	Spatial transcriptomic profiling of prostate cancer reveals zone specific androgen receptor signaling and immune infiltration
A0426	Lipopolysaccharide from gut microbiota promotes prostate cancer growth through histamine H1 receptor signaling
A0427	Sequential analysis of macro molecules accessibility unveils altered chromatin solubility patterns and epigenomic dysfunction in prostate cancer
11:46 - 11:55	Discussion
11:55 - 12:00	Closing remarks

Insight in the overactive bladder and the bladder pain syndrome

Abstract Session 24

Sunday 3 July
10:30 - 12:00

Location Purple Area, Room Elicium 1
Chairs D.S. Engeler, St. Gallen (CH)
D.A.W. Janssen, Nijmegen (NL)
J.H. Kim, Seoul (KR)

10:30 - 10:33

Introduction

- A0429** **Investigation of the protective effect of hypericum perforatum extract on lipopolysaccharide induced cystitis**
I.H. Sukur, Bingöl (TR)
- A0430** **The role of Hyaluronic acid and GAG-therapy in urothelial barrier function and repair in vitro**
C.J. van Ginkel, Nijmegen (NL)
- A0431** **Including psychological assessment in bladder pain pathway addresses significant unmet need**
S.N. Yew, Nantgarw (GB)
- A0432** **Clinical features and urodynamic findings in elderly males with chronic prostatitis**

10:41 - 10:52

Discussion

- A0433** **Translational Research in BPS/IC: How can silodosin improve pain and frequency both in mice and female patients?**
P. Abreu-Mendes, Vila Nova de Gaia (PT)
- A0434** **Soybean extracts (glycine max) associated with curcuma, boswellia, pinus and urtica (PROSTAFLOG®) are able to improve quality of life in patients affected by CP/CPPS: Is the pro-inflammatory cytokine IL-8 decreasing the physiopathological link?**
T. Cai, Trento (IT)
- A0435** **Extracorporeal shock wave therapy in association with bromelain and escin for managing patients affected by chronic pelvic pain syndrome: Results of a prospective, randomized clinical trial**
T. Cai, Trento (IT)

10:58 - 11:09

Discussion

- A0436** **Oxidative stress causes nocturnal polyuria via the SPAK-NCC pathway in the kidney: Amelioration by a novel antioxidant, silicon component agents**
Y. Sekii, Osaka (JP)
- A0437** **A novel bladder fibrosis pathway through PDGFRα+ cells associated with estrogen deficiency and replacement**
- A0438** **Inhibition of smooth muscle contraction in isolated human detrusor tissues by mirabegron requires concentrations out of therapeutic range, and is limited to neurogenic contractions**
R. Huang, Aschaffenburg (DE)

Scientific Programme - EAU22 Amsterdam

A0439	Flavonoid nobiletin inhibits IL-1b-induced Cx43 upregulation and gap junction communication in urothelial cells and attenuates Cyclophosphamide induced cystitis in mice J. Kono, Kyoto (JP)
11:17 - 11:28	Discussion
A0440	What are the patient's understanding about fecal and urinary incontinence management?
A0441	The bladder or the kidney: Who is affected the most by hormonal therapy in postmenopausal women with and without nocturnal polyuria?
A0442	Persistence of overactive bladder pharmacological treatment in women as reflected from large-scale real-world data of prescription claims: A retrospective cohort study (2010-2020)
A0443	Meta-analysis of efficacy and safety of Mirabegron plus Solifenacin combination therapy in comparison with Solifenacin monotherapy in overactive bladder
A0444	Efficacy of low-intensity shock wave therapy on persistent storage symptoms after transurethral surgery for benign prostatic obstruction: Preliminary results of a randomized controlled trial
A0445	Sacral Neuromodulation with the InterStim™ system for lower urinary tract dysfunctions (SOUNDS): 5-Year results of clinical effectiveness, Quality of Life, patient-reported outcomes and safety in a French multicenter observational study E. Chartier-Kastler, Paris (FR)
A0446	Evaluation of rechargeable InterStim™ micro system performance and safety: 3-month results from the OAB cohort of the ELITE study D. Elterman, Toronto (CA)
A0447	OASIS pivotal trial to evaluate the safety and efficacy of the RENOVA iStim System™ for the treatment of women with overactive bladder F.M.J. Martens, Nijmegen (NL)
11:44 - 11:55	Discussion
11:55 - 12:00	Closing remarks

Prosthetics in reconstructive urology: Business as usual or still experimental

Thematic Session 05

Sunday 3 July
10:30 - 12:00

Location

Purple Area, Room Elicium 2

Chairs

J.P.F.A. Heesakkers, Maastricht (NL)
L.A. Kluth, Frankfurt (DE)

Learning objectives

The development and implementation of urological prostheses is as well exciting and tricky. They need to be good and safe to stand the test of time and they should benefit the patients. So prudent step by step development and implementation is essential. On the other hand it is impossible to oversee all the issues that may occur and to avoid them, because finally the proof of the pudding is in the eating. This session deals with nowadays prosthesis development and implementation with all rules, laws and directives that apply. Classic prosthesis that stood the test of time are discussed and compared to the modern needs and developments in the near future.

10:30 - 10:35

Welcome and introduction

J.P.F.A. Heesakkers, Maastricht (NL)

10:35 - 10:45

State-of-the-art lecture How to minimize Hippocrates' 'Primum non nocere' in prosthesis development?

R. Dmochowski, Nashville (US)

10:45 - 10:55

State-of-the-art lecture Artificial bladder: Myth or reality?

J Adamowicz, Bydgoszcz (PL)

10:55 - 11:15

50 years after AUS introduction

10:55 - 11:05

This prosthesis is unbeatable

D.M. Castro Díaz, Santa Cruz de Tenerife (ES)

11:05 - 11:15

Room for improvement

T. Hüscher, Mainz (DE)

11:15 - 11:25

Mesh for prolaps: Current status

To be confirmed

11:25 - 11:35

Mesh for stress incontinence: Harmless or tricky

N. Thiruchelvam, Cambridge (GB)

11:35 - 11:45

Use of grafting materials during penile prosthesis implantation in patients with severe Peyronie's disease: Which patch is the best?

J Romero-Otero, Madrid (ES)

11:45 - 11:55

State-of-the-art lecture EU Medical Device Directive: Implications for prosthesis development

L.A. Kluth, Frankfurt (DE)

11:55 - 12:00

Closing remarks

J.P.F.A. Heesakkers, Maastricht (NL)

Prostate cancer biopsy protocols and methods of targeting

Abstract Session 25

Sunday 3 July
10:30 - 12:00

Location

Orange Area, Room 2

Chairs

J. Grummet, Caulfield North (AU)
To be confirmed
J.P. Radtke, Düsseldorf (DE)

Biopsies strategy

10:30 - 10:33

Introduction

A0448 **How has the COVID-19 pandemic influenced prostate cancer? Tertiary uni-center analysis of diagnosis and treatment times**
C. Minguez Ojeda, Madrid (ES)

A0449 **Assessing the regional variability of a pre-biopsy mpMRI and targeted prostate cancer diagnostic pathway**
D.T. Reddy, London (GB)

A0450 **Can prostate biopsy be avoided in all patients with negative MRI? Results of a multicentric study**
T.A. Nguyen, BREST (FR)

A0451 **Repeat prostate biopsies for Atypical Small Acinar Proliferation in the era of Multiparametric Magnetic Resonance Imaging**
B.L. Teixeira, Aveiro (PT)

A0452 **A prospective blinded validation of the rapid prostate cancer risk calculator for patients following initial multiparametric magnetic resonance imaging**
E.J. Bass, London (GB)

A0453 **Reducing prostate MRIs and biopsies with risk stratification before and after MRI**
P. Davik, (NO)

A0454 **Moving beyond PSA: Identifying the optimal diagnostic strategy to assess prostate cancer risk**
D. Cheung, Toronto (CA)

10:47 - 11:01

Discussion

Systematic biopsies along with targeted biopsy

A0455 **Target vs. Target plus Standard biopsy in naïve patients: Results of a prospective randomized controlled trial**
E. Checcucci, Venaria Reale (IT)

A0456 **Optimizing the prostate biopsy template: Additional value of contralateral and ipsilateral systematic biopsies in patients with an unilateral lesion on magnetic resonance imaging**

Scientific Programme - EAU22 Amsterdam

A0457	The prognostic value of the number of positive targeted cores in men with positive multiparametric magnetic resonance imaging of the prostate. Results from a large, multi-institutional series A. Stabile, Milan (IT)
A0458	Role of target biopsy, perilesional biopsy, and random biopsy in the detection of clinically significant prostate cancer by mpMRI-guided transrectal ultrasound fusion biopsy in biopsy naïve patients with positive mpMRI: Less is not more
A0459	Perilesional template for systematic prostate biopsy can avoid overdiagnosis of indolent prostate cancer A. Sigle, Freiburg (DE)
A0460	Novel biopsy scheme in men with multiple multiparametric MRI visible lesions undergoing transperineal prostate biopsy
A0461	Additional systematic to MRI-targeted biopsy in prostate cancer diagnosis: A double-edged sword A. Sigle, Freiburg (DE)
A0462	Assessment of systematic and combined MRI-targeted biopsy for prostate cancer diagnosis during 10 years of practice at a single institution
A0463	Prostate cancers detected at multi-parametric MRI targeted versus systematic biopsies: are they equal? Results from a large multi-institutional series
A0464	The importance of MRI-targeted biopsy for tumors in Anterior fibromuscular stroma
11:21 - 11:35	Discussion
	Methods of biopsy for targeting
A0465	MRI-guided biopsy for prostate cancer diagnosis: Less is more
A0466	PROST: The future of robotic prostate biopsy A. Piro, modena (IT)
A0467	Diagnostic performance of Fusion (US/MRI guided) prostate Biopsy: Comparison of elastic transrectal versus rigid transrectal versus rigid transperineal fusion system M. Ferriero, Rome (IT)
11:41 - 11:55	Discussion
11:55 - 12:00	Closing remarks

PCa localised imaging grade prediction, reporting and markers

Abstract Session 26

Sunday 3 July
10:30 - 12:00

Location Yellow Area, Room Forum
Chairs To be confirmed
To be confirmed
G. Marra, Turin (IT)

10:30 - 10:34

Introduction

MRI and PET imaging for grade prediction

- | | |
|----------------------|--|
| A0469 | Cribriform cancer is equally visible to non-cribriform cancer on multiparametric MRI: An analysis using texture features
S. Uehara, Tokyo (JP) |
| A0470 | A novel approach for 3D reconstruction of the prostate gland that allows tumour location, volume estimation, and Gleason characterization
A. Sachdeva, Manchester (GB) |
| A0471 | Is a quantitative analysis of dynamic contrast-enhanced MRI of added value for prostate cancer diagnosis?
S. Turco, Eindhoven (NL) |
| A0472 | 68Ga-PSMA PET SUVmax predicts gleason pattern 4 at biopsy in intermediate risk prostate cancer
A. Xue, Melbourne (AU) |
| A0473 | PI-RADS 4 and 5 lesions are the risk factors for biochemical recurrence in the low-intermediate risk prostate cancer
K.H. Kim, Busan (KR) |
| A0474 | 68Ga-PSMA PET SUVmax predicts adverse pathology and pathologic upgrading in intermediate risk prostate cancer
A. Xue, Melbourne (AU) |
| 10:48 - 10:59 | Discussion |
| | MRI reporting |
| A0475 | Exploring the value of using patient-oriented mri reports in clinical practice
A. Lund, Toronto (CA) |
| A0476 | Inter-reader agreement of the Prostate Imaging Quality (PI-QUAL) scoring system: A two-reader, two-centre study
G. Giannarini, Udine (IT) |
| A0477 | Outcomes from an international survey on prostate MRI reading and interpretation training among urology residents: Where are we now?
S. Ippoliti, King's Lynn (GB) |

A0478	Interreader agreement with Prostate Imaging Reporting and Data System (PI-RADS) Version 2.1 to improve the detection rate of prostate cancer in MRI/TRUS software fusion prostate biopsy J. Kim, Yangsansi (KR)
11:07 - 11:18	Discussion
	Markers
A0479	Clinicopathological significance of exosomal proteins CD9, CD63 and DNA mismatch repair proteins in prostate adenocarcinoma and benign hyperplasia K. Folkmanis, Siegen (DE)
A0480	The spatial landscape of clonal somatic mutations in benign and malignant prostate epithelia
A0481	Proclarix aids in resolving indeterminate multi-parametric magnetic resonance imaging for the improved diagnosis of prostate cancer
A0482	Clinical significance of α2,3-sialylated prostate-specific antigen density and MRI for high-grade prostate cancer in biopsy-naïve men with elevated PSA level. T. Yoneyama, Hirosaki (JP)
A0483	Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: A diagnostic meta-analysis
A0484	Simultaneous analysis of serum α2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer K. Hatano, Suita (JP)
A0485	Developing an immune-related gene prognostic index associated with progression and providing new insights into the tumor immune microenvironment of prostate cancer F. Dechao, Chengdu (CN)
A0486	Pentraxin-3: A novel serum biomarker to predict the risk of prostate cancer in patients submitted to prostate biopsy G.M. Busetto, Rome (IT)
A0487	Urinary tyrosine and tryptophan as potential biomarkers for prostate cancer H. Nasimi, Odense M (DK)
A0488	Liquid biopsy-based exo-oncomiRNAs can predict prostate cancer aggressiveness M. Alves Santiago, Tarragona (ES)
A0489	Liquid biopsy of prostate-derived tumor cells enriched from seminal fluid as a non-invasive alternative to prostate biopsy: Study feasibility C. Saitta, Pieve Emanuele (IT)
A0490	Post-biopsy cell-free DNA from blood in primary prostate cancer: How to get genetics data for decision making
A0491	Network analysis integrating microRNA expression profiling with MRI biomarkers and clinical data for prostate cancer early detection: A proof-of-concept study M. Pecoraro, Rome (IT)

Scientific Programme - EAU22 Amsterdam

11:44 - 11:55

Discussion

11:55 - 12:00

Closing remarks

History of urology pearls

Abstract Session 27

Sunday 3 July 10:30 - 12:00	Location	Grey Area, Room Emerald
	Chairs	J.C. Goddard, Leicester (GB) P. Dik, Zeist (NL) D. Schultheiss, Giessen (DE)
10:30 - 10:33	Introduction	
A0492	Did François de Lapeyronie have Peyronie's disease himself? A suspected diagnosis made after 320 years M.S. Rahnama'i, Brunssum (NL)	
10:35 - 10:39	Discussion	
A0493	Auguste Nélaton – Who is the person behind this famous name? J.K. Badawi, Luzern (CH)	
10:41 - 10:45	Discussion	
A0494	Sir Philip's exhausted ball and other stories I.B. Barsoum, Cairo (EG)	
A0495	Daniel Sánchez de Rivera y Moset (1882-1952): Humanist and pioneer in sexual medicine J. Angulo Cuesta, Madrid (ES)	
A0496	Ladies first: The female founder members of BAUS K.S.J. Ball, Nottingham (GB)	
A0497	Visigoth fountains and xenodochia to treat renal colic in early medieval Hispania J. Angulo Cuesta, Madrid (ES)	
A0498	The journey of the “Lichtleiter”, the first ever cystoscope: An ode to Philipp Bozzini and his great invention H.S. Talwar, Rishikesh (IN)	
A0499	History of partial nephrectomy in treatment of T1 renal cancer	
A0500	The Father of neuro-urology - an unusual choice for a film star K.S.J. Ball, Nottingham (GB)	
10:59 - 11:19	Discussion	
A0501	Voiding dysfunction 1000 years ago: Terminology and causes	
A0502	Adrien Proust (1834-1903) and the Cordon sanitaire D. Schultheiss, Giessen (DE)	
11:23 - 11:31	Discussion	

Scientific Programme - EAU22 Amsterdam

A0503	Urolagnia and 'Watersports': The story behind the tabooed but a surprisingly common sexual fetish using urine H.S. Talwar, Rishikesh (IN)
A0504	Orificial surgery at the turn of the 20th century: Not exactly a precursor of current NOTES, but another embarrassing chapter in the history of modern surgery
A0505	From torture to therapy: The history of human castration A. Nacchia, Prata Sannita (IT)
A0506	‘Aphrodite’ and ‘Priapus’: The mother-son duo from Greek mythology and their link to urology H.S. Talwar, Rishikesh (IN)
A0507	Publication trend for COVID-19 in Urology: What have Urologists researched in a year and a half of the Pandemic? F. Crocerossa, Cosenza (IT)
11:41 - 11:53	Discussion
11:53 - 11:58	Closing remarks

Controversies on EAU Guidelines II

EAU Guidelines Session

Sunday 3 July
11:45 - 13:15

Location Orange Area, eURO Auditorium 1

Chairs S. Minhas, London (GB)
N. Mottet, Saint-Étienne (FR)
J.A. Witjes, Nijmegen (NL)

Discussants A. Bossi, Villejuif (FR)
To be confirmed
A. Salonia, Milan (IT)

Speakers P. Cornford, Liverpool (GB)
A. Henry, Leeds (GB)
N. Mottet, Saint-Étienne (FR)
J.A. Efstathiou, . (US)
G.N. Thalmann, Bern (CH)
J.A. Witjes, Nijmegen (NL)
S. Minhas, London (GB)
A. Salonia, Milan (IT)
G. Corona, Bologna (IT)
S. Minhas, London (GB)
D. Raggi, Milan (IT)
E.C. Serefoglu, Istanbul (TR)

Learning objectives

Guidelines follow evidence but evidence may be weak or controversial. The EAU Guideline Office has put together three controversial topics where clear recommendations are difficult or impossible. Guideline panel members and experts in the field will explain and discuss pro's and con's of the different concepts.

Local relapse after EBRT for PCa: Re-irradiate or surgery. This session should show the limitations of both options (when not to choose for that option) and what to expect with regard to cure rates and complications.

For invasive bladder cancer options are surgery or trimodal therapy (TMT). The session should learn where both options are possible, but also when TMT might be less optimal. Also follow up of especially TMT should be discussed.

The final part is QOL in cancer survivors. We see more survivors, and QOL gets increasingly more attention. This part of the session will give information on survivorship, sexual health and reproduction possibilities after uro-oncological treatment and surgery.

11:45 - 11:46

Welcome and introduction

11:46 - 12:14

Debate Local relapse after external beam radiotherapy for prostate cancer

11:46 - 11:49

Introduction
N. Mottet, Saint-Étienne (FR)

11:49 - 11:54

Re-irradiation is a real valid option
A. Henry, Leeds (GB)

11:54 - 11:59

Only surgery should be considered
P. Cornford, Liverpool (GB)

11:59 - 12:14

Discussion

Scientific Programme - EAU22 Amsterdam

12:14 - 12:42	Debate A patient with a T2N0M0 bladder tumour cystectomy vs. trimodality treatment
12:14 - 12:17	Introduction J.A. Witjes, Nijmegen (NL)
12:17 - 12:22	Cystectomy G.N. Thalmann, Bern (CH)
12:22 - 12:27	Trimodality treatment J.A. Efstathiou, . (US)
12:27 - 12:42	Discussion
12:42 - 13:15	Debate Is sexual and reproductive health still a matter of debate in the GU oncologic patient?
12:42 - 12:45	Introduction
12:45 - 12:50	Survivorship first D. Raggi, Milan (IT)
12:50 - 12:55	Reproduction health is relevant E.C. Serefoglu, Istanbul (TR)
12:55 - 13:00	Sexual function is the key point G. Corona, Bologna (IT)
13:00 - 13:15	Discussion

Robot-assisted laparoscopic radical cystectomy

ESU Course 30

Sunday 3 July
12:00 - 14:00

Location Grey Area, Room G102

Chair P. Wiklund, Stockholm (SE)

Learning objectives

The course is video based. The steps in the surgical treatment of muscle invasive bladder cancer by conventional laparoscopy and robot-assisted technique will be described. The surgical technique to perform Male and female cystectomy, lymph node dissection, urinary diversion with extracorporeal and intracorporeal technique, conduits as well as orthotopic neobladders, will be shown. Indications, contraindications, outcomes and handling of complications will be discussed.

- The surgical steps in nerve sparing and non-nerve sparing male cystectomy.
- The surgical steps in female cystectomy with and without organ sparing technique.
- The surgical steps in lymph node dissection during cystectomy.
- The technique in urinary diversion, conduit and neobladder, with intra and extracorporeal technique.
- Indications, outcomes and complications after minimally invasive cystectomy.
- The handling of the most common complications after minimally invasive cystectomy.

Introduction

P. Wiklund, Stockholm (SE)

Laparoscopic cystectomy in males (video-based teaching)

Robot-assisted technique with nerve sparing technique

C.J. Wijburg, Arnhem (NL)

Laparoscopic cystectomy in Females (video based teaching)

Robot-assisted cystectomy with organ preservation

P. Wiklund, Stockholm (SE)

Laparoscopic urinary diversion (video-based teaching)

Intracorporeal: Bricker

C.J. Wijburg, Arnhem (NL)

Intracorporeal: Neobladder

P. Wiklund, Stockholm (SE)

Challenge the expert: Controversies in laparoscopic and robotic cystectomy

Oncological outcomes in laparoscopic cystectomy: Challenger

C.J. Wijburg, Arnhem (NL)

Oncological outcomes in laparoscopic cystectomy: Pro

P. Wiklund, Stockholm (SE)

Complications and functional outcomes in laparoscopic cystectomy: Pro

P. Wiklund, Stockholm (SE)

Discussion

P. Wiklund, Stockholm (SE)

How we manage upper tract tumours

ESU Course 31

Sunday 3 July
12:00 - 14:00

Location Grey Area, Room G103

Chair S. Shariat, Vienna (AT)

Learning objectives

This course will address contemporary concepts and controversies in UTUC such as:

- Accurate staging and its role in clinical decision making/risk stratification.
- Risks, benefits, and side effects of current and novel therapeutic approaches including endoscopic and minimal-invasive surgery.
- Optimal management of the bladder cuff as well as indication and extent of lymphadenectomy.
- Systemic therapy for high-risk and metastatic patients.

Epidemiology, diagnosis, evaluation

M. Rouprêt, Paris (FR)

Prognostic and predictive factors, pathology

S. Shariat, Vienna (AT)

Treatment of low risk cancer (high grade Ta, T1 and carcinoma in situ (CIS))

M. Rouprêt, Paris (FR)

Treatment of localised high risk (invasive) and metastatic cancer

S. Shariat, Vienna (AT)

How to proceed with hematuria

ESU Course 32

Sunday 3 July
12:00 - 14:00

Location

Grey Area, Room G104

Chair

H. Mostafid, Guildford (GB)

Learning objectives

Hematuria is one of the most common indications for urologic evaluation, and is recognized as a sign of potentially important illness. Therefore, knowledge of the differential diagnosis, principles of evaluation, and strategies for management of hematuria is critical. This course is designed for the practicing urologist, to provide a guidelines-based and case-oriented approach to the evaluation and management of hematuria.

After attending the course, participants will:

- Understand guideline recommendations for initial evaluation of asymptomatic microscopic hematuria.
- Describe existing data regarding hematuria screening.
- Recognize intravesical treatment regimens and associated side effect profiles for hemorrhagic cystitis.
- Create strategies for treating refractory hemorrhagic cystitis, upper urinary tract, and prostate-related bleeding.

Course introduction and background to hematuria

H. Mostafid, Guildford (GB)

Review of microscopic hematuria

H. Mostafid, Guildford (GB)

AUA guidelines (and beyond) on microscopic hematuria

B. Linder, Rochester (US)

Cases and questions focusing on microhematuria

B. Linder, Rochester (US)

H. Mostafid, Guildford (GB)

Evaluation and management of gross hematuria and hemorrhagic cystitis

B. Linder, Rochester (US)

H. Mostafid, Guildford (GB)

Prostate-, urethral- and upper urinary tract bleeding

H. Mostafid, Guildford (GB)

Cases and questions focusing on gross hematuria

B. Linder, Rochester (US)

H. Mostafid, Guildford (GB)

Renal transplantation: Technical aspects, diagnosis and management of early and late urological complications

ESU Course 33

Sunday 3 July
12:00 - 14:00

Location Grey Area, Room G105

Chair F.J. Burgos Revilla, Madrid (ES)

Learning objectives

Renal transplantation is an essential part of Urology. The aim of the course is to show a complete vision of renal transplant from organ procurement to the resolution of postoperative and late potential complications developed after kidney implantation. The content of this travel along transplantation process includes:

- Medical and surgical recipient evaluation.
- Deceased donor procurement techniques depending on different scenarios: brain death or non heart beating donor.
- Approaches to live donor nephrectomy: Laparoscopic (conventional, minilap, single-port, robotic, transvaginal) or open.
- Renal implantation options: Open or laparoscopic assisted by robot.
- Diagnosis and treatment of complications associated to kidney transplant

Interaction between assistants and faculty is established in basis to clinical cases open to discussion. The focus will be in tips, tricks and surgical details after video sessions. The faculty is integrated by Prof. Burgos-Revilla and Prof. Figueiredo, both past chairman of ESTU and head of departments of EAU certificated Host Center for Fellowship in Kidney Transplant.

Introduction

F.J. Burgos Revilla, Madrid (ES)

Presentation of the course: Relevance of kidney transplant related techniques in different fields of urology

F.J. Burgos Revilla, Madrid (ES)

Surgical aspects of deceased donor nephrectomy in different scenarios: Brain-death / non heart beating donor

A.J. Figueiredo, Coimbra (PT)

Living donor nephrectomy: Technical alternatives

F.J. Burgos Revilla, Madrid (ES)

Tips, tricks, controversies and clinical cases for open discussion

F.J. Burgos Revilla, Madrid (ES)

Tips, tricks, controversies and clinical cases for open discussion

A.J. Figueiredo, Coimbra (PT)

Renal transplantation: Open and Laparoscopic robot-assisted approaches

A.J. Figueiredo, Coimbra (PT)

Tips, tricks , controversies and difficult cases for open discussion

F.J. Burgos Revilla, Madrid (ES)

A.J. Figueiredo, Coimbra (PT)

How to diagnose and manage complications following renal transplantation
F.J. Burgos Revilla, Madrid (ES)

Clinical cases for open discussion

F.J. Burgos Revilla, Madrid (ES)

A.J. Figueiredo, Coimbra (PT)

Management and outcome in invasive and locally advanced bladder cancer

ESU Course 34

Sunday 3 July
12:00 - 14:00

Location Grey Area, Room G106

Chair B. Malavaud, Toulouse (FR)

Learning objectives

MIBC is a multifaceted entity where one size no longer fits all, supporting the development of personalized and, in selected cases, organ-preserving strategies. Are the advances in imaging, molecular biology, conservative surgery; medical oncology and radiotherapy strong enough to shift the current pre-eminence of the ablative approach toward a more integrated and conservative perspective? If yes, what are the ideal candidates?

- One size does not fit all and urologists are central to the development of personalized treatment in MIBC.
- Patients selection is critical and based on advances in imaging, resection techniques and pathology.
- Organ preservation is feasible in a significant proportion of patients.
- Radical cystectomy and pre-emptive chemotherapy are essential to optimize results in aggressive conditions.

Introduction

B. Malavaud, Toulouse (FR)

Cystectomy in the management of bladder invasive and locally-advanced bladder cancer (MIBC)

M. Burger, Regensburg (DE)

Elements for a multidimensional approach to MIBC

B. Malavaud, Toulouse (FR)

Bladder-sparing approaches to muscle invasive bladder cancer

M. Burger, Regensburg (DE)

Overview of systemic treatments in metastatic bladder cancer

B. Malavaud, Toulouse (FR)

Concluding remarks

B. Malavaud, Toulouse (FR)

Prostate cancer update: 2021-2022

ESU Course 35

Sunday 3 July
12:00 - 14:00

Location Grey Area, Room G107

Chair F. Montorsi, Milan (IT)

Learning objectives

This course is aimed at critically reviewing key manuscripts published during the previous 12 months and devoted to the management of prostate cancer patients with a particular focus on basic research, screening, diagnosis, staging, and local and systemic therapies. Practice-changing manuscripts published in peer-reviewed journals between April 2019 and March 2020 will be identified and discussed for each topic. For every paper a clear take home message applicable to the every-day clinical practice will be identified and discussed. The main objective of the course is to inform participants on the latest and most significant novelties related to the contemporary management of prostate cancer patients.

Clinical implications of basic research

F. Montorsi, Milan (IT)

Screening: Novel biomarkers

M. Graefen, Hamburg (DE)

Diagnosis: Multiparametric magnetic resonance imaging (mpMRI) and MRI-targeted biopsies

F. Montorsi, Milan (IT)

Staging: Imaging and predictive models

M. Graefen, Hamburg (DE)

Treatment of localised prostate cancer: Active surveillance

F. Montorsi, Milan (IT)

Treatment of localised prostate cancer: Radical prostatectomy

M. Graefen, Hamburg (DE)

Treatment of localised prostate cancer: External beam radiotherapy and brachytherapy

M. Graefen, Hamburg (DE)

Treatment of localised prostate cancer: Focal therapy

F. Montorsi, Milan (IT)

Management of recurrence after treatment with curative intent

F. Montorsi, Milan (IT)

Management of hormone sensitive metastatic prostate cancer

F. Montorsi, Milan (IT)

Management of castration-resistant prostate cancer

M. Graefen, Hamburg (DE)

Surgery-in-Motion: Technical innovations in the evolving world of robotic surgery

European Urology

Sunday 3 July
12:15 - 13:45

Location Grey Area, eURO Auditorium 2

Chair To be confirmed

Learning objectives

The Surgery-in-Motion session is dedicated to robotic surgery. Experts in the field will provide explanations and video demonstrations of various surgical techniques and discuss why they do it “their way”.

12:15 - 12:20

Welcome and introduction

To be confirmed

12:20 - 12:35

New kids on the block

R. De Groote, Aalst (BE)

12:35 - 12:50

Confocal microscope

S. Puliatti, Modena (IT)

12:50 - 13:05

3D-imaging and augmented reality

F. Porpiglia, Turin (IT)

13:05 - 13:20

Image guided surgery

H.G. Van Der Poel, Amsterdam (NL)

13:20 - 13:35

AI and automation

P. De Backer, Ghent (BE)

13:35 - 13:45

Discussion

PIONEER real-world evidence, big data and prostate cancer

European public-private research network funding through the IMI

Sunday 3 July
12:15 - 13:45

Location Green Area, Room 1

Chair J. N'Dow, Aberdeen (GB)

Learning objectives

Insights into the practical application of real-world data for improved outcomes for patients with prostate cancer and a better understanding of EU initiatives for secondary use of health data.

12:15 - 12:20

Session introduction Big Data, RWE why it's important to multiple stakeholders
J. N'Dow, Aberdeen (GB)

12:20 - 12:30

Challenges and barriers to the use of health data at the EU level
N. Hughes, Beerse (BE)

12:30 - 12:40

The European Health Data Space: Mission, vision and impact
C.H. Van Gool, Maastricht (NL)

12:40 - 12:50

Vice chair of the Phase I Cancer Mission Board EU Research Mission on Cancer: How the EU plans to improve the lives of more than 3 million people by 2030
C. Chomienne, Paris (FR)

12:50 - 13:00

Uncovering the natural history of prostate cancer in data from millions of patients across the globe: How to run a studyathon
B. De Meulder, Vourles (FR)

13:00 - 13:10

How Big Data analysis connects with real practice: Baseline characteristics and outcomes of 10,485 prostate cancer patients on delayed palliative management
V. Sakalis, Thessaloniki (GR)

13:10 - 13:20

How Big Data analysis connects with real practice: Clinical Characterisation and outcomes of prostate cancer patients undergoing immediate vs. conservative management
G. Gandaglia, Milan (IT)

13:20 - 13:30

Making research accessible to patients: Their perspective on being involved in the PIONEER studyathon
G. Hooker, London (GB)

13:30 - 13:40

Real-world evidence implementation in guidelines development, is the data quality there?
M.J. Roobol, Rotterdam (NL)

13:40 - 13:45

Session summary Where do we go from here?
J. N'Dow, Aberdeen (GB)

Ureteric adventures

Video Session 9

Sunday 3 July
12:15 - 13:45

Location Green Area, Room 2

Chairs J. Ockrim, London (GB)
To be confirmed
M. Waterloos, Ghent (BE)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

12:15 - 12:18

Introduction

V55 **Robot-assisted laparoscopic ureteroplasty with buccal mucosa**
M. Oderda, Turin (IT)

V58 **Robot-assisted surgery for ureteral strictures: Technical aspects and results in a single center**

V59 **Utility of robotic platform for upper and mid ureteric reconstruction: Our experience at MPUH, Nadiad**

V60 **Robot assisted reconstruction of the ureteral and ileal outflow tract in patients with a history of radical cystectomy plus single stoma cutaneous ureterostomy-5 cases of initial experience**
Q. Lu, Nanjing (CN)

V61 **Laparoscopic management of xanthogranulomatous pyelonephritis: Comparison of two different yet similar cases**
C. Laranjo Tinoco, Gualtar Braga (PT)

13:35 - 13:40

Closing remarks

Improvements in metastatic prostate cancer: Focus on imaging and treatment

Abstract Session 28

Sunday 3 July
12:15 - 13:45

Location Green Area, Room 3
Chairs E. Castro, Madrid (ES)
N. Fossati, Lugano (CH)
To be confirmed

Salvage lymphnode dissection

12:15 - 12:18

Introduction

A0508 How to optimize patient selection before salvage lymph node dissection for nodal recurrent prostate cancer: A novel risk stratification tool
N. Fossati, Lugano (CH)

A0509 What is the optimal management of nodal oligorecurrent prostate cancer? Results from a large series of patients treated with salvage lymph node dissection
N. Fossati, Lugano (CH)

A0510 Guidewire-marking before robotic salvage lymph node dissection for in-field lymph node recurrences after radical prostatectomy: Initial experiences
J. Linxweiler, Homburg/saar (DE)

A0511 Cohort study of oligorecurrent prostate cancer patients: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery

12:26 - 12:34

Discussion

DDR alteration

A0512 Lifetime risk of prostate cancer death among high-risk germline mutation carriers
R. Clark, Toronto (CA)

A0513 BRCA1/2 and ATM mutated metastatic prostate cancers may present with low serum PSA

12:38 - 12:46

Discussion

mHSPC

A0514 Sustained castration to < 20 ng/dl for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study
B. Tombal, Brussels (BE)

A0515 Redefining disease burden in predicting survival outcomes in an era of multi-modal therapies for hormone sensitive prostate cancer
X.Y. Yang, Singapore (SG)

A0516 The changing landscape of systemic therapy in the treatment of newly-diagnosed metastatic prostate cancer
N. Lumen, Ghent (BE)

A0517	<p>Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES</p> <p>A. Stenzl, Tübingen (DE)</p>
A0518	<p>PSMA-flare after ADT evaluated with 18F-PSMA-1007 PET/CT in hormone-sensitive metastatic prostate cancer: Possible predictor of tumour aggressiveness?</p> <p>S. Malaspina, Turku (FI)</p>
12:56 - 13:04	<p>Discussion</p>
	<p>Side effects of treatment</p>
A0519	<p>Exploring the association between cardiovascular disease risk and gonadotropin releasing hormones agonists (GnRH) and prostate cancer diagnosis in men with type 2 diabetes mellitus: A nationwide, population-based cohort study</p> <p>E. Lin, London (GB)</p>
A0520	<p>Major adverse cardiovascular event risk following androgen deprivation therapy initiation by cardiovascular history</p>
A0521	<p>Change in atherogenic lipids during prostate cancer treatment with Gonadotropin Releasing Hormones agonists (GnRH) in men with type 2 diabetes mellitus: A nationwide, population-based cohort study</p> <p>E. Lin, London (GB)</p>
A0522	<p>Changes in pituitary–gonadal hormones after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): Results from a randomised clinical trial</p> <p>K. Kvorning Ternov, Hellerup (DK)</p>
A0523	<p>Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer</p> <p>E. Vjaters, Riga (LV)</p>
13:14 - 13:22	<p>Discussion</p>
	<p>nmCRPC and mCRPC</p>
A0524	<p>Sabizabulin has both cytotoxic and cytostatic activity in Phase 1b/2 clinical of men with metastatic castration resistant prostate cancer who progressed on androgen receptor targeting agents</p>
A0525	<p>KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)–naïve patients with metastatic castration-resistant prostate cancer (mCRPC)</p> <p>T. Todenhöfer, Tübingen (DE)</p>
A0526	<p>Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups</p> <p>C. Würnschimmel, Hamburg (DE)</p>
A0527	<p>Disease trajectories and outcomes for men with castration resistant prostate cancer by use of nation-wide population-based observational data</p> <p>E. Ventimiglia, Milan (IT)</p>

Scientific Programme - EAU22 Amsterdam

A0528	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): An international multicenter study
-------	--

13:32 - 13:40	Discussion
---------------	------------

13:40 - 13:45	Closing remarks
---------------	-----------------

Andrology - Male sexual dysfunction, diagnosis and therapy

Abstract Session 29

Sunday 3 July
12:15 - 13:45

Location Green Area, Room 4
Chairs N. Al-Hathal, Riyadh (SA)
J.I. Martínez Salamanca, Madrid (ES)
To be confirmed

Basic research and epidemiology

12:15 - 12:19

Introduction

A0529

Pro-erectile facilitator effect of LIB-01 in type 2 diabetic rats
R. Assaly, Montigny-Le-Bretonneux (FR)

A0530

Is impotence a life-threatening condition?
R. Virag, Paris (FR)

A0531

Type D personality is the independent predictor of moderate to severe erectile dysfunction in young males

12:25 - 12:35

Discussion

Diagnosis

A0532

Erectile dysfunction and impaired sexual quality of life in men with overactive bladder: A single cohort analysis

A0533

Is there a point to performing a penile duplex ultrasound? The long-term answer
A. Morgado, Maia (PT)

A0534

Relevance of self-masturbation-related vs. coital erectile function in the real-life management of patients with erectile dysfunction

12:41 - 12:51

Discussion

Therapy

A0535

The atherosclerotic cardiovascular disease risk score is a reliable tool to identify patients with arteriogenic erectile dysfunction at dynamic penile color doppler duplex ultrasound: Findings from a real-life cross-sectional study
E. Pozzi, Milan (IT)

A0536

Predictors of phosphodiesterase type 5 Inhibitors (PDE5I)-discontinuation – Is a previous PDE5I-exposure at first clinical evaluation related with a higher PDE5I-drop-out risk?

A0537

Antegrade versus retrograde common iliac artery revascularization and occurrence of erectile dysfunction
A. Baudo, San Donato Mse Milano (IT)

A0538

Randomized sham-controlled trial to evaluate the safety and effectiveness of radial waves for erectile dysfunction
H.A. Corredor Ayala, Bogota (CO)

A0541	5 years follow-up outcomes of pelvic floor rehabilitation protocol in subjects with lifelong premature ejaculation: The definitive long-term evaluation
13:05 - 13:15	Discussion
	Post-prostate surgery ED and penile implants
A0542	Medications mostly associated with ejaculatory disorders: Assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries
A0543	Risk of orgasmic function impairment after HoLEP – findings of a prospective real-life trial (ExpHo) P. Capogrosso, Varese (IT)
A0544	Sexual function recovery following open and robotic radical prostatectomy: Results of an academic penile rehabilitation program
A0545	5 years after nerve-sparing radical prostatectomy and 3 years after finishing penile rehabilitation study programs: What's up with our patients? A. Bannowsky, Fockbek (DE)
A0546	Trend on erectile rehabilitation after radical prostatectomy: Results of an international survey among urologists
A0547	Corporotomy localization in inflatable penile implant surgery: Learning curve and comparing different surgical approaches in high volume surgeons N.L. Lauwers, Genk (BE)
A0548	Trends of utilization and comparison between AMS® vs. Coloplast Titan® Inflatable Penile Protheses (IPPs) in Italy – results from a national registry (INSIST-ED)
13:29 - 13:39	Discussion
13:39 - 13:45	Closing remarks

Testicular cancer - Tailoring treatments to reduce toxicities

Abstract Session 30

Sunday 3 July
12:15 - 13:45

Location Green Area, Room 5
Chairs J.L. Boormans, Rotterdam (NL)
R. Hamilton, Toronto (CA)
To be confirmed

Basic research

12:15 - 12:19

Introduction

A0549 **The molecular and epigenetic function of the signaling molecule CD24 in germ cell tumors and its suitability as a therapeutic target using antibodies and NK-CAR cells**
M.A. Skowron, Dusseldorf (DE)

A0550 **KRAS mutation in germ tumors with somatic transformation: Genetic pattern by FoundationOne CDx test**

A0551 **Role of new and emerging biomarkers OCT3/4 and NANOG in testicular seminoma**
M. Tomić, Zagreb (HR)

A0552 **The prognostic significance of TIM-3 expressing tumor-infiltrating lymphocytes in testicular germ cell tumors**
K.H. Kim, Seoul (KR)

A0553 **Studying the interaction of germ cell tumors with the microenvironment reveals novel factors involved in cisplatin resistance**
M.A. Skowron, Dusseldorf (DE)

A0554 **Immune cell infiltration of testicular germ cell tumors – a clinical approach**
F. Dittmar, Gießen (DE)

12:31 - 12:41

Discussion

Stage 1-2 and primary RPLND

A0555 **Safety of minimizing intensity of follow-up on active surveillance for clinical stage I testicular germ cell tumors**
R. Hamilton, Toronto (CA)

A0556 **Completion orchidectomy post chemotherapy: A single-centre 10-year retrospective**

A0557 **Non-seminomatous testicular germ cell tumours with teratoma-free primaries are associated with a reduced early relapse-free and overall survival**
P. Paffenholz, Cologne (DE)

A0558 **Complications of primary open or robotic RetroPeritoneal Lymph Node Dissection (RPLND) in stage II A/B patients with seminoma – results from the prospective phase II PRIMETEST trial**

12:49 - 12:59

Discussion

	Post-chemo RPLND
A0559	Treatment outcomes for men with stage 2 non-seminoma undergoing primary RetroPeritoneal Lymph Node Dissection (RPLND): A systematic review A. Neuenschwander, St.Gallen (CH)
A0560	Differentially expressed mRNA/proteins can distinguish viable germ cell tumors and teratomas from necrosis in retroperitoneal lymph node resections after chemotherapy (pcRPLND) T. Nestler, Koblenz (DE)
A0561	Utility of CT rendering and Radiomic Features analysis in post-chemotherapy retroperitoneal lymph node dissection
A0562	Surgical and oncological outcomes of post chemotherapy laparoscopic retroperitoneal lymph node dissection in stage IIA-III non seminomatous germ-cell tumors S. Nazzani, Milan (IT)
A0563	Robot-assisted retroperitoneal Lymph-Node Dissection (RPLND) for post-chemotherapy testis cancer residual masses: A monocentric experience A. Khaddad, Villenave-D'Ornon (FR)
13:09 - 13:19	Discussion
	Systemic therapy and QOL
A0564	Sealing the leak: A 10-year multicentre experience managing refractory post retroperitoneal lymph node dissection chylous ascites J. O'Brien, East Melbourne (AU)
A0566	Medium to long term health-related quality of life and treatment-related side-effects in patients treated with a single dose of adjuvant carboplatin for high-risk seminoma – results from a pilot study W. Cazzaniga, Milan (IT)
A0567	Health-related quality of life and treatment-related side-effects in patients who have been in remission from testicular cancer for 12-24 months W. Cazzaniga, Milan (IT)
A0568	Improved quality of care for patients with germ-cell cancer: The interdisciplinary testis cancer clinic L. Funk, Zürich (CH)
13:29 - 13:39	Discussion
13:39 - 13:45	Closing remarks

Surgical management of male and female SUI: Tapes, balloons, sphincters and more

Abstract Session 31

Sunday 3 July
12:15 - 13:45

Location Purple Area, Room Elicium 1
Chairs F. Farag, Ipswich (GB)
W.A. Hübner, Korneuburg (AT)
K. Stav, Beer Yaakov (IL)

12:15 - 12:18

Introduction

- | | |
|----------------------|--|
| A0569 | Preoperative MRI pelvic floor versus preoperative urodynamics, in prediction of urinary incontinence improvement after Sacrocolpopexy: In females with Mixed Urinary Incontinence and Pelvic Organ Prolapse
A.F. Hussein, Cairo (EG) |
| A0570 | A comparative study for long-term surgical outcomes between TVT and TOT procedures in obese and non-obese women with stress urinary incontinence |
| A0571 | Partially absorbable mesh in midurethral slings may be associated with decreased success rates for the treatment of female stress urinary incontinence
T. Hüscher, Bad Wiessee (DE) |
| A0572 | Evaluation of the effect of umbilical cord derived urethral slings in bilateral pudendal nerves injury-induced urinary incontinence in female rats
U. Pinar, Paris (FR) |
| A0573 | Continence outcomes in females post mid-urethral sling excision |
| A0574 | Mid-term results of ReMEEX sling system for female stress urinary incontinence with various indication and feasibility of re-adjustment
H. Kim, Seongnam (KR) |
| A0575 | Results of periurethral adjustable balloons (ACT™) in the treatment of stress urinary incontinence in women after pelvic radiotherapy |
| A0576 | Robot-assisted artificial urinary sphincter implantation in female patients: An international multicenter series of 182 patients
B. Peyronnet, Rennes (FR) |
| A0577 | Initial results of a minimally invasive non-surgical treatment for Stress Urinary Incontinence (SUI)
J. Yong, Singapore (SG) |
| 12:36 - 12:58 | Discussion |
| A0578 | Usefulness of transperineal ultrasound as a method of membranous urethral length measurement compared to magnetic resonance in men prior to radical prostatectomy |
| A0579 | Dynamic compression of the urethra – mechanism of action of a male transobturator sling with 5-year imaging follow-up |

Scientific Programme - EAU22 Amsterdam

A0580	Bulbospongiosus muscle-sparing male sling implantation for postprostatectomy incontinence: Evaluation of safety and efficacy outcomes E. Sacco, Rome (IT)
A0581	Treatment of male stress urinary incontinence with the adjustable male sling ARGUS® in patients with fragile urethra G. Ameli, Vienna (AT)
A0582	Transcorporal vs. bulbar artificial urinary sphincter implantation in male patients with fragile urethra
A0583	A comparison of artificial urinary sphincter approaches: Perineal cuff plus abdominal vs. sub-inguinal counterincision for pressure regulating balloon placement
A0584	Bladder neck contractures stabilize after artificial urinary sphincter placement K. Krughoff, Durham (US)
A0585	Pre-existing detrusor overactivity leads to earlier artificial urinary sphincter failure and need for revision K. Krughoff, Durham (US)
A0586	Comparative urodynamic study in cadaver of urethral pressure profilometry between the UroMems artificial urinary sphincter and the AMS800™ E. Chartier-Kastler, Paris (FR)
A0587	An innovative strategy to continence recovery: The potential role of Human Dental Pulp Stem Cells to urethral sphincter regeneration A. Zordani, Belluno (BL) (IT)
A1193	Preclinical evaluation of a novel artificial urinary sphincter in a wether model E. Chartier-Kastler, Paris (FR)
13:20 - 13:40	Discussion
13:40 - 13:45	Closing remarks

LUTS/BPH - Basic research and medical therapy

Abstract Session 32

Sunday 3 July
12:15 - 13:45

Location Purple Area, Room Elicium 2
Chairs N. Bhojani, Montreal (CA)
M.C. Michel, Mainz (DE)
To be confirmed

12:15 - 12:20

Introduction

A0588

Medications mostly associated with urinary retention: Assessment of the Eudravigilance (EV) and the Food and Drug Administration (FDA) Pharmacovigilance database entries

A0589

A novel therapeutic strategy using ultrasound mediated-microbubbles drug delivery system to treat prostatic hyperplasia

12:24 - 12:34

Discussion

A0590

Trans-ethnic genome-wide association study reveals new therapeutic targets for benign prostatic hyperplasia

A0591

The association between human gut microbiota and prostate enlargement

A0592

Study of the histological components and the development of the prostate in human fetuses
L.A. Favorito, Rio de Janeiro (BR)

A0593

The effect of GPER inhibition on prostatic enlargement and chronic inflammation in high fat diet induced obesity rat model

A0594

Involvement of Yes-associated protein 1 in inflammation-induced benign prostatic hyperplasia

A0595

The protective effects of CSF-1R inhibition on Bladder Outlet Obstruction (BOO) induced remodeling

12:46 - 13:06

Discussion

A0596

Silencing of CDC42 in prostate stromal cells inhibits contraction and growth-related functions, which is mimicked by ML141

A0597

Inhibition of α 1-adrenergic, non-adrenergic and neurogenic human prostate smooth muscle contraction by the isoflavone compounds genistein and puerarin
R. Huang, Aschaffenburg (DE)

A0598

Pharmacological characterization of the β 3-adrenoceptor agonists ZD7114, ZD2079 and BRL37344 in human prostate smooth muscle contraction
R. Huang, Aschaffenburg (DE)

A0599

WNK463 and HTH01-015 simultaneously inhibit neurogenic and α 1-blocker-resistant, non-adrenergic contractions of human prostate tissues, and growth-related functions of prostate stromal cells

Scientific Programme - EAU22 Amsterdam

A0600	Post-receptor signaling by G protein-coupled, contractile receptors is a prerequisite for cytoskeletal organization and cell proliferation in human prostate smooth muscle cells
A0601	YM254890 inhibits prostate smooth muscle contraction by fully disrupting intracellular post-receptor signaling
A0602	Small molecule GAP inhibitor QS11 promotes adrenergic and non-adrenergic prostate smooth muscle contraction
13:20 - 13:40	Discussion
13:40 - 13:45	Closing remarks

Prostate biopsies: Which route, which complications, which pathological results?

Abstract Session 33

Sunday 3 July
12:15 - 13:45

Location Orange Area, Room 2
Chairs To be confirmed
To be confirmed
R.C.N. Van Den Bergh, Nieuwegein (NL)

Biopsy route

12:15 - 12:19

Introduction

- A0603** **Prostate cancer detection rate of transrectal versus transperineal MRI-TRUS fusion prostate biopsy: experience in 794 cases**
R. Hogenhout, Rotterdam (NL)
- A0604** **Prospective results of in-office freehand transperineal prostate biopsies under local anaesthesia - leaving the transrectal route behind**
A. Bilé Silva, Lisboa (PT)
- A0605** **A prospective comparative study of the accuracy and complications of transrectal and transperineal prostate biopsy in the MRI era**
J. Kovacic, Matcham (AU)
- A0606** **Transperineal versus transrectal targeted prostate biopsy: A multicenter matched pairs study of the Turkish Urooncology Association**
M.Y. Koparal, Rize (TR)

12:27 - 12:39

Discussion

Infectious complications

- A0607** **Complications after transrectal prostate biopsy with antibiotic prophylaxis versus transperineal without antibiotic prophylaxis: Comparison of two clinical practices**
R. Hogenhout, Rotterdam (NL)
- A0608** **Zero prophylactic antibiotics in local anaesthetic transperineal prostate biopsy under antibiotics stewardship initiative; our institutional experience**
N. Biradar, Romford (GB)
- A0609** **Complications after transrectal ultrasound guided biopsies in screening for prostate cancer with PSA followed by MRI – results from the Göteborg prostate cancer screening 2 trial**
- A0610** **Current role of prophylactic antibiotics in transperineal prostate biopsies**
F. Bianco, Miami Lakes (US)

12:47 - 12:59

Discussion

Pathology grade assignment and prediction

Scientific Programme - EAU22 Amsterdam

A0611	Crowdsourcing of artificial intelligence algorithms for diagnosis and Gleason grading of prostate cancer in biopsies K. Kartasalo, Solna (SE)
A0612	Remote instant prostate pathology based on artificial intelligence enhanced ultrasound (AI-US): From biopsy to diagnosis in 30 min T. Loch, Flensburg (DE)
A0613	A robust artificial intelligence approach for histopathological evaluation of prostate biopsies N. Mulliqi, Stockholm (SE)
A0614	MRI and MRI-targeted biopsy can detect cribriform cancer of the prostate S. Uehara, Tokyo (JP)
A0615	Histological variants of prostate cancer are under-reported in prostate biopsies assessed outside tertiary referral centers: A plea for biopsy review for optimal patient management
A0616	Stimulated raman histology allows for rapid pathologic examination of unprocessed, fresh prostate biopsies M. Mannas, Vancouver (CA)
A0617	Individualized risk prediction of metastatic recurrence in patients candidate to radical prostatectomy: A new model using clinical, mri and mri-guided biopsy parameters J. Olivier, Lille (FR)
A0618	Definition and predictors of upgrading at final pathology in prostate cancer patients undergoing mri-targeted and systematic biopsies: Results from a large, multi-institutional series G. Gandaglia, Milan (IT)
A0619	Grade and stage misclassification in unfavorable intermediate vs high-risk NCCC prostate cancer candidates for RT plus short vs long-term androgen ADT
A0621	Optimized grade group for reporting prostate cancer grade in both systematic and MRI-targeted biopsies
A0622	Do pre-operative PI-RADS assessment scores add value to prostate cancer biopsy grading in estimating post-operative grading? M. Fernandez Salamanca, Amsterdam (NL)
A0624	Role of PSA density in prediction of significant prostate cancer among Asian men with MRI-guided biopsies: A multicenter evaluation P.K-F. Chiu, Hong Kong (HK)
13:27 - 13:39	Discussion
13:39 - 13:45	Closing remarks

Complex surgery in urology

Abstract Session 34

Sunday 3 July
12:15 - 13:45

Location Yellow Area, Room Forum

Chairs To be confirmed
J. Rautiola, Stockholm (SE)
To be confirmed

Speaker To be confirmed

12:15 - 12:18

Introduction

Adrenal

[A0625](#)

Clinical cure vs. a novel trifecta system for evaluating long-term outcomes of minimally-invasive partial or total adrenalectomy for unilateral primary aldosteronism: Results of a multicentric series

[A0626](#)

Adrenalectomy for metastasis: The impact of primary histology on survival outcome
M. Ferriero, Rome (IT)

[A0627](#)

Cortisol regulates adrenaline synthesis via phenylethanolamine N-methyltransferase in surgical specimens of pheochromocytoma
K. Numakura, Akita (JP)

12:24 - 12:39

Discussion

Complex bladder surgery

[A0628](#)

Radical cystectomy for bladder cancer in patients previously treated for prostate cancer: Perioperative and oncological outcomes
S. Tappero, Genova (IT)

[A0629](#)

Robot-assisted partial cystectomy versus open partial cystectomy for patients with urachal cancer

[A0630](#)

Radical vs. partial cystectomy for urachal carcinoma: A population-based analysis
R.S. Flammia, Rome (IT)

12:45 - 13:00

Discussion

Endometriosis

[A0631](#)

Clinical and surgical predictors of urinary tract endometriosis after primary surgical treatment: A single high-volume centre experience

[A0632](#)

Surgical approach of patients with deep infiltrating endometriosis with urological involvement
D. Lorente Garcia, Barcelona (ES)

13:04 - 13:19

Discussion

Miscellaneous

Scientific Programme - EAU22 Amsterdam

A0633	The management and outcomes of vesicovaginal fistula R. Barratt, London (GB)
A0634	Prognostic nomogram for predicting long-term survival in patients with retroperitoneal liposarcoma
A0635	Duplex ureters in potential living kidney donors P. Kotecha, London (GB)
13:25 - 13:40	Discussion
13:40 - 13:45	Closing remarks

Basic research and new drugs in paediatric urology

Abstract Session 35

Sunday 3 July
12:15 - 13:45

Location Grey Area, Room Emerald
Chairs To be confirmed
N. Baydilli, Kayseri (TR)
To be confirmed

12:15 - 12:19

Introduction

A0636

Influence of myostatin inhibitor on smooth muscle cells regeneration
D. Eberli, Zürich (CH)

A0638

ACTG2-autosomal dominant visceral myopathy: Identification of novel variants using data from Genomics England 100,000 Genomes Project
R. Geraghty, Newcastle-upon-Tyne (GB)

A0639

Temperature is not critical for the differentiation of gonocytes into ad spermatogonia and fertility outcome in cryptorchid boys
F. Hadziselimovic, Liestal (CH)

12:27 - 12:37

Discussion

A0640

Is augmentation ileocystoplasty safe in pediatric population with GFR as low as 30 ml/min? Prospective study

A0641

Minimally-invasive mitrofanoff procedure in children: An analysis of learning curve over a 18-years period

A0642

SENS-U: Continuous home monitoring of natural nocturnal bladder filling in children with nocturnal enuresis - a feasibility study
P. Dik, Zeist (NL)

A0643

The comparasion of anxiety levels in children who underwent invasive or non-invasive urodynamic studies

A0644

The roles of vitamin b12, 25(oh) d, and folate in primary nocturnal enuresis: A single center experience in an immigration area
A. Keles, Istanbul (TR)

12:47 - 12:57

Discussion

A0645

Configuration and validation of the Toronto nomogram of antenatal ultrasound index generated from Bayesian meta-regression analysis in predicting Posterior Urethral Valves (PUV)
J.K.J. Kim, Toronto (CA)

A0646

Additional late imaging in diuretic renography in children
L. Steinkellner, Linz (AT)

A0647

Mean platelet volume is the most valuable hematologic parameter in differentiating testicular torsion from epididymitis within the golden time

Scientific Programme - EAU22 Amsterdam

A0648	Preliminary experience with adjustable periuretral balloons (ACT™) to treat stress urinary incontinence due to intrinsic sphincter deficiency in children
13:05 - 13:15	Discussion
A0649	Mirabegron and Solifenacin in treatment of primary nocturnal enuresis with reduced nocturnal bladder capacity: A randomized double blind placebo controlled study M. Omran, Zagazig (EG)
A0650	Scheduled management of primary nocturnal enuresis in pediatric age group. A new approach S. Kotb, Cairo (EG)
A0651	Beta-3 adrenoceptor agonist for the treatment of bladder dysfunction in children: A systematic review and meta-analysis J.K.J. Kim, Toronto (CA)
A0652	Incontinence in boys and girls following succesful primary closure of bladder extrophy: Management with orthotopic ileal neobladder and costruction of anterior intrapelvic neourethra derived from detrusor wall M. Wishahi, Cairo (EG)
A0653	Treating incontinence in children with OAB with dual therapy consisting of a beta-3-adrenoreceptor agonist and antimuscarinic agent P. Dik, Zeist (NL)
A0654	The effect of duration between sessions on biofeedback treatment in children with dysfunctional voiding
A0655	Is YouTube an accurate and/or comprehensive source of information for monosymptomatic enuresis nocturna? Y. Issi, Izmir (TR)
13:29 - 13:39	Discussion
13:39 - 13:45	Closing remarks

Genetic profiling in prostate cancer: Already prime time?

Thematic Session 06

Sunday 3 July
13:30 - 15:00

Location Orange Area, eURO Auditorium 1

Chairs P. Albers, Düsseldorf (DE)
A. Villers, Lille (FR)

Panel S. Carlsson, New York (US)
M.R. Cooperberg, San Francisco (US)
J. Gómez Rivas, Madrid (ES)
N. Mottet, Saint-Étienne (FR)
To be confirmed
D. Stoppa-Lyonnet, Paris (FR)

Learning objectives

This session will address the current knowledge about molecular screening for prostate cancer. Which tests on which samples for which patients? How to manage a patient carrier of BRCA mutation who comes to your clinic for genetic counselling ? In addition, what is the place of genetic profiling for active surveillance indication and follow-up and at the time of castration resistant stage

13:30 - 13:33

Welcome and introduction

13:33 - 13:41

Molecular screening for germline mutations in practice: When and how?
J. McHugh, London (GB)

13:41 - 13:49

STHLM3 Screening Trial for prostate cancer including genetic profiling: Does it improve screening?
T. Nordström, Stockholm (SE)

13:49 - 13:59

BRCA 2 mutation

13:49 - 13:51

Case presentation 40 year old healthy man with BRCA 2 mutation
J. Olivier, Lille (FR)

13:51 - 13:59

What means genetic counselling in practice: Standards and requirements
D. Stoppa-Lyonnet, Paris (FR)

13:59 - 14:40

Active surveillance based on genetic profiling?

13:59 - 14:01

Case presentation 50 year old men with ISUP 1 cancer
J. Gómez Rivas, Madrid (ES)

14:01 - 14:09

Discussant Yes - active surveillance only with genetic profiling
M.R. Cooperberg, San Francisco (US)

14:09 - 14:17

Discussant No - active surveillance based on clinical and histological parameters only
S. Carlsson, New York (US)

14:17 - 14:25

Genetic testing: Challenging the guidelines (NCCN, EAU, AUA)
N. Mottet, Saint-Étienne (FR)

14:25 - 14:40

Panel discussion Optimal way to counsel before active surveillance

Scientific Programme - EAU22 Amsterdam

14:40 - 14:58	mCRPC
14:40 - 14:42	Case presentation 60 year old men with mCRPC and progression I. Heidegger, Innsbruck (AT)
14:42 - 14:50	From metastatic tissue to liquid biopsy for all patients with mCRPC? I. Casanova-Salas, Valencia (ES)
14:50 - 14:58	State-of-the-art lecture Management of mCRPC based on genetic profiling E. Castro, Madrid (ES)
14:58 - 15:00	Closing remarks

Female stress urinary incontinence: Practical surgical management

Thematic Session 07

Sunday 3 July
14:00 - 15:30

Location Grey Area, eURO Auditorium 2

Chairs
F. Cruz, Porto (PT)
V. Phé, Paris (FR)
M.C. Lapitan, Manila (PH)

Learning objectives

The treatment most frequently offered to women with stress incontinence not adequately managed by conservative methods are mid-urethral synthetic or autologous fascial slings. Their use across Europe shows variations mainly caused by patients representatives questioning the long-term consequences of synthetic mesh in the body. Surgical indication of a mid-urethral sling is usually straightforward in women with predominant stress urinary incontinence but may be inadequate to treat women with mixed or recurrent stress urinary incontinence. The latter might be particularly difficult to solve and may require the use of bulking agents or complex surgeries including artificial urinary sphincters or even urinary diversion.

14:00 - 14:10 **State-of-the-art lecture** **Current use of synthetic slings in European countries**
G. Karsenty, Marseille (FR)

14:10 - 14:38 **Pure SUI without prior anti-incontinence surgery**

14:10 - 14:11 **Case presentation**
To be confirmed

14:11 - 14:15 **Flash presentation** **Synthetic mid urethral sling (MUS)**
To be confirmed

14:15 - 14:19 **Flash presentation** **Autologous sling**
N.I. Osman, Sheffield (GB)

14:19 - 14:23 **Flash presentation** **Peri-urethral injection**
To be confirmed

14:23 - 14:38 **Discussion**

14:38 - 15:10 **SUI recurrence after a transobturator tape (TOT) and fixed urethra**

14:38 - 14:39 **Case presentation**
To be confirmed

14:39 - 14:43 **Flash presentation** **A new synthetic MUS**
S.A. Arlandis, Valencia (ES)

14:43 - 14:47 **Flash presentation** **Autologous sling**
C. Harding, Newcastle upon Tyne (GB)

14:47 - 14:51 **Flash presentation** **Peri-urethral injection**
T. Hüscher, Mainz (DE)

14:51 - 14:55 **Flash presentation** **Artificial sphincter**
B. Peyronnet, Rennes (FR)

Scientific Programme - EAU22 Amsterdam

14:55 - 15:10	Discussion
15:10 - 15:25	Debate Nightmare case with failure of curative options
15:10 - 15:11	Case presentation F. Farag, Ipswich (GB)
15:11 - 15:16	Consider (continent and incontinent) urinary diversion M.A. Perrouin Verbe, Nantes (FR)
15:16 - 15:21	Optimize palliative care M. Tutolo, Milan (IT)
15:21 - 15:25	Discussion
15:25 - 15:30	Surgical innovations for women SUI: What's in the pipeline? E. Costantini, Perugia (IT)

Lymph nodes in prostate cancer

Abstract Session 36

Sunday 3 July
14:00 - 15:30

Location Green Area, Room 4
Chairs To be confirmed
S. Joniau, Leuven (BE)
R.J. Karnes, Rochester (US)

Selection for PLND

14:00 - 14:04

Introduction

A0656 Development of a novel nomogram to identify candidates for extended pelvic lymph-node dissection in prostate cancer using MRI and PSMA pet
D. Meijer, Amsterdam (NL)

A0657 External validation and comparison of two nomograms predicting the probability of lymph node involvement in patients subjected to robotic radical prostatectomy and concomitant lymph node dissection

A0658 Impact of the time elapsed between prostate biopsy and surgery on the accuracy of the Briganti nomogram predicting lymph node invasion in men with clinically localized prostate cancer
G. Gandaglia, Milan (IT)

14:10 - 14:20

Discussion

PSMA-PET

A0659 68 Ga-PSMA PET/CT for preoperative lymph node staging of high risk prostate cancer

A0660 Diagnostic accuracy of 18F-PSMA-1007 PET/CT in primary staging of intermediate- and high-risk prostate cancer with extended lymph node dissection used as reference method
A.S. Bjartell, Malmö (SE)

A0661 Can pelvic lymph node dissection be omitted at the time of radical prostatectomy in patients with a negative preoperative 68Ga-PSMA PET/CT? The importance of patient risk stratification according to individual risk of lymph node metastases
E. Mazzone, Milan (IT)

A0662 Lymph node staging with 18F-PSMA-1007 PET/CT in newly diagnosed prostate cancer using histopathological evaluation as a reference

A0663 First clinical application of the novel PSMA-11-derived hybrid molecule PSMA-914 for preoperative PET/CT imaging and fluorescence-guided surgery of prostate cancer
C.A. Jilg, Freiburg (DE)

14:30 - 14:40

Discussion

Sentinal nodes

Scientific Programme - EAU22 Amsterdam

A0665	Feasibility of radio-guided lymph node dissection in primary oligometastatic prostate cancer patients: An interim analysis M.G.M. Schilham, Nijmegen (NL)
A0666	Do SPECT CT and sentinel node technique increase the diagnosis of metastatic disease in prostate cancer? J. Perez Ardavin, Valencia (ES)
A0667	Less is more: Usefulness of the sentinel node technique in radical prostatectomy J. Perez Ardavin, Valencia (ES)
A0668	Oncological outcomes of sentinel lymph node procedure-based radiotherapy versus imaging-based radiotherapy for clinically localized prostate cancer – a multicenter, retrospective, propensity score weighted comparison H.A. De Barros, Amsterdam (NL)
A0669	Safety and efficacy of personalized LND vs. ePLND during radical prostatectomy. PersonalymPCA: A randomized phase II study M. Ramírez-Backhaus, Valencia (ES)
14:52 - 15:02	Discussion
	Extend of PLND
A0670	Challenging the dogma: Should unilateral pelvic lymph node dissection be envisioned in the multiparametric prostate MRI era? A. Martini, Milan (IT)
A0671	Clinical implication of periprostatic lymph node invasion in the prostate cancer with robotic radical prostatectomy in Korean ethnicity
A0672	A more extended pelvic lymph node dissection decreases recurrence rates in selected prostate cancer patients undergoing radical prostatectomy
A0673	Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Urooncology Association F. Ok, Sarıçam - Adana (TR)
A0674	Extended pelvic lymph node dissection during robotic prostate surgery firmly reduces biochemical recurrence: A propensity score-matched analysis for intermediate- to high-risk prostate cancer
A0675	Survival after radical prostatectomy vs. radiation therapy in clinical node-positive prostate cancer F. Chierigo, Schio (IT)
15:14 - 15:24	Discussion
15:24 - 15:30	Closing remarks

Current status in radical cystectomy

Video Session 10

Sunday 3 July
14:00 - 15:30

Location Green Area, Room 2

Chairs A. Hosseini, Stockholm (SE)
J.D. Kelly, London (GB)
I.M. Van Oort, Nijmegen (NL)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

14:00 - 14:03

Introduction

V62

Implementation of robotic radical cystectomy with intracorporeal neobladder reconstruction: Step-by-step description of the technique

V63

Functional and oncological outcomes of female pelvic organ preserving robot-assisted radical cystectomy

V64

Totally intracorporeal ileal neobladder- Da Vinci X & 3D laparoscopy- technical advices for optimization after initial 67 cases
E.C. Bujoreanu, Cluj Napoca (RO)

V65

Robot-assisted “Y”-shaped orthotopic ileal neobladder by stapler: Surgical technique and report of perioperative and functional outcomes

V66

Robotic radical cystectomy with intracorporeal ileal conduit: Surgical technique, perioperative, functional and oncologic outcomes

15:18 - 15:23

Closing remarks

Men's health: An update on hypogonadism management

Thematic Session 09

Sunday 3 July
14:00 - 15:30

Location Green Area, Room 3
Chairs M.M. Fode, Herlev (DK)
Z. Kopa, Budapest (HU)
To be confirmed

14:00 - 14:15	State-of-the-art lecture What should we be measuring in men with hypogonadal symptoms? L. Antonio, Leuven (BE)
14:15 - 14:53	Testosterone therapy: Still considered safe and sound?
14:15 - 14:22	In the aging male? M. Zitzmann, Münster (DE)
14:22 - 14:29	In men with diabetes or metabolic syndrome? M. Maggi, Florence (IT)
14:29 - 14:36	In PDE5 inhibitor - nonresponders? G. Corona, Bologna (IT)
14:36 - 14:43	In men who desire to conceive? P. Sangster, London (GB)
14:43 - 14:53	Discussion
14:53 - 15:08	State-of-the-art lecture Managing clinical hypogonadism in castrated prostate cancer patients A. Salonia, Milan (IT)
15:08 - 15:18	Guidelines snapshot Male hypogonadism: What do the updated EAU guidelines say? S. Minhas, London (GB)
15:18 - 15:28	State-of-the-art lecture Hypogonadism and severe COVID-19: The chicken and the egg P. Capogrosso, Milan (IT)
15:28 - 15:30	Closing remarks

Controversies in paediatric urology

Thematic Session 08

Sunday 3 July
14:00 - 15:30

Location Green Area, Room 1

Chairs A-F. Spinoit, Ghent (BE)
To be confirmed

Moderators F. O'Kelly, Dublin (IE)
C. Radmayr, Innsbruck (AT)

Learning objectives

Pediatric urology is a special part of urology in which many controversies exist. The aim of this session is to highlight those controversies and to initiate a lively discussion together with the distinguished speakers and the audience. A challenge on the treatment of vesicoureteral reflux as well as the endocrine treatment of undescended testis will be discussed. Other controversies such as male circumcision and endoscopic treatment of obstructed megaureters will also be highlighted during the session. All residents in urology, pediatric urologists as well as urologists who are interested in pediatric urology are welcome to join this interesting event.

14:00 - 14:05 **Flash presentation** Medical approach to children who may have been sexually abused
To be confirmed

14:05 - 14:10 **Flash presentation** Sexual function in adult patients who have undergone augmentation cystoplasty in childhood
B. Bañuelos Marco, Berlin (DE)

14:10 - 14:20 **State-of-the-art lecture** Circumcision practice in monotheistic religions: A historical perspective
M.I. Karaman, Istanbul (TR)

14:20 - 14:30 **State-of-the-art lecture** Endoscopic treatment options for primary obstructive megaureter: What is the evidence?
To be confirmed

14:30 - 14:40 **Discussion**

14:40 - 15:05 **Case discussion** Bilateral grade III vesicoureteral reflux

14:40 - 14:42 **Case presentation**
F. O'Kelly, Dublin (IE)

14:42 - 14:47 **Subureteric injection**
J.M. Nijman, Groningen (NL)

14:47 - 14:52 **Ureteral reimplantation**
B. Haid, Linz (AT)

14:52 - 14:55 **Expert summary**
To be confirmed

14:55 - 15:05 **Discussion**

15:05 - 15:30 **Debate** Is endocrine treatment for undescended testis of any benefit at all?

Scientific Programme - EAU22 Amsterdam

15:05 - 15:07	Introduction C. Radmayr, Innsbruck (AT)
15:07 - 15:12	Yes B. Burgu, Ankara (TR)
15:12 - 15:17	No J.M. Lammers, Groningen (NL)
15:17 - 15:20	Expert summary S. Sforza, Florence (IT)
15:20 - 15:30	Discussion

Penile cancer - Novel models and nodal disease

Abstract Session 37

Sunday 3 July
14:00 - 15:30

Location Green Area, Room 5
Chairs O.R. Brouwer, Amsterdam (NL)
To be confirmed
To be confirmed

Basic research and novel models

14:00 - 14:03

Introduction

- | | |
|-----------------------|---|
| A0676 | Generation and molecular characterization of paired human penile epithelial primary cell lines derived from patients with penile cancer
A. Muneer, London (GB) |
| A0677 | Establishment of a Patient-Derived Tumor Xenograft (PDTX) biobank in advanced penile cancer for preclinical drug testing and biomarker identification
L. Elst, De Klinge (BE) |
| A0678 | Development of patient-derived penile cancer primary cell cultures and xenografts
J. Linxweiler, Homburg/saar (DE) |
| A0679 | Assessment of APOBEC3 expression as prognostic marker in squamous cell carcinoma of the penis |
| A0680 | Impact of resistance to cisplatin and osimertinib on dissemination properties of penile cancer cells |
| A0681 | Correlation of the expression of microRNA and their predicted targets with prognosis and mortality of penile squamous cell carcinoma
C.B. Murta, São Paulo (BR) |
- 14:15 - 14:29**
- Discussion**
- Inguinal staging and management**
- | | |
|-----------------------|---|
| A0682 | Ex-vivo fluorescence confocal microscopy analysis for penile cancer biopsies
R. Almeida-Magana, London (GB) |
| A0683 | Diagnostic accuracy of dynamic sentinel lymph node biopsy for penile cancer in men with non-palpable and palpable inguinal lymph nodes
E. Lee, London (GB) |
| A0684 | Does time to dynamic sentinel lymph node biopsy affect recurrence-free survival in penile squamous cell carcinoma?
J. Churchill, Manchester (GB) |
| A0685 | Video Endoscopic Inguinal Lymphadenectomy (VEIL) vs. Open Inguinal Lymphadenectomy (OILND) for penile carcinoma: A retrospective study
R. Zanotti, Sao Paulo (BR) |

Scientific Programme - EAU22 Amsterdam

A0686	Inguinal lymph node dissection for penile cancer: Results of a minimally invasive approach from a multicenter database A. Brasseti, Rome (IT)
A0687	Inguinal lymphadenectomy for penile cancer using a fascial sparing technique - outcomes from a single centre
A0688	Morbidity following lymphadenectomy for penile cancer in a Swedish national cohort D. Glombik, Örebro (SE)
A0689	Penile cancer in younger men – a more aggressive disease?
14:45 - 14:59	Discussion
	Pelvi and metastatic disease
A0690	Glasgow prognostic score is a pre-surgical prognostic marker of inguinal lymph node metastasis extranodal extension in penile cancer
A0691	Survival in N3 penile cancer: Does pelvic lymphadenopathy predict a worse prognosis than inguinal extra-nodal extension? J. Churchill, Manchester (GB)
A0692	Outcomes of penile cancer stratified by nodal staging: Importance of pelvic nodal involvement U. Chandankhede, Mumbai (IN)
A0693	A prospective study of chemoradiotherapy for patients with locoregionally advanced penile carcinoma: Safety, efficacy and the role of HPV-status on treatment response H-M. De Vries, Leiden (NL)
A0694	Patterns of recurrence in penile cancer: Implications for surveillance strategies A. Arora, Mumbai (IN)
A0695	Collaborative resilience program to enhance quality of life for post-penectomy patients: Dyadic coping perspective
15:11 - 15:25	Discussion
15:25 - 15:30	Closing remarks

Laboratory research on urethral strictures and preclinical and clinical aspects of neurourology

Abstract Session 38

Sunday 3 July
14:00 - 15:30

Location

Purple Area, Room Elicium 1

Chairs

B. Dybowski, Pruszkow (PL)

D. Eberli, Zürich (CH)

G. Van Koeveeringe, Maastricht (NL)

14:00 - 14:04

Introduction

A0696

Histological comparison of buccal mucosa grafts for urethroplasty: Are inner cheek and sublingual area sharing the same properties and vascular supply?
F. Campos Juanatey, Santander (ES)

A0698

Novel PHB/PLA/TPS scaffold seeded by UDSCs as unique source for tissue engeneering in urethral repair
S. Žiaran, Bratislava (SK)

A0700

Hypoandrogenism as risk factor for urethral stricture development: A multivariate logistic regression analysis

A0701

Is the Urethral stricture score (U-score) a valid prognosticator in low complexity anterior urethral strictures? Making the case for further granular intraoperative stricture assessment
M.W. Vetterlein, Hamburg (DE)

A0702

Bladder cryo-injury induced detrusor underactivity rat model: Early effects of adipose-derived stem cell sheet and their differentiation
S. Teraoka, Yonago (JP)

14:00 - 15:30

Discussion

Neurogenic bladder

A0703

Molecular signature of detrusor overactivity identified in human bladders showing functional improvement after deobstruction
K. Monastyrskaya, Bern (CH)

A0705

The lumbosacral cord repulsive environment does not halt sprouting of bladder afferents and NDO emergence in a NGF concentration-dependent process following spinal cord injury
T. Antunes Lopes, Porto (PT)

A0706

Current impact of sexual and urinary symptoms in patients with multiple sclerosis and future perspectives: Results from a prospective, blinded, real-life study
M. Tutolo, Milano (IT)

A0707

A vigorous machine learning-based framework for the identification of LUTD biomarkers
A. Akshay, Berne (CH)

A0708

Early diagnosis of bladder cancer in people with neurogenic bladder
G. Sampogna, Milan (IT)

Scientific Programme - EAU22 Amsterdam

A0709	Duration of diabetes mellitus does not have influence on onset of bladder outlet obstruction D. Nale, Belgrade (RS)
14:32 - 14:47	Discussion
A0711	Robot-assisted supratrigonal cystectomy and augmentation cystoplasty for neurological bladder in adults: Comparison of extracorporeal vs. intracorporeal diversion B. Peyronnet, Rennes (FR)
A0712	Intravesical botulinum toxin use in detrusor overactivity: A comparison of long-term outcomes in patients with Multiple Sclerosis and Idiopathic Detrusor Overactivity J. Kealey, Box Hill (AU)
A0713	Clean intermittent catheterisation is a challenge in patients suffering from multiple sclerosis: Our experience with 227 patients V. Keppenne, HUY (BE)
14:55 - 15:10	Discussion
15:10 - 15:15	Closing remarks

Minimally invasive therapies for male lower urinary tract symptoms

Abstract Session 39

Sunday 3 July
14:00 - 15:30

Location Purple Area, Room Elicium 2
Chairs To be confirmed
A. Tubaro, Rome (IT)
To be confirmed

14:00 - 14:04

Introduction

Prostatic arteries embolization

A0715

Holmium Laser Enucleation of the Prostate (HoLEP) vs. Prostate Artery Embolization (PAE) in the treatment of Lower urinary tract symptoms (NCT04236687): Initial results of a Randomized Controlled Trial (RCT).
R. Bultó Gonzalvo, Badalona (ES)

A0716

Prostatic artery embolization compared to trans-urethral resection of the prostate and prostatic urethral lift: A real-world population-based study
K. Zorn, Montreal (CA)

14:10 - 14:20

Discussion

Prostatic urethral lift

A0717

Two year efficacy of prostatic urethral lift for benign prostatic hyperplasia: A systematic review and meta-analysis

A0718

Outcomes following the Prostatic Urethral Lift (PUL) are independent of prostate size and shape within real-world and controlled trial settings
C. Gratzke, Freiburg (DE)

A0719

Randomised Controlled trial comparing safety and efficacy of Urolift to Monopolar TURP

A0720

Pooled outcomes from five Prostatic Urethral Lift (PUL) controlled studies reveal most patients can shift to lower IPSS symptom severity after treatment

A0721

De Novo BPH prescription rates are higher after TURP and PVP compared to PUL: A US healthcare claims analysis
S.A. Kaplan, New York (US)

14:30 - 14:40

Discussion

Rezūm

A0722

Urinary and sexual outcomes after water vapour intraprostatic injection (Rezūm procedure): Results from prospective multicentric Italian study
L. Cindolo, Vasto - Chieti (IT)

A0723

Patient-reported outcome measures and surgical retreatment rates from 181 patients treated with water vapor thermal therapy (Rezūm™)

Scientific Programme - EAU22 Amsterdam

A0724	Change in prostate volume reduction and symptomatic improvement in men treated with Rezum convective water vapour thermal therapy D. Elterman, Toronto (CA)
A0725	Pharmacotherapy vs. minimally invasive therapies as initial therapy for patients with benign prostate hyperplasia: A microsimulation model D. Elterman, Toronto (CA)
A0726	Real-world evidence of patient perceptions and willingness to pay for a minimally surgical procedure for benign prostatic hyperplasia D. Elterman, Toronto (CA)
14:52 - 15:02	Discussion
	Emerging new innovative options
A0728	Transperineal laser ablation for BPH: 3 month outcomes F. Bianco, Miami Lakes (US)
A0729	Transperineal interstitial laser ablation of the prostate as a minimally-invasive and effective therapeutic option for benign prostatic hyperplasia
A0730	The Butterfly transurethral device for BPH - more than one year experience R. Katz, Zefat (IL)
A0731	Ejaculation sparing thulium laser enucleation of the prostate: A observational prospective study
A0732	Functional improvement and preservation of sexual function 3 years after treatment with the optilume BPH catheter system S.A. Kaplan, New York (US)
A0733	Transurethral ultrasound ablation (TULSA) for benign prostatic hyperplasia: Three-month clinical outcomes A. Viitala, Helsinki (FI)
15:14 - 15:24	Discussion
15:24 - 15:30	Closing remarks

Prostate biopsy indication and strategy: Which role for which imaging by MRI, PET, US

Abstract Session 40

Sunday 3 July
14:00 - 15:30

Location

Orange Area, Room 2

Chairs

P.J.L. De Visschere, Ghent (BE)

G. Fiard, Grenoble (FR)

R.A. Rendon, Halifax (CA)

MRI

14:00 - 14:04

Introduction

A0734

Biparametric quantitative MRI for prostate cancer detection

A0735

Multiple suspicious PI-RADS lesions prior to mpMRI ultrasound fusion biopsy: Is it sufficient to target exclusively the index lesion?

P. Rachubinski, Gronau (DE)

A0736

Does a positive multi-parametric MRI always warrant prostate biopsy? The importance of integrating clinical and imaging data based on a large, multi-institutional series

A. Stabile, Milan (IT)

A0737

Artificial intelligence in diagnostic and therapeutic decision making in prostate cancer – do patients favor AI-enhanced urologists?

T. Westhofen, München (DE)

A0738

Has the introduction of mpMRI in the diagnostic pathway of prostate cancer led to improved oncological outcomes after radical prostatectomy? Result from a large single-institutional series

A. Stabile, Milan (IT)

A0739

Does every suspicion of prostate cancer need imaging – a risk-based approach to reduce unnecessary mpMRI

J.R. Gonçalves Correia, Viana Do Castelo (PT)

A0740

A comparison of the PLUM and RPCRC- MRI-based prostate cancer risk prediction models in two North American and European cohorts

S. Remmers, Rotterdam (NL)

A0741

Does previous prostatic surgery affect the accuracy of multiparametric MRI in detecting clinically significant prostate cancer? Results from a single center, high volume series

A0742

Detection of clinically significant prostate cancer in mpMRI visible lesions: Size matters. Results from a large, two-institutional series

A. Stabile, Milan (IT)

14:22 - 14:31

Discussion

MRI and PET

A0743	<p>Update from the PEDAL trial: A prospective single arm paired comparison of ability to diagnose and locate prostate cancer between multiparametric MRI and 18F-PSMA-PET/CT</p> <p>V. Tran, Melbourne (AU)</p>
A0744	<p>Diagnostic accuracy, concordance and certainty with 68Ga-PSMA-11 PET/MRI fusion compared to mpMRI and 68Ga-PSMA-11 PET/CT alone for prostate cancer diagnosis: A PRIMARY trial sub-study</p> <p>P.N. Doan, Northmead (AU)</p>
A0745	<p>Fluorine-18 (18F) Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) and the diagnosis and staging of primary Prostate Cancer (PCa)</p>
A0746	<p>Dual-Tracer PET/CT-Targeted, mpMRI-Targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer</p>
14:39 - 14:48	<p>Discussion</p>
	<p>Ultrasound</p>
A0747	<p>Diagnostic performance of mixed targeted prostate biopsy approaches using micro-ultrasound and MRI-fusion biopsies</p> <p>D. Maffei, Villa Lagarina (IT)</p>
A0748	<p>Comparative analyses of micro-ultrasound versus MRI-targeted biopsy for the diagnosis of clinically significant prostate cancer. Preliminary results from the prospective US-MIRROR Trial</p>
A0749	<p>A prospective multicenter comparison study of a risk-adapted ultrasound-directed and MRI-directed diagnostic pathway in prostate cancer suspected biopsy naïve men</p>
A0750	<p>Micro-ultrasound-guided biopsy for prostate cancer reduces underestimation of index lesion extension at final pathology compared to mri/ultrasound prostate fusion biopsy: Impact on ablation therapy templates</p>
A0751	<p>Diagnostic performance of micro-ultrasound guided reclassification biopsies in patients under active surveillance for prostate cancer</p> <p>D. Maffei, Villa Lagarina (IT)</p>
A0752	<p>Biopsy-region-based multiparametric ultrasound imaging for prostate cancer localization</p> <p>P. Chen, Eindhoven (NL)</p>
A0753	<p>Assessing the role of high-resolution micro-ultrasound among patients with a negative multiparametric MRI and a persistent suspicion of prostate cancer</p>
15:02 - 15:11	<p>Discussion</p>
	<p>MRI and 5-ARI</p>
A0754	<p>Diagnosis of prostate cancer in men treated with 5-alpha-reductase inhibitors with multi-parametric MRI: results of a multicenter international collaboration</p>
A0755	<p>5-alpha reductase inhibitors and magnetic resonance imaging scans of prostates</p> <p>Z. Wang, Singapore (SG)</p>

Scientific Programme - EAU22 Amsterdam

15:15 - 15:24

Discussion

15:24 - 15:30

Closing remarks

Bladder cancer radical therapy, surgery and QOL impact

Abstract Session 41

Sunday 3 July
14:00 - 15:30

Location Yellow Area, Room Forum
Chairs N. Al-Hamdani, Baghdad (IQ)
P. Gontero, Turin (IT)
A. Masson-Lecomte, Paris (FR)

14:00 - 14:03

Introduction

Staging and progression

A0756 **Health Related Quality of Life (HRQOL) four years after radical cystectomy – does the type of urinary diversion matter?**
Y. Volz, München (DE)

A0757 **Predictors of early health-related quality of life deterioration in patients receiving radical cystectomy with urinary diversion: Results from a single centre randomized controlled trial**
R. Mastroianni, Rome (IT)

A0758 **Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology – Young Academic Urologists**

14:09 - 14:16

Discussion

Radical cystectomy

A0759 **Robot assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy: Results from the iROC prospective randomised controlled trial**
J.W.F. Catto, Sheffield (GB)

A0761 **Long-term oncologic outcomes and predictors of recurrence, cancer-specific and overall survival: Results from a high-volume center large consecutive series of robot assisted radical cystectomy with intracorporeal urinary diversion**
G. Tuderti, Roma (IT)

A0762 **Propensity matched comparison of radical cystectomy with trimodality therapy for muscle invasive bladder cancer (MIBC): A multi-institutional study**
A.R. Zlotta, Toronto (CA)

A0763 **Management and outcomes of non-muscle invasive bladder recurrence after complete response to trimodality therapy for muscle-invasive bladder cancer: A monocentric experience**

A0764 **Should we limit robot-assisted radical cystectomy with totally intracorporeal urinary diversion to neobladder patients? Head to head comparison of outcomes between robotic vs. open ileal conduit and robotic vs. open neobladder**
R. Mastroianni, Rome (IT)

A0765 **Perioperative complications after radical cystectomy for bladder cancer: An international multicenter collaboration**

Scientific Programme - EAU22 Amsterdam

A0766	Prediction of 90-day mortality after radical cystectomy for bladder cancer in large-scale multicenter collaboration study E. Laukhtina, Vienna (AT)
A0767	Recovery of patient-reported QOL after cystectomy for bladder cancer
A0768	Trimodal therapy versus radical cystectomy for T2 bladder cancer: real-world evidence from Ontario M.S. Wettstein, Zurich (CH)
14:36 - 14:46	Discussion
	Remnant abstracts systemic treatment
14:48 - 14:55	Discussion
	Quality of life and markers
A0770	Predictors of health-related quality of life deterioration in the first year after radical cystectomy with urinary diversion: Results from a single centre randomized controlled trial R. Mastroianni, Rome (IT)
A0771	Acute kidney injury and its duration in patients treated with radical cystectomy in the Enhanced Recovery After Surgery era: Optimizing the selection of patients for restrictive fluid therapy
A0772	Understanding the impact of the social construct of race on receipt of radical cystectomy in the largest equal access health system in the US: The Veterans Affairs Health System
15:01 - 15:08	Discussion
	Radical surgery
A0773	Radical cystectomy video consensus: A simple and effective way to improve awareness of patients undergoing radical cystectomy F. Prata, Rome (IT)
A0774	Intravesical injection with abobotulinumtoxin-A in patients with bladder pain syndrome/ interstitial cystitis S. Hajebrahimi, Tabriz (IR)
A0775	Open vs. robot-assisted radical cystectomy with totally intracorporeal urinary diversion: functional outcomes comparison from a single centre randomised controlled trial R. Mastroianni, Rome (IT)
A0776	Early oncologic outcomes of open vs. robot-assisted radical cystectomy with totally intracorporeal urinary diversion: Single centre prospective randomised controlled trial R. Mastroianni, Rome (IT)
A0777	Radical cystectomy vs systemic therapy in non-metastatic bladder cancer with advanced lymph nodal disease (cN2/N3 disease) using inverse probability weighting analysis H. Garg, San Antonio (US)

Scientific Programme - EAU22 Amsterdam

15:18 - 15:25

Discussion

15:25 - 15:30

Closing remarks

Recent advances in surgical treatment options for paediatric urology

Abstract Session 42

Sunday 3 July
15:45 - 17:15

Location Grey Area, Room Emerald
Chairs To be confirmed
To be confirmed
To be confirmed

15:45 - 15:49

Introduction

A0778

Secular trends in pediatric urolithiasis surgical incidence and management in Ontario, Canada: A population based retrospective cohort study
J. Bjazevic, London (CA)

A0779

Outcomes from practice of Retrograde Intrarenal Surgery (RIRS) in a paediatric setting of various age groups: A global study across 8 centres
E.J. Lim, Singapore (SG)

A0780

The efficacy and safety of RIRS in the surgical treatment of kidney stones in pediatric patients from a single pediatric urology center
N. Baydilli, Kayseri (TR)

15:55 - 16:03

Discussion

A0781

Vesicoureteral Reflux Index; from medical publication to clinical application

A0782

The long term result and efficacy of endoscopic treatment of vesicoureteric reflux using dextranomer / hyaluronic acid: Over 15-year experience in a single-center
D.G. Moon, Seoul (KR)

A0783

Predisposing factors for postoperative febrile urinary tract infection episodes even after successful endoscopic injection therapy in children with primary vesicoureteral reflux
N. Baydilli, Kayseri (TR)

16:09 - 16:17

Discussion

A0784

Clinical study of urethroplasty combined free grafting of internal preputial lamina with onlay local pedicled flap

A0785

Penile perception score after hypospadias repair on late diagnosed sexual development disorders
M.C. Karaburun, Ankara (TR)

A0787

Surgical correction of gliding testes, single incision is enough

16:23 - 16:31

Discussion

A0788

Assistant port is unnecessary for robotic-assisted laparoscopic pyeloplasty in children: A non-randomized comparative study
M.S. Silay, Istanbul (TR)

A0789	Competency in open and laparoscopic pyeloplasty: A cumulative sum learning curve analysis of a single surgeon experience J.K.J. Kim, Toronto (CA)
A0791	The use of Tutoplast® fascia lata assisting fascial closure of pediatric renal transplant recipients with donor size discrepancy B. Bañuelos Marco, Berlin (DE)
A0792	Ureterocelelectomy for extravesical ureterocele: What happens in the long-term follow-up? I. Selvi, Istanbul (TR)
16:41 - 16:49	Discussion
A0793	A cross-sectional needs assessment and attitudes survey of paediatric urologists towards gaps and areas of perceived importance in adolescent transitional care F. O'Kelly, Dublin (IE)
A0794	Incidence of fertility preservation procedures in prepubertal and pubertal individuals with cancer C.H. Delgado, Monterrey (MX)
A0795	Prediction of Wilms' tumor relapse risk using genetic and metabolomic markers A. Abdelhalim, Mansoura (EG)
A0796	Does p53, Ki67 and Cyclin a immunohistochemical assay predict wilms tumor mortality?
A0797	Bladder Cancer risk in children and adolescents with rare disorders: Experience from Costello syndrome. N. Foschi, Rome (IT)
16:59 - 17:07	Discussion
17:07 - 17:13	Closing remarks

Practical management of non-muscle-invasive bladder cancer (NMIBC)

ESU Course 36

Sunday 3 July
14:30 - 17:30

Location Grey Area, Room G102

Chair J.A. Witjes, Nijmegen (NL)

Learning objectives

Our main objective is to not only enrich what you know about NMIBC, but to also equip you with frontline strategies when dealing with common and complex patient cases.

This course will commence with discussions on NMIBC diagnostic opportunities then proceed to the best practices and the pitfalls to avoid in transurethral resection (TUR). Get to know the techniques, tips and tricks, potential problems/complications, TUR with enhanced imaging, en-bloc resection and more through videos and lively discussions with key opinion leaders.

Further into the course, you will familiarise yourself with the new modalities and the limitations of recommendations on additional risk-adapted intravesical treatment. These will be followed by deliberations on typical problems encountered, complications during and after intravesical therapy, and strategies on how you can prevent them.

Another course highlight you can look forward to is how you can deal with abnormal cytology including locations outside the bladder.

Introduction

J.A. Witjes, Nijmegen (NL)

Diagnosis, markers and innovations

J. Palou, Barcelona (ES)

TUR technique: Tips and tricks; problems; En bloc resection; TUR and the location, including diverticula, ureteral meatus; Re-TUR; PDD, SPIES, NBI etc.: With several cases and video's

M. Babjuk, Prague (CZ)

Complications during surgery and what to do: Obturator nerve contraction, intra and extraperitoneal perforation, bleeding etc.

J. Palou, Barcelona (ES)

Risk groups and guideline treatment: What is clearly established

J.A. Witjes, Nijmegen (NL)

Comments on guideline treatment including BCG shortage and new treatment modalities

M. Babjuk, Prague (CZ)

Complications of intravesical therapy, including case

J.A. Witjes, Nijmegen (NL)

How to deal with abnormal cytology including locations outside the bladder (UUT and urethra) and its limitations

J. Palou, Barcelona (ES)

Advanced course on upper tract laparoscopy: Kidney, ureteropelvic junction (UPJ), ureter and stones

ESU Course 37

Sunday 3 July
14:30 - 17:30

Location Grey Area, Room G103

Chair F. Porpiglia, Turin (IT)

Learning objectives

Surgery of the kidney by means of laparoscopy is standard of care, and has replaced open surgery to a great extent.

Approach: Transperitoneal, retroperitoneoscopy, posterior, direct through the mesentery of the colon. Each approach has specific advantages also depending on the procedure to be performed.

Procedures: Ablative, reconstruction, stone surgery.

Presentation: Power-point, interactive, videos, tips and tricks, complications.

- For surgery of the kidney, the daVinci robot is often an overkill. Also it is not available everywhere. Therefore standard laparoscopy is still of importance and should be mastered by every endoscopic surgeon.
- Choice of the perfect approach makes the respective surgery easier and safer.
- Standard laparoscopy is greatly facilitated by 3D vision.
- When mastering both laparoscopic surgical skills as well as the surgical concept of the respective procedure complications can either be avoided or managed appropriately.

Approach: Transperitoneal, retroperitoneoscopy

B. Petrut, Cluj Napoca (RO)

Kidney: Nephrectomy, management of cysts

M.C. Mir Maresma, Valencia (ES)

Ureter: Nephroureterectomy, end-to-end anastomosis, replacement

F. Porpiglia, Turin (IT)

Pyeloplasty: Indication – techniques – problems

F. Porpiglia, Turin (IT)

Stone surgery

M.C. Mir Maresma, Valencia (ES)

Complication management

B. Petrut, Cluj Napoca (RO)

Questions, tips and tricks

M.C. Mir Maresma, Valencia (ES)

F. Porpiglia, Turin (IT)

B. Petrut, Cluj Napoca (RO)

Percutaneous nephrolithotripsy (PCNL)

ESU Course 38

Sunday 3 July
14:30 - 17:30

Location Grey Area, Room G104

Chair E. Liatsikos, Patras (GR)

Learning objectives

Aim of this course is to describe in detail the surgical techniques of all available treatment options in percutaneous surgery of renal stones. In addition, to tips and tricks aiming into improving the efficacy of the operation, the most common complications associated with the procedure will be reviewed focusing on their prevention and proper management.

Objectives

- Describe the basic percutaneous nephrolithotripsy techniques.
- Provide tips to improve the efficacy of the operation.
- Provide evidence on the comparison of percutaneous with ureteroscopic and extracorporeal treatment options; Which approach for which stone.
- Describe associate complications including their management.

Guidelines on stone treatment

T. Knoll, Sindelfingen (DE)

PCNL instrumentation – Suite organisation, wires, dilators and lithotriptors

C.M. Scoffone, Turin (IT)

From skin to stone: Step-by-step access using only fluoroscopy (Prone position)

E. Liatsikos, Patras (GR)

From skin to stone: Step-by-step access using ultrasonography (US) and fluoroscopy (Supine position)

C.M. Scoffone, Turin (IT)

MiniPerc- Indications, equipment and technique

T. Knoll, Sindelfingen (DE)

Tips and tricks in PCNL

E. Liatsikos, Patras (GR)

Round table: Complications of PCNL: Diagnosis, management, prevention

E. Liatsikos, Patras (GR)

T. Knoll, Sindelfingen (DE)

C.M. Scoffone, Turin (IT)

Management of BPO: From medical to surgical treatment, including setbacks and operative solutions (SOS)

ESU Course 39

Sunday 3 July
14:30 - 17:30

Location Grey Area, Room G105

Chair T.R.W. Herrmann, Frauenfeld (CH)

Learning objectives

- To help delegates understand the principles and evidence behind the assessment and medical management of a BPO patient.
- To summarise / review the evidence base for electro surgery and lasers for surgical management of BPO.
- To help delegates understand the factors that influence the patient's and surgeon's choice of treatment modalities.
- Setbacks and Operative Solutions (SOS): Tips and Tricks to improve outcomes and avoid complications.

Introduction/scene setting BPO 2022

T.R.W. Herrmann, Frauenfeld (CH)

Assessment and medical management

To be confirmed

Surgical management – Electrosurgery

T.R.W. Herrmann, Frauenfeld (CH)

Surgical management – Lasers and less invasive options

S.A. Ahyai, Göttingen (DE)

Setbacks and operative solutions / Case presentations

S.A. Ahyai, Göttingen (DE)

T.R.W. Herrmann, Frauenfeld (CH)

To be confirmed

Surgery or radiotherapy for localised and locally advanced prostate cancer

ESU Course 40

Sunday 3 July
14:30 - 17:30

Location Grey Area, Room G106

Chair R.J.A. Van Moorselaar, Amsterdam (NL)

Learning objectives

This course will summarize the decision process and indications for patients with localized and locally advanced disease and will help to select the optimal treatment including active surveillance based on most recent oncological and functional data.

After this course participants have updated their knowledge on:

- Surgical and radiotherapeutic treatment modalities.
- The optimal indication for which treatment option.
- Oncological and functional results.
- New options for adjuvant treatment.

14:30 - 17:30

Introduction

R.J.A. Van Moorselaar, Amsterdam (NL)

- **Localised prostate cancer**

- **Treatment options in localised prostate cancer**
J.P.M. Sedelaar, Nijmegen (NL)

- **Oncological and functional results of radiation therapy**
A. Bossi, Villejuif (FR)

- **Oncological and functional results of radical prostatectomy**
R.J.A. Van Moorselaar, Amsterdam (NL)

- **Advanced prostate cancer**

- **Radiotherapy with or without hormonal treatment in advanced prostate cancer**
A. Bossi, Villejuif (FR)

- **Adjuvant therapies following radical prostatectomy**
R.J.A. Van Moorselaar, Amsterdam (NL)

- **Results of radical prostatectomy for T3 disease**
J.P.M. Sedelaar, Nijmegen (NL)

14:30 - 17:30

Take home messages

R.J.A. Van Moorselaar, Amsterdam (NL)

Office management of male sexual dysfunction

ESU Course 41

Sunday 3 July
14:30 - 17:30

Location Grey Area, Room G107

Chair C. Stief, Munich (DE)

Learning objectives

The course is aimed at providing practical advice on how to diagnose and treat a patient with

Premature ejaculation or ED. It will allow

- An up-to-date understanding of the aetiology of ED and EP.
- An adequate work up enabling an individually adopted regimen.
- Currently available treatment options as topical and oral drugs, testosterone and devices.
- Post-prostatectomy ED with various approaches.

Introduction

C. Stief, Munich (DE)

Diagnostics: What is necessary?

D. Hatzichristou, Thessaloniki (GR)

Testosterone replacement

C. Stief, Munich (DE)

Oral therapy for erectile dysfunction and premature ejaculation

D. Hatzichristou, Thessaloniki (GR)

Therapy of erectile dysfunction when pills fail

D.J. Ralph, London (GB)

The role of regenerative medicine for ED treatment (shockwaves, PRP, stem cells)

D. Hatzichristou, Thessaloniki (GR)

Surgical topics: Penile implants, priapism, Peyronie's disease

D.J. Ralph, London (GB)

What to do after radical prostatectomy?

C. Stief, Munich (DE)

Joint session of the EAU and the Advanced Prostate Cancer Consensus (APCCC)

EAU Specialty Session

Sunday 3 July
15:15 - 17:15

Location Orange Area, eURO Auditorium 1

Chairs N. Mottet, Saint-Étienne (FR)
C. Sweeney, Boston (US)

Moderators N. Mottet, Saint-Étienne (FR)
B. Tombal, Brussels (BE)

Discussants G. Baciarello, Milan (IT)
A. Briganti, Milan (IT)
S. Fanti, Bologna (IT)
R.J. Jones, Glasgow (GB)
L. Marandino, Milan (IT)
A. Padhani, Northwood (GB)
C. Sweeney, Boston (US)
F. Turco, Bellinzona (CH)
Y. Ürün, Ankara (TR)
T. Zilli, Geneva (CH)

Learning objectives

Learn about current gaps on evidence in metastatic hormone sensitive prostate cancer management; Learn about controversies and state of the art of high volume de novo disease; How to optimally use PSMA based imaging; When to use metastases directed therapy in situation where metastases are only seen in PSMA PET.

15:15 - 15:20

Introduction and short summary of APCCC 2021
To be confirmed

15:20 - 16:25

Metastatic hormone sensitive prostate cancer

15:20 - 15:25

Case presentation De novo high volume elderly patient
F. Turco, Bellinzona (CH)

15:25 - 15:35

Ideal imaging in this setting
A. Padhani, Northwood (GB)

15:35 - 15:45

Adding an AR-targeted drug alone to ADT
G. Baciarello, Milan (IT)

15:45 - 15:55

Adding Docetaxel alone or plus an AR targeted drug to ADT
Y. Ürün, Ankara (TR)

15:55 - 16:05

Are there arguments for ADT alone?
R.J. Jones, Glasgow (GB)

16:05 - 16:15

Summary Optimal treatment for high volume de novo patients who are elderly
C. Sweeney, Boston (US)

16:15 - 16:25

Questions and answers

16:25 - 17:00

PSMA-based imaging

Scientific Programme - EAU22 Amsterdam

16:25 - 16:30	Case presentation High-risk with suspicious bone lesions in PSMA L. Marandino, Milan (IT)
16:30 - 16:40	Different tracers with different pitfalls in this setting S. Fanti, Bologna (IT)
16:40 - 16:50	How to optimally manage such situations: How to confirm metastases seen in PSMA PET and how to treat? A. Briganti, Milan (IT)
16:50 - 17:00	What is the evidence for radical local treatment plus/minus metastases directed therapy (MDT) of all lesions? T. Zilli, Geneva (CH)
17:00 - 17:10	Discussion
17:10 - 17:15	Closing remarks N. Mottet, Saint-Étienne (FR)

Practical tips for pelvic laparoscopic surgery: Cystectomy, radical prostatectomy adenomectomy and sacrocolpopexy

ESU Course 42

Sunday 3 July
15:30 - 17:30

Location Grey Area, Room G109

Chair J.M. Gaya Sopena, Barcelona (ES)

Learning objectives

Patient positioning and trocar placement

J.M. Gaya Sopena, Barcelona (ES)

Laparoscopic adenomectomy and radical prostatectomy

P. Kallidonis, Patras (GR)

Laparoscopic radical cystectomy

J.M. Gaya Sopena, Barcelona (ES)

Laparoscopic reconstructive surgery of the pelvic floor and sacrocolpopexy

P. Kallidonis, Patras (GR)

Identify and solve complications

J.M. Gaya Sopena, Barcelona (ES)

AI in urology

Thematic Session 10

Sunday 3 July
15:45 - 17:15

Location Grey Area, eURO Auditorium 2

Chairs J. N'Dow, Aberdeen (GB)
K.A.O. Tikkinen, Helsinki (FI)

Learning objectives

The EAU Congress 2022 session on artificial intelligence (AI) gives practising urologist a great overview on opportunities and challenges in AI in near urologic future. In the session, you will learn the basics of AI, what AI means for urologists and what are the relevant ethical considerations. We will also cover AI's importance for patients and describe the opportunities for the future clinical practice guidelines development. The session will end with a debate between AI-powered "real world data" and "evidence-based medicine" with systematic reviews and randomized trials.

15:45 - 15:47	Welcome and introduction
15:47 - 15:57	Basics of explainable artificial intelligence To be confirmed
15:57 - 15:59	Discussion
15:59 - 16:09	What explainable artificial intelligence means for urologist now and in the future? P. Lambin, Maastricht (NL)
16:09 - 16:11	Discussion
16:11 - 16:21	Ethics in artificial intelligence R. Malpani, Geneva (CH)
16:21 - 16:23	Discussion
16:23 - 16:33	Patients' perspective on artificial intelligence To be confirmed
16:33 - 16:35	Discussion
16:35 - 16:45	Personalising care through explainable artificial intelligence powered individualising of Guidelines To be confirmed
16:45 - 16:47	Discussion
16:47 - 17:12	Debate Real-World Data with explainable artificial intelligence vs. Evidence-based medicine
16:47 - 16:57	Pro: Real-World Data with artificial intelligence To be confirmed
16:57 - 17:07	Pro: Evidence-based medicine systematic reviews and randomized control trials P. Dahm, Minneapolis (US)
17:07 - 17:12	Discussion

17:12 - 17:15

Closing remarks

Risk stratification and treatment for recurrent disease

Abstract Session 11

Friday 1 July
14:15 - 15:45

Location Green Area, Room 5
Chairs D. Murphy, Melbourne (AU)
M. Valerio, Lausanne (CH)
To be confirmed

14:15 - 14:19

Introduction

Detectable PSA

A0183	Impact of persistent PSA in salvage radical prostatectomy patients for recurrent prostate cancer F. Preisser, Frankfurt Am Main (DE)
A0184	Time without PSA recurrence after radical prostatectomy as a predictor of prostate cancer death
A0185	Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: The key role of PSA kinetics N. Fossati, Lugano (CH)
A0186	Survival estimates of men with biochemically recurrent prostate cancer after radical prostatectomy in a national cohort
A0187	External validation of new risk groups of progression and death in patients with biochemical relapse after prostatectomy, proposed by the European Association of Urology
14:29 - 14:36	Discussion
	PSMA PET
A0188	PSMA PET disease extent for European Association of Urology biochemical recurrence risk groups: An international multicentre study W. Fendler, Essen (DE)
A0189	Oncological outcomes in patients with recurrent prostate cancer staged with PSMA PET/CT: Results from 3 European tertiary centers L. Bianchi, Bologna (IT)
A0190	Optimizing timing and indications for 68Ga-PSMA PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy D. Robesti, Milan (IT)
A0191	Correlation between 18f-dcfpyl pet detected local recurrence and radical prostatectomy histopathology: A pilot study J. Wynn, Ballarat (AU)

A0192	<p>Restaging prostate-specific membrane antigen positron emission tomography/ computed tomography is associated with improved oncological outcome in men who underwent salvage radiation therapy for biochemically recurrent prostate cancer</p> <p>D. Meijer, Amsterdam (NL)</p>
A0193	<p>Effect of 18F-DCFPyL PET/CT (=PSMA PET) on the management of patients with suspected limited residual/recurrent disease following radical prostatectomy: Results of a prospective, multicenter registry trial</p>
14:48 - 14:55	<p>Discussion</p>
	<p>PSA kinetics</p>
A0194	<p>PSA doubling time as predictor of relapse after early salvage radiation therapy: When should imaging be used to select patients who might not benefit from early local treatments?</p> <p>N. Fossati, Lugano (CH)</p>
A0195	<p>Validation of prostate specific antigen doubling time kinetics following radical prostatectomy to guide active observation and intervention</p> <p>E. Huang, Orange (US)</p>
14:59 - 15:06	<p>Discussion</p>
	<p>Metastasis directed treatment</p>
A0196	<p>Robot-assisted PSMA-radioguided salvage surgery in recurrent prostate cancer using a DROP-IN gamma probe - a prospective feasibility study</p> <p>H.A. De Barros, Amsterdam (NL)</p>
A0197	<p>PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute toxicity of a randomized phase II trial</p> <p>P. Ost, Ghent (BE)</p>
A0198	<p>The key role of concomitant androgen-deprivation therapy on the efficacy of imaging guided treatments in men with biochemical recurrent prostate cancer after radical prostatectomy and 68Ga-PSMA PET/CT scan</p> <p>D. Robesti, Milan (IT)</p>
A0199	<p>Active observation of biochemical recurrence without treatment following radical prostatectomy: Long term analysis of outcomes</p> <p>T. Ahlering, Orange (US)</p>
A0200	<p>Event-Free survival after 68Ga-PSMA-11 PET/CT in recurrent Hormone-Sensitive Prostate Cancer (HSPC) patients eligible for salvage therapy</p> <p>F. Ceci, Milano (IT)</p>
A0201	<p>A timely administration of metastasis-directed therapy can reduce the risk of disease progression in men with positive 68Ga-PSMA PET/CT for biochemical recurrence after radical prostatectomy</p> <p>E. Mazzone, Milan (IT)</p>
A0202	<p>Stereotactic radiotherapy for 68Ga-PSMA and 18F-FDG PET/CT detected lesions in early non-metastatic castration-resistant prostate cancer (PSA≤2ng/ml): A prospective single-center study</p>

Scientific Programme - EAU22 Amsterdam

15:20 - 15:27	Discussion
	Systemic treatment
A0203	Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: Analysis of real-life data from Eudra-Vigilance database
A0204	Osteoporosis. Is it really a side effect of ADT? J.Y. Ku, Busan (KR)
15:31 - 15:38	Discussion
15:38 - 15:45	Closing remarks

Urological curiosities

Video Session 12

Sunday 3 July 15:45 - 17:15	Location Green Area, Room 2
	Chairs D. Bouchier-Hayes, Galway (IE) S. Tyritzis, Athens (GR) To be confirmed All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.
15:45 - 15:48	Introduction
V75	Radical cystectomy in renal transplant recipients: The advantages of the robotic approach
V76	Robotic-Assisted Laparoscopic Left Seminal Vesiculectomy and Distal Left Ureterectomy for a patient with Zinner Syndrome S.H.B Belbina, austin (US)
V77	Complex robot-assisted bladder diverticulectomy with endoscopic assistance
V78	Suction spatula: A new device to aid to do minimally invasive partial nephrectomy
V79	Ureteric stenting with a fully coated polymeric stent – a new therapy option for ureteral injuries during cesarean section J. Neymeyer, Berlin (DE)
V80	Endoscopic combined retrograde and antegrade approach (ECIRS) in the management of forgotten encrusted ureteral stent
V81	A novel modification for ureteral reimplantation technique (Combined technique) in pediatric patients: A preliminary case series
17:06 - 17:11	Closing remarks

Awards ceremony and focal therapies

Video Session 11

Sunday 3 July 15:45 - 17:15	Location Green Area, Room 1
	Chairs E. Barret, Paris (FR) J. Gómez Rivas, Madrid (ES) F. Van Der Aa, Leuven (BE) All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.
15:45 - 15:48	Introduction
V70	High-intensity focused ultrasound (hifu) focal therapy for prostate cancer with mri-us fusion ablation navigation C.H. Yee, Hong Kong (HK)
V71	Targeted microwaves ablation of prostate cancer with 3D MRI/US fusion imaging (NCT04627896) M. Oderda, Turin (IT)
V72	Colored perfusion areas-based 3D virtual models: The Rainbow Kidney as a new tool to optimize the clamping strategy during robot-assisted partial nephrectomy D. Amparore, Turin (IT)
V73	A video demonstration and case series of a modified split thickness skin graft technique using Artiss Sealant® performed with penile cancer procedures J. Churchill, Manchester (GB)
V74	Eight-yr experience of robotic IVC thrombectomy: surgical technique, perioperative and oncologic outcomes
16:56 - 17:15	Award announcements and closing remarks

Reproductive health - Male infertility and andrological effects of COVID-19

Abstract Session 43

Sunday 3 July
15:45 - 17:15

Location Green Area, Room 3
Chairs J. Dupree, Ann Arbor (US)
To be confirmed
P. Sangster, London (GB)

15:45 - 15:48

Introduction

Basic research

A0799 **The effect of the microbiome on the level of anti-inflammatory interleukin 37 in the semen of fertile and infertile men**

A0800 **Ultrastructural, endocrinological and reproductive effects of experimental unilateral cryptorchidism on the contralateral exocrine testicular function in the rabbit model**
F. Dimitriadis, Kalamaria, Thessaloniki (GR)

15:54 - 16:05

Discussion

Epidemiology and Diagnosis

A0801 **Associations between seminal microbiota composition and ROS in men with fertility disorders**
S. Mowla, London (GB)

A0802 **Couples presenting to Infertility Clinics - Are they really infertile?**
K. Khoja, London (GB)

A0803 **Delayed absent ejaculation in men presenting to the fertility clinic – retrospective cohort study**
R. Ahmed, London (GB)

A0804 **Timed intercourse exacerbates the risk of sexual dysfunction in men and women without an improvement in time to pregnancy**

A0805 **Age at presentation of infertile men has stably increased over the last two decades: Analysis from a longitudinal study**
L. Boeri, Milan (IT)

A0806 **Evaluation of the bone-testis axis in patients with azoospermia undergoing surgical sperm retrieval**
J. Kilb-Köklü, Gießen (DE)

A0807 **The effect of historical CMV infection on sperm parameters in white-European infertile men: Findings from a real-life cross-sectional study**
F. Belladelli, Milan (IT)

A0808 **The impact of different WHO reference criteria for semen analysis in clinical practice: Who will benefit from the new 2021 cutoffs for normal sperm parameters?**

Scientific Programme - EAU22 Amsterdam

16:21 - 16:32	Discussion
	Therapy and sperm retrieval
A0809	The effect of semen parameters on pregnancy rate from assisted reproduction technologies: Systematic review and meta-analysis F. Del Giudice, Rome (IT)
A0811	Low birth weight is associated with sperm dna fragmentation and assisted reproductive technology outcomes in primary infertile men – results of a cross-sectional study L. Boeri, Milan (IT)
A0812	Surgical sperm retrieval and assisted conception outcomes in patients with Klinefelter syndrome with /without hormone stimulation S. Rintoul-Hoad, London (GB)
A0813	The role of varicocele correction in men with a clinical varicocele and non-obstructive azoospermia T. De Vringer, Rotterdam (NL)
16:42 - 16:53	Discussion
	Andrological aspects of COVID-19
A0815	Changes of sperm parameters in men recovered from COVID-19: A comparison between pre-COVID and post-COVID period
A0816	Effect of SARS-CoV-2 infection upon male sexual function: A multi-center analytic study H. Khouni, Tunis (TN)
16:59 - 17:10	Discussion
17:10 - 17:15	Closing remarks

Postoperative risk estimation and multimodal treatment of prostate cancer

Abstract Session 44

Sunday 3 July
15:45 - 17:15

Location Green Area, Room 4
Chairs V.J. Gnanapragasam, Cambridge (GB)
A.S. Rannikko, Helsinki (FI)
To be confirmed

Confounders

15:45 - 15:49

Introduction

A0817 **Preoperative health-related quality of life accurately predicts metastasis-free survival for high-risk prostate cancer patients following radical prostatectomy**
T. Westhofen, München (DE)

A0818 **The surgical learning curve for cancer control after robot-assisted radical prostatectomy**
C.A. Bravi, Milan (IT)

A0819 **Baseline description of clinical characteristics and first postoperative data of the SPCG-15 population**
M. Gongora, Stockholm (SE)

A0820 **Cancer related self-perception for prostate cancer after radical prostatectomy**

A0821 **Metabolomics of Black-White differences in risk of prostate cancer biochemical recurrence**
B.J. Trock, Baltimore (US)

A0822 **Understanding the factors for disparity in prostate cancer- and all-cause mortality associated with Hispanic ethnicity using lifetime regression models**
H. Garg, San Antonio (US)

16:01 - 16:11

Discussion

Risk estimation

A0823 **Biochemical recurrence risk adjusted follow-up after radical prostatectomy**
G. Andres Boville, Madrid (ES)

A0825 **Oncological outcomes, patterns of recurrence and impact of competing causes of mortality in clinically node-positive prostate cancer patients treated with radical prostatectomy**

A0826 **The risk of recurrence in cN1 prostate cancer patients treated with radical prostatectomy varies according to preoperative staging. A comparison between 68Ga-PSMA-PET versus conventional imaging in a large, multi-institutional study**

A0827 **Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients - a nationwide cohort study**
A.W. Mogensen, Aalborg (DK)

16:21 - 16:31

Discussion

	Pathology
A0828	Postoperative recurrence can be predicted by both length and Gleason pattern at positive surgical margin after radical prostatectomy.
A0829	Unexpected low metastatic potential to lymph-nodes of isolated tumor cell and cluster-cord in ISUP 5 prostate adenocarcinoma: A mono-institutional cohort analysis with clinic-pathological correlation
A0830	When can we de-intensify treatments in ISUP Grade Group 5 prostate cancer? Long-term results of a single center, high volume series
A0831	Not all adverse pathology features are equal: Identifying optimal candidates for adjuvant radiotherapy among patients with adverse pathology at radical prostatectomy E. Mazzone, Milan (IT)
16:39 - 16:49	Discussion
	Multimodal treatment
A0832	Outcomes comparison between the robot-assisted radical prostatectomy with extended pelvic lymph node dissection and neoadjuvant chemohormonal therapy without extended pelvic lymph node dissection in patients with organ confined high-risk prostate cancer S. Hatakeyama, Hirosaki (JP)
A0833	When Is Neoadjuvant Androgen Deprivation Therapy Beneficial for Highly Aggressive Prostate Cancer Before Radical Prostatectomy? Implications for Multimodal Tailored Approaches and Trials Design
A0834	Radiation therapy after radical prostatectomy is associated with higher other-cause mortality C. Würnschimmel, Lucerne (CH)
A0835	Delaying post-operative radiation therapy after radical prostatectomy is associated with increased functional outcomes: Results from a large single, referral center series
A0836	Health-related quality of life following cytoreductive radical prostatectomy in patients with de-novo oligometastatic prostate cancer
16:59 - 17:09	Discussion
17:09 - 17:15	Closing remarks

Males LUTS, nocturia and NOUR: From evaluation to treatment

Abstract Session 45

Sunday 3 July
15:45 - 17:15

Location Green Area, Room 5
Chairs A.K. Chawla, Manipal (IN)
M. Drake, Bristol (GB)
M. Tutolo, Milano (IT)

15:45 - 15:51

Introduction

Epidemiology and symptoms

A0837 **Impact of urinary incontinence on sexual function in patients presenting for lower urinary tract symptoms**

A0838 **Association between dietary inflammatory index and urinary flow rate: A nationwide study, nhanes 2009-2016**
L. Yifan, Chengdu (CN)

A0839 **The circadian syndrome predicts lower urinary tract symptoms suggestive of benign prostatic hyperplasia better than metabolic syndrome in aging males: A 4-year follow-up study**
Y. Xiong, Chengdu (CN)

15:57 - 16:07

Discussion

Focus on nocturia

A0840 **Which affects nocturnal frequency most: Urgency or sleep disorders?**
Y. Okumura, Fukui (JP)

A0841 **Relationship between nocturia and sleep problem in cross-sectional and longitudinal analysis: The Nagahama study**
H. Negoro, Ibaraki (JP)

A0842 **Nocturia as a risk factor of all-cause and cardiovascular disease mortality: Data from the national health and nutrition examination survey**
S.T. Cho, Seoul (KR)

A0843 **Placebo and nocebo response in the medical treatment of adults with nocturia: A systematic review and meta-analysis**

16:15 - 16:25

Discussion

Investigation of pathophysiology of bladder dysfunction

A0844 **How does variation of outflow resistance affect detrusor contraction in men with LUTS?**
P.F.W.M. Rosier, Nijmegen (NL)

A0845 **Development and validation of a deep learning system for sound-based prediction of urinary flow**
H.J. Lee, Singapore (SG)

Scientific Programme - EAU22 Amsterdam

A0847	The role of urodynamics in the evaluation of lower urinary tract symptoms after postoperative radiotherapy M.G. Çulha, Istanbul (TR)
A0848	Bladder NIRS: A non-invasive method functional to distinguish between detrusor underactivity (DU) and bladder outlet obstruction (BOO) in men with LUTS
16:35 - 16:45	Discussion
	Treatment
A0849	10-year follow-up observation of idiopathic detrusor underactivity in the elderly living in community: Treatment and urodynamic changes
A0850	Modulatory effect of kilohertz frequency alternating current neuromodulation of the pudendal nerves on the anal canal and anal sphincter in the rat R.L. Coolen, Rotterdam (NL)
A0851	The Effect of Sacral Neuromodulation (SNM) on Nocturia in patients with Overactive Bladder Syndrome (OAB) J.M.W. Janssen , Maastricht (NL)
A0852	Two-staged sacral neuromodulation procedure for the treatment of non-obstructive urinary retention: A multi-center study assessing predictors of success R.L. Coolen, Rotterdam (NL)
A0853	Bladder outlet obstruction or underactive bladder? C. Persu, Bucharest (RO)
16:55 - 17:05	Discussion
17:05 - 17:15	Closing remarks

Clinical assessment of urethral strictures

Abstract Session 46

Sunday 3 July
15:45 - 17:15

Location Purple Area, Room Elicium 1
Chairs To be confirmed
F.E. Martins, Lisbon (PT)
J Romero-Otero, Madrid (ES)

15:45 - 15:49

Introduction

A0854 **The impact of COVID-19 on urethroplasty surgical wait-times in a Canadian referral center**
L.R. Garabed, Montreal (CA)

A0856 **The most common location for stricture after transurethral prostate surgery (TPS) is the bulbomembranous urethra: False!**
M. Bandini, Milan (IT)

15:55 - 16:05

Discussion

A0857 **Efficacy of topical triamcinolone for intermittent catheterization following internal urethrotomy: A systematic review and meta-analysis of randomized controlled trials**
F.H. Fazlur Rahman, Pangkalpinang (ID)

A0858 **Role of endoscopic management of recurrent stricture after anastomotic urethroplasty: Single centre experience**
M. Nafie, Sharkia (EG)

A0859 **Predictive factors of recurrence of urethral strictures after a first internal uretrotomy**
S. Zouari, Tunis (TN)

A0860 **Modified uss prom for dviu and non transecting urethroplasty for short bulbar urethral strictures**
A.K. Chawla, Manipal (IN)

A0861 **Long-term outcomes of urethral stricture treatment with the Optilume paclitaxel-coated balloon**

A0862 **Robotic YV plasty for bladder neck vs. vesico-urethral anastomotic stricture**

16:17 - 16:27

Discussion

A0863 **Prospective multicentre long-term analysis of oral morbidity after oral mucosa grafts harvesting for substitution or augmentation urethroplasties**
E. Fernández Guzman, Santander (ES)

A0864 **Female ventral-onlay buccal mucosa graft urethroplasty supported with Martius labial fat pad flap: Our early results**
O. Kose, Sakarya (TR)

A0865 **Dorsal onlay oral mucosa graft urethroplasty for female urethral stricture**

Scientific Programme - EAU22 Amsterdam

A0866	Which technique for female urethroplasty to the best available evidence: A single centre experience E. Berdondini, Torino (IT)
-------	--

16:35 - 16:45	Discussion
----------------------	-------------------

A0867	A new technique of widening urethral plate in short bulbar strictures P. Joshi, Pune (IN)
-------	---

A0868	Proof-of-concept study to improve risk prediction after anterior urethroplasty by prospective intraoperative assessment of anatomico-morphological stricture features P. Marks, Hamburg (DE)
-------	--

A0869	New approach with fat grafting in the management of urethro-genital lichen sclerosus disease E. Berdondini, Torino (IT)
-------	---

A0870	Is supracrural rerouting (Step 4) becoming anecdotal in the management of pelvic fracture urethral injury?
-------	---

A0872	Redo urethroplasty for hypospadias-associated long segment urethral strictures
-------	---

A0873	Back to the future: Is the use of fasciocutaneous penile flap increasing in contemporary years for reconstructing the anterior urethra? M. Bandini, Milan (IT)
-------	--

16:59 - 17:09	Discussion
----------------------	-------------------

17:09 - 17:15	Closing remarks
----------------------	------------------------

Ablative surgery for BPO relief: Laser, robot and aquablation

Abstract Session 47

Sunday 3 July
15:45 - 17:15

Location Purple Area, Room Elicium 2
Chairs B. Geavlete, Bucharest (RO)
V. Misrai, Toulouse (FR)
P. Nyirády, Budapest (HU)

15:45 - 15:50

Introduction

Endoscopic enucleation: Holmium and thulium

- | | |
|----------------------|--|
| A0874 | Prostate volume is associated with optimal TRIFECTA outcomes after HoLEP – results from a prospective trial (ExpHo)
P. Capogrosso, Varese (IT) |
| A0875 | Energy density in high-power (100w) holmium laser enucleation of the prostate (holep) - retrospective analysis of procedural, and functional outcomes among 1,515 patients |
| A0876 | First 100 patients of a randomised controlled trial to assess the benefit to apply MOSES™ technology in holmium laser enucleation of the prostate: Surgical and functional outcomes
C. Lopez Molina, BARCELONA (ES) |
| A0878 | Evaluation of the learning curve for Thulium laser enucleation of the prostate using multiple outcome measures |
| A0879 | Pulsed vs. continuous TFLEP: A multi-institution trial to compare intra and early post-operative outcomes
G. Bozzini, Como (IT) |
| 16:02 - 16:12 | Discussion |
| | Vaporisation of the prostate |
| A0880 | Comparing three surgical techniques for BPH treatment: Transurethral resection, laser vaporization and laser enucleation of the prostate |
| A0881 | Long term outcome of a randomized clinical trial comparing thulium vaporization of the prostate versus monopolar TURP, the test of time |
| A0882 | A randomized controlled trial comparing 1470nm diode laser vs. plasmakinetic enucleation of the prostate for treating benign prostatic hyperplasia
D. Jiang, Shen Zhen (CN) |
| A0883 | Safety and efficacy of greenlight pvp in octogenarians: Evaluation of the global greenlight group database
K. Zorn, Montreal (CA) |
| A0884 | Propensity-score analysis comparing perioperative and functional outcomes between XPS 180 W-photovaporization and GreenLight laser enucleation of the prostate: Reasons to discard vaporization and move to enucleation |

Scientific Programme - EAU22 Amsterdam

16:22 - 16:32	Discussion
	Robotic approach
A0885	Peri-operative outcomes of open versus robot-assisted simple prostatectomy: Results from two high-volume centres
A0886	Robotic vs. open simple prostatectomy for benign prostatic hyperplasia in large glands: Single-centre study
A0887	Impact of obesity on peri-operative and long-term functional outcomes after robotic assisted simple prostatectomy
A0888	Is robot-assisted simple prostatectomy associated with worse outcomes in obese patients? M. Paciotti, Rozzano, Milan (IT)
16:40 - 16:50	Discussion
	Aquablation
A0889	Five-Year Outcomes after Aquablation Compared to TURP: The Final WATER Study Results P.J. Gilling, Tauranga (NZ)
A0890	Tertiary care center experience: Functional and endoscopic results after aquablation in patients with benign prostatic hyperplasia-related lower urinary tract symptoms D. Amparore, Turin (IT)
A0891	Aquablation for benign prostatic hyperplasia in large prostates (80-150cc): 4-year results N. Bhojani, Montreal (CA)
A0892	Aquablation: Multi-Pass Impact T. Bach, Hamburg (DE)
A0893	Aquablation in very large prostates (>150mL): Technique and multicenter case series A. Glaser, Glenview (US)
17:00 - 17:10	Discussion
17:10 - 17:15	Closing remarks

Update on rare and complex urology

ERN eUROGEN

Sunday 3 July
15:45 - 17:15

Location	Orange Area, Room 2
Chairs	M. Battye, Nijmegen (NL) W.F.J. Feitz, Nijmegen (NL)
Speakers	R. Cornes, London (GB) K. Manzie, (GB) J. Osborne, (GB)
Panel	R. Cornes, London (GB) M. Fossum, Stockholm (SE) J.F. Langenhuijsen, Nijmegen (NL) M. Mancini, Padua (IT) K. Manzie, (GB) G. Mosiello, Rome (IT) J. Osborne, (GB)

Learning objectives

The ERN eUROGEN session will update you on the European Reference Networks (ERNs): The recent largest health care innovation in Europe involving 30 million patients with a rare disease or complex condition. This program on uro-recto-genital rare diseases and complex conditions involves the whole spectrum from congenital anomalies to lifelong care and complex functional and rare urogenital tumours. It delivers virtual highly specialised advice to health care professionals across Europe using innovative IT tools. The network collaborates on clinical guidelines, training and education and research - aimed at improving care for your patients. Additional information is available on www.eurogen-ern.eu

15:45 - 15:55

Programme manager presentation Update on ERN eUROGEN developments
M. Battye, Nijmegen (NL)

15:55 - 16:10

ERN Patient Advocacy Group (ePAG) lecture Penile cancer: The way forward?

16:10 - 16:25

Workstream 1 (rare congenital uro-recto-genital anomalies) lecture Congenital neurogenic bladder dysfunction: What the adult urologist needs to know
G. Mosiello, Rome (IT)

16:25 - 16:40

Workstream 2 (functional urogenital conditions requiring highly specialised surgery) lecture Vesico-vaginal fistula: Management strategies and keys to successful treatment
M. Mancini, Padua (IT)

16:40 - 16:55

Workstream 3 (rare urogenital tumours) lecture Expansion of the network with tremendous opportunities for rare urogenital tumours
J.F. Langenhuijsen, Nijmegen (NL)

16:55 - 17:05

The COVID-19 pandemic Patient impact in 10 European centers for uro-recto-genital care
M. Fossum, Stockholm (SE)

17:05 - 17:15

Panel discussion Presenters' views on rare diseases in 2030

Advanced bladder cancer: Staging, predicting factors and systemic therapy

Abstract Session 48

Sunday 3 July
15:45 - 17:15

Location Yellow Area, Room Forum

Chairs T. Seisen, Paris (FR)
P. Wiklund, Stockholm (SE)
A.R. Zlotta, Toronto (CA)

Staging and progression

15:45 - 15:48

Introduction

A0894 The diagnostic issue of variant histologies in bladder cancer: does the centre have an impact in detection accuracy?

A0895 Prognostic value and therapeutic implications of an integrative molecular subtype and immune content classifier in localized muscle-invasive bladder cancer

A0896 A genomic urine assay to detect urinary tract recurrences in patients with bladder cancer treated with radiotherapy

A0897 Neoadjuvant pembrolizumab may result in long-term outcome improvement in biomarker-unselected patients with Muscle-Invasive Bladder Cancer (MIBC): Updated results from PURE-01

A0898 Outcomes according to histological variants of urothelial carcinoma after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial
C. Pfister, Bois Guillaume (FR)

A0899 Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: A systematic review and network meta-analysis of oncologic and toxicity outcomes
E. Laukhtina, Vienna (AT)

16:00 - 16:11

Discussion

Quality of life and markers

A0900 The role of FDG PET in the staging of bladder cancer patients candidate for radical cystectomy

A0901 External validation of the Bladder Cancer Research Consortium (BCRC) nomogram for predicting survival after radical cystectomy
N. Corsi, Detroit (US)

A0902 Tumour-infiltrating lymphocytes and their impact on survival in squamous cell carcinoma of the bladder
L. Eismann, Munich (DE)

16:17 - 16:28

Discussion

Radical surgery

A0903	Modeling the contribution of preoperative VI-RADS score to predict final pathologic lymph-node involvement in patients with MIBC undergone radical cystectomy F. Del Giudice, Rome (IT)
A0904	Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma and the potential impact of informative censoring A. Martini, Milan (IT)
A0905	A multicenter cohort of patients treated with concurrent chemoradiotherapy for muscle invasive bladder carcinoma: Results of the past 10 years
A0906	First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial
A0907	Immuno- versus chemo-therapy as first line treatment for advanced urothelial cancer: A systematic review and meta-analysis D. Raggi, Milan (IT)
A0908	Retrospective analysis of a cohort of patients with metastatic bladder cancer with metastatic sites limited to the pelvis and retroperitoneum treated at a single institution A. Bertucci, Marseille (FR)
16:40 - 16:51	Discussion
	Follow up
A0909	Impact of non-muscle invasive bladder cancer treatment history on the efficacy of pembrolizumab for patients with metastatic urothelial carcinoma R. Taoka, Kagawa (JP)
A0910	Expanding the use of targeted therapy for Urothelial Bladder Cancer (UBC): Non-FGFR3 Receptor Tyrosine Kinase (RTK) Gene Rearrangements (ReAr) and Fusions (Fus) A. Necchi, Milan (IT)
A0911	Feasibility of 68Ga-FAPI-46 PET/CT for detection of metastatic spread in urothelial carcinoma L.M. Unterrainer, Munich (DE)
A0912	Circulating tumor DNA is a strong predictor in patients treated with systemic therapy for urothelial carcinoma E. Laukhtina, Vienna (AT)
16:59 - 17:10	Discussion
17:10 - 17:15	Closing remarks

Stones - Epidemiology, basic research and metabolics

Abstract Session 49

Sunday 3 July
14:00 - 15:30

Location Grey Area, Room Emerald
Chairs P.M. Ferraro, Rome (IT)
C.C. Seitz, Vienna (AT)
To be confirmed

14:00 - 14:02

Introduction

A0913 **The recovery of renal functions following reversal of unilateral ureteric obstruction in hypertensive subjects**

A0914 **Inflammatory cytokines promote fibrosis in obstructed ureters**
A. Reicherz, Herne (DE)

14:06 - 14:13

Discussion

A0915 **High concentration oxalate promotes intrarenal calcium oxalate crystals deposition via altering macrophage M1 polarization with change of the IRF-1/ miR-301/CSF-1 signals**

A0916 **The impact of promoter hypermethylation of VDR, CLDN, and CasR genes in recurrent stone formation**

A0917 **The preliminary exploration of roles miRNAs derived from urinary exosomes play in kidney stone formation**

A0918 **Time-restricted feeding inhibits calcium oxalate stone formation in high-fat diet mice: Biological markers, pathways and validation**

A0919 **Effect of phytate on hypercalciuria secondary to bone resorption in patients with urinary stones**

14:23 - 14:30

Discussion

A0920 **Kidney stones are associated with the higher risk of tooth loss**
J. Wang, Chengdu (CN)

A0921 **Relationship between dietary patterns and gut microbiota in kidney stone and non-kidney stone individuals**
Y. Chi, Chengdu (CN)

14:34 - 14:41

Discussion

A0922 **Enterobacter cloacae: A villain in CaOx stone disease?**

A0923 **Comparing urine and stone microbiome in urolithiasis patients**
J. Vesper, Vienna (AT)

A0924 **New perspectives on an old grouping: The genomic and phenotypic differences of Oxalobacter formigenes**

Scientific Programme - EAU22 Amsterdam

A0925	BBP-711 for the treatment of hyperoxaluria: A first-in-human, randomized, placebo-controlled safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers S.H. Adler, San Francisco (US)
14:49 - 14:56	Discussion
A0926	Preparation, antibacterial properties, and application of alginate gel composite capable of binding to sandy calcium-based stones W.H. Song, Yangsan-si (KR)
A0927	Is preoperative metabolic profiling to reduce the risk of kidney stones after bariatric surgery in patients with a history of stone formation helpful? T. Campschroer, Arnhem (NL)
A0928	Prediction of chemical composition of urinary stone through deep learning
A0929	A novel prediction of uric acid component in nephrolithiasis using simple clinical information: A machine learning-based model
15:04 - 15:11	Discussion
A0932	Association between Healthy Eating Index–2015 and kidney stones in US adults: A cross-sectional analysis of the NHANES 2007-2018 Y. Xiao, Chengdu (CN)
A0933	U-shaped association between sleep duration and kidney stones in 34,190 American adults: National Health and Nutrition Examination Survey 2007-2018 J. Cui, Chengdu (CN)
15:19 - 15:26	Discussion
15:26 - 15:30	Closing remarks

Liquid biomarkers in 2022 and beyond: Ready for prime time?

Plenary Session 07

Monday 4 July
08:00 - 10:15

Location Orange Area, eURO Auditorium 1

Chairs L. Dyrskjød, Aarhus (DK)
A. Stenzl, Tübingen (DE)

Learning objectives

Liquid biomarkers have been documented to harbor diagnostic, prognostic and predictive value. Several clinical trials now investigate if the use of liquid biomarkers for guiding treatment decisions have an impact on patient outcome and quality of life. The audience will learn about the current status of liquid biopsy analysis (both plasma and urine based) in bladder- prostate- and kidney cancer, and specific patient cases will be discussed. Furthermore, the audience will have an idea what to expect in the near future regarding clinical use, and regarding novel tumor agnostic approaches to liquid biopsy cancer detection.

08:00 - 08:07

Welcome and introduction

08:07 - 08:43

Rapid-fire debate Liquid biomarkers in urothelial cancer

08:07 - 08:12

Case presentation ctDNA dynamics in advanced bladder cancer
J. Bjerggaard Jensen, Aarhus N (DK)

08:12 - 08:19

Treatment monitoring of bladder cancer by urine testing
J.L. Boormans, Rotterdam (NL)

08:19 - 08:26

Plasma ctDNA analysis in advanced disease
L. Dyrskjød, Aarhus (DK)

08:26 - 08:33

Is urine tumour DNA analysis in advanced disease informative?
R.T. Bryan, Birmingham (GB)

08:33 - 08:43

Panel discussion

08:43 - 09:19

Rapid-fire debate Liquid biomarkers in prostate cancer

08:43 - 08:48

Case presentation Evolving androgen resistance: Detection through ctDNA
To be confirmed

08:48 - 08:55

The role of liquid biomarkers in the diagnosis of prostate cancer
C. Jeronimo, Porto (PT)

08:55 - 09:02

Risk assessment by urine testing
J.A. Schalken, Nijmegen (NL)

09:02 - 09:09

Plasma ctDNA analysis for monitoring treatment response
N. Fonseca, Vancouver (CA)

09:09 - 09:19

Panel discussion

09:19 - 09:55

Rapid-fire debate Liquid biomarkers in kidney cancer

Scientific Programme - EAU22 Amsterdam

09:19 - 09:24	Case presentation Risk stratification: Using circulating ctDNA to stage renal cancer S. Rossi, Cambridge (GB)
09:24 - 09:31	Early detection of renal cancer by plasma and urine analysis G.D. Stewart, Cambridge (GB)
09:31 - 09:38	Monitoring of treatment response S. Turajlic, London (GB)
09:38 - 09:45	Liquid biopsies for detecting actionable targets in renal cancer Z. Zengin, Duarte (US)
09:45 - 09:55	Panel discussion
09:55 - 10:10	State-of-the-art lecture Tumour agnostic pan-cancer analysis strategies To be confirmed
10:10 - 10:15	Closing remarks

Stones: The sky is the limit

Plenary Session 08

Monday 4 July
08:00 - 10:00

Location Grey Area, eURO Auditorium 2

Chairs S. Proietti, Milan (IT)
T. Knoll, Sindelfingen (DE)

Challenger P.J.S. Osther, Fredericia (DK)

Panel M.D. Duvdevani, Mevaseret-Zion (IL)
P.M. Kronenberg, Lisbon (PT)
A. Miernik, Freiburg (DE)
Ö. Ulvik, Bergen (NO)

Moderators N. Bernardo, Buenos Aires (AR)
To be confirmed

Learning objectives

Is sky the limit for the treatment of urinary calculi? And where is the sky? This plenary session discusses difficult and supposedly easy clinical scenarios considering new and upcoming technology.

08:00 - 08:02

Welcome and introduction

08:02 - 08:12

State-of-the-art lecture Cystine stones in children: How to prevent recurrences
To be confirmed

08:12 - 08:22

State-of-the-art lecture Use of access sheaths in children
B. Somani, Southampton (GB)

08:22 - 08:32

Confederación Americana de Urología (CAU) lecture Follow-up schedule for stone disease: Is there a perfect algorithm?
M.D. Baptistussi, Ribeirao Preto (BR)

08:32 - 08:56

Panel discussion Laser lithotripsy: High- or low power, holmium or thulium fiber, or something else?

08:32 - 08:33

Introduction
P.J.S. Osther, Fredericia (DK)

08:33 - 08:35

High power holmium
M.D. Duvdevani, Mevaseret-Zion (IL)

08:35 - 08:37

Low power holmium
P.M. Kronenberg, Lisbon (PT)

08:37 - 08:39

Thulium fiber
Ö. Ulvik, Bergen (NO)

08:39 - 08:41

Pulsed thulium
A. Miernik, Freiburg (DE)

08:41 - 08:56

Discussion

08:56 - 09:06

State-of-the-art lecture Burst wave ESWL: Ready for prime time?
To be confirmed

Scientific Programme - EAU22 Amsterdam

09:06 - 09:26	Debate Are disposable ureteroscopes 'gone with the wind'?
09:06 - 09:11	Yes! T. Tailly, Ghent (BE)
09:11 - 09:16	No! E. Emiliani, Barcelona (ES)
09:16 - 09:26	Discussion
09:16 - 09:26	N. Bernardo, Buenos Aires (AR)
09:16 - 09:26	E. Emiliani, Barcelona (ES)
09:16 - 09:26	T. Tailly, Ghent (BE)
09:26 - 09:36	State-of-the-art lecture Post-operative imaging: Balancing cost versus practicality A. Pietropaolo, Southampton (GB)
09:36 - 09:58	Case discussion Bilateral stones
09:36 - 09:38	Case presentation To be confirmed
09:38 - 09:43	Simultaneous PCNL in one session O. Angerri Feu, Barcelona (ES)
09:43 - 09:48	Staged PCNL To be confirmed
09:48 - 09:58	Discussion
09:58 - 10:00	Closing remarks

Ultrasound in urology

ESU Course 43

Monday 4 July
08:30 - 11:30

Location Grey Area, Room G102

Chair T. Loch, Flensburg (DE)

Learning objectives

Ultrasound is the basic imaging tool of the urologist and almost all urologists are using ultrasound in daily practice. Despite this, training and teaching of urological ultrasound is not provided in a satisfactory manner. The aim of the course is to provide the technical basics and standards for the use of ultrasound in urology. After the course the delegate should know the ideal settings for reliable and informative urological ultrasound as well as the normal and pathological findings.

- Covering urological organs: kidney, ureter, bladder, testis and penis.
- Standard patient positioning.
- Best choice of transducers and settings.
- Standard operating procedures (SOP).
- Normal, benign and malignant pathologic findings.
- Interventional and intraoperative ultrasound.

Technical basics and new technologies

T. Loch, Flensburg (DE)

Standardisation, tuning, acquisition and reporting of ultrasound exams

S. Kruck, Pforzheim (DE)

Ultrasound of the kidney and ureter

S. Kruck, Pforzheim (DE)

Ultrasound of the bladder

T. Loch, Flensburg (DE)

Ultrasound of the testis

T. Loch, Flensburg (DE)

Ultrasound of the penis

S. Kruck, Pforzheim (DE)

Prolapse management and female pelvic floor problems

ESU Course 44

Monday 4 July
08:30 - 11:30

Location Grey Area, Room G103

Chair E. Kocjancic, Chicago (US)

Learning objectives

This course gives practical information about prolapse management by urologists. From anatomy to mesh implant, the recent revival of native tissue repairs and the management of complications. Also laparoscopic and robotic approaches will be evaluated.

Case 1: What can go wrong in the female pelvic floor support

Evaluation of female pelvic floor and basic anatomical concepts

E. Kocjancic, Chicago (US)

Imaging

To be confirmed

Pelvic organ prolapse (POP) classifications and its clinical usefulness

E. Costantini, Perugia (IT)

Case 2: Anterior prolapse

Site specific repair

To be confirmed

Use of biological and synthetic meshes

E. Kocjancic, Chicago (US)

Use of pessaries

E. Costantini, Perugia (IT)

Case 3: Vaginal vault prolapse

Vaginal approach

E. Kocjancic, Chicago (US)

Open colposacropexy

E. Costantini, Perugia (IT)

Laparoscopic and robotic colposacropexy

To be confirmed

Case 4: POP and urinary incontinence

Functional evaluation

E. Costantini, Perugia (IT)

Stress incontinence and POP

To be confirmed

Urgency incontinence and POP

E. Kocjancic, Chicago (US)

Case 5: Complications of POP surgery

Interactive discussion on different clinical scenarios

To be confirmed

E. Kocjancic, Chicago (US)

E. Costantini, Perugia (IT)

Discussion and conclusion

E. Kocjancic, Chicago (US)

The infertile couple: Urological aspects

ESU Course 45

Monday 4 July
08:30 - 11:30

Location Grey Area, Room G104

Chair M. Dinkelman-Smit, Rotterdam (NL)

Learning objectives

This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion for both partners, focusing on the possible urological, hormonal and genetic causes of male infertility. In terms of therapy, this course will provide updated information on evidence based data and will discuss the importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain why proper training and skills perfection is key to successful case management. A successful IVF/ICSI outcome depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation. We will also provide information on genetic aspects and stress the responsibility of the urologist as an adviser and gatekeeper for the treatment of the infertile couple.

Diagnostic work-up, medical treatment

A. Salonia, Milan (IT)

Pathophysiology, diagnosis and treatment of varicocele

M. Dinkelman-Smit, Rotterdam (NL)

Microsurgical refertilisation

M. Dinkelman-Smit, Rotterdam (NL)

Sperm retrieval techniques and genetic aspects of IVF/ICSI

A. Salonia, Milan (IT)

Advanced course on urethral stricture surgery

ESU Course 46

Monday 4 July
08:30 - 11:30

Location Grey Area, Room G105

Chair L. Martínez-Piñeiro , Madrid (ES)

Learning objectives

The advanced urethral stricture course will cover the assessment and surgical treatment of strictures of the penile, bulbar and posterior urethra. General principles of assessment and follow up, oral mucosa harvest and complications will be reviewed with evidence. Techniques of penile, bulbar and full length urethroplasty will be discussed and compared and cases reviewed with audience participation encouraged.

Pelvic fracture urethral injuries will also be discussed together with management techniques. Female urethroplasty will also be discussed and assessed.

Prior knowledge of relevant anatomy and basic endoscopic techniques will be helpful to those attending the course.

General principles in urethral stricture surgery. Preoperative workup and follow-up. Indications of endourological treatments.

P. Nyirády, Budapest (HU)

Penile urethroplasty. Lichen sclerosus.

P. Nyirády, Budapest (HU)

Bulbar urethroplasty. Grafts, anastomotic and combined techniques, Perineal urethrostomy.

F. Campos Juanatey, Santander (ES)

Posterior urethroplasty (pelvic fracture distraction injuries, bladder neck contractures).

L. Martínez-Piñeiro , Madrid (ES)

Female urethroplasty

F. Campos Juanatey, Santander (ES)

Discussion / Cases

L. Martínez-Piñeiro , Madrid (ES)

P. Nyirády, Budapest (HU)

Updated renal, bladder and prostate cancer guidelines 2022: What has changed?

ESU Course 47

Monday 4 July
08:30 - 11:30

Location Grey Area, Room G106

Chair H.G. Van Der Poel, Amsterdam (NL)

Learning objectives

During the course recent practice changing alterations in the guidelines will be discussed. Based on the clinical recommendations the highlights of the guidelines one prostate, renal and bladder cancer as changed in the 2020 updates will be presented and illustrated by clinical cases. A basic knowledge of the guidelines information is assumed for participating trainees.

Introduction

H.G. Van Der Poel, Amsterdam (NL)

Update renal cancer: Localised

A. Volpe, Novara (IT)

Discussion

Update renal cancer: Metastasised

A. Volpe, Novara (IT)

Discussion

Update bladder cancer: Non-muscle invasive

J.L. Domínguez Escrig, Valencia (ES)

Discussion

Update bladder cancer: Muscle invasive

L.S. Mertens, Amsterdam (NL)

Discussion

Update prostate cancer: Localised

R.C.N. Van Den Bergh, Nieuwegein (NL)

Discussion

Update prostate cancer: Metastasised

D. Tilki, Hamburg (DE)

Discussion

Prostate cancer imaging: When and how to use it

ESU Course 48

Monday 4 July
08:30 - 11:30

Location Grey Area, Room G107

Chair J. Walz, Marseille (FR)

Learning objectives

Recently new imaging technologies have been developed to improve the diagnosis and management of prostate cancer. These are multiparametric MRI, choline PET and new ultrasound based technologies.

The course's aim is to provide:

- An overview on the currently available imaging tools for prostate cancer.
- Practical information about their use.
- A critical assessment of their clinical performance and their limitations.

Introduction and objective of course

J. Walz, Marseille (FR)

Diagnosis of prostate cancer

Standardization, acquisition and reporting of multiparametric MRI

I.G. Schoots, Rotterdam (NL)

Reading of a prostate MRI and use of MRI for diagnosis of prostate cancer

I.G. Schoots, Rotterdam (NL)

MRI guided biopsy and image fusion (mp MRI and Ultrasound)

J. Walz, Marseille (FR)

What are possible alternatives to multiparametric MRI?

J. Walz, Marseille (FR)

Staging of prostate cancer

Staging with CT, MRI and bone scintigraphy

G. Villeirs, Ghent (BE)

MRI in local staging of prostate cancer

G. Villeirs, Ghent (BE)

Recurrent disease

Use of PET in the management of prostate cancer (initial staging and recurrence)

J. Walz, Marseille (FR)

MRI in detection of locally recurrent prostate cancer

G. Villeirs, Ghent (BE)

When to do imaging of the prostate? Case discussion and current practical questions

I.G. Schoots, Rotterdam (NL)

G. Villeirs, Ghent (BE)

J. Walz, Marseille (FR)

Closure and evaluation

J. Walz, Marseille (FR)

Improving your communication and presentation skills

ESU Course 49

Monday 4 July
08:30 - 11:30

Location Grey Area, Room G109

Chair D. Veneziano, Reggio Calabria (IT)

Learning objectives

An effective communicator needs to be flexible, energetic and enthusiastic. Making a presentation puts you on public display. An audience not only listens to your ideas, it also responds to the way you use your voice and your body. You need more than a well written presentation to make an impact: you will also need to deliver it in a lively, flexible and interesting way.

In this course we deliver tips and tricks for inspiring, invoking energy, confidence and safety in your presentation style. The course will be performed in TED format, with no podium available and itinerant talks in from of the slides.

At the end of this course, participants should be able to:

- Understand how Guidelines recommendations are formulated.
- Highlight the changes and the gaps of the different Guidelines discussed at the course.
- Be familiar with the strength of the evidence of the current Guidelines.
- Apply knowledge gained in this course to develop an evidence-based practice in the management of patients.

Introduction

D. Veneziano, Reggio Calabria (IT)

J. Gómez Rivas, Madrid (ES)

How to deliver an effective talk. Verbal language

J. Gómez Rivas, Madrid (ES)

Non-verbal language. Tips and tricks

J. Gómez Rivas, Madrid (ES)

TED talks: How to structure a successful presentation

D. Veneziano, Reggio Calabria (IT)

Optimising your presentations with the latest software and hardware

D. Veneziano, Reggio Calabria (IT)

How to present the results of your research

G. Cacciamani, Los Angeles (US)

Mastering the stage. The expert opinion

M.J. Ribal Caparros, Barcelona (ES)

Closing remarks

D. Veneziano, Reggio Calabria (IT)

Guidelines session: Urolithiasis

Thematic Session 11

Monday 4 July
10:30 - 12:00

Location Grey Area, eURO Auditorium 2

Chairs E. Liatsikos, Patras (GR)
A. Skolarikos, Athens (GR)

Learning objectives

Dear Attendees

We aim to discuss interesting and debated topics of the urinary stone disease. Radiation exposure and protection measures are presented. Three debates will be discussed hoping for your active participation. We will clarify whether small asymptomatic renal stones should be treated or not. The literature currently focuses on intrarenal pressure and temperature during endourological surgery, but do we really have to measure these parameters intraoperatively? Will the new "kid in the block", Thulium laser, overcome the gold standard HoYAG laser? We present new proposals on stone follow up, based on Urolithiasis Panel systematic work.

Looking forward to see you all

Skolarikos Andreas

EAU Urolithiasis Guidelines Chair

10:30 - 10:31

Introduction

A. Skolarikos, Athens (GR)

10:31 - 10:41

State-of-the-art lecture Imaging and radiation protection

A. Skolarikos, Athens (GR)

10:41 - 10:59

Debate The 5 mm caliceal stone

10:41 - 10:43

Introduction

A. Petřík, Ceske Budejovice (CZ)

10:43 - 10:47

Treat

L. Tzelves, Athens (GR)

10:47 - 10:51

Observe

R. Lombardo, Rome (IT)

10:51 - 10:59

Discussion

A. Petřík, Ceske Budejovice (CZ)

10:59 - 11:19

Debate Do we need to measure intrarenal pressure and temperature during endourology?

10:59 - 11:01

Introduction

A. Papatsoris, Athens (GR)

11:01 - 11:06

Yes

A. Neisius, Trier (DE)

11:06 - 11:11

No

J. Baard, Amsterdam (NL)

Scientific Programme - EAU22 Amsterdam

11:11 - 11:19	Discussion A. Papatsoris, Athens (GR)
11:19 - 11:29	State-of-the-art lecture Medical prophylaxis in the high-risk patient: Temporary vs. life long G. Gambaro, Verona (IT)
11:29 - 11:49	Debate Best clinical practice in ureteroscopy: Laser type
11:29 - 11:31	Introduction E.K. Bres-Niewada, Pruszkow (PL)
11:31 - 11:36	Holmium YAG C.M. Cracco, Turin (IT)
11:36 - 11:41	Thulium fiber A. Petřík, Ceske Budejovice (CZ)
11:41 - 11:49	Discussion E.K. Bres-Niewada, Pruszkow (PL)
11:49 - 11:59	State-of-the-art lecture What is new in the EAU 2022 Uolithiasis Guidelines? To be confirmed
11:59 - 12:00	Closing remarks E. Liatsikos, Patras (GR)

Difficult cases in renal transplantation

Thematic Session 12

Monday 4 July
10:30 - 12:00

Location

Green Area, Room 1

Chairs

A. Breda, Barcelona (ES)

E. Lledó García, Madrid (ES)

10:30 - 10:40

Living donor nephrectomy: Different techniques in 2022

R. Boissier, Marseille (FR)

10:40 - 10:45

Discussion

10:45 - 10:55

Right donor nephrectomy: Indications and results

M. Musquera Felip, Barcelona (ES)

10:55 - 11:00

Discussion

11:00 - 11:10

Different transplant techniques: External/internal iliac artery, inferior epigastric, splenic artery and more

F.J. Burgos Revilla, Madrid (ES)

11:10 - 11:15

Discussion

11:15 - 11:25

Robotic kidney transplantation: Update for the ERUS WG

R. Campi, Florence (IT)

11:25 - 11:30

Discussion

11:30 - 11:40

Kidney transplant in non-functioning bladders

A.J. Figueiredo, Coimbra (PT)

11:40 - 11:45

Discussion

11:45 - 11:55

Surgical complication in kidney transplantation and their management

P. Ditonno, Bari (IT)

11:55 - 12:00

Discussion

Liquid -and tumour biomarkers in prostate cancer

Abstract Session 50

Monday 4 July
10:30 - 12:00

Location Green Area, Room 3
Chairs To be confirmed
C. Jeronimo, Porto (PT)
W.M. Van Weerden, Rotterdam (NL)

Liquid biomarkers

10:30 - 10:34	Introduction
10:34 - 10:42	Novel biomarkers for prostate cancer detection and prognosis To be confirmed
A0934	Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer
A0935	Combination of urinary-exosomal AMACR, ERG and PCA3 surpasses diagnostic power of serum PSA for patients with suspected prostate cancer K. Erdmann, Dresden (DE)
A0937	Pre-surgery blood levels of leucine-rich alpha-2-glycoprotein 1 identify patients with a high risk of progressing to castration-resistant prostate cancer I.J. Guldvik, Oslo (NO)
A0938	Circulating tumor cell-based PSA mRNA expression has the potential to be used as a biomarker for replacing serum PSA level in advanced prostate
A0939	Plasmatic exosome number and size distinguish prostate cancer patients from healthy individuals: A prospective clinical study M. Maggi, Rome (IT)
A0940	Identification of the (cancer) extracellular vesicle surface proteome and its application to detect prostate cancer in urine I. Bijnsdorp, Amsterdam (NL)
10:56 - 11:07	Discussion
	Tumour biomarkers
A0941	Identification and genome-wide profiling of TET1-overexpressing prostate cancer reveal a collective activation of zinc-finger transcription factors and zinc-finger anti-viral proteins T. Dansranjav, Giessen (DE)
A0942	DNA methylation aberrations predicts recurrence both in tumor and normal appearing prostate tissue C. Pedersen, Trondheim (NO)
A0943	Expression analysis of prostate cancer Hoechst 33342 side populations identifies the differing origins of CRPC

Scientific Programme - EAU22 Amsterdam

A0944	Identification and validation of a poor prognosis subtype of primary prostate cancer with Midkine abundance
A0945	Molecular characterization to delineate the clonal evolution of primary prostate cancer with synchronous lymph node metastasis
A0946	The expression of androgen receptor splice variant 7 at radical prostatectomy predicts the risk of progression in untreated non-metastatic prostate cancer patients M. Maggi, Rome (IT)
A0947	Hsa_circ_0005221 promotes prostate cancer progression through miR-339-5p/STAT5a C. Saisai, Nanjing (CN)
11:21 - 11:32	Discussion
	TME and genetics
A0948	Multimomics spatial mapping of lipid metabolism in prostate cancer M.K. Andersen, Trondheim (NO)
A0949	Gut microbiota signatures are associated with prostate cancer risk P.J. Boström, Turku (FI)
A0950	Inflammatory chemokines upregulated in the tumor microenvironment of prostate cancer patients experiencing relapse after radical prostatectomy S. Krossa, Trondheim (NO)
A0951	Genetic analysis identifies TNFRSF13B involved in prostate cancer progression
A0952	Identification of IDH1 mutation and candidate drug in prostate adenocarcinoma by integrated bioinformatic analysis
11:42 - 11:54	Discussion
11:54 - 12:00	Closing remarks

Trauma and urogenital reconstruction

Abstract Session 52

Monday 4 July
10:30 - 12:00

Location Green Area, Room 5
Chairs M. Matuszewski, Gdansk (PL)
To be confirmed
To be confirmed

10:30 - 10:33

Introduction

Ureteral and renal injuries

A0971

Use of allium ureteral stents for managing iatrogenic ureteric injuries
R. Geraghty, Newcastle-upon-Tyne (GB)

A0972

Low diagnostic and clinical accuracy of repeated imaging in asymptomatic blunt renal injuries – experiences of a high-volume urological trauma center
A.K. Lindner, Innsbruck (AT)

A0973

Impact of hospital volume on the outcomes of renal trauma management
B. Peyronnet, Rennes (FR)

A0974

Clinical values of DMSA SPECT in follow-up evaluation of renal injuries after conservative management
S.H. Yu, Gwang-Ju (KR)

10:41 - 10:52

Discussion

Beyond the bladder

A0975

Beyond the bladder: Evidence of histological rearrangement and urethral denervation after thoracic spinal cord injury
T. Antunes Lopes, Porto (PT)

A0976

Gross hematuria associated with anticoagulation and antiplatelet drugs – relevance of co-medication and pharmacological interactions
L. Lawaczek, Tübingen (DE)

10:58 - 11:09

Discussion

Reconstructive

Phalloplasty and vaginal plasty

A0978

Our experience in laparoscopy assisted peritoneal pull-through vaginoplasty in transgender women
B. Stojanovic, Belgrade (RS)

A0979

Comparison of clinical outcomes after phalloplasty with versus without urethral lengthening in transgender men
F.P.W. de Rooij, Amsterdam (NL)

Scientific Programme - EAU22 Amsterdam

A0980	Urethral complications after musculocutaneous latissimus dorsi phalloplasty in transmen B. Stojanovic, Belgrade (RS)
A0981	Musculocutaneous latissimus dorsi free flap phalloplasty: Animal training model for reconstructive surgeons V. Kojovic, Belgrade (RS)
A0982	The effect of colpectomy on lower urinary tract function in transgender men F.P.W. de Rooij, Amsterdam (NL)
A0983	Surgical, functional and patients' reported outcomes of adult acquired buried penis surgical management M. Preto, Turin (IT)
11:21 - 11:32	Discussion
	Organ prolapse and more
A0985	Capio TM Slim Suture Device x Tissue Anchoring System has different results in treatment of advanced pelvic organ prolapse? Prospective and Randomized study: Partial Results with 12 months follow-up R.J. Moreira, Sao Paulo (BR)
A0986	Exstrophy-Epispadias-Complex: Are the kidneys and kidney function spared? R. Cleper, Tel Aviv (IL)
A0987	Mesh repair in the elderly with recurrent pelvic organ prolapse – long term functional outcome with mean follow up of 15 years
A0988	Is there an added value of dynamic MRI of the pelvic floor to the Clinical POP-Q Examination before management of Pelvic Organ Prolapse in females? A double blinded prospective study in a tertiary care center
A0989	Anterior colporrhaphy and sacrospinous hysteropexy in women with pelvic organ prolapse: Urodynamic findings and functional outcomes R. Balsamo, Napoli (IT)
11:44 - 11:55	Discussion
11:55 - 12:00	Closing remarks

Optimising treatment in locally advanced disease

Abstract Session 53

Monday 4 July
10:30 - 12:00

Location Purple Area, Room Elicium 1
Chairs S. Dabestani, Malmö (SE)
T. Klatte, Berlin (DE)
F-C. Von Rundstedt, Wuppertal (DE)

10:30 - 10:33

Introduction

A0990

Evaluating renal tumors by SPARE can save the effort of making three-dimensional imaging

T. Watanabe, Okayama (JP)

A0992

Machine learning approach to predict pT3a upstaging of clinically localized renal cell carcinoma and oncological outcomes after surgery (UroCCR 15 study)

A0993

The anatomical location of lymphadenopathies at imaging predicts the risk of lymph node invasion at final pathology in patients with renal cell carcinoma

G. Rosiello, Bacoli (IT)

10:41 - 10:52

Discussion

A0994

Gender disparities in kidney surgery: A real-life snapshot for a large prospective, multicenter observational study (the RECORD2 Project)

A.A. Grosso, Florence (IT)

A0995

⁸⁹Zr-girentuximab positron emission tomography in clear cell renal cell carcinoma: Safe and accurate

R.I.J. Merckx, Nijmegen (NL)

A0996

Oncological outcomes of patients with non-clear cell renal cell cancers: Subtypes of unclassified and translocation renal cell cancers

F. Gökalp, Hatay (TR)

A0997

Imaging intensity after surgery for clear cell renal cell carcinoma

F. Belladelli, Milan (IT)

11:00 - 11:11

Discussion

A0998

Impact of patient and lifestyle factors in patients with stage III & IV renal cancer: A Danish nationwide study

A0999

Hemodynamic alterations during radical nephrectomy with inferior vena cava (IVC) thrombectomy: A prospective observational pilot study

H. Garg, San Antonio (US)

A1000

Oncologic outcomes in patients diagnosed with pT3a non-metastatic renal cell cancer according to renal vein thrombus or fat invasion

A1001

Robot-assisted radical nephrectomy and inferior vena cava level I-III thrombectomy: Perioperative and mid-term oncologic outcomes

Scientific Programme - EAU22 Amsterdam

A1002	A comparative analysis of minimal invasive vs. open radical nephrectomy for stage III renal cell carcinoma H. Garg, San Antonio (US)
11:21 - 11:32	Discussion
A1003	Sustainable multidisciplinary team referral for non-metastatic renal cell carcinoma: A survival-based recommendation
A1004	Application of the KEYNOTE-564 trial results to real life population: Which patients with advanced kidney cancer should receive adjuvant pembrolizumab
A1005	Adjuvant therapy after surgical resection of nonmetastatic renal-cell carcinoma: One size does not fit all Z-E. Khene, Rennes (FR)
A1006	Renal parenchymal infiltration is the primary determinant of prognosis of patients with non-metastatic clear cell renal cell carcinoma H. Tanaka, Tokyo (JP)
A1007	Impact of positive vascular margins status after surgical resection of non-metastatic renal cell carcinoma with caval tumour thrombus: A propensity score multicentre study Z-E. Khene, Rennes (FR)
A1008	Pembrolizumab outperforms tyrosine kinase inhibitors in the adjuvant therapy of patients with high-risk renal cell carcinoma: A systematic review and network meta-analysis E. Laukhtina, Vienna (AT)
11:44 - 11:55	Discussion
11:55 - 12:00	Closing remarks

Guidelines session: Complications of prostate cancer treatment and their management

Thematic Session 13

Monday 4 July
10:30 - 12:00

Location Purple Area, Room Elicium 2

Chairs T.J. Greenwell, London (GB)
To be confirmed

Learning objectives

The learning objectives for this session are:

To recognise, assess, weigh the evidence and decide on the best management of, the complications of prostate cancer treatment in particular, erectile dysfunction, stress urinary incontinence, bladder neck stenosis and prostate-rectal fistula..

To assess the evidence and decide on the utility of penile rehabilitation for the management of post treatment erectile dysfunction.

To assess and manage primary stress incontinence, the complications of its treatment and recurrent stress incontinence.

To assess the evidence and decide on the most appropriate management of bladder neck stenosis.

To assess and manage prostatic fistula.

10:30 - 10:55	Debate Primary erectile dysfunction post radical prostatectomy: To rehabilitate or not?
10:30 - 10:35	Introduction D.J. Ralph, London (GB)
10:35 - 10:40	Pro To be confirmed
10:40 - 10:45	Con A. Cocci, Florence (IT)
10:45 - 10:55	Discussion D.J. Ralph, London (GB)
10:55 - 11:05	State-of-the-art lecture Male stress urinary incontinence To be confirmed
11:05 - 11:15	State-of-the-art lecture Recurrent stress urinary incontinence after complications from an artificial urinary sphincter F. Van Der Aa, Leuven (BE)
11:15 - 11:45	Debate What is the best management of bladder neck stenosis?
11:15 - 11:20	Introduction T.J. Greenwell, London (GB)
11:20 - 11:25	Minimally Invasive is best F. Campos Juanatey, Santander (ES)
11:25 - 11:30	Bladder Neck V-Y Plasty is best M.W. Vetterlein, Hamburg (DE)

Scientific Programme - EAU22 Amsterdam

11:30 - 11:35	Redo vesico-urethral anastamosis is best F.E. Martins, Lisbon (PT)
11:35 - 11:45	Discussion T.J. Greenwell, London (GB)
11:45 - 11:55	State-of-the-art lecture Management of Prostato-Rectal Fistula J Romero-Otero, Madrid (ES)
11:55 - 12:00	Discussion and closing remarks
11:55 - 12:00	T.J. Greenwell, London (GB)
11:55 - 12:00	To be confirmed

The patient's choice of how to treat prostate cancer?

Abstract Session 51

Monday 4 July
10:30 - 12:00

Location Green Area, Room 4
Chairs P. Hoskin, Northwood (GB)
To be confirmed
K. Touijer, New York (US)

Brachytherapy

10:30 - 10:34

Introduction

- | | |
|-----------------------|--|
| A0953 | Long-term prostate cancer mortality, all-cause survival and morbidity following prostate brachytherapy |
| A0954 | Evidence that life expectancy is increased in prostate cancer patients treated with low dose-rate (LDR) brachytherapy |
| A0955 | Optimisation of rectal dosimetry in LDR prostate brachytherapy |
| A0956 | Comparison between long-term outcomes of low-dose-rate brachytherapy and radical prostatectomy in patients with intermediate-risk prostate cancer: Propensity match scoring analysis
F. Urabe, Chuo-ku, Tokyo (JP) |
| A0957 | Comparison of low-dose-rate brachytherapy versus radical prostatectomy in patients with intermediate-risk prostate cancer: A propensity-matched multi-institutional study
H. Tsumura, Sagamihara (JP) |
| 10:44 - 10:59 | |
| Discussion | |
| EBRT + | |
| A0958 | A nationwide study on the added value of (neo)adjuvant ADT in addition to modern dose-escalated external beam radiotherapy in men with high-risk localized prostate cancer
B.L. Heesterman, Utrecht (NL) |
| A0959 | Mapping EAU guideline practice variations across Europe: An audit of ADT before surgery in locally advanced and high-risk prostate cancer in 6315 cases across 31 European countries
S. MacLennan, Aberdeen (GB) |
| A0960 | Protective effects of metformin against biochemical failure following radical prostatectomy or radiation therapy in localized prostate cancer
L. Huynh, Orange (US) |
| A0961 | Health economics - implication of hypofractionated radiotherapy in prostate cancer
S. Acharya, Lakhimpur (IN) |

A0962	MR-guided adaptive versus CT-guided stereotactic radiotherapy for prostate cancer: Where is the best cost-benefit balance? A. Castelluccia, Roma (IT)
A0963	The Oncotype DX Genomic Prostate Score® assay is associated with time to distant metastasis and prostate cancer death after external beam radiation therapy in localized prostate cancer: A retrospective study
11:11 - 11:26	Discussion
	Salvage treatment
A0964	Outcomes of salvage robotic-assisted radical prostatectomy comparing patients with primary focal therapy versus whole gland ablation: A multicentric collaborative data
A0965	Comparative effectiveness analysis of oncological and functional outcomes after salvage radical treatment with surgery or radiotherapy following primary focal or whole-gland ablative therapy for localised prostate cancer
A0967	Outcomes of Salvage Robot-Assisted Radical Prostatectomy (S-RARP) post focal ablation for prostate cancer in comparison with primary Robot-assisted Radical Prostatectomy (RARP); a matched analysis
A0968	Peri- and postoperative outcomes of salvage robot-assisted radical prostatectomy in prostate cancer patients: A high-volume center experience
A0969	The role of lymph node dissection in patients undergoing salvage radical prostatectomy for radiation recurrent prostate cancer F. Quhal, Vienna (AT)
A0970	Effects of prior local therapy by radical prostatectomy or radiotherapy on the efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer from aramis M. Saar, Aachen (DE)
11:40 - 11:55	Discussion
11:55 - 12:00	Closing remarks

Patient poster presentations

Patient information session

Monday 4 July 12:00 - 13:00	Location	Grey Area, Room Emerald
12:00 - 12:01	Introduction	
PA01	The EAU Policy Office - working with and for patients S. Collen , Brussels (BE)	
12:06 - 12:10	Discussion	
PA02	Solutions for supporting deprived populations of patients and carers M. Costin, Chinnor (GB)	
12:15 - 12:19	Discussion	
PA03	Bladder cancer patients and health professionals co-creating patient information booklets L. Makaroff, Chinnor (GB)	
12:24 - 12:28	Discussion	
PA04	ReIMAGINE: A prostate cancer research consortium with impact due to its patient and public involvement and engagement	
12:33 - 12:37	Discussion	
PA05	Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: >2000 respondents, with focus on older patients R. Giles, Duivendrecht (NL)	
12:42 - 12:46	Discussion	
PA06	Giving patients a voice in the design and delivery of care	
12:51 - 12:55	Discussion	
12:55 - 13:00	Announcement of the Top 3 presentations	

Laparoscopy for beginners

ESU Course 52

Monday 4 July
12:00 - 14:00

Location Grey Area, Room G103

Chair X. Cathelineau, Paris (FR)

Learning objectives

With the large widespread of mini-invasive surgery, improving knowledge of practical aspects of laparoscopy is mandatory.

Knowledge of:

- Indications and contra-indications of laparoscopic approach.
- How to choose and use the instrumentation, in order to optimize the procedure and minimize adverse effects.
- Air insufflations parameters and optimal access in laparoscopic urology.
- How to prevent, recognize and manage complications.

This course aims to provide all this knowledge in an interactive and practical way (video clip, open discussion), in order to assist beginners in laparoscopy shortening their learning curve and optimizing the success of their laparoscopic procedures.

- Laparoscopic surgery: For which patients and which procedures?
- Masterize the armentarium.
- Tips and tricks to optimize the procedure.
- New potential and future evolutions.

Indications for laparoscopy

T.M. Ribeiro De Oliveira, Lisbon (PT)

Instrumentation and haemostatis

X. Cathelineau, Paris (FR)

Peritoneal access and effects of pneumoperitoneum

T.M. Ribeiro De Oliveira, Lisbon (PT)

Avoiding complications

X. Cathelineau, Paris (FR)

Prostate biopsy: Tips and tricks

ESU Course 53

Monday 4 July
12:00 - 14:00

Location

Grey Area, Room G104

Chair

P. Hammerer, Braunschweig (DE)

Learning objectives

- Provide an update on recent imaging techniques like TRUS, Elastography, Histoscanning, multiparametric magnetic resonance imaging (mpMRI) and nuclear imaging techniques for prostate cancer diagnosis.
- Explain standard reporting systems for ultrasound and mpMRI like PI-RADS.
- Discuss different prostate biopsy techniques.
- Tips and Tricks to reduce morbidity of prostate biopsies.

Indications for TRUS and biopsy

P. Hammerer, Braunschweig (DE)

Practical aspects of TRUS and TRUS-guided biopsies

P. Hammerer, Braunschweig (DE)

Indications for rebiopsy

C. Moore, London (GB)

Update on new technical developments

C. Moore, London (GB)

Perioperative immunotherapy and multidisciplinary management of localized genitourinary cancers

ESU Course 23

Saturday 2 July
14:30 - 17:30

Location Grey Area, Room G109

Chair A. Necchi, Milan (IT)

Learning objectives

Results obtained from large immunotherapy trials paved the way of a revolutionary road in the treatment of locally advanced and metastatic urothelial bladder cancer (UBC). For clear-cell renal cell carcinoma (RCC), use of immunotherapy combinations (with either other immune checkpoint inhibitors or targeted therapy/ antiangiogenic drugs) resulted in a shifting paradigm for the first-line therapy of advanced disease.

For both of these tumors, developments of immunotherapy trials in earlier disease stages are progressing at an impressively quick step. Therefore, as never before, there is a need for updates on the multidisciplinary management of these patients. In prostate cancer, clinical trials with the use of immune-checkpoint inhibitors revealed a new therapeutic road, mainly in biomarker-selected patients and in combination therapy strategies.

In brief, the aims of the course will be the following:

- To provide urologists with the state-of-the art on the use of immune-checkpoint inhibitors in UBC and RCC.
- To provide urologists with an overview of the ongoing clinical trials throughout the clinical stages, with a special focus on perioperative stages.
- To discuss the optimal clinical management of patients with organ-confined UBC and RCC who are candidates for an immune-checkpoint inhibitor treatment, including the management of side effects.

Introduction

A. Necchi, Milan (IT)

Immune checkpoint inhibitors in the perioperative setting of urothelial cancer:

Background - State-of-the art and ongoing developments

A. Necchi, Milan (IT)

Clinical cases debate: Neoadjuvant checkpoint inhibition vs standard chemotherapy

J. Bedke, Tübingen (DE)

A. Necchi, Milan (IT)

Management of RCC in the perioperative setting

Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy

A. Bex, Amsterdam (NL)

Clinical cases debate: Neoadjuvant vs adjuvant immunotherapy in localized RCC

J. Bedke, Tübingen (DE)

A. Bex, Amsterdam (NL)

Safety of immune-checkpoint inhibitors in the perioperative setting of GU malignancies

Benchmark of surgical safety results

A. Bex, Amsterdam (NL)

Questions and answers

Predictive biomarkers of immunotherapy efficacy across the GU malignancies

What the literature data tell us

A. Necchi, Milan (IT)

Clinical cases debate: biomarker-driven patient selection vs unselective perioperative strategies

J. Bedke, Tübingen (DE)

A. Bex, Amsterdam (NL)

A. Necchi, Milan (IT)

Conclusion

A. Necchi, Milan (IT)

Testicular cancer

ESU Course 55

Monday 4 July
12:00 - 14:00

Location Grey Area, Room G106

Chair P. Albers, Düsseldorf (DE)

Learning objectives

The ESU Course on testicular cancer will cover all important issues in the diagnosis and treatment of patients with germ cell cancer. There will be time for discussion during and after the presentations. Case reports will be discussed to highlight special situations of controversy. In addition, short video clips will be presented to demonstrate surgical techniques in retroperitoneal residual tumour resection.

In brief, following items will be presented and discussed:

- EAU Guideline recommended staging procedures classifications like IGCCCG.
- Stage-by-stage treatment of low stage disease including TIN.
- Chemotherapy and indication of post chemotherapy surgery according to EAU guidelines.
- Recommended follow-up investigations, long-term toxicities, 2nd malignancies.

Testis cancer: Early stages

N.W. Clarke, Manchester (GB)

Testis cancer: Case discussion

N.W. Clarke, Manchester (GB)

Testis cancer: Advanced stages

P. Albers, Düsseldorf (DE)

Testis cancer: Case discussion

P. Albers, Düsseldorf (DE)

Prostate cancer challenges and controversies from guidelines to real-world

ESU Course 56

Monday 4 July
12:00 - 15:00

Location

Grey Area, Room G107

Chair

F. Gómez Veiga, Salamanca (ES)

Learning objectives

Prostate cancer represents an essential daily activity with a high impact on moving health resources and everyday decisions, including complex situations and weak evidence.

Guidelines are essential to take decisions, but there are gaps or not enough evidence to make a decision in some cases. We need to learn personalised choices in a continuous evolution of knowledge.

Based on multiple interactive choice questions, the course tries to analyse the risk benefits of different approaches with a practical view – real world - with a critical review from screening to mCRPC based on guidelines.

At the end of the course, the participants must be confident in the:

- Optimally use PSA, new biomarkers and role of MRI to minimise unnecessary biopsy in men at risk for prostate. Cost-effectiveness.
- Stratify factors to different approaches to local and local advanced treatment and personalises elections.
- Select risk patients to diagnose and manage after local progression.
- The best election and new tools to diagnose and treat advanced tumours, mHSPC, nmCRPCM or mCRPC. A critical review of new alternatives.

Introduction

F. Gómez Veiga, Salamanca (ES)

Prostate cancer: First take a decision or share decision making

F. Gómez Veiga, Salamanca (ES)

PSA is dead? New markers are profitable. Where we go

A.S. Bjartell, Malmö (SE)

First biopsy: MRI guided biopsy to reduce overdiagnosis or standard biopsy

F. Gómez Veiga, Salamanca (ES)

Local disease, who to treat or not, and how

R. Sanchez-Salas, Paris (FR)

Radiotherapy versus surgery in locally advanced prostate cancer; the battle continues

N. Mottet, Saint-Étienne (FR)

Progression after local treatment, to treat or not to treat

R. Sanchez-Salas, Paris (FR)

How to define oligometastatic and how to treat it

N. Mottet, Saint-Étienne (FR)

What is the best strategy to treat in the naïve metastatic setting

F. Gómez Veiga, Salamanca (ES)

nmCRPC: How to identify patients and define the best option to treat
N. Mottet, Saint-Étienne (FR)

mCRPC: How to start and how to continue and vice-versa
A.S. Bjartell, Malmö (SE)

Precision and personalised medicine. New roadmaps
A.S. Bjartell, Malmö (SE)

Summary of recent advances and controversies and future directions
F. Gómez Veiga, Salamanca (ES)

Peno-scrotology and basic lower urinary tract endoscopy – Questions you are scared to ask

ESU Course 50

Monday 4 July
12:00 - 14:00

Location Grey Area, Room G109

Chair C.S. Biyani, Leeds (GB)

Learning objectives

The course is designed to introduce the application of basic surgical knowledge and principles for the 1st and 2nd year residents. The course will provide the learners with basic knowledge and skills in developing a safe and methodological approach to their initial application of surgical knowledge. The course includes case discussions and learner activity.

Intended learning outcomes.

After this course you will be able to:

- Discuss the basic principles, indications and techniques in basic urological surgery of the scrotum and penis and basic endourology.
- Reason and plan for basic urological procedures based on the anatomy and the individual previous medical history.
- Choose the most appropriate surgical technique in common basic urological conditions.
- Discuss and understand the most common surgical risks in basic urological surgery and endoscopy.

Physical examination of the genitourinary tract

C.S. Biyani, Leeds (GB)

P. Gordon, Leeds (GB)

Penile surgery

C.S. Biyani, Leeds (GB)

P. Gordon, Leeds (GB)

Scrotal surgery

C.S. Biyani, Leeds (GB)

P. Gordon, Leeds (GB)

Basic endoscopic procedures (urethral catheterisation, cystoscopy, nephrostomy)

C.S. Biyani, Leeds (GB)

P. Gordon, Leeds (GB)

Stones and endourology - URS and stenting

Abstract Session 61

Monday 4 July 12:14 - 13:45	Location	Orange Area, Room 2
	Chairs	W. Gamal, Sohag (EG) G. Giusti, Basiglio (IT) K. Sarica, Istanbul (TR)
12:14 - 12:17	Introduction	
A1029	Real-world practice stone-free rates after ureteroscopy from a surgical collaborative: Much to improve	
A1030	Analysis of morbidity and mortality after retrograde intrarenal surgery in patients with renal calculi: Evaluation of 146,189 patients from a nationwide German database	
12:23 - 12:34	Discussion	
A1032	To investigate the clinical efficacy of ureteroscopy in the treatment of ureteral stones under ultrasound guided paravertebral nerve block anesthesia Y. Wu, Wuhan (CN)	
A1033	60w superpulse thulium fiber laser for RIRS in large volume stones (>1000 mm3) – a prospective study on efficacy and outcomes G. Soundarya , Hyderabad (IN)	
A1034	Feasibility, efficacy and safety of retrograde intrarenal surgery in less than 1 year age group: A case series V. Chandra Mohan, Hyderabad (IN)	
12:40 - 12:51	Discussion	
A1035	Measurement of learning in flexible ureteroscopy, with a 3D printed kidney model	
A1036	Feasibility of laser lithotripsy using robotic retrograde intrarenal surgery system easyUretero and Auriga XL™ Holmium laser in porcine model	
A1037	The efficacy of preoperative ureteral stenting in ureteral calculi coexisting with ipsilateral renal calculi for retrograde intrarenal surgery: Compared to percutaneous nephrostomy	
A1038	Tubeless ureterorenoscopy. Our experience using 120-W laser and dusting technique. Postoperative pain, complications and readmissions	
A1039	Deciding need of double J stenting after ureteroscopy peroperatively using a validated score for ureteric injury	
A1040	Does drainage method after flexible ureteroscopy for renal stones affect the treatment outcomes or quality of life? A. Elsayy, Mansoura (EG)	
13:03 - 13:14	Discussion	

A1041	Magnetic double-J vs. traditional double-J stent: Evaluation of tolerance and impact on quality of life M. Diranzo Garcia, Carlet (ES)
A1042	Efficacy of the combination of tamsulosin and methylprednisolone on postoperative early pain and outcomes after uncomplicated and unstented ureteroscopic lithotripsy. A randomized controlled trial P. Gupta, Greater Noida (IN)
A1043	Evaluating the encrustation features due to the short-term ureteral stent placement using micro-computed tomography: The results from a prospective study S. Fukui, Hirakata (JP)
A1044	Ureteral stent encrustation: Evaluation of forgotten encrustation calcification score, kidney ureter bladder score and encrustation burden score as predictors of a complex surgery A. Nacchia, Prata Sannita (IT)
A1045	Efficacy of tamsulosin versus mirabegron for ureteric stent related symptoms: Prospective randomized questionnaire based comparison M. Garg, Jebel Ali / Dubai (AE)
A1046	Evaluating the role of stents on strings and other non cystoscopic removal methods in children: A systematic review on behalf of the European Association of Urology (EAU) Young Academic Urology (YAU) Urolithiasis Working Party
A1047	Ureteric Stent Removal by String: A cost saving technique during pandemic
13:28 - 13:39	Discussion
13:39 - 13:44	Closing remarks

Key questions in adjuvant treatment of renal cell carcinoma

Thematic Session 14

Monday 4 July
12:15 - 13:45

Location Orange Area, eURO Auditorium 1

Chairs J. Bedke, Tübingen (DE)
M-O. Grimm, Jena (DE)

Panel I. Duran, Santander (ES)
T. Klatte, Bournemouth (GB)
To be confirmed
M.C. Mir Maresma, Valencia (ES)
T. Powles, London (GB)
M. Schwab, Stuttgart (DE)
I. Duran, Santander (ES)
T. Klatte, Bournemouth (GB)
To be confirmed
M.C. Mir Maresma, Valencia (ES)
T. Powles, London (GB)
M. Schwab, Stuttgart (DE)

Learning objectives

Adjuvant PD-1 blockade has improved disease-free survival in RCC. This session will focus on the optimal selection of patients for an adjuvant treatment in RCC and highlights pathological, clinical and molecular differences. The positive data of immune checkpoint inhibitors will be discussed and compared to TKI treatment in adjuvant RCC, including oligometastatic patients who had metastasectomy. In brief, the aims are:

- To understand the role of adjuvant immunotherapy in RCC
- How to select patients for adjuvant therapy
- How to treat oligometastatic RCC patients

12:15 - 12:18

Welcome and introduction

M-O. Grimm, Jena (DE)

12:18 - 12:48

Patient selection is key, who is at risk?

12:18 - 12:28

The pathologist's view

To be confirmed

12:28 - 12:38

Patient selection, the mRNA view

M. Schwab, Stuttgart (DE)

12:38 - 12:48

Patient selection, the clinicians view

T. Klatte, Bournemouth (GB)

12:48 - 12:58

All in for immune checkpoint inhibitors or any role for TKI left?

T. Powles, London (GB)

12:58 - 13:08

Is it justified to treat M1 NED patients

M.C. Mir Maresma, Valencia (ES)

13:08 - 13:18

Is side effect management different in the adjuvant space compared to mRCC?

I. Duran, Santander (ES)

Scientific Programme - EAU22 Amsterdam

13:18 - 13:30

Panel discussion pT3a, cN0

13:18 - 13:20

Case presentation

To be confirmed

13:20 - 13:30

Discussion

13:30 - 13:42

Panel discussion M1 NED after metastasectomy

13:30 - 13:32

Case presentation

Y. Abu Ghanem, Ramat Gan (IL)

13:32 - 13:42

Discussion

13:42 - 13:45

Closing remarks

J. Bedke, Tübingen (DE)

Semi-live surgery: Robotic cystectomy

Thematic Session 15

Monday 4 July
12:15 - 13:45

Location Grey Area, eURO Auditorium 2

Chairs A. Stenzl, Tübingen (DE)
H.G. Van Der Poel, Amsterdam (NL)

Learning objectives

Robot surgery has changed the way urologists perform cystectomy and urinary derivation. Early studies showed potentially lower complications rates and less blood loss for the robot approach. Technically, robot-assisted derivation reconstruction can be challenging. Experts will show their setup and approach to robot cystectomy and derivation and briefly discuss tips and tricks for surgical practice

12:15 - 12:25

Semi-live video Robot-assisted radical cystectomy with ileal conduit
P. Wiklund, Stockholm (SE)

12:25 - 12:30

Discussion

12:30 - 12:40

Semi-live video Sexual-sparing robot assisted radical cystectomy in females
J. Walz, Marseille (FR)

12:40 - 12:45

Discussion

12:45 - 12:55

Semi-live video Robotic intracorporeal continent catheterizable pouch in children
To be confirmed

12:55 - 13:00

Discussion

13:00 - 13:10

Semi-live video Use of bowel segments in robotic urinary reconstruction
R. Thomas, New Orleans (US)

13:10 - 13:15

Discussion

Partial nephrectomy road maps

Video Session 13

Monday 4 July
10:30 - 12:00

Location Green Area, Room 2

Chairs Y. Abu Ghanem, Ramat Gan (IL)
U. Capitanio, Milan (IT)
To be confirmed

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

10:30 - 10:33

Introduction

V82

Deep learning in robot-assisted partial nephrectomy: Advent of realistic augmented reality
P. De Backer, Aalst (BE)

V83

The art of data labelling for building supervised computer Vision models for kidney surgery
M. Bhandari, Novi (US)

V84

Sutureless purely off-clamp robot-assisted partial nephrectomy: Nuclear renal scan findings from a pilot study
A. Brassetti, Rome (IT)

V85

Robotic partial nephrectomies with selective/superselective clamping of renal artery branch by using indocyanine green (ICG)

V86

Surgical management of challenging renal tumors with imperative indication: The knowledge of anatomy with 3D virtual models drives the decision making
D. Amparore, Turin (IT)

V87

Step by step 3D virtual models assistance in case of complex robotic partial nephrectomies
D. Amparore, Turin (IT)

V88

Robotic partial nephrectomy for complex hilar renal masses - key techniques for a successful outcome
J. O'Brien, East Melbourne (AU)

11:51 - 11:56

Closing remarks

Novel approaches in retroperitoneal and transplant surgery

Video Session 14

Monday 4 July
12:15 - 13:45

Location Green Area, Room 2

Chairs To be confirmed
J.F. Langenhuijsen, Nijmegen (NL)
M. Musquera Felip, Barcelona (ES)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

12:15 - 12:18

Introduction

V89

Single-port retroperitoneoscopic adrenalectomy: Initial results and standardization of the technique
D. Vazquez-Martul , A Coruña (ES)

V90

Adrenal relapse management after previous kidney and adrenal oncologic surgery: Laparoscopy and retroperitoneoscopy
S. Fernández-Pello Montes, Gijón (ES)

V91

Robot-assisted kidney transplantation and multiple renal arteries grafts
A. Abella Serra, Barcelona (ES)

V92

Ex vivo ureteroscopy of diseased donor kidney

V93

3D Augmented reality-guided robotic-assisted kidney transplantation: Revealing the concealed
A. Piana, Turin (IT)

V94

Overcoming the boundaries in 3D laparoscopy: Retroperitoneal lymph node dissection post chemotherapy
V.H. Schitcu, Cluj Napoca (RO)

V95

Robot assisted retroperitoneal lymph node dissection: Learning curve from a tertiary care centre
S. Tyagi, Hapur (IN)

13:32 - 13:37

Closing remarks

Advanced urothelial cancer - Organoids, response mechanisms and biomarkers

Abstract Session 56

Monday 4 July
12:15 - 13:45

Location Green Area, Room 3
Chairs R.T. Bryan, Birmingham (GB)
B. Faltas, New York (US)
T. Zuiverloon, Den Haag (NL)

Immune checkpoint

12:15 - 12:18

Introduction

- A1065** The clinical value of PD-L1 status as predictive biomarker in first-line treatment of urothelial carcinoma of the bladder
- A1066** FASN is the key regulator of fatty acid metabolism and related to immunotherapy in bladder cancer
X. Qiao, Chengdu (CN)
- A1067** Circulating extracellular vesicles carrying Firmicutes can predict response to pembrolizumab in urothelial carcinoma
A. Kawashima, Sakai (JP)
- A1068** Immunohistochemical evaluation of immune checkpoint antigens and stem cell markers on early versus late passage organoids from urothelial carcinoma cells
R. Geng, Tuebingen (DE)

12:26 - 12:34

Discussion

UTUC

- A1069** Transcriptomic profiling of upper tract urothelial carcinoma: Utility of the consensus molecular classification of bladder cancer, differential immune signatures and molecular heterogeneity
A. Masson-Lecomte, Paris (FR)
- A1070** Prognosis value of preoperative biomarkers: Neutrophil-to-lymphocyte Ratio, Monocyte-to-lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma
S. Zouari, Tunis (TN)
- A1071** Cancer-associated fibroblasts induce tumor progression by modulating tumor/stromal expression of HHLA2 in upper tract urothelial carcinoma
D. Nishihara, Tochigi (JP)
- A1072** Whole exome and RNA sequencing of upper tract urothelial carcinoma primary and recurrent tumors revealed their clonal relatedness, molecular evolution and association with prognosis
Y. Bao, Chengdu (CN)

12:42 - 12:50

Discussion

Organoids and extracellular vesicles

A1073	Single cell sequencing of parental bladder cancer and subsequent organoids reveals differential cell preservation R. Seiler, Bellmund (CH)
A1074	Patient derived bladder cancer organoids can be generated from rinsing urine - establishment, and evaluation of a simplified approach P. Pollehne, Tübingen (DE)
A1075	Patient derived bladder cancer organoids – changes in growth and expression profile during longterm culture
A1076	Exosome derived circTPRS1 promotes malignant phenotype and CD8+ T cell exhaustion in bladder cancer microenvironment through modulating reactive oxygen species equilibrium via GLS1 mediated glutamine metabolism alternation
12:58 - 13:06	Discussion
	Resistance/response mechanisms
A1077	Proteogenomic characterization of muscle invasive bladder cancer identifies mechanisms of resistance and potential targets for therapy S. Lerner, Houston (US)
A1078	ML324, a JMJD2/KDM4 histone demethylase inhibitor repressed the growth of bladder cancer via miR133a-1/KLF15 regulation J. Zhang, Chengdu (CN)
A1079	Epigenetic treatment with BET inhibitor PLX51107 sensitizes urothelial carcinoma cells to cisplatin and PARP inhibitors G. Niegisch, Düsseldorf (DE)
A1080	MicroRNA-99a-5p induces bladder cancer cells senescence and improves gemcitabine sensitivity by targeting SMARCD1
A1081	A novel therapeutic strategy against gemcitabine and cisplatin resistance with a new Pan-RAS inhibitor
13:16 - 13:26	Discussion
	Biomarkers
A1082	Serum total cell-free DNA as a marker for invasive evaluation in total cystectomy T. Narita, Hiroaki (JP)
A1083	Prognostic impact of perioperative circulating levels of Insulin-like growth factor-I (IGF-I) and its binding proteins, IGFBP-2 and IGFBP-3, on disease outcomes after radical cystectomy
A1084	Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: Are they the same tumors?
A1085	Characterization of tumor-specific markers of extracellular vesicles derived from urological tumors K. Junker, Homburg (DE)
13:32 - 13:38	Discussion

13:34 - 13:39

Closing remarks

Modern renal transplantation

Abstract Session 57

Monday 4 July
12:15 - 13:45

Location Green Area, Room 4
Chairs R. Boissier, Marseille (FR)
To be confirmed
To be confirmed

12:15 - 12:18

Introduction

Kidney preservation and more

A1086 **Machine-derived data and molecular markers as indicators of organ quality in normothermic machine perfusion with whole blood**
A.E. Yakaç, Dresden (DE)

A1087 **Multi-photon microscopy for the evaluation of interstitial fibrosis in extended criteria donor kidneys: A proof-of-concept pilot study**
W.Z. So, Kent Ridge (SG)

A1088 **Candidate variants for prediction of kidney transplantation rejection**

A1089 **Protective effects of regulatory T cells in renal ischemia/reperfusion injury in mice**

A1090 **The effect of everolimus on ureteral anastomosis and renal ischemia reperfusion injury**
F. Sandikci, Ankara (TR)

12:28 - 12:35

Discussion

Prediction cityscan models

A1091 **How did we improve the model performance of the supervised computer vision model for laparoscopic live donor nephrectomy**
M. Bhandari, Novi (US)

A1092 **Computed tomography based, 3D segmentation method for renal volume measurement in comparison to the actual renal volume of transplanted kidney: A prospective study**

A1093 **In the era of computed tomography volumetry: Is isotope renography still routinely required in the preparation and selection of living kidney donors?**
B. Ali-El-Dein, Mansoura (EG)

12:41 - 12:48

Discussion

Miscellaneous

A1094 **Are pre-transplant kidney biopsies safe? A cross-sectional study**
J. Lorigo, Quiaios (PT)

A1095 **Robotic versus open kidney transplantation from deceased donors: The first prospective observational study**
R. Campi, Florence (IT)

Scientific Programme - EAU22 Amsterdam

A1096	Use of right kidneys versus left kidneys in living-donor robot-assisted kidney transplantation: A comparative analysis A. Abella Serra, Barcelona (ES)
12:54 - 13:01	Discussion
	Miscellaneous
A1097	Orthotopic kidney transplant: Transplantation beyond the iliac vessels T. Ajami Fardoun, Barcelona (ES)
A1098	Kidney transplantation in patients ≥80 years: Retrospective multicenter study J. Bertholle Gil, Lluçmajor (ES)
A1099	Contemporary management of renal transplant recipients with de novo urinary stones. A single institution experience
13:07 - 13:14	Discussion
	Miscellaneous
A1100	Outcomes and complications in kidney transplantation from Donors after Circulatory Death (DCD): Differences between type II-uncontrolled and type III-controlled DCD J. Medina Polo, Madrid (ES)
A1101	Perioperative and functional outcomes after kidney transplantation from uncontrolled donors after circulatory death vs. expanded-criteria donors after brain death vs. standard-criteria donors: Toward an evidence-based refinement of allocation strategies R. Campi, Florence (IT)
A1102	The effect of donor age on pediatric kidney graft survival L. Oomen, Nijmegen (NL)
13:20 - 13:27	Discussion
	Miscellaneous
A1103	Comparative analysis of perioperative complications in kidney transplant patients with coronary artery disease on dual antiplatelet drugs
A1104	Diabetes mellitus in expanded criteria donors may impair the outcomes of dual kidney transplantation Y.Q. Tan, Singapore (SG)
A1105	Transplant renal artery stenosis: Study of incidence using doppler ultrasound, risk factors and analysis effect in graft outcomes C. Calzas Montalvo, Madrid (ES)
13:33 - 13:40	Discussion
13:40 - 13:45	Closing remarks

Rare diseases with special focus on von Hippel-Lindau

Abstract Session 58

Monday 4 July
12:15 - 13:15

Location Green Area, Room 5
Chairs To be confirmed
To be confirmed
P.D. Violette, Woodstock (CA)

Von Hippel-Lindau disease

12:23 - 12:26

Introduction

A1106 **The risk of Von Hippel-Lindau disease according to individual sporadic cancer in a multidisciplinary program: external validation of the VHL Alliance guidelines for genetic referral**
A. Larcher, Milan (IT)

A1107 **Risk of age-related tumour development in patients with von Hippel-Lindau disease**

A1108 **Hazard of death in von Hippel-Lindau disease patients depends on genotype and onset age as well as first affected lesion**

12:32 - 12:47

Discussion

Miscellaneous

A1109 **Impact of long term indwelling JJ stent on renal parenchyma and estimated glomerular function rate (eGFR)**
N. Branger, Marseille (FR)

A1110 **Validation of a simplified prognostic model for survival in patients with extrinsic malignant ureteral obstruction treated with tandem ureteral stents**

A1111 **A randomized study using combination of statin and ascorbic acid for prevention of contrast-induced nephropathy (NCT03391830)**

A1112 **Arterio-ureteral fistula: A nationwide cross-sectional questionnaire analysis**
K. Kamphorst, Utrecht (NL)

12:55 - 13:10

Discussion

13:10 - 13:15

Closing remarks

Novel therapies and biomarkers in renal cancer

Abstract Session 59

Monday 4 July
12:15 - 13:45

Location Purple Area, Room Elicium 1
Chairs K. Junker, Homburg (DE)
To be confirmed
To be confirmed

Novel therapies

12:15 - 12:19

Introduction

A1113 IL-7 and CCL19 producing CAR-T cells enhance antitumor efficacy against solid cancer by preventing antigen-loss tumor relapse

A1114 Multi-Omics analysis of metastatic fumarate hydratase-deficient renal cell carcinoma in paired primary tumors and metastases

A1115 CAIX-specific CAR-NK targeting renal cell carcinoma
J.C. Oosterwijk-Wakka, Nijmegen (NL)

A1116 Autophagy as a new therapeutic pathway
V. Stuehler, Tuebingen (DE)

A1117 Glutamine inhibition induces cellular senescence in renal cell carcinoma by targeting SLC1A5

12:29 - 12:39

Discussion

Novel biomarkers (immunology)

A1118 The adding value of COntrolling NUTritional status (CONUT) score to pre-operative counselling on significant early loss of renal function after radical nephrectomy for cancer
L. Ongaro, Udine (IT)

A1119 Gut microbiota composition in Chinese patients with renal cell carcinoma
Y. Chen, Shanghai (CN)

A1120 An immune microenvironment related tumor microbiome signature to predict prognosis in clear cell renal cell carcinoma
Y.Y. Xie, Beijing (CN)

A1121 Immunological markers and somatic mutations as predictors for therapy selection in metastatic renal cell carcinoma
V. Stuehler, Tuebingen (DE)

A1122 Characterization of the tumor immune microenvironment between primary and paired asynchronous metastatic clear cell renal cell carcinoma

A1123 Cancer-associated adipose-derived mesenchymal stem cells promote migration and invasion in kidney cancer
Y. Muto, Akita (JP)

Scientific Programme - EAU22 Amsterdam

12:51 - 13:01	Discussion
	Novel biomarkers (other)
A1124	Large-scale genomic analysis of renal cell carcinoma using 1,532 Japanese patients and 5,996 controls
A1125	Characterisation of disease progression in low-risk renal cell carcinoma patients by multiomics data M. Rivedal, Bergen (NO)
A1126	Assessment of HER2 protein overexpression and gene amplification in renal collecting duct carcinoma: Therapeutic implication
A1127	The male gender and different cut-off value of Ki-67 index may predict metastasis risk of pheochromocytoma and paraganglioma
A1128	Role of Matrix assisted Laser Desorption/ionization (MALDI)- Mass Spectrometry Imaging (MSI): A novel tool to study bioenergetic signature in kidney cancer H. Garg, San Antonio (US)
A1129	Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents
13:13 - 13:23	Discussion
	Extracellular vesicles and various
A1130	Effects of microvesicles on the growth and environment of renal carcinoma xenografts in a mouse model M. Ferragu, Angers (FR)
A1131	Exosomal antitumor microRNA-1 as a therapeutic target and a tumor marker in renal cell carcinoma
A1132	Analysis of extracellular vesicles as mediators of Sunitinib resistance in renal cell carcinoma A. Zaccagnino, Homburg/Saar (DE)
13:29 - 13:39	Discussion
13:39 - 13:45	Closing remarks

Improving functional outcome of prostatectomy

Abstract Session 60

Monday 4 July
12:15 - 13:45

Location Purple Area, Room Elicium 2
Chairs To be confirmed
H. Isbarn, Hamburg (DE)
To be confirmed

Before surgery

12:15 - 12:19

Introduction

A1133 **Service evaluation of the utilisation and impact of PredictProstate on clinical decision-making in a prostate cancer specialist multidisciplinary service**
I. Pryle, Cambridge (GB)

A1134 **Prehabilitation program before robotic radical prostatectomy improves perioperative outcomes and continence recovery**
R.G. Rahota, Oradea, Bihor (RO)

12:23 - 12:31

Discussion

Continence

A1135 **The position of urethrovesical anastomosis after robotic radical prostatectomy assessed by MRI predicts early functional recovery: A cohort analyses from a randomized clinical trial**
M. Triquell Llaurodo, Barcelona (ES)

A1136 **Significance of position of vesico-urethral anastomosis together with postoperative membranous urethral length for short term continence recovery following robot-assisted laparoscopic radical prostatectomy**

A1137 **The impact of detrusor wall hypertrophy and presence of overactive bladder on urine continence return in patients after radical prostatectomy due to prostate cancer**

A1138 **Feasibility of first postoperative day foley catheter removal after robotic assisted radical prostatectomy**
A.d.O. Paludo, Porto Alegre (BR)

A1139 **Correlation of urine loss after catheter removal and early continence in men undergoing radical prostatectomy**
B. Hoeh, Frankfurt am Main (DE)

12:41 - 12:49

Discussion

Retzius sparing

A1140 **Retzius-sparing robot assisted radical prostatectomy has similar 1-year functional and oncological outcomes as standard robot-assisted radical prostatectomy: Results from a high volume UK centre**

Scientific Programme - EAU22 Amsterdam

A1141	Comparison of retzius-sparing versus standard approach robotic assisted laparoscopic prostatectomy for localized prostate cancer: A systematic review and meta-analysis from KSER update series
A1142	Learning curve for Retzius-Sparing Robot-Assisted Radical Prostatectomy (RS-RARP): Experience of two high volume UK surgeons
A1143	Role of dorsal vascular complex preservation in robot-assisted radical prostatectomy
12:57 - 13:05	Discussion
	Improving outcome
A1144	Transrectal ultrasound guided hydro dissection of the rectum-vesicular layer before robot assisted radical prostatectomy: Proposal of a new technique to improve early recovery of continence and erectile function
A1145	Continence after introducing NeuroSAFE in radical prostatectomy
A1146	Surgeon volume and patient-reported urinary continence 1 year after radical prostatectomy. Nation-wide population-based study R. Arnsrud Godtman, Göteborg (SE)
A1147	Assessing the quality of learning curve through a standardized proficiency score and the impact of learning curve on trifecta outcomes of robot-assisted radical prostatectomy (RALP): Results of a multicentric series
A1148	Pathological, functional and oncological best-case scenarios after robot-assisted radical prostatectomy – can we improve quality of life?
13:15 - 13:23	Discussion
	New technology
A1150	Initial experience with 3D visualization in laparoscopic radical prostatectomy. A bicentric case series S. Deger, Ostfildern (DE)
A1151	Surgical, oncological and functional outcomes following robotic- assisted radical prostatectomy using the SynchroSeal™ advanced diathermy instrument
A1152	3D laparoscopic versus robot assisted laparoscopic prostatectomy, a randomized prospective study. Preliminary 1-year functional results H. Haapiainen, Seinäjoki (FI)
13:31 - 13:39	Discussion
13:39 - 13:45	Closing remarks

Guidelines, evidence-based medicine and education

Abstract Session 55

Monday 4 July 12:15 - 13:45	Location	Green Area, Room 1
	Chairs	M.I. Omar, Aberdeen (GB) M.J. Ribal Caparros, Barcelona (ES) S. Canfield, Houston (US)
12:15 - 12:18	Introduction	
12:15 - 12:20	OPTIMA: New research project aims to improve treatment for patients with prostate, breast and lung cancer through artificial intelligence J. N'Dow, Aberdeen (GB)	
A1048	Duration of follow-up and timing of discharge in adult patients with urolithiasis after surgical or medical intervention: A systematic review and meta-analysis from the European Association of Urology Guideline Panel on Urolithiasis L. Tzelves, Athens (GR)	
A1049	What is the ideal follow up after kidney stone treatment? A systematic review and follow-up algorithm from the European Association of Urology urolithiasis panel R. Lombardo, Rome (IT)	
12:24 - 12:32	Discussion	
A1050	Systematic review of active surveillance for clinically localized prostate cancer to develop recommendations regarding selection, monitoring and reclassification thresholds P-P.M. Willemse, Utrecht (NL)	
A1051	Clinical characterization and outcomes of prostate cancer patients undergoing immediate vs. conservative management: A PIONEER study G. Gandaglia, Milan (IT)	
A1052	Recommendations for using Big Data in Prostate Cancer: The experience from the PIONEER Watchful Waiting Study-a-thon	
A1053	Outcomes of importance to men with advanced prostate cancer: PIONEER interview study	
A1054	Baseline characteristics and outcomes of 10.485 prostate cancer patients on delayed palliative management: A report from PIONEER, a big data for better outcome programme J. Gómez Rivas, Madrid (ES)	
A1055	The PIONEER watchful waiting for prostate cancer apps - a first practical application of using big data for prostate cancer B. De Meulder, Vourles (FR)	
12:44 - 12:56	Discussion	
A1056	What are the benefits and harms of the surgical management options for adult buried penis? A systematic review M. Falcone, Torino (IT)	

Scientific Programme - EAU22 Amsterdam

A1057	A systematic review and meta-synthesis of qualitative evidence on overactive bladder for the development of a Core Outcome Set
13:00 - 13:12	Discussion
A1058	Levels of scientific evidence underlying urological guidelines' recommendations: A comprehensive review
A1059	Do European Association of Urology (EAU) guidelines adhere to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology? D.A. González-Padilla, Madrid (ES)
A1060	Intraoperative adverse event reporting in urology: Global ICARUS survey results T. Sholklapper, Los Angeles (US)
A1061	Climate-smart actions in the operating theatre for improving sustainability practices: A systematic review U. Pinar, Paris (FR)
A1062	Minimising litigation in urology: Lessons learnt from the UK over a 20-year period J. Lane, London (GB)
A1063	Evaluation of uroLogical tEaching in bRitish medical school Nationally: the LEARN multicentre cross-sectional study A. Asif, Camberley (GB)
A1064	Pathways and perceived barriers to paediatric urology subspecialisation: A study of incumbent attitudes and opinions F. O'Kelly, Dublin (IE)
13:26 - 13:38	Discussion
13:38 - 13:43	Closing remarks

Advanced course on laparoscopic renal surgery

ESU Course 51

Monday 4 July
12:15 - 15:15

Location Grey Area, Room G102

Chair A. Breda, Barcelona (ES)

Learning objectives

Minimally invasive surgery has steadily improved over the last years. Today one can approach with confidence new, difficult and challenging situations. The course is structured to evaluate and explore the increasing indications and possible complications of laparoscopic and robotic kidney surgery. This course will focus upon common and uncommon complications and how to manage and prevent them. In addition, special situations such as single port inguinal approach, zero ischemia time, cava thrombus, accidental splenectomy and living donor nephrectomy will be presented.

Introduction

A. Breda, Barcelona (ES)

Transperitoneal renal surgery: Step by step

A. Breda, Barcelona (ES)

Retroperitoneal renal surgery: Step by step

A. Breda, Barcelona (ES)

P.J. Zondervan, Amsterdam (NL)

Complex kidney cases

A. Breda, Barcelona (ES)

P.J. Zondervan, Amsterdam (NL)

Intraoperative complications: Incidence and management

P.J. Zondervan, Amsterdam (NL)

Postoperative complications: Incidence and management

A. Breda, Barcelona (ES)

Special cases

A. Breda, Barcelona (ES)

P.J. Zondervan, Amsterdam (NL)

Update on stone disease

ESU Course 54

Monday 4 July
12:15 - 15:15

Location

Grey Area, Room G105

Chair

B. Somani, Southampton (GB)

Learning objectives

The previously devastating burden of urinary tract urolithiasis has been reduced by modern stone therapy. Complex branched stones are rare, and therapy has moved largely to the outpatient setting. Nevertheless, successful management requires competence in all aspects of stone management. After a brief review of new developments in present treatment strategies, these will be further explored by interactive case presentations.

- Stone disease aetiology is multi-factorial, relating in large part to genetics, diet (salt, calorie and protein intake), hydration status factors and ageing.
- The clinical presentation is changing with a growing base of elderly and obese patient cohorts in developed nations.
- Today's challenge is employing the ideal initial and salvage approaches for specific situations - individuals, including judicious selection of prevention strategies.
- Patients should be given choices and counselled about the risk benefits and potential outcomes of all appropriate reasonable approaches.

Introduction

B. Somani, Southampton (GB)

Shock wave lithotripsy (SWL)

M. Straub, Munich (DE)

Medical aspects of urinary stones

M. Straub, Munich (DE)

Cases

M. Straub, Munich (DE)

Uretero-Renoscropy

E.K. Bres-Niewada, Warsaw (PL)

Cases

E.K. Bres-Niewada, Warsaw (PL)

Percutaneous nephrolithotomy and questions and answers

B. Somani, Southampton (GB)

Cases

B. Somani, Southampton (GB)

All you need to know about castration-resistant prostate cancer (CRPC)

Thematic Session 16

Monday 4 July
14:00 - 15:30

Location	Orange Area, eURO Auditorium 1
Chairs	L-M. Krabbe, Münster (DE) A. Morgans, Boston (US)
Panel	S. Chowdhury, London (GB) N.W. Clarke, Manchester (GB) D. Olmos, Madrid (ES) R.C.N. Van Den Bergh, Nieuwegein (NL) U. Vogl, Bellinzona (CH)

14:00 - 14:02	Welcome and introduction
14:02 - 14:12	Update on M0 CRPC L-M. Krabbe, Münster (DE)
14:12 - 14:22	What are the clinically relevant prognostic factors in mCRPC? N.W. Clarke, Manchester (GB)
14:22 - 14:37	When to order and how to read a NGS somatic testing report D. Olmos, Madrid (ES)
14:37 - 14:52	Systemic treatment options for mCRPC and how to sequence them U. Vogl, Bellinzona (CH)
14:52 - 15:02	PSMA theranostics in the mCRPC space S. Chowdhury, London (GB)
15:02 - 15:12	Innovative future treatment options for mCRPC A. Morgans, Boston (US)
15:12 - 15:30	Case discussion Patient with mHSPC treated with ADT and NHT upfront and progressing
15:12 - 15:15	Case presentation R.C.N. Van Den Bergh, Nieuwegein (NL)
15:15 - 15:30	Discussion

Complications in stone treatment

Thematic Session 17

Monday 4 July
14:00 - 15:30

Location Grey Area, eURO Auditorium 2

Chairs A. Pietropaolo, Southampton (GB)
J. Rassweiler, Heilbronn (DE)

Learning objectives

Even if endourological procedures usually are not associated with major side-effects, there is always a risk for severe and even fatal complications.

We are glad to provide a panel of experts in the different fields of minimally invasive stone management. The main aim of this session, however, is to stimulate the discussion among European urologists about the optimal management and prevention of the presented pitfalls. Thus, we want to stimulate this exchange of opinions and practical experiences during this session. We are looking forward to your active attendance.

14:00 - 14:05

Welcome and introduction

J. Rassweiler, Heilbronn (DE)

14:05 - 14:15

Urosepsis after ureteroscopy: Predictors and management of a potentially fatal complication

S. Ferretti, Parma (IT)

14:15 - 14:20

Discussion

14:20 - 14:30

Stent encrustation: Prevention and treatment strategies in the modern era

P. Juliebø-Jones, Bergen (NO)

14:30 - 14:35

Discussion

14:35 - 14:50

Nightmare scenarios and management of percutaneous stone surgery

T. Tailly, Ghent (BE)

14:50 - 14:55

Discussion

14:55 - 15:05

Complications of laparoscopic and robot-assisted stone surgery

A.S. Gözen, Heilbronn (DE)

15:05 - 15:10

Discussion

15:10 - 15:20

Complication of shockwave lithotripsy, what has changed?

K. Sarica, Istanbul (TR)

15:20 - 15:25

Discussion

15:25 - 15:30

Summary and closing remarks

A. Pietropaolo, Southampton (GB)

Management of defects in genetic and epigenetic factors influencing the male reproductive potential

Thematic Session 18

Monday 4 July
14:00 - 15:30

Location Green Area, Room 1

Chairs G.I. Russo, Catania (IT)
N. Sofikitis, Ioannina (GR)
J.O.R. Sønksen, Herlev (DK)

Learning objectives

Male gamete genetic and epigenetic factors may influence spermatogenesis and the sperm capacity to penetrate the oocyte coverings, activate the oocyte and trigger optimal early embryonic development with capacity for implantation. Thus damage in sperm DNA integrity or a functional defect in sperm centrosome or PLCzeta activity may result in early embryonic development arrest. Increased sperm DNA fragmentation index due to enhanced oxidative stress attributable to testicular pathophysiologies such as varicocele or high paternal age may be alleviated by treating the primary testicular disease or by administration of antioxidant substances. However, the excessive administration of antioxidants may have a harmful effect on sperm physiology.

14:00 - 14:15

Sperm epigenetic abnormalities
To be confirmed

14:15 - 14:35

Sperm DNA fragmentation: What is the impact?

14:15 - 14:25

Sperm DNA fragmentation assays and how to interpret them?
To be confirmed

14:25 - 14:35

Impact on ART
F. Dimitriadis, Kalamaria, Thessaloniki (GR)

14:35 - 15:00

Case-based debate OAT + elevated SDF due to varicocele: Can we improve the male reproductive capacity by reducing sperm DNA fragmentation?

14:35 - 14:40

Case presentation
M.G. Gül, Konya (TR)

14:40 - 14:45

Administration of antioxidant supplements
To be confirmed

14:45 - 14:50

Performance of varicocelelectomy
M. Shabbir, London (GB)

14:50 - 14:55

Don't even bother, go for ICSI
To be confirmed

14:55 - 15:00

Rebuttals and concluding remarks

15:00 - 15:30

Paternal DNA

15:00 - 15:10

Genetic evaluation of the infertile man and what appears on the therapeutic horizon?
To be confirmed

Scientific Programme - EAU22 Amsterdam

15:10 - 15:20

The impact of paternal age on natural male fertility potential and on the outcome of ART
M. Dinkelman-Smit, Rotterdam (NL)

15:20 - 15:30

Questions and answers

Androgen receptor and cellular plasticity in prostate cancer: How to improve therapies

Thematic Session 19

Monday 4 July
14:00 - 15:30

Location

Green Area, Room 2

Chairs

Z. Culig, Innsbruck (AT)

W.M. Van Weerden, Rotterdam (NL)

Learning objectives

1. To gain knowledge on the latest developments in understanding the molecular mechanisms that drive prostate cancer progression
2. To understand what new therapeutic targets may come from these new insights and for which patient groups
3. To acquire insight what is the clinical potential of such new concepts and how these may contribute to improving the management of prostate cancer

14:00 - 14:15

Androgen receptor transcription program in advanced prostate cancer
W. Zwart, Amsterdam (NL)

14:15 - 14:20

Discussion

14:20 - 14:35

Chemokines and their receptors in regulation of prostate cancer growth
A. Alimonti, Bellinzona (CH)

14:35 - 14:40

Discussion

14:40 - 14:55

Cellular plasticity and possibilities to improve PCa therapy
To be confirmed

14:55 - 15:00

Discussion

15:00 - 15:15

Alternative androgen receptor targeting to overcome androgen resistance: Targeting of AR dimerisation
F. Claessens, Leuven (BE)

15:15 - 15:20

Discussion

15:20 - 15:30

Questions and answers

Surgical management and quality outcome in prostate cancer treatment

Abstract Session 62

Monday 4 July
14:00 - 15:30

Location Purple Area, Room Elicium 2
Chairs G. Karazanashvili, Tbilisi (GE)
To be confirmed
P. Stattin, Uppsala (SE)

Patients perception

14:00 - 14:03

Introduction

- A1153** **Predicting patient-reported symptom clusters in prostate cancer patients: A machine learning approach**
E. Rammant, Ghent (BE)
- A1154** **Differences of quality of life between German and Dutch prostate cancer patients, who are treated with robot-assisted radical prostatectomy: Implications for international multicenter randomized controlled trials**
- A1156** **Assessing the role of frailty status on surgical, oncologic and functional outcomes in patients treated with robot-assisted radical prostatectomy for prostate cancer**
G. Rosiello, Bacoli (IT)
- 14:11 - 14:21** **Discussion**
- Complications**
- A1157** **The timing of (salvage) radiotherapy influences the outcomes of bladder neck incision for bladder neck stenosis after robot-assisted radical prostatectomy**
H. Veerman, Volendam (NL)
- A1158** **Urinary continence outcome of patients with epithelialized cavity formation after excessive vesicourethral anastomotic leak post radical prostatectomy**
D.K. Filipas, Hamburg (DE)
- A1159** **Climacturia and penile length shortening: Adverse outcomes following robot-assisted radical prostatectomy**
L. Huynh, Orange (US)
- A1160** **Are extended pelvic lymph node dissection-related complications still an issue in contemporary patients treated with robot-assisted radical prostatectomy? A prospective assessment using a standardized collection system**
- A1161** **Lymph swelling after radical prostatectomy and pelvic lymph node dissection**
- A1162** **Hypoxemia of the lower limbs during robot-assisted radical prostatectomy**
L. Haeuser, Herne (DE)
- A1163** **Increased awareness of surgical outcomes improves long-term functional outcomes after robot-assisted radical prostatectomy. A prospective assessment following implementation of prospective data collection**

14:35 - 14:45

Discussion

	Margins
A1164	Prospective evaluation of a side-specific nomogram to predict extraprostatic extension: Implementation leads to reduced positive surgical margin rates J.G. Heetman, Nieuwegein (NL)
A1165	Identification of pathologic factors associated with intraoperative positive surgical margins at NeuroSAFE for clinical decision-making on nerve-sparing surgery
A1166	The surgical learning curve for positive surgical margins after robot-assisted radical prostatectomy: Results from a multi-institutional collaboration C.A. Bravi, Milan (IT)
A1167	The influence of operative time and blood loss on surgical margins and functional outcomes at laparoscopic versus robotic-assisted radical prostatectomy: A prospective multicenter study M. Maggi, Rome (IT)
A1168	Topographic description of the site of positive MpMRI and impact on the risk of positive surgical margins at robot-assisted nerve sparing radical prostatectomy: Implications for accurate surgical approaches
14:55 - 15:05	Discussion
	Outcome
A1169	Real-life adverse events related to PDE-5 I treatment: Analysis of the EudraVigilance database J. Stira, Rome (IT)
A1170	Predictors of trainers' proficiency during the learning curve of robot-assisted radical prostatectomy: Results from a multicentric series
A1171	Ten-year outcome of a prospective randomised trial comparing laparoscopic versus robot-assisted radical prostatectomy E. Checcucci, Venaria Reale (IT)
A1172	Potential negative impact of post BX prostatitis on BCR free survival following surgery for prostate cancer
A1173	Impact of disease status heterogeneity of the STAMPEDE trial arm J population on oncological outcomes in high-risk nonmetastatic prostate cancer S. Hatakeyama, Hiroasaki (JP)
15:15 - 15:25	Discussion
15:25 - 15:30	Closing remarks

Stones and endourology - Lasers, heat and pressure

Abstract Session 63

Monday 4 July
14:00 - 15:30

Location Orange Area, Room 2
Chairs To be confirmed
P. Kallidonis, Patras (GR)
R. Umbach, Sindelfingen (DE)

14:00 - 14:05

Introduction

- | | |
|--|--|
| A1174 | Use of Moses 2.0 with extended frequency and optimized Moses vs. high power laser in MiniPCNL: Interim analysis of a randomized controlled trial
E. Emiliani, Barcelona (ES) |
| A1175 | Thulium fiber laser vs. Holmium:YAG for ureteroscopic lithotripsy: Outcomes from a clinical prospective randomised trial
Ö. Ulvik, Bønes (NO) |
| A1177 | Thulium fiber LASER (TFL) vs. Holmium LASER (HOL) for kidney stones in RIRS (Retrograde intrarenal Surgery): A randomised controlled trial |
| 14:13 - 14:21 Discussion | |
| A1178 | Thulium fibre laser achieves faster lithotripsy during ureteroscopic treatment of upper urinary tract stones: An observational study emulating a target trial
E. Ventimiglia, Milan (IT) |
| A1180 | Mini-PCNL with suction using Trilogy™ or Thulium fiber laser: Comparison of two novel energy sources |
| A1181 | Thulium fiber laser: Soltive vs Quanta - initial clinical experience |
| 14:29 - 14:37 Discussion | |
| A1182 | Treatment of ureteral stone with LithoEvo device and Vapor Tunnel tool
G. Bozzini, Como (IT) |
| A1183 | Laser companies pre-settings: Can we trust them?
A. Sierra Del Rio, Barcelona (ES) |
| A1184 | LithoFree: Extraction of kidney stone dust residues post-laser-lithotripsy using magnetic separation |
| 14:43 - 14:51 Discussion | |
| A1185 | The effect of prolonged laser activation on intrafluid temperature. Is the low power safer? An in vitro experimental study
A. Peteinaris, Patras (GR) |
| A1186 | Renal temperatures and thermal profiles during ureteroscopy with Thulium Fiber Laser and Holmium YAG laser: Findings from a preclinical study
M.S. Asoy, Bergen (NO) |

Scientific Programme - EAU22 Amsterdam

A1187	Evaluation of relationship with temperature and laser tip distance in high-power holmium laser use by measurement of thermography and thermometer: Ex-vivo phantom study
A1188	Thermography-based comparison of irrigation temperatures between Moses Mode and Virtual Basket Mode: An in-vitro phantom study S. Yamashita, Wakayama (JP)
14:59 - 15:07	Discussion
A1189	Intrarenal pressures during percutaneous nephrolithotomy and flexible ureteroscopy: A porcine kidney model
A1190	Development of an automated irrigation system synchronized with an ultra miniature fiber optic pressure sensor for regulating intrapelvic pressure during ureteroscopy: An ex vivo preclinical study
A1191	Intrarenal backflow during endoluminal irrigation of the renal pelvis: Dynamic gadolinium-enhanced MRI visualizing backflow at increasing intrarenal pressures in anaesthetized pigs H.U. Jung, Odense C (DK)
A1192	Novel syphon ureteric access sheath has the potential to improve renal pressures and irrigant flow
15:15 - 15:23	Discussion
15:23 - 15:30	Closing remarks

Stones and endourology - Percutaneous and ureteroscopic management

Abstract Session 54

Monday 4 July
10:30 - 12:00

Location Orange Area, Room 2
Chairs O.R. Durutovic, Belgrade (RS)
To be confirmed
B.M. Zeeshan Hameed, Mangaluru (IN)

10:30 - 10:34

Introduction

A1009 **Miniaturized percutaneous nephrolithotomy versus retrograde intrarenal surgery in the treatment of 10 – 20 mm lower pole renal stone: A propensity score-matched analysis**
A. Sakly, Monastir (TN)

A1010 **A comparison among RIRS and miniPERC for renal stones between 1 and 2 cm using fiber dust: a RCT**
G. Bozzini, Como (IT)

A1011 **Tubeless mini-percutaneous nephrolithotomy versus retrograde intrarenal surgery for ≤2 cm renal stones: A prospective study**
E.H. Galeti, Nellore (IN)

10:40 - 10:48

Discussion

A1012 **Comparison of renal parenchymal trauma after standard, mini and ultra-mini percutaneous tract dilation in porcine models**
K.D. Pagonis, Rio-Patras (GR)

A1013 **Supine vs. prone percutaneous nephrolithotomy - a randomised comparative study**

10:52 - 11:00

Discussion

A1014 **Propensity score-matched analysis comparing retrograde intrarenal surgery with percutaneous nephrolithotomy in anomalous kidneys**
E.J. Lim, Singapore (SG)

A1015 **Efficacy and safety of percutaneous nephrolithotomy in patients with chronic kidney disease: Outcomes from a tertiary care center**
H.S. Talwar, Rishikesh (IN)

A1016 **Miniature percutaneous nephrolithotomy or retrograde intrarenal surgery? A better procedure for management of proximal ureteric calculus**
V. Krishna Vennamaneni, hyderabad (IN)

A1017 **Evaluation of efficacy and safety profile of simultaneous bilateral endoscopic surgery (SBES) in bilateral urolithiasis patients**

11:08 - 11:16

Discussion

A1018 **How good is the surgeon? Comparison of CT versus intraoperative assessment of stone free status post PCNL in a retrospective cohort study**
M-C. Rassweiler-Seyfried, Mannheim (DE)

Scientific Programme - EAU22 Amsterdam

A1019	Robotic-assisted versus manual Uro-Dyna CT-guided puncture in an ex-vivo kidney model B. Grüne, Frankfurt (DE)
A1021	Comparison of EMS Swiss Trilogy lithotripsy and Pneumatic lithotripsy in percutaneous nephrolithotomy (PCNL) for stones larger than 2.5 cm M. Asif, Peshawar (PK)
11:24 - 11:32	Discussion
A1022	Acute kidney injury after mini and standard percutaneous nephrolithotomy: Pattern of presentation and predictors
A1023	Delayed post-percutaneous nephrolithotomy hemorrhage: Are there any predictive factors difference between Arteriovenous fistula (AVF) and Pseudoaneurysm (PA)? A three-year Multicentric case-control study A. Haghpanah, Shiraz (IR)
A1024	Creation and internal validation of a new nomogram to predict hemorrhagic and infectious complications after percutaneous nephrolithotomies G. Mazzon, Portogruaro (VE) (IT)
A1025	Machine learning can predict the need for post-PCNL transfusion and infectious complications with an extremely high degree of accuracy: Analysis of UK BAUS PCNL database R. Geraghty, Newcastle-upon-Tyne (GB)
A1026	A novel nomogram for predicting postoperative sepsis for patients with solitary, unilateral and proximal ureteral stones after treatment using percutaneous nephrolithotomy or flexible ureteroscopy
A1027	The comprehensive complication index as a tool for reporting the burden of complications after percutaneous nephrolithotomy: Is it time to leave the Clavien-Dindo classification behind? L. Boeri, Milan (IT)
A1028	3D printed models decentralise surgical skills training for retrograde intrarenal surgery and percutaneous nephrolithotomy in the COVID-19 era J. Coles-Black, Templestowe (AU)
11:46 - 11:54	Discussion
11:54 - 12:00	Closing remarks

Game changer session 1

Friday 1 July 07:30 - 08:00	Location	Orange Area, eURO Auditorium 1
--------------------------------	----------	--------------------------------

Game changer session 2

Friday 1 July 07:30 - 08:00	Location	Grey Area, eURO Auditorium 2
--------------------------------	----------	------------------------------

Post plenary discussion 'Challenges in renal cancer': Meet the experts

Friday 1 July 10:15 - 10:45	Location	Foyer eURO Auditorium 1
	Learning objectives	Join the post plenary discussion; a unique opportunity to meet (a part of) the experts of plenary session 1 and to ask questions related to the topic of their expertise!
10:15 - 10:45	Faculty	
10:15 - 10:45	To be confirmed	
10:15 - 10:45	M. Jewett, Toronto (CA)	
10:15 - 10:45	T.S. O'Brien, London (GB)	

Post plenary discussion 'Going viral in urology': Meet the experts

Friday 1 July 10:45 - 11:15	Location	Foyer eURO Auditorium 1
	Learning objectives	Join the post plenary discussion; a unique opportunity to meet (a part of) the experts of plenary session 2 and to ask questions related to the topic of their expertise!
10:45 - 11:15	Faculty	
10:45 - 11:15		C.R. Chapple, Sheffield (GB)
10:45 - 11:15		P.E. Spiess, Tampa (US)
10:45 - 11:15		F.M.E. Wagenlehner, Giessen (DE)

Joint Session of the European Association of Urology (EAU) and the Japanese Urological Association (JUA)

Urology beyond Europe

Friday 1 July
13:15 - 15:45

Location Yellow Area, Room E103

Chairs T. Ichikawa, Chiba (JP)
J. N'Dow, Aberdeen (GB)

Moderators M. Eto, Fukuoka (JP)
B. Ljungberg, Umeå (SE)
To be confirmed
To be confirmed
T. Ichikawa, Chiba (JP)
L. Tzelles, Athens (GR)

Panel To be confirmed
U. Capitanio, Milan (IT)
To be confirmed
M. Shiozaki, Matsumoto (JP)
To be confirmed
B. Somani, Southampton (GB)
T. Yagisawa, Tokyo (JP)
S. Yamashita, Wakayama (JP)

Learning objectives

The aim of this session is to provide the audience an insight in specific topics of current clinical practice in urology. The selected themes this year are urolithiasis and renal tumour. For each topic, the discussion will follow two pathways: on one hand a synthesis of the most recent scientific evidence will be examined, on the other hand, complex scenarios will be discussed by top-class experts. The audience will learn how to face complex clinical decision-making in case of urolithiasis, and locally advanced or metastatic renal cell carcinoma based on the actual EAU-Guidelines.

13:15 - 13:25

Welcome and introduction

13:15 - 13:25

T. Ichikawa, Chiba (JP)

13:15 - 13:25

J. N'Dow, Aberdeen (GB)

13:25 - 14:10

Renal cancer

13:25 - 13:35

Treatment of renal cell carcinoma: Current status and future directions
To be confirmed

13:35 - 13:45

Current strategies in treatment of locally advanced renal cell carcinoma
To be confirmed

13:45 - 14:10

How to manage this situation?

14:10 - 14:55

Stones

14:10 - 14:20

Research and treatment innovation for urolithiasis
K. Taguchi, Nagoya (JP)

Scientific Programme - EAU22 Amsterdam

14:20 - 14:30	Imaging and metabolic follow-up after urinary stone intervention: How to follow and when to discharge? To be confirmed
14:30 - 14:55	How do you treat this patient?
14:55 - 15:35	EAU-JUA exchange experiences
14:55 - 15:05	Establishment of preventive methods for kidney stone formation in space - Effects of bisphosphonates on astronauts on board the International Space Station for a long time A Okada, Nagoya (JP)
15:05 - 15:15	To be confirmed
15:15 - 15:25	Frailty and overactive bladder in community-dwelling older adults in Japan K. Omae, Fukushima (JP)
15:25 - 15:35	To be confirmed
15:35 - 15:45	Conclusion To be confirmed

EAU Opening Ceremony

Friday 1 July
18:00 - 19:45

Location Orange Area, eURO Auditorium 1

Opening performance by pianist Wibi Soerjadi & the Sand Magician

Opening address

Chris Chapple, Sheffield (GB), EAU Secretary General

Announcement of the new EAU Honorary Members

Citation by Chris Chapple, Sheffield (GB)

Presentation of the EAU Willy Gregoir Medal 2022

Citation by Chris Chapple, Sheffield (GB)
Presented to: Karl-Erik Andersson, Lund (SE)

The EAU is proud to present the Willy Gregoir Medal to an important senior urologist who contributed in an extraordinary way to the development of the urological specialty in Europe.

Presentation of the EAU Frans Debruyne Life Time Achievement Award 2022

Citation by Chris Chapple, Sheffield (GB)
Presented to: Joan Palou, Barcelona (ES)

The EAU wishes both to honour and acknowledge the important and longstanding contribution by a distinguished colleague to the activities and development of the EAU.

Presentation of the EAU Crystal Matula Award 2022

Citation by Chris Chapple, Sheffield (GB)
Presented to: Veeru Kasivisvanathan, London (GB)

This prestigious prize is granted to a promising younger urological academician.

Presentation of the EAU Hans Marberger Award 2022

Citation by Chris Chapple, Sheffield (GB)
Presented to: Alberto Martini, Milan (IT)

The Hans Marberger Award is awarded for the best European paper published on Minimally Invasive Surgery in urology.

EAU Innovators in Urology Award

Citation by Chris Chapple, Sheffield (GB)
Presented to: Yves Fradet, Quebec, Canada

For inventions and clinical contributions which have had a major impact on influencing the treatment and/or diagnosis of a urological disease.

EAU Ernest Desnos Prize

Citation by Chris Chapple, Sheffield (GB)
Presented to: Alain Jardin (on behalf of the Cercle Félix Guyon), Paris (FR)

This prize is granted to a professional (person or company) in urology who contributed in an extraordinary manner to the History of Urology.

Presentation of the EAU Prostate Cancer Research Award 2022

Citation by Chris Chapple, Sheffield (GB)
Presented to: Tobias Nordström, Stockholm (SE)

The EAU Prostate Cancer Research Award is awarded for the best paper published on clinical or experimental studies in prostate cancer.

Presentation 50th Anniversary EAU

Kicking off an Anniversary Year: 50 years of the EAU
Amsterdam and the EAU: A long History
Special Guest

Closing performance by the Sand Magician

ESU/ESUT/ESUI Hands-on Training Course in Prostate MRI reading for urologists

HOT 01

Saturday 2 July
09:00 - 12:30

Location Grey Area, Room G108

Chair To be confirmed

Tutors To be confirmed
To be confirmed

Learning objectives

This course will provide interactive teaching from expert Faculty in prostate MRI reading and interpretation and help Urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS and Likert scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their own laptops followed by a reference reading provided by expert radiologists and pathological verification.

ESU/ESFFU Hands-on Training Course in Urodynamics

HOT 04

Saturday 2 July
09:00 - 12:00

Location

Grey Area, Room G002

Learning objectives

This course aims to provide a practical course offering an interactive “hands-on” environment for doctors, nurses and technicians to improve their skills in urodynamics, with an emphasis on practical aspects including equipment used, interpretation of traces, quality control and trouble-shooting. The use of recorded tests, access to equipment and small groups means that individual problems can be addressed. Because of the small group format of the course, individual needs can be addressed. Access to teaching aids and equipment will simulate the clinical scenario as much as possible within the constraints of the conference setting. The aim is to teach and emphasise good Urodynamics practice using accepted international standards. At the end of the workshop delegates should feel more confident in their practice of urodynamics.

Post plenary discussion 'Nightmares in surgery of retroperitoneal disease':
Meet the experts

Saturday 2 July 10:45 - 11:15	Location	Foyer eURO Auditorium 1
	Learning objectives	Join the post plenary discussion; a unique opportunity to meet (a part of) the experts of plenary session 3 and to ask questions related to the topic of their expertise!
10:45 - 11:15	Faculty	
10:45 - 11:15	To be confirmed	
10:45 - 11:15	A. Minervini, Florence (IT)	

Post plenary discussion 'Perioperative treatment of urothelial cancer in 2022': Meet the experts

Saturday 2 July
11:15 - 11:45

Location Foyer eURO Auditorium 1

Learning objectives

Join the post plenary discussion; a unique opportunity to meet (a part of) the experts of plenary session 4 and to ask questions related to the topic of their expertise!

11:15 - 11:15

Faculty

11:15 - 11:15

P. Black, Vancouver (CA)

11:15 - 11:15

J.W.F. Catto, Sheffield (GB)

11:15 - 11:15

J. Palou, Barcelona (ES)

ESU/ESFFU Hands-on Training Course in Sacral Neuromodulation

HOT 06

Saturday 2 July
14:15 - 15:45

Location

Grey Area, Room G002

Learning objectives

A practical hands-on workshop that will allow the participants to practise on models the different steps of performing sacral neuromodulation including primary percutaneous nerve evaluation, tined lead and battery implantation and programming and also troubleshooting.

- Understand the indications for SNM
- Be able to perform the different steps of the procedure in a standardised format
- Be able to troubleshoot problems with SNM

ESU/ESFFU Hands-on Training Course in Sacral Neuromodulation

HOT 07

Saturday 2 July
16:00 - 17:30

Location

Grey Area, Room G002

Learning objectives

A practical hands-on workshop that will allow the participants to practise on models the different steps of performing sacral neuromodulation including primary percutaneous nerve evaluation, tined lead and battery implantation and programming and also troubleshooting.

- Understand the indications for SNM
- Be able to perform the different steps of the procedure in a standardised format
- Be able to troubleshoot problems with SNM

Game changer session 3

Sunday 3 July 07:30 - 08:00	Location	Orange Area, eURO Auditorium 1
--------------------------------	----------	--------------------------------

Game changer session 4

Sunday 3 July 07:30 - 08:00	Location	Grey Area, eURO Auditorium 2
--	-----------------	------------------------------

ESU/ESFFU Hands-on Training Course in Urodynamics

HOT 05

Sunday 3 July
08:30 - 11:30

Location

Grey Area, Room G002

Learning objectives

This course aims to provide a practical course offering an interactive “hands-on” environment for doctors, nurses and technicians to improve their skills in urodynamics, with an emphasis on practical aspects including equipment used, interpretation of traces, quality control and trouble-shooting. The use of recorded tests, access to equipment and small groups means that individual problems can be addressed. Because of the small group format of the course, individual needs can be addressed. Access to teaching aids and equipment will simulate the clinical scenario as much as possible within the constraints of the conference setting. The aim is to teach and emphasise good Urodynamics practice using accepted international standards. At the end of the workshop delegates should feel more confident in their practice of urodynamics.

ESU/ESUT/EULIS Hands-on Training Course in Endoscopic stone treatment - step 1

HOT 18

Sunday 3 July
09:00 - 09:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic endoscopic skills can be acquired and learned. Skills associated with cystoscopy, rigid and flexible ureteroscopy are trained by the validated exercises of the Endoscopic stone treatment (EST s1). Experienced Endourologists will guide you to master navigation skills needed with hand-eye-coordination for cystoscopy, rigid ureteroscopy in a model, placement of access sheath and flexible ureteroscopy in the K-Box. The course can be used as an additional training to prepare for the EST S1 examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

ESU/ESUT Hands-on Training Course in Basic laparoscopy

HOT 11

Sunday 3 July
09:00 - 09:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme. Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- You will improve your laparoscopic skills such as depth perception and bimanual dexterity

ESU/ESUT Hands-on Training Course in Basic laparoscopy

HOT 12

Sunday 3 July
10:00 - 10:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme. Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- You will improve your laparoscopic skills such as depth perception and bimanual dexterity

ESU/ESUT/EULIS Hands-on Training Course in Endoscopic stone treatment - step 1

HOT 19

Sunday 3 July
10:00 - 10:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic endoscopic skills can be acquired and learned. Skills associated with cystoscopy, rigid and flexible ureteroscopy are trained by the validated exercises of the Endoscopic stone treatment (EST s1). Experienced Endourologists will guide you to master navigation skills needed with hand-eye-coordination for cystoscopy, rigid ureteroscopy in a model, placement of access sheath and flexible ureteroscopy in the K-Box. The course can be used as an additional training to prepare for the EST S1 examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

Post plenary discussion 'PCa high risk local treatment': Meet the experts

Sunday 3 July 10:30 - 11:00	Location	Foyer eURO Auditorium 1
	Learning objectives	Join the post plenary discussion; a unique opportunity to meet (a part of) the experts of plenary session 5 and to ask questions related to the topic of their expertise!
10:30 - 11:00	Faculty	
10:30 - 11:00		N.W. Clarke, Manchester (GB)
10:30 - 11:00		To be confirmed
10:30 - 11:00		N. Mottet, Saint-Étienne (FR)

Post plenary discussion 'Personalised surgical management of LUTS/BPO':
Meet the experts

Sunday 3 July 11:00 - 11:30	Location	Foyer eURO Auditorium 1
	Learning objectives	Join the post plenary discussion; a unique opportunity to meet (a part of) the experts of plenary session 6 and to ask questions related to the topic of their expertise!
11:00 - 11:30	Faculty	
11:00 - 11:30		C. Gratzke, Freiburg (DE)
11:00 - 11:30		To be confirmed
11:00 - 11:30		To be confirmed

ESU/ESUT Hands-on Training Course in Basic laparoscopy

HOT 13

Sunday 3 July
11:00 - 11:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme. Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- You will improve your laparoscopic skills such as depth perception and bimanual dexterity

ESU/ESUT/EULIS Hands-on Training Course in Endoscopic stone treatment - step 1

HOT 20

Sunday 3 July
11:00 - 11:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic endoscopic skills can be acquired and learned. Skills associated with cystoscopy, rigid and flexible ureteroscopy are trained by the validated exercises of the Endoscopic stone treatment (EST s1). Experienced Endourologists will guide you to master navigation skills needed with hand-eye-coordination for cystoscopy, rigid ureteroscopy in a model, placement of access sheath and flexible ureteroscopy in the K-Box. The course can be used as an additional training to prepare for the EST S1 examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

ESU/ESUT/EULIS Hands-on Training Course in Endoscopic stone treatment - step 1

HOT 21

Sunday 3 July
13:00 - 13:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic endoscopic skills can be acquired and learned. Skills associated with cystoscopy, rigid and flexible ureteroscopy are trained by the validated exercises of the Endoscopic stone treatment (EST s1). Experienced Endourologists will guide you to master navigation skills needed with hand-eye-coordination for cystoscopy, rigid ureteroscopy in a model, placement of access sheath and flexible ureteroscopy in the K-Box. The course can be used as an additional training to prepare for the EST S1 examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

ESU/ESUT Hands-on Training Course in Basic laparoscopy

HOT 14

Sunday 3 July
13:00 - 13:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme. Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- You will improve your laparoscopic skills such as depth perception and bimanual dexterity

ESU/ESUT/ESUI Hands-on Training Course in Fusion Biopsy, Introduction

HOT 08

Sunday 3 July
13:45 - 15:45

Location

Grey Area, Room G002

Learning objectives

MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow.

The course will provide an overview on MRI reading, technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. During the second half of the course, the participants are able to try out different Fusion biopsy machines in small groups.

At the end of the course, the participants understand the advantages, handling and limitations of MRI Ultrasound fusion biopsies.

ESU/ESUT/ESUI Hands-on Training Course in Prostate MRI reading for urologists

HOT 02

Sunday 3 July
14:00 - 17:30

Location Grey Area, Room G108

Chair To be confirmed

Tutors To be confirmed

To be confirmed

To be confirmed

Learning objectives

This course will provide interactive teaching from expert Faculty in prostate MRI reading and interpretation and help Urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS and Likert scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their own laptops followed by a reference reading provided by expert radiologists and pathological verification.

ESU/ESUT/EULIS Hands-on Training Course in Endoscopic stone treatment - step 1

HOT 22

Sunday 3 July
14:00 - 14:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic endoscopic skills can be acquired and learned. Skills associated with cystoscopy, rigid and flexible ureteroscopy are trained by the validated exercises of the Endoscopic stone treatment (EST s1). Experienced Endourologists will guide you to master navigation skills needed with hand-eye-coordination for cystoscopy, rigid ureteroscopy in a model, placement of access sheath and flexible ureteroscopy in the K-Box. The course can be used as an additional training to prepare for the EST S1 examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

ESU/ESUT Hands-on Training Course in Basic laparoscopy

HOT 15

Sunday 3 July
14:00 - 14:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme. Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- You will improve your laparoscopic skills such as depth perception and bimanual dexterity

ESU/ESUT/EULIS Hands-on Training Course in Endoscopic stone treatment - step 1

HOT 23

Sunday 3 July
15:00 - 15:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic endoscopic skills can be acquired and learned. Skills associated with cystoscopy, rigid and flexible ureteroscopy are trained by the validated exercises of the Endoscopic stone treatment (EST s1). Experienced Endourologists will guide you to master navigation skills needed with hand-eye-coordination for cystoscopy, rigid ureteroscopy in a model, placement of access sheath and flexible ureteroscopy in the K-Box. The course can be used as an additional training to prepare for the EST S1 examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

ESU/ESUT Hands-on Training Course in Basic laparoscopy

HOT 16

Sunday 3 July
15:00 - 15:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme. Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- You will improve your laparoscopic skills such as depth perception and bimanual dexterity

ESU/ESUT/ESUI Hands-on Training Course in Fusion Biopsy, Introduction

HOT 09

Sunday 3 July
16:00 - 18:00

Location

Grey Area, Room G002

Learning objectives

MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow.

The course will provide an overview on MRI reading, technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. During the second half of the course, the participants are able to try out different Fusion biopsy machines in small groups.

At the end of the course, the participants understand the advantages, handling and limitations of MRI Ultrasound fusion biopsies.

ESU/ESUT/EULIS Hands-on Training Course in Endoscopic stone treatment - step 1

HOT 24

Sunday 3 July
16:00 - 16:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic endoscopic skills can be acquired and learned. Skills associated with cystoscopy, rigid and flexible ureteroscopy are trained by the validated exercises of the Endoscopic stone treatment (EST s1). Experienced Endourologists will guide you to master navigation skills needed with hand-eye-coordination for cystoscopy, rigid ureteroscopy in a model, placement of access sheath and flexible ureteroscopy in the K-Box. The course can be used as an additional training to prepare for the EST S1 examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

ESU/ESUT Hands-on Training Course in Basic laparoscopy

HOT 17

Sunday 3 July
16:00 - 16:50

Location

Orange Area, Room 3

Learning objectives

In this course, basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme. Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- You will improve your laparoscopic skills such as depth perception and bimanual dexterity

Game changer session 5

Monday 4 July 07:30 - 08:00	Location	Orange Area, eURO Auditorium 1
--------------------------------	----------	--------------------------------

Game changer session 6

Monday 4 July 07:30 - 08:00	Location	Grey Area, eURO Auditorium 2
--------------------------------	----------	------------------------------

Roundtable WFIPP/EAU: Sustainable continence care

Patient information session

Monday 4 July
09:00 - 10:30

Location Grey Area, Room Emerald

Chairs To be confirmed
To be confirmed

Learning objectives

Learn about the environmental impact of waste products in continence care; What is sustainable continence care; Self-management in continence care; The role of sacral neuromodulation in the management of pelvic floor dysfunction.

09:00 - 09:03

Welcome and introduction

09:03 - 09:13

Sustainable continence care: How do we minimise the waste produced by absorbents?
To be confirmed

09:13 - 09:18

Voting

09:18 - 09:33

The 'Green'Deal': EU policy regarding sustainable continence care
To be confirmed

09:33 - 09:38

Voting

09:38 - 09:46

Healthcare Professional (HCP) and Patient Advocate Group (PAG) partnership in sustainable continence care

09:38 - 09:46

To be confirmed

09:38 - 09:46

To be confirmed

09:46 - 09:51

Voting

09:51 - 09:59

How does a patient manage incontinence issues through selfcare/self-management?
To be confirmed

09:59 - 10:04

Voting

10:04 - 10:16

The role of Sacral Neuromodulation in the management of pelvic floor dysfunction
To be confirmed

10:16 - 10:21

Voting

10:21 - 10:26

WFIP Digital Platform for Patients and Healthcare Professionals (HCP): Example of sustainable continence care
To be confirmed

10:26 - 10:30

Concluding Remarks: Focusing on - How does he envision the future for sustainable continence care
To be confirmed

ESU/ESUT/ESUI Hands-on Training Course in Prostate MRI reading for urologists

HOT 03

Monday 4 July
09:00 - 12:30

Location Grey Area, Room G108

Chair To be confirmed

Tutor To be confirmed

Learning objectives

This course will provide interactive teaching from expert Faculty in prostate MRI reading and interpretation and help Urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS and Likert scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their own laptops followed by a reference reading provided by expert radiologists and pathological verification.

Roundtable: Fatigue in prostate cancer patients

Patient information session

Monday 4 July
10:45 - 11:45

Location Grey Area, Room Emerald
Chair To be confirmed

Learning objectives
Learn how fatigue in prostate cancer patients is experienced and managed; the perspective of a urologist, a nurse, a patient advocate, a patient and a caregiver. This session includes a Q&A section by voting.

10:45 - 10:55 **What is fatigue & how does it impact PCa patients?**
To be confirmed

10:55 - 11:35 **Expert panel**

Expert
I.M. Van Oort, Nijmegen (NL)

Patient
R. Wassersug, Vancouver (CA)

Patient advocate
To be confirmed

Nurse
To be confirmed

Caregiver
To be confirmed

11:35 - 11:40 **Voting**
To be confirmed

11:40 - 11:45 **Concluding remarks**
To be confirmed

ESU/ESUI Hands-on Training Course in Urological ultrasound

HOT 10

Monday 4 July
09:30 - 11:00

Location

Grey Area, Room G002

Learning objectives

Ultrasonography is an essential instrument in the management of urological patients, both in the diagnostic phase and during follow-up after treatment. It is an evolving technology with increasing performance. Since it is becoming cheaper and user friendly, it is more available in every urological office. The knowledge and the use of this method should be part of the standard background and armamentarium of each urologist.

This hands-on-course aims to provide urologists with the necessary baseline training to implement abdominal ultrasound as well as transrectal ultrasound of the prostate as a routine diagnostic tool in daily practice. It will provide basic information by short and concise lectures followed by extensive practical exercise.

Aim and objectives

- At the end of the course, the participants understand the advantages, handling and limitations of ultrasound in the urological practice.

Target audience: urologists, interested in the diagnostic ability of urological ultrasound

Best EAU22 abstracts selected by the Scientific Committee

Best abstracts

Monday 4 July
10:30 - 12:00

Location Orange Area, eURO Auditorium 1

Chairs P. Albers, Düsseldorf (DE)
A. Stenzl, Tübingen (DE)

Learning objectives

This session presents the best of abstracts submitted to EAU22 and selected by the tracks of the Scientific Congress Office (SCO). The selected abstracts will be discussed by a member of the SCO or a specialist in the field. By this, the selected abstracts will be highlighted and their content will be commented. In addition, prize winning abstracts will be presented by the authors followed by a discussion of a member of the SCO.

10:30 - 10:32

Introduction

P. Albers, Düsseldorf (DE)

10:32 - 10:57

Best oncology abstracts

10:32 - 10:42

Prostate cancer

A0197 PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute toxicity of a randomized phase II trial

A0272 3-year outcomes from the prospective 'MRIAS' trial: A novel active surveillance protocol which incorporates multiparametric MRI to reduce frequency of biopsy in men with prostate cancer

A0611 Crowdsourcing of artificial intelligence algorithms for diagnosis and Gleason grading of prostate cancer in biopsies

A0937 Pre-surgery blood levels of leucine-rich alpha-2-glycoprotein 1 identify patients with a high risk of progressing to castration-resistant prostate cancer

To be confirmed

10:42 - 10:47

Renal cancer

A1122 Characterization of the tumor immune microenvironment between primary and paired asynchronous metastatic clear cell renal cell carcinoma

A1124 Large-scale genomic analysis of renal cell carcinoma using 1,532 Japanese patients and 5,996 controls

To be confirmed

10:47 - 10:52

Bladder cancer

A0068 Non-muscle invasive bladder cancer subtypes with differential response to intravesical bacillus Calmette-Guerin treatment

A0234 Assessing the impact of BCG on progression of NMIBC in the new EAU high risk and very high-risk groups

M. Rouprêt, Paris (FR)

10:52 - 10:57

Penile cancer

A0691 Survival in N3 penile cancer: Does pelvic lymphadenopathy predict a worse prognosis than inguinal extra-nodal extension?

O.R. Brouwer, Amsterdam (NL)

10:57 - 11:22

Best non-oncology abstracts

10:57 - 11:02

Benign lower urinary tract diseases

A0442 Persistence of overactive bladder pharmacological treatment in women as reflected from large-scale real-world data of prescription claims: A retrospective cohort study (2010-2020)

A0590 Trans-ethnic genome-wide association study reveals new therapeutic targets for benign prostatic hyperplasia

A0710 Efficacy and safety of sacral neuromodulation for neurogenic lower urinary tract dysfunction: A randomised, sham-controlled, double-blind, multicentre clinical trial

J-N.L. Cornu, Rouen (FR)

11:02 - 11:07

Uro-genital reconstruction

A0863 Prospective multicentre long-term analysis of oral morbidity after oral mucosa grafts harvesting for substitution or augmentation urethroplasties

To be confirmed

11:07 - 11:12

Urolithiasis

A1025 Machine learning can predict the need for post-PCNL transfusion and infectious complications with an extremely high degree of accuracy: Analysis of UK BAUS PCNL database

T. Knoll, Sindelfingen (DE)

11:12 - 11:17

Infections

A0111 Report on microbial and resistance patterns of the causative pathogens of nosocomially-acquired urinary tract infections: Preliminary data analysis of the GPIU-Studies 2015-2020

A0112 Risk factors of infectious complications after benign prostatic hyperplasia surgery: Preliminary results from the retrospective and multicenter TOCUS cohort

To be confirmed

11:17 - 11:22

Paediatrics

A0779 Outcomes from practice of Retrograde Intrarenal Surgery (RIRS) in a paediatric setting of various age groups: A global study across 8 centres

To be confirmed

11:22 - 11:52

Discussion on prize winning abstracts

Oncology prize winning abstracts

11:22 - 11:32

First prize A0759 Robot assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy: Results from the iROC prospective randomised controlled trial

2 minutes pre-recorded abstract presentation

8 minutes discussion

A. Stenzl, Tübingen (DE)

11:32 - 11:42

Second prize A0455 Target vs. Target plus Standard biopsy in naïve patients: Results of a prospective randomized controlled trial

2 minutes pre-recorded abstract presentation

8 minutes discussion

J. Walz, Marseille (FR)

Non-oncology prize winning abstract

11:42 - 11:52

First prize A0590 Trans-ethnic genome-wide association study reveals new therapeutic targets for benign prostatic hyperplasia

2 minutes pre-recorded abstract presentation

8 minutes discussion

C. Gratzke, Freiburg (DE)

11:52 - 11:55

Closing remarks

P. Albers, Düsseldorf (DE)

Post plenary discussion 'Liquid biomarkers in 2022 and beyond: Ready for prime time?': Meet the experts

Monday 4 July
10:30 - 11:00

Location Foyer eURO Auditorium 1

Learning objectives

Join the post plenary discussion; a unique opportunity to meet (a part of) the experts of plenary session 7 and to ask questions related to the topic of their expertise!

10:30 - 11:00

Faculty

10:30 - 11:00

J.L. Boormans, Rotterdam (NL)

10:30 - 11:00

L. Dyrskjød, Aarhus (DK)

10:30 - 11:00

J.A. Schalken, Nijmegen (NL)

Functional urology

Patient information session

Monday 4 July
07:45 - 08:45

Location Grey Area, Room Emerald

Chair To be confirmed

Learning objectives

To inform the audience about living with incontinence.

07:45 - 08:03

Towards a future of sustainable continence care: 'Green' care and therapy initiatives

M.R. Van Balken, Arnhem (NL)

08:03 - 08:15

Incontinence and absorbent products (pads)

To be confirmed

08:15 - 08:30

GETSBI study (IC-BPS)

08:15 - 08:30

D.A.W. Janssen, Nijmegen (NL)

08:15 - 08:30

To be confirmed

08:30 - 08:33

Q&A

08:33 - 08:45

Sustainable continence care

To be confirmed

Post plenary discussion 'Stones: The sky is the limit': Meet the experts

Monday 4 July 11:00 - 11:30	Location	Foyer eURO Auditorium 1
	Learning objectives	Join the post plenary discussion; a unique opportunity to meet (a part of) the experts of plenary session 8 and to ask questions related to the topic of their expertise!
11:00 - 11:30	Faculty	
11:00 - 11:30	To be confirmed	
11:00 - 11:30	P.J.S. Osther, Fredericia (DK)	

Kidney cancer session

Patient information session

Monday 4 July
13:15 - 14:15

Location Grey Area, Room Emerald

Chair To be confirmed

Learning objectives

- Recognising how communication between HCPs and (kidney) cancer patients can be improved
- Understanding when and how shared decision-making should be applied
- Appreciating the benefit of kidney cancer hospital networks in reducing practice variation and improving patient experience

13:15 - 13:20

Introduction

To be confirmed

13:20 - 13:30

How communication between HCPs and (kidney) cancer patients can be improved
C.N. Tillier, Amsterdam (NL)

13:30 - 13:45

Shared decision making in kidney cancer
To be confirmed

13:45 - 14:00

The benefit of kidney cancer hospital networks and practice variation
P.J. Zondervan, Amsterdam (NL)

14:00 - 14:15

Discussion

To be confirmed

Bladder cancer

Patient information session

Monday 4 July
14:30 - 15:30

Location Grey Area, Room Emerald

Chairs L. Makaroff, Chinnor (GB)
E. Rogers, Galway (IE)

Learning objectives

- To learn how to have meaningful patient-physician relationships to create patient support networks
- To learn about patient needs assessments for information and support
- To learn how to develop patient information and support resources

14:30 - 14:36

Evidence-based approaches to patient support
To be confirmed

14:36 - 14:46

Urologists and patients working together to establish peer support networks
To be confirmed

14:46 - 14:56

Helping patients find the hospital that's right for them
To be confirmed

14:56 - 15:06

Building community at a national level
To be confirmed

15:06 - 15:16

Advocating for equitable access to treatment
To be confirmed

15:16 - 15:30

Panel discussion

Prostate cancer

Patient information session

Monday 4 July
15:45 - 16:45

Location Grey Area, Room Emerald

Chair E. Rogers, Galway (IE)

Learning objectives

Improving the quality of life of prostate cancer patients through awareness and empowerment.

15:45 - 15:48

Programme overview
E. Rogers, Galway (IE)

15:48 - 15:57

Is this the real revolution? A realisation among low-risk prostate patients and their physicians that the best treatment may be no “treatment” at all! How this approach is becoming the leading treatment in such low-risk patients
To be confirmed

15:57 - 16:06

A more evolutionary view - How do long term prostate patients view the benefit from developments in diagnosis and treatment over the past two decades?
To be confirmed

16:06 - 16:15

A case history. Improving awareness of prostate cancer and why no man need die of it - if caught early enough
S.A. Clark-Wehinger, Meudon (FR)

16:15 - 16:24

How patients decided to push quality of life as a major factor in trials and treatment and how patient power was enhanced by EUPROMS 1.0 and EUPROMS 2.0
E-G. Carl, Tornesch (DE)

16:24 - 16:33

The future patient role in dealing with prostate cancer and its relevance to Quality of Life (QoL) of patients and their partners
A. Deschamps, Antwerp (BE)

16:33 - 16:45

Q&A moderated by EAU Patient Office
E. Rogers, Galway (IE)

Best of EAU22

Monday 4 July 15:45 - 17:45	Location	Orange Area, eURO Auditorium 1
--------------------------------	----------	--------------------------------

Life after cancer

Patient information session

Monday 4 July
17:00 - 17:30

Location Grey Area, Room Emerald

Chair To be confirmed

Learning objectives

- Presentation of guidelines on survivorship
- Impact of cancer and cancer treatment on sexuality and intimacy
- Right to be forgotten and/or co-morbidities

17:00 - 17:05

Overview and introduction: How cancer survivors can take the lead in improving their quality of life

To be confirmed

17:05 - 17:12

Let's break the taboo around cancer and sexuality!

To be confirmed

17:12 - 17:19

Tackling the unmet needs of life after cancer diagnosis, treatment and survivorship

A. Cardone, Brussels (BE)

17:19 - 17:30

Questions and answers

